Patent Publication Number: US-2022218813-A1

Title: Hiv vaccines and methods of using

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63/137,521, filed on Jan. 14, 2021; U.S. Provisional Application No. 63/149,820, filed on Feb. 16, 2021 and U.S. Provisional Application No. 63/170,900, filed on Apr. 5, 2021, which are hereby incorporated herein by reference in their entireties for all purposes. 
    
    
     SEQUENCE LISTING 
     The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 12, 2021 is named 1355-US-NP.txt and is 508,767 bytes in size. 
     BACKGROUND 
     HIV remains one of the leading causes of mobility and mortality globally, with over 38 million infected globally and 690,000 deaths in 2019 (UNAIDS. Fact Sheet—World AIDS Day 2020. unaidsorg/en/resources/fact-sheet. 2020). The last three decades have seen significant improvements in therapeutics for HIV. The development of highly active anti-retroviral therapy has improved survival for people living with HIV, and reduced morbidity from HIV related immunosuppression and opportunistic infections (Johnson, et al.,  PLoS Med.  2013; 10(4):e1001418; May, et al.,  AIDS . (2014) 28(8):1193-202; Rodger, et al.,  AIDS . (2013) 27(6):973-9; Samji, et al.,  PLoS One . (2013) 8(12):e81355). In recent years antiretroviral treatment (ART) regimens have been simplified to once daily pills with longer acting oral and injectable therapeutics on the horizon (Swindells, et al.,  N Engl J Med . (2020) 382(12):1112-23; Orkin, et al.,  N Engl J Med . (2020) 382(12):1124-35; Link, et al.,  Nature . (2020) 584(7822):614-8). Despite these advances in therapeutics, to date there has only been two well documented examples of cure, both of which required severe immunosuppression and bone marrow transplantation (Gupta, et al.,  Lancet HIV . (2020) 7(5):e340-e7; Hutter, et al.,  N Engl J Med . (2009) 360(7):692-8). Unlike many self-limited infectious diseases, the HIV virus integrates itself into its host genome, and establishes latency in resting memory CD4+ T cells (Eisele, et al.,  Immunity . (2012) 37(3):377-88). These cells form the HIV latent reservoir that cannot be cleared by standard antiretroviral therapy. Reservoir cells are also protected from immune surveillance and clearance mechanisms, as they do not express viral antigens enabling them to evade recognition and clearance by cytotoxic T cells. The reservoir is long-lived and despite detectable reductions in the size of the reservoir, viral rebound is observed following discontinuation of ART (Henrich, et al.,  Ann Intern Med . (2014) 161(5):319-27; Henrich, et al.,  J Infect Dis . (2013) 207(11):1694-702). Activating the reservoir with latency reversing agents will need to be coupled with an effective mechanism to stimulate cytotoxic T cells and eliminate the infected reservoir cells (Ait-Ammar, et al.,  Front Microbiol . (2019) 10:3060; Mothe, et al.,  Front Immunol . (2020) 11:823; Fidler, et al.,  Lancet . (2020) 395(10227):888-98). A therapeutic vaccine designed to generate antigen specific effector T cell responses can be an additional component of an HIV cure strategy. 
     T cell vaccines hold significant promise in therapeutic areas such as oncology. High levels of tumor infiltrating CD8+ lymphocytes are associated with better prognosis in some cancers, leading to significant interest in developing vaccines that can induce tumor specific cytotoxic CD8+ T cells. Although previous approaches have had limited success (Rosenberg, et al.,  Nature Medicine . (2004) 10(9):909-15), the use of novel delivery platforms, improved techniques in antigen discovery and immune modulation hold some promise (Ott, et al.,  Nature . (2017) 547(7662):217-21). Similarly, T cells play an important role in the control of HIV viremia. Antigen specific T cells that arise in acute HIV infection are responsible for driving the initial drop in viremia (Borrow, et al.,  J Virol . (1994) 68(9):6103-10; Koup, et al.,  J Virol . (1994) 68(7):4650-5). HIV infected human long-term non-progressers or elite controllers are characterized by having strong effective antigen specific T cell responses. In SIV infection (a non-human primate model of human HIV infection) antigen specific T cells either generated naturally or through vaccination have been associated with viral control (Schmitz, et al.,  Science . (1999) 283(5403):857-60; Jin, et al.,  J Exp Med . (1999) 189(6):991-8). Despite this data, T-cells vaccines for prevention have had limited success in inducing T cell responses of limited breadth or efficacy (Buchbinder, et al.,  Lancet . (2008) 372(9653):1881-93; Janes, et al.,  J Infect Dis . (2013) 208(8):1231-9; Excler, et al.,  Curr Opin HIV AIDS . (2016) 11(6):607-13). Therapeutic vaccine trials with T cell vaccines have also shown limited efficacy (Mothe, et al.,  Front Immunol . (2020) 11:823; Colby, et al.,  Nature Medicine . (2020) 26(4):498-501). These trials have used viral vectors such as adenoviruses (human and chimpanzee) as well as modified vaccinia Ankara (MVA) virus and with full length viral antigens or shorter constructs (Barouch, et al.,  Lancet . (2018) 392(10143):232-43; Mothe, et al.,  EClinical Medicine . (2019) 11:65-80). Data from these studies suggest that following vaccination the breadth of antigen specific T cells generated is low. Although these vaccine-induced T cells secrete IFN-γ in standard ELISpot assays the demonstrated lack of efficacy suggests that these T cells may not have full cytotoxic activity. 
     Immunogen design is a component of any therapeutic HIV vaccine to generate the right antigen specific response, targeted at a conserved region and with cytotoxic activity. Natural infection has demonstrated that the immune response will tend to focus on highly immunodominant variable regions within HIV for example in HIV envelope or Nef, or variable regions in HIV Gag (Addo, et al.  J Virol . (2003) 77(3):2081-92; Betts, et al.,  J Virol.  2001; 75(24):11983-91). These responses generate T cells from which the virus can rapidly escape without a fitness cost (Liu, et al.,  J Virol . (2006) 80(19):9519-29). An effective HIV vaccine will need to avoid these regions and drive the establishment of de novo responses that focus the immune response to conserved regions of the virus where conservation is required to maintain viral function. 
     Previous HIV vaccines have primarily focused on designing immunogens that provide universal coverage by addressing global HIV viral diversity and have generated full length sequences or have adapted algorithms to generate constructs of conserved regions (Korber, et al.,  Hum Vaccin Immunother . (2020) 16(3):713-722; Fischer, et al.,  Nature Medicine . (2007) 13(1):100-6). All of these approaches have primarily evaluated consensus sequences assessing inter patient variability to determine regions of conservation, and concatenated to provide global sequence coverage. However, within an HIV infected individual there are several circulating quasispecies. Some of these viral quasispecies are generated as a result of T cell driven pressure and reflect pre-existing escape route for the virus should a T cell response directed at it emerge (Liu, et al.,  J Virol . (2006) 80(19):9519-29; Korber, et al., 2020, supra; Price, et al.,  Proc Natl Acad Sci USA . (1997) 94(5):1890-5). That the targeting of conserved regions by previous vaccines did not consider quasispecies together with identification of highly conserved immunogenic regions, may in part explain their limited efficacy (Hanke, et al.,  Expert Rev Vaccines . (2019) 18(10):1029-41). 
     SUMMARY 
     Provided are fusion polypeptides comprising a plurality of polypeptide segments of one or more human immunodeficiency virus-1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol and nef. In some embodiments, the plurality of polypeptide segments comprises or consists of polypeptide segments encoded by HIV-1 genes pol and nef, and does not comprise polypeptide segments encoded by HIV-1 genes env, tat, rev, vpr, vif and/or vpu. In some embodiments, the plurality of polypeptide segments comprises or consists of polypeptide segments encoded by HIV-1 genes gag, pol and nef, and does not comprise polypeptide segments encoded by HIV-1 genes env, tat, rev, vpr, vif and/or vpu. In some embodiments, the plurality polypeptide segments are derived from conserved regions in a population of viral proteome sequences. In some embodiments, the conserved regions are greater than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% conserved amongst HIV-1 species in interpatient populations. In some embodiments, the conserved regions are conserved amongst one or more of HIV-1 clades A-K, e.g., one or more of clades A, B, C, D and G, or recombinant forms of one or more of HIV-1 clades A-K, and combinations thereof. In some embodiments, the fusion polypeptides comprise at least 4 and up to 6 polypeptide segments, e.g., 4, 5 or 6 polypeptide segments. In some embodiments, each polypeptide segment is at least 10 amino acids in length, and up to about 225 amino acids in length, e.g. from at least 10 amino acids in length up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220 or 225 amino acids in length. In some embodiments, the full-length of the fusion polypeptide comprises at least about 330 amino acids and up to about 505 amino acids (without a signal peptide) or up to about 550 amino acids (including a signal peptide), e.g., at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545 or 550 amino acids. In some embodiments, the full-length of the fusion polypeptide is no longer than 550 amino acids (with a signal peptide) or no longer than 505 amino acids (without a signal peptide), e.g., no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335 or 330 amino acids. In some embodiments, the full-length of the fusion polypeptide comprises at least 350 amino acids and up to 385 amino acids, e.g., at least 350 amino acids and up to 365 amino acids. In some embodiments, the full-length of the fusion polypeptide comprises at least 390 amino acids and up to 395 amino acids. In some embodiments, each polypeptide segment comprises or consists of one or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises three or more predicted T cell epitopes, e.g., four, five, six or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by one or more human HLA class I alleles (e.g. 1, 2, 3, 4, 5 or 6 alleles), e.g. within a single subject or amongst multiple patients. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by at least by a human A*0201 HLA class I molecule. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that are intracellularly processed and presented by one or more human HLA class II alleles (e.g. 1, 2, 3, 4, 5 or 6 alleles), e.g. within a single subject. In some embodiments, one or more of the polypeptide segments is abutted or fused to an adjacent segment. In some embodiments, one or more of the polypeptide segments is joined to an adjacent segment by one or more peptide linkers. In some embodiments, the one or more peptide linkers is selected from one or more of a polyalanine, a polyglycine, Gln-Glu-Glu (QEE), Lysine (L), Isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL), Leu-Ile-Lys (LIK), Pro-Pro-Val (PPV), Ser-Glu-Gly (SEG), a cleavable linker, a flexible linker, a rigid linker, and combinations thereof. In some embodiments, the flexible linker is selected from Gln-Glu-Glu (QEE) (SEQ ID NO: 51), Lysine (L), Isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO: 54) and Ser-Glu-Gly (SEG) (SEQ ID NO:55). In some embodiments, the flexible linker comprises a polyalanine linker or a polyglycine linker, e.g., comprising or consisting of 2 or 3 contiguous alanine residues, e.g. AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49) or AAX, wherein X is any amino acid (e.g. A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y) (SEQ ID NO: 50). In some embodiments, the flexible linker comprises or consists of GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58) or GGGS (SEQ ID NO: 59). In some embodiments, the cleavable linker is selected from a 2A cleavable peptide (e.g. foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), a furin recognition/cleavage sequence (e.g. RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the cleavable linker comprises or consists of a furin recognition/cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the cleavable linker comprises or consists of the amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), or comprises or consists of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more, of the polypeptide segments comprising or consisting of amino acid residues corresponding to Gag 1-53; Gag 147-369; Pol 56-117; Pol 129-320; Pol 367-431 Pol 542-606; Pol 586-606; Pol 683-708, Pol 747-827; Pol 840-909; Pol 840-920; Pol 932-1003; Nef 64-76; Nef 64-99 or Nef 117-148, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide does not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide does not comprise any polypeptide segments having an amino acid sequence of any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more, polypeptide segments selected from SEQ ID NOs: 4-33. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively: (a) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708 and Nef 117-148; (b) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431 and Nef 64-99; (c) amino acid residues corresponding to: Pol 542-606; Pol 747-827; Pol 840-920; Pol 932-1003 and Nef 64-99; (d) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708; Pol 747-827; Pol 840-920 and Nef 117-148; (e) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431; Pol 542-606; Pol 932-1003 and Nef 64-99; (f) amino acid residues corresponding to: Gag 147-369, Pol 586-606, Pol 683-708 and Pol 840-920; (g) amino acid residues corresponding to: Pol 129-320, Pol 747-827, Pol 932-1003 and Nef 64-76; or (h) amino acid residues corresponding to: Gag:147-369, Pol 747-827, Pol 840-909 and Nef 64-76. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments: (a) SEQ ID NOs: 4, 6, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18 and 32, respectively; (b) SEQ ID NOs: 5, 7, 19 and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19 and 33, respectively; (c) SEQ ID NOs: 8, 10, 12 and 30 or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12 and 30, respectively; (d) SEQ ID NOs: 9, 11, 13 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13 and 31, respectively; (e) SEQ ID NOs: 14, 20, 24, 26 and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 20, 24, 26 and 30, respectively; (f) SEQ ID NOs: 15, 21, 25, 27 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 21, 25, 27 and 31, respectively; (g) SEQ ID NOs: 4, 6, 18, 20, 24 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18, 20, 24 and 32, respectively; (h) SEQ ID NOs: 5, 7, 19, 21, 25 and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19, 21, 25 and 33, respectively; (i) SEQ ID NOs: 8, 10, 12, 14, 26 and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12, 14, 26 and 30, respectively; (j) SEQ ID NOs: 9, 11, 13, 15, 27 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13, 15, 27 and 31, respectively; (k) SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (1) SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, respectively; (m) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; (n) SEQ ID NOs: 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively; (o) SEQ ID NOs: 6, 20, 22 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 22 and 28, respectively; (p) SEQ ID NOs: 7, 21, 23 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively; (q) SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (r) SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, respectively; (s) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; or (t) SEQ ID NOs: 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 4, 18 and 32, respectively; SEQ ID NOs: 7, 5, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 5, 33 and 19, respectively; SEQ ID NOs: 12, 30, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, respectively; SEQ ID NOs: 9, 31, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 31, 13 and 11, respectively; SEQ ID NOs: 14, 26, 20, 30 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, respectively; SEQ ID NOs: 15, 31, 21, 27 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 21, 27 and 25, respectively; SEQ ID NOs: 32, 18, 4 and 6, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 32, 18, 4 and 6, respectively; SEQ ID NOs: 7, 33, 5 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19, respectively; SEQ ID NOs: 8, 30, 12 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 12 and 10, respectively; SEQ ID NOs: 13, 31, 9 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11, respectively; SEQ ID NOs: 26, 30, 14, 20 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 14, 20 and 24, respectively; SEQ ID NOs: 31, 27, 15, 25 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 31, 27, 15, 25 and 21, respectively; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, respectively; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 4, 24, 32 and 18, respectively; SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively; SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively; SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 32, 24, 4, 6 and 18, respectively; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 19, 5, 33 and 21, respectively; SEQ ID NOs: 26, 30, 12, 14, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 12, 14, 8 and 10, respectively; SEQ ID NOs: 15, 31, 9, 27, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, respectively; SEQ ID NOs: 24, 6, 16 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, respectively; SEQ ID NOs: 7, 19, 17 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 19, 17 and 25, respectively; SEQ ID NOs: 24, 16, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 16, 6 and 18, respectively; SEQ ID NOs: 7, 25, 17 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 17 and 19, respectively; SEQ ID NOs: 26, 20, 10 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 20, 10 and 28, respectively; SEQ ID NOs: 21, 27, 11 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 21, 27, 11 and 29, respectively; SEQ ID NOs: 26, 10, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, respectively; SEQ ID NOs: 11, 27, 21 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 27, 21 and 29, respectively; SEQ ID NOs: 22, 6, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 20 and 28, respectively; SEQ ID NOs: 23, 7, 21 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 23, 7, 21 and 29, respectively; SEQ ID NOs: 22, 20, 6 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 20, 6 and 28, respectively; or SEQ ID NOs: 7, 21, 23 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. 
     Further provided are compound fusion polypeptides comprising at least a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides being independently selected from the fusion polypeptides as described above and herein. In some embodiments, the compound fusion polypeptide comprises or consists of the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the compound fusion polypeptide comprises or consists of the following first fusion polypeptide and second fusion polypeptide in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a cleavable linker. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a cleavable linker selected from a 2A cleavable peptide (e.g. foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), a furin recognition/cleavage sequence (e.g. RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a furin recognition/cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a 2A cleavable peptide comprising or consisting of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67, or having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. 
     With respect to further embodiments of the fusion polypeptides and the compound fusion polypeptides, in some embodiments, the fusion polypeptide or the compound fusion polypeptide further comprises an N-terminal signal peptide or leader sequence. In some embodiments, the signal peptide or leader sequence is from a source protein selected from a serum protein, a cytokine, a chemokine, a chaperone protein, an invariant protein, and a protein that directs proteins to the lysosomal compartment. In some embodiments, the signal peptide or leader sequence is from a source protein selected from colony stimulating factor 2 (CSF2, GM-CSF), tissue type plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-GAMMA, invariant chain), serum albumin (ALB), polyubiquitin B/C (UBB/UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosomal associated membrane protein 1 (LAMP-1) and lysosomal associated membrane protein 2 (LAMP-2). In some embodiments, the signal peptide or leader sequence is selected from an amino acid sequence of any one of SEQ ID NOs: 115-126, or an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 115-126. In some embodiments, the fusion polypeptide and/or the compound fusion polypeptide are recombinantly produced or chemically synthesized. In some embodiments, the fusion polypeptide and/or the compound fusion polypeptide are capable of inducing, promoting or stimulating an immune response in a human. In some embodiments, the fusion polypeptide and/or the compound fusion polypeptide are capable of inducing, promoting or stimulating an immune response against HIV-1 in a human. In some embodiments, the fusion polypeptide and/or the compound fusion polypeptide are capable of inducing, promoting or stimulating proliferation and/or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells and CD4+ T cells. 
     Further provided are polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptide, as described above and herein. In some embodiments, the polynucleotide comprises cDNA, mRNA, self-amplifying RNA (SAM, saRNA), self-replicating RNA, or self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotide comprises self-replicating or self-amplifying alphavirus replicons. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. Further provided are expression cassettes comprising one or more polynucleotides described herein operably linked to one or more regulatory sequences, e.g., a promoter. In some embodiments, the polynucleotide is operably linked to and under the control of a constitutive promoter. In some embodiments, the promoter is selected from a CMV promoter, a CAG promoter and an EF1a promoter. 
     Further provided are lipoplexes, e.g., lipid nanoparticles (LNPs) comprising one or more polynucleotides described herein, e.g., encoding one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, e.g., one or more polynucleotides comprising a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the lipoplexes, e.g., lipid nanoparticles (LNPs) comprise one or more polynucleotides described herein, e.g., encoding one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, e.g., one or more polynucleotides comprising a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. 
     Further provided are vectors comprising one or more polynucleotides or one or more expression cassette, described herein. In some embodiments, the vector comprises or consists of one or more polynucleotides encoding one or more fusion polypeptides comprising the following polypeptide segments comprising in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs:100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the first and second fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the first and second fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the vector comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the vector comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NOs: 130 or SEQ ID NO: 131, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 130 or SEQ ID NO: 131, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 132 or SEQ ID NO: 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 132 or SEQ ID NO: 133, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 139, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 142, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 148. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 140, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 140, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 146. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 143, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 143, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 149. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 150, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 152. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 151, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 153. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 154, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 154, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 157. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 155, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 158. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 156, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 159. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are in a single open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is in a first open reading frame and the second polynucleotide encoding the second fusion polypeptide is in a second open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are in a single expression cassette. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is in a first expression cassette and the second polynucleotide encoding the second fusion polypeptide is in a second expression cassette. In some embodiments, the vector is a plasmid vector, a bacterial vector or a viral vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a DNA virus or an RNA virus. In some embodiments, the viral vector is replication defective, replication deficient, replication attenuated or replication competent. In some embodiments, the viral vector is from a virus selected from adenovirus, adeno-associated virus, arenavirus, alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, maraba virus and vaccinia virus. In some embodiments, the viral vector is from a virus from a taxonomical family selected from Adenoviridae, Arenaviridae, Herpesviridae (e.g. Cytomegalovirus), Poxviridae (e.g. Vaccinia virus, e.g. modified vaccinia Ankara (MVA)), Flaviviridae (e.g. Yellow fever virus), Rhabdoviridae (e.g. Vesiculovirus, e.g. Maraba vesiculovirus), Togaviridae (e.g., Alphavirus, e.g., Venezuelan equine encephalitis virus). In some embodiments, the viral vector is an arenavirus vector selected from Lymphocytic choriomeningitis mammarenavirus (LCMV), Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus), Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Machupo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV). In some embodiments, the viral vector is an arenavirus vector selected from Lymphocytic choriomeningitis mammarenavirus (LCMV) or Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus). In some embodiments, the arenavirus vector comprises a bi-segmented genome. In some embodiments, the arenavirus vector comprises a tri-segmented genome. In some embodiments, the viral vector is a human adenovirus or a simian adenovirus (e.g., a chimpanzee adenovirus, a gorilla adenovirus or a rhesus adenovirus). In some embodiments, the viral vector is an adenovirus vector selected from adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g. ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (AdC9), ChAd10 (AdC10), ChAd11 (AdC11), ChAd17 (AdC17), ChAd16 (AdC16), ChAd19 (AdC19), ChAd20 (AdC20), ChAd22 (AdC22), ChAd24 (AdC24), ChAdY25, ChAd26 (AdC26), ChAd28 (AdC28), ChAd30 (AdC30), ChAd31 (AdC31), ChAd37 (AdC37), ChAd38 (AdC38), ChAd43 (AdC43), ChAd44 (AdC44), ChAd55 (AdC55), ChAd63 (AdC63), ChAdV63, ChAd68 (AdC68), ChAd73 (AdC73), ChAd82 (AdC82), ChAd83 (AdC83), ChAd143 (AdC143), ChAd144 (AdC144), ChAd145 (AdC145), ChAd147 (AdC147)), gorilla adenovirus (e.g. GC44, GC45, GC46) and rhesus adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66). 
     Further provided are host cells comprising one or more polynucleotides, one or more expression cassettes, or one or more vectors, as described herein. In some embodiments, the one or more polynucleotides are not integrated into the host cell genome, e.g., are episomal. In some embodiments, the one or more polynucleotides are integrated into the host cell genome. In some embodiments, the host cell is a mammalian cell, e.g., a human cell. In various embodiments, the host cell can be in vitro or in vivo. 
     Further provided are immunogenic compositions. In various embodiments, the immunogenic compositions comprise one or more of the fusion polypeptides or compound fusion polypeptides, one or more polynucleotides, or one or more vectors, as described herein, and a pharmaceutically acceptable carrier. In some embodiments, the immunogenic composition comprises two or more of the fusion polypeptides or compound fusion polypeptides, two or more polynucleotides, two or more vectors, as described herein. In some embodiments, the one or more polynucleotides are DNA, cDNA, mRNA, or self-replicating RNA. In some embodiments, the immunogenic composition comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the immunogenic composition comprises the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides, first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers, SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers, SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 200, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 201, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 202, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 204, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 105, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 107, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 206, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 207, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 208, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 223, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the immunogenic composition comprises the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors of such an immunogenic composition are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors of such an immunogenic composition are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises a compound fusion polypeptide, a vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the immunogenic composition comprises a compound fusion polypeptide, a vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In various embodiments of the immunogenic compositions, the first and second viral vectors can be Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the immunogenic composition comprises a single vector comprising one or more polynucleotides encoding first and second fusion polypeptides. In some embodiments, the immunogenic composition further comprises one or more of an adjuvant, a detergent, a micelle-forming agent, and an oil. In some embodiments, the immunogenic composition is formulated for administration via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal and mucosal (e.g. buccal, intranasal, intrarectal, intravaginal). In some embodiments, the immunogenic composition is formulated as a liquid, a suspension or an emulsion. In some embodiments, the immunogenic composition is lyophilized. 
     Further provided are kits comprising one or more unitary doses of one or more of the fusion polypeptides, one or more compound fusion polypeptides, one or more polynucleotides, one or more vectors, or one or more immunogenic compositions, as described herein. In some embodiments, the kit comprises two or more of the fusion polypeptides, two or more compound fusion polypeptides, two or more polynucleotides, two or more vectors, or two or more immunogenic compositions, as described herein. In some embodiments, the one or more unitary doses are in a single container. In some embodiments, one or more unitary doses are in two or more separate containers. In some embodiments, the kit comprises one or more containers selected from vials, ampules and pre-loaded syringes. In some embodiments, the kit comprises one or more containers comprising the one or more fusion polypeptides, one or more polynucleotides or one or more vectors in an aqueous solution. In some embodiments, the one or more unitary doses are the same. In some embodiments, the one or more unitary doses are the different. In some embodiments, the kit comprises one or more unitary doses of one or more viral vectors and the unitary doses are in the range of about 10 3  to about 10 12  viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g. from about 10 4  to about 10 7  viral FFU or PFU or IU or vp, e.g. from about 10 3  to about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14  or 10 15  viral FFU or PFU or IU or vp. In some embodiments, the kit comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the kit comprises one or more fusion polypeptides, one or more vectors, or one or more lipoplexes (LNPs), comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the kit comprises one or more fusion polypeptides, one or more vectors, or one or more lipoplexes (LNPs), comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the kit comprises the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the kit comprises the following first fusion polypeptide and second fusion polypeptide, one or more vectors, or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 200, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 201, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 202, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 203, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 204, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 205, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 105 or 206, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 107 or 207, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 208, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 222, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 222, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 223, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In various embodiments of the kits, the viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the kit comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the kit comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the kit comprises the following first polynucleotide and second polynucleotide, one or more vectors, or one or more lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In various embodiments, one or more of the first, second, third and fourth vectors are adenoviral vectors. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the kit comprises a compound fusion polypeptide, a vector, or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the kit comprises a compound fusion polypeptide, a vector, or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the kit further comprises one or more unitary doses of one or more additional therapeutic agents. In some embodiments, the kit comprises one or more agents that activate latent HIV, e.g., one or more latency reversing agents (LRAs). In some embodiments, the kit comprises one or more LRAs selected from agonists or activators of one or more toll-like receptors (TLRs), histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, inhibitor of apoptosis proteins (IAP) antagonists, and second mitochondria-derived activator of caspases (SMAC) mimetics. In some embodiments, the kit comprises one or more agonists or activators of one or more toll-like receptors (TLRs). In some embodiments, the TLR agonist or activator is selected from a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR7 agonist, a TLR8 agonist and a TLR9 agonist. In some embodiments, the TLR7 agonist is selected from GS 9620 (vesatolimod), R848 (Resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from GS-9688 (Selgantolimod), R848 (Resiquimod) and NKTR-262 (dual TLR7/TLR8 agonist). In some embodiments, the kit comprises one or more interleukin receptor agonists of an interleukin selected from IL-2, IL-7, IL-12 and IL-15. In some embodiments, the kit comprises one or more cytokines selected from IL-2, IL-7, IL-12, IL-15, and variants thereof. In some embodiments, the kit comprises one or more innate immune activators. In some embodiments, the one or more innate immune activators comprises an agonist of a receptor selected from fms related tyrosine kinase 3 (FLT3), stimulator of interferon genes (STING) receptor, DExD/H-box helicase 58 (DDX58; a.k.a., RIG-I), nucleotide binding oligomerization domain containing 2 (NOD2). In some embodiments, the kit comprises an agonist of fms related tyrosine kinase 3 (FLT3). In some embodiments, the kit comprises one or more antagonists or inhibitors of an inhibitory immune checkpoint protein or receptor and/or one or more activators or agonists of a stimulatory immune checkpoint protein or receptor. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associating 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activating 3 (LAG3, CD223); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); retinoic acid early transcript IE (RAETIE; ULBP4); retinoic acid early transcript 1G (RAETIG; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activating 3 (CD223); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin like receptor C3 (KLRC3, NKG2E); killer cell lectin like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T-cell inhibitory immune checkpoint proteins or receptors are selected from CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the kit comprises one or more agonists or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. In some embodiments the T-cell stimulatory immune checkpoint proteins or receptors are selected from CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK-cell inhibitory immune checkpoint proteins or receptors are selected from killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin like receptor D1 (KLRD1, CD94). In some embodiments, the kit comprises one or more agonists or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the NK-cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the kit comprises and antibody that binds to CTLA4. In some embodiments, the proteinaceous or antibody inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4) and AK-104 (CTLA4/PD-1). In some embodiments, the proteinaceous inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-013 (PD-1/LAG-3), FS-118 (LAG-3/PD-L1) MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), RO-7121661 (PD-1/Tim-3), XmAb-20717 (PD-1/CTLA4), AK-104 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1), and INBRX-105 (4-1BB/PDL1). In some embodiments, the one or more immune checkpoint inhibitors comprises a small molecule inhibitor of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. In some embodiments, the kit further comprises one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors and capsid inhibitors. 
     Further provided are methods for eliciting an immune response to human immunodeficiency virus (HIV) in a subject in need thereof, comprising administering to the subject a fusion polypeptide, a compound fusion polypeptide, a polynucleotide, a vector, a lipoplex (e.g., LNP) or an immunogenic composition, as described herein. Also provided are methods of treating or preventing human immunodeficiency virus (HIV) in a subject in need thereof, comprising administering to the subject a fusion polypeptide, a compound fusion polypeptide, a vector, a lipoplex (e.g., LNP) or an immunogenic composition, as described herein. In some embodiments the method entails administering a single vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide. In some embodiments, two or more fusion polypeptides, two or more compound fusion polypeptides, two or more polynucleotides encoding the fusion polypeptides, two or more viral expression vectors comprising polynucleotides encoding the fusion polypeptides, two or more lipoplexes (e.g., LNPs) or two or more immunogenic compositions, as described herein, are administered to the subject simultaneously or concurrently. In some embodiments, two or more fusion polypeptides, or two or more polynucleotides or two or more viral expression vectors encoding the fusion polypeptides, are in the form of a bivalent antigen composition. In some embodiments, the method entails administering a first fusion polypeptide and a second fusion polypeptide, one or more polynucleotides encoding the first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, or one or more lipoplexes (e.g., LNPs), the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the method entails administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipoplexes (e.g., LNPs), the one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the method entails administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipoplexes (e.g., LNPs), the one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the method entails administering the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides, one or more vectors or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the method entails administering the following first fusion polypeptide and second fusion polypeptide, one or more vectors, or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 200, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 201, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 202, that is at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 203, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 204, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 205, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 105, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 107, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 207, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the method entails administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 223, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the method entails administering a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the method entails administering a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In various embodiments, the first and second viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the first and second viral vectors or first and second lipoplexes (e.g., LNPs) are co-administered concurrently. In some embodiments, the methods entail administering the following first polynucleotide and second polynucleotide, one or more vectors, or one or more lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the method entails administering first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively, wherein the first and second viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the method entails administering first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively, wherein the first and second viral vectors are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the method entails administering a compound fusion polypeptide, a vector, or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the method entails administering a compound fusion polypeptide, a vector, or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the methods entail administering a polynucleotide (e.g., in a vector, in a lipoplex (e.g., LNP)) comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the methods entail administering a polynucleotide (e.g., in a vector, in a lipoplex (e.g., LNP)) comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 211. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 213. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 215. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 217. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the subject is infected with HIV-1, is suspected of being infected with HIV-1, or is at risk of being infected with HIV-1. In some embodiments, the subject is chronically infected with HIV-1. In some embodiments, the subject is acutely infected with HIV-1. In some embodiments, the subject has an HIV-1 infection of Fiebig stage IV or earlier, e.g. Fiebig stage III, Fiebig stage II or Fiebig stage I. In some embodiments, the fusion polypeptide, the compound fusion polypeptide, the polynucleotide, the vector, the lipoplex (e.g., LNP) or the immunogenic composition is administered via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal and mucosal (e.g. buccal, intranasal, intrarectal, intravaginal). In some embodiments, the method entails administering from about 10 3  to about 10 12  viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g. from about 10 4  to about 10 7  viral FFU or PFU or IU or vp, e.g. from about 10 3  to about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14  or 10 15  viral FFU or PFU or IU or vp, per administration. In some embodiments, the methods comprise a prime-boost regimen comprising administering a priming composition at a first time point and administering one or more boosting compositions at one or more subsequent time points. In some embodiments, the methods comprise repeating the prime-boost regimen one or more iterations. In some embodiments, the administrations of the priming composition and the one or more boosting compositions are spaced at least 1 week, 2 weeks, 3 weeks or 1 month apart, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months apart. In some embodiments, the priming composition and the boosting composition comprise the same immunogenic composition. In some embodiments, the priming composition and the boosting composition comprise different immunogenic compositions. In some embodiments, the priming composition and the boosting composition comprise the same one or more fusion polypeptides and same viral expression vector. In some embodiments, the priming composition and the boosting composition comprise different fusion polypeptides and/or different viral expression vectors. In some embodiments, the methods comprise priming with a first viral expression vector, and boosting with a second viral expression vector. In some embodiments, the prime-boost regimen comprises: (a) Priming with one or more viral expression vectors and boosting with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA or self-replicating RNA; (b) Priming with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA or self-replicating RNA, and boosting with one or more viral expression vectors; (c) Priming with one or more viral expression vectors, and boosting with one or more viral expression vectors, wherein the one or more viral expression vectors in the priming composition and the one or more viral expression vectors in the boosting composition are from identical, related or unrelated taxonomical families; (d) Priming with one or more replication-deficient viral expression vectors and boosting with one or more replication-deficient viral expression vectors, wherein the one or more replication-deficient viral expression vectors in the priming composition and the one or more replication-deficient viral expression vectors in the boosting composition are from identical, related or unrelated taxonomical families; (e) Priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-attenuated viral expression vectors, wherein the one or more replication-attenuated viral expression vectors in the priming composition and the one or more replication-attenuated viral expression vectors in the boosting composition are from identical, related or unrelated taxonomical families; (f) Priming with one or more replication-deficient viral expression vectors and boosting with one or more replication-attenuated viral expression vectors; (g) Priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-deficient viral expression vectors; (h) Priming with one or more Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors and boosting with one or more Pichinde mammarenavirus viral expression vectors; (i) Priming with one or more Pichinde mammarenavirus viral expression vectors and boosting with one or more Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors; (j) Priming with one or more replication deficient Pichinde mammarenavirus viral expression vectors and boosting with one or more replication deficient Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors; (k) Priming with one or more replication deficient Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors and boosting with one or more replication deficient Pichinde mammarenavirus viral expression vectors; (l) Priming with one or more arenavirus viral expression vectors and boosting with one or more adenovirus viral expression vectors; (m) Priming with one or more adenovirus viral expression vectors and boosting with boosting composition comprising one or more arenavirus viral expression vectors; (n) Priming with one or more adenovirus viral expression vectors and boosting with boosting composition comprising one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA); (o) Priming with one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA) and boosting with boosting composition comprising one or more adenovirus viral expression vectors; (p) Priming with one or more chimpanzee adenoviral (ChAd) expression vectors and boosting with boosting composition comprising one or more self-amplifying or self-replicating RNA (saRNA or samRNA); (q) Priming with one or more self-amplifying or self-replicating RNA (saRNA or samRNA) and boosting with boosting composition comprising one or more chimpanzee adenoviral (ChAd) expression vectors; (r) Priming with one or more poxvirus viral expression vectors and boosting with one or more arenavirus viral expression vectors; (s) Priming with one or more arenavirus viral expression vectors and boosting with boosting composition comprising one or more poxvirus viral expression vectors; (t) Priming with one or more poxvirus viral expression vectors and boosting with one or more adenovirus viral expression vectors; or (u) Priming with one or more adenovirus viral expression vectors and boosting with boosting composition comprising one or more poxvirus viral expression vectors. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, one or more vectors, or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; and (2) Boosting with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, one or more vectors, or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, one or more vectors, one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; (b) SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; (c) SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; (d) SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and/or (e) SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; and (2) Boosting with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, one or more vectors, or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; (b) SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; (c) SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or (d) SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively or one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 105, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 109, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 105 or 206, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 107 or 207, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 105, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 107, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 207, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 208, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 222, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 222, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 223, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 223, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 107, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 111, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 111, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 200, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 201, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201, respectively. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 200, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 201, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 202, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 203, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 202, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 203, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 204, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204; and (2) Boosting with an immunogenic composition comprising a viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 205, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 204, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 205, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and (b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; and (2) Boosting with an immunogenic composition comprising a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; and (2) Boosting with an immunogenic composition comprising first and second viral vectors, or first and second lipoplexes (e.g., LNPs), comprising the following polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145 respectively; and (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; and (2) Boosting with an immunogenic composition comprising a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 162 and 163, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. In some embodiments, the prime-boost regimen comprises: (1) Priming with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; and (2) Boosting with an immunogenic composition comprising a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 166 and 167, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. In some embodiments, the viral vectors in the priming composition are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors and the viral vectors in the boosting composition are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In various embodiments, the viral vectors in the priming composition are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors and the viral vectors in the boosting composition are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225; and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the viral vector(s) in the priming composition and the viral vector(s) in the boosting composition are adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the viral vectors in the priming composition and the viral vectors in the boosting composition are replication deficient. In some embodiments, the viral vectors in the priming composition and the viral vectors in the boosting composition are replication attenuated. In some embodiments, the subject is not receiving antiretroviral therapy (ART) or ART is discontinued prior to administration of the one or more compositions. In some embodiments, ART is discontinued after one or more administrations of the compositions. In some embodiments, the methods entail administering to the subject one or more additional therapeutic agents, e.g. two, three, four, or more additional therapeutic agents. In some embodiments, the methods entail co-administering one or more agents that activate latent HIV, e.g., one or more latency reversing agents (LRAs). In some embodiments, the one or more LRAs are selected from agonists or activators of one or more toll-like receptors (TLRs), histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, inhibitor of apoptosis proteins (IAP) antagonists, and second mitochondria-derived activator of caspases (SMAC) mimetics. In some embodiments, the methods entail co-administering one or more agonists or activators of one or more toll-like receptors (TLRs). In some embodiments, the TLR agonist or activator is selected from a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR7 agonist, a TLR8 agonist and a TLR9 agonist. In some embodiments, the TLR7 agonist is selected from GS 9620 (vesatolimod), R848 (Resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from GS-9688 (Selgantolimod), R848 (Resiquimod) and NKTR-262 (dual TLR7/TLR8 agonist). In some embodiments, the methods entail co-administering one or more interleukin receptor agonists of an interleukin selected from IL-2, IL-7, IL-12 and IL-15. In some embodiments, the methods entail co-administering one or more cytokines selected from IL-2, IL-7, IL-12, IL-15, and variants thereof. In some embodiments, the methods entail co-administering one or more innate immune activators. In some embodiments, the one or more innate immune activators comprises an agonist of a receptor selected from fms related tyrosine kinase 3 (FLT3), stimulator of interferon genes (STING) receptor, DExD/H-box helicase 58 (DDX58; a.k.a., RIG-I), nucleotide binding oligomerization domain containing 2 (NOD2). In some embodiments, the methods entail co-administering an agonist of fms related tyrosine kinase 3 (FLT3). In some embodiments, the methods entail co-administering one or more antagonists or inhibitors of an inhibitory immune checkpoint protein or receptor and/or one or more activators or agonists of a stimulatory immune checkpoint protein or receptor. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associating 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activating 3 (LAG3, CD223); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAETIE; ULBP4); retinoic acid early transcript 1G (RAETIG; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activating 3 (CD223); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin like receptor C3 (KLRC3, NKG2E); killer cell lectin like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the methods entail co-administering one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T-cell inhibitory immune checkpoint proteins or receptors are selected from CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the methods entail co-administering one or more agonists or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the T-cell stimulatory immune checkpoint proteins or receptors are selected from CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the methods entail co-administering one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK-cell inhibitory immune checkpoint proteins or receptors are selected from killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin like receptor D1 (KLRD1, CD94). In some embodiments, the methods entail co-administering one or more agonists or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the NK-cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the methods entail co-administering an antibody that binds to CTLA4. In some embodiments, the proteinaceous or antibody inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4) and AK-104 (CTLA4/PD-1). In some embodiments, the proteinaceous inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-013 (PD-1/LAG-3), FS-118 (LAG-3/PD-L1) MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), RO-7121661 (PD-1/TIM-3), XmAb-20717 (PD-1/CTLA4), AK-104 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1), and INBRX-105 (4-1BB/PDL1). In some embodiments, the one or more immune checkpoint inhibitors comprises a small molecule inhibitor of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. In some embodiments, the methods further comprise administering to the subject one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors and capsid inhibitors. In some embodiments, the methods further comprise administering to the subject one or more anti-HIV antibodies or antigen-binding fragments thereof. In some embodiments, the one or more anti-HIV antibodies or antigen-binding fragments thereof binds to HIV gp120. In some embodiments, the anti-HIV antibody or antigen-binding fragment thereof comprises a broadly neutralizing antibody. In some embodiments, the one or more anti-HIV antibodies or antigen-binding fragments thereof that bind, inhibit, and/or neutralize HIV, compete with or comprise VH and VL variable domains of a broadly neutralizing antibody (bNAb) against HIV. In some embodiments, one or more anti-HIV antibodies or antigen-binding fragments thereof that bind, inhibit, and/or neutralize HIV, bind to an epitope or region of gp120 selected from: (i) third variable loop (V3) and/or high mannose patch comprising a N332 oligomannose glycan; (ii) CD4 binding site (CD4bs); (iii) second variable loop (V2) and/or Env trimer apex; (iv) gp120/gp41 interface; or (v) silent face of gp120. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV, binds to an epitope or region of gp120 in the third variable loop (V3) and/or high mannose patch comprising a N332 oligomannose glycan and competes with or comprises VH and VL regions from an antibody selected from GS-9722, PGT-121, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, 10-1074-J, GS-2872, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. In some embodiments, the antibody or antigen-binding fragment thereof binds to an epitope or region of gp120 in the CD4 binding site (CD4bs) and competes with or comprises VH and VL regions from an antibody selected from b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01 VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N49-P7, NC-Cowl, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV, binds to an epitope or region of gp120 in the second variable loop (V2) and/or Env trimer apex and competes with or comprises VH and VL regions from an antibody selected from PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E and VRC38.01. In some embodiments, the antibody or antigen-binding fragment binds to an epitope or region of gp120 in the gp120/gp41 interface and competes with or comprises VH and VL regions from an antibody selected from PGT-151, CAP248-2B, 35022, 8ANC195, ACS202, VRC34 and VRC34.01. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV, binds to an epitope or region of the gp120 silent face and competes with or comprises VH and VL regions from antibody selected from VRC-PG05 and SF12. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV, binds to an epitope or region of gp41 in the membrane proximal region (MPER). In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV, binds to an epitope or region of gp41 in the membrane proximal region (MPER) and competes with or comprises VH and VL regions from an antibody selected from 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV, binds to an epitope or region of the gp41 fusion peptide and competes with or comprises VH and VL regions from an antibody selected from VRC34 and ACS202. In some embodiments of the methods, after one or more administrations of the one or more fusion polypeptides, compound fusion polypeptides, polynucleotides, vectors, lipoplexes (e.g., LNPS) or immunogenic compositions, optionally in combination with one or more additional therapeutic agents, the subject does not exhibit symptoms of HIV or AIDS in the absence of anti-retroviral treatment (ART) for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or more. In some embodiments of the methods, after one or more administrations of the one or more fusion polypeptides, compound fusion polypeptides, polynucleotides, vectors, lipoplexes (e.g., LNPS) or immunogenic compositions, optionally in combination with one or more additional therapeutic agents, the subject has a viral load copies/ml blood of less than 500, e.g. less than 400, less than 300, less than 200, less than 100, less than 50, in the absence of anti-retroviral treatment (ART) for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or more. 
     Further provided are methods of designing a fusion polypeptide that is capable of eliciting an immune response against one or more viral target antigens, the method comprising: (a) identifying in silico one or more regions of sequence conservation in a population of polypeptide sequences encoded by a viral gene, the population from an interpatient virus population; (b) identifying in silico the two most prevalent polypeptide sequences from the one or more conserved regions identified in step a), and generating multivalent polypeptide segments from the conserved regions; and (c) arranging the polypeptide segments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide segments. In some embodiments, step (c) comprises reducing or eliminating junctional 9-mers that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments. Further provided are methods of designing a fusion polypeptide that is capable of eliciting an immune response against one or more viral target antigens, the method comprising: (a) identifying in silico one or more regions of sequence conservation in a first population of polypeptide sequences encoded by a viral gene, the first population from an interpatient virus population; (b) optionally, identifying in silico the two most prevalent polypeptide sequences from the one or more conserved regions identified in step a); and (c) arranging the retained polypeptide segments into one or more contiguous fusion polypeptides, such that the junctions connecting the polypeptide segments avoid or reduce creating epitopes capable of binding human MHC class I or human MHC class II molecules, e.g., with a predicted binding affinity IC50 value of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments. In some embodiments, step (c) comprises reducing or eliminating viral polypeptide 9-mers that have at least 55% (5 of 9 amino acid residues), e.g., at least 65% (6 of 9 amino acid residues), e.g., at least 75% (7 of 9 amino acid residues), e.g., at least 85% (8 of 9 amino acid residues), amino acid sequence identity to a human protein. In some embodiments, the multivalent polypeptide segments are bivalent polypeptide segments. In some embodiments, the fusion polypeptide design method further comprises the step of identifying variant subsequences within one or more regions of sequence conservation in an intrapatient population of polypeptide sequences encoded by a viral gene, e.g., using deep sequencing data. In some embodiments, the fusion polypeptide design method further comprises the step of identifying conserved regions of a polypeptide encoded by a viral gene, such that at least 70% of the variant subsequences within the one or more regions of sequence conservation in the intrapatient population are within the bivalent polypeptide segments. In some embodiments, the fusion polypeptide design method further comprises the step of shortening the length of the fusion polypeptide, e.g., by at least 10%, 15%, 20%, 25%, 30%, or more, retaining polypeptide segment subsequences comprising epitopes (i) predicted in silico, and (ii) confirmed in vitro. Further provided are methods for producing a multivalent antigen, the method comprising constructing, in silico, a set of multivalent amino acid sequences within structurally conserved regions of a population of viral proteome sequences by a method comprising: (a) aligning the population of viral proteome sequences; (b) creating, for each sequence in the alignment, a set of 9-amino acid subsequences (“9-mers”) starting with the N-terminal amino acid, each subsequence overlapping the preceding subsequence by eight amino acids such that each sequence of length 1 in the alignment contains (1-8) 9-mers; (c) calculating a frequency for each unique 9-mer starting at a position i in each sequence of the alignment and identifying the two or more most common unique 9-mers at each position; (c)(1) wherein frequency is calculated as the number of times the unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment; (d) calculating a multivalent conservation for each position by summing the proportion of sequences in the alignment containing either of the two or more most common unique 9-mers; (e) creating an alignment of conserved regions by extracting the sequences in the alignment having a multivalent conservation of greater than 80% or greater than 90%; (f) determining a frequency for each pair of unique 9-mers at each position in the alignment of conserved regions; (g) connecting 9-mer pairs in adjacent positions of the alignment of conserved regions that share an overlap of eight amino acids; (h) creating a directed acyclic graph in which each 9-mer pair is a node and the edges between adjacent nodes are formed from the connected 9-mer pairs in the adjacent positions with the weight of each edge equal to the frequency of the downstream 9-mer pair, (h)(1) adding a source node and connecting it with all of the nodes in the first position, (h)(2) adding a sink node and connecting it with all of the nodes in the last position, and (h)(3) negating all of the weights; (i) finding an optimal path in the directed acyclic graph from the source node to the sink node where the optimal path is defined in terms of the sum of the frequencies of all 9-mer pairs in the directed acyclic graph; (j) building a multivalent antigen by connecting two or more 9-mers in adjacent positions within the optimal multivalent 9-mer path if they share an overlap of eight amino acids, thereby creating two or more sequences of connected 9-mers which together form the multivalent antigen; and (k) optionally, rearranging the polypeptide segments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide segments. In some embodiments, the multivalent conservation is bivalent conservation and wherein the multivalent antigen is a bivalent antigen. In some embodiments, in step (a) the conserved regions are further defined by performing one or more of the following steps: (i) removing segments of fewer than 35 amino acids in length, e.g., from 9 amino acids to 10, 15, 20, 25, 30 or 35 amino acids in length; (ii) removing segments determined to have less than 90% multivalent (e.g., bivalent) conservation; (iii) removing segments determined to be weakly immunogenic or non-immunogenic, e.g., as demonstrated in in vitro or in vivo; and/or (iv) including additional segments determined to be immunogenic, e.g., as demonstrated in in vitro or in vivo. In some embodiments, the step of rearranging the peptide segments to reduce or avoid creation of deleterious epitopes is performed by a method comprising one or more of in silico HLA binding analysis and human proteome cross-recognition analysis. In some embodiments, the fusion polypeptide design method further comprises the step of inserting a linker sequence between one or more adjacent segments. In some embodiments, the fusion polypeptide design method further comprises improving the multivalent (e.g., bivalent) antigen produced in step (h) by removing junctional 9-mers that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments. In some embodiments, the method further comprises improving the multivalent (e.g., bivalent) antigen produced in step (h) by removing 9-mers that have at least 55% (5 of 9 amino acid residues), e.g., at least 65% (6 of 9 amino acid residues), e.g., at least 75% (7 of 9 amino acid residues), e.g., at least 85% (8 of 9 amino acid residues), amino acid sequence identity with human peptides or that have the same T cell receptor (TCR) facing residues with human proteins. In some embodiments, the fusion polypeptide design method further comprises the step of rearranging the polypeptide segments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide segments. In some embodiments, the step of rearranging the peptide segments to reduce or avoid creation of deleterious epitopes is performed by a method comprising one or more of in silico HLA binding analysis and human proteome cross-recognition analysis. In some embodiments, the fusion polypeptide design method further comprises the step of identifying variant subsequences within one or more regions of sequence conservation in an intrapatient population of polypeptide sequences encoded by a viral gene, e.g., using deep sequencing data. In some embodiments, the fusion polypeptide design method further comprises the step of identifying conserved regions of a polypeptide encoded by a viral gene, such that at least 70% of the variant subsequences within the one or more regions of sequence conservation in the intrapatient population are within the bivalent polypeptide segments. In some embodiments, the fusion polypeptide design method further comprises the step of shortening the length of the fusion polypeptide, e.g., by at least 10%, 15%, 20%, 25%, 30%, or more, retaining polypeptide segment subsequences comprising epitopes (i) predicted in silico, and (ii) confirmed in vitro. With respect to the fusion polypeptide design methods, in some embodiments, the one or more viral target antigens are from a mammalian virus, e.g., a human virus. In some embodiments, the one or more viral target antigens are from a virus selected from human immunodeficiency virus (HIV), hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus (HSV), Ebola virus, Zika virus and Chikungunya virus. In some embodiments, the interpatient virus population is from a population of patients who have not received antiretroviral therapy (ART). In some embodiments, the interpatient virus population is from a population of patients who have received antiretroviral therapy (ART). Further provided are fusion polypeptides made according to the fusion polypeptide design methods, described herein, wherein the fusion polypeptide elicits an immune response against a virus in a mammal, e.g., a human. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  illustrates a 6-step workflow for designing a fusion polypeptide to elicit an antiviral response. 
         FIG. 2  illustrates a representative methodology of a population-based vaccine construct approach. 
         FIG. 3  illustrates the steps of the conserved walking analysis (CWA) algorithm, as described herein. 
         FIGS. 4A-4B .  FIG. 4A  illustrates how “bivalent conservation” can be determined based on the prevalence of the two most common 9-mers among all considered viral sequences in a population.  FIG. 4A  discloses the sequences corresponding to Patients 1-10 as SEQ ID NOS 168-169, 169-170, 169, 169, 171-172 and 172-173, respectively, in order of appearance.  FIG. 4A  also discloses “QNLQGQMVH” as SEQ ID NO: 174, “QNIQGQMVH” as SEQ ID NO: 175 and “PNIQGQMVH” as SEQ ID NO: 176.  FIG. 4B  illustrates how the conserved regions are identified based on the “bivalent conservation” distribution across 9-mer positions. HIV-1 Gag p24 was used as the representative protein. 
         FIGS. 5A-5C .  FIG. 5A  illustrates unique 9-mers extracted from aligned natural sequences.  FIG. 5A  discloses SEQ ID NOs 177-183, respectively, in order of columns.  FIG. 5B  illustrates a directed acyclic graph built based on 9-mer pair nodes and their connection.  FIG. 5B  discloses “GIIIIIIII” as SEQ ID NO: 180, “AIIIIIIII” as SEQ ID NO: 181, “IIIIIIIIK” as SEQ ID NO: 182, “IIIIIIIIH” as SEQ ID NO: 183 and “IIIIIIIIR” as SEQ ID NO: 184.  FIG. 5C  illustrates how 9-mers in connected 9-mer pairs are connected. When there are two options available for the connection, the ultimate connection is determined by the prevalence of each connection in naturally occurring sequences.  FIG. 5C  discloses “GIIIIIIII” as SEQ ID NO: 180, “AIIIIIIII” as SEQ ID NO: 181, “IIIIIIIIK” as SEQ ID NO: 182 and “IIIIIIIIH” as SEQ ID NO: 183. 
         FIG. 6  illustrates the results of human proteome cross-recognition analysis.  FIG. 6  discloses SEQ ID NOs 185-188, respectively, in order of columns. 
         FIG. 7  illustrates how polypeptide segment arrangement analysis can reduce or eliminate possible presentation of deleterious or undesirable epitopes injunction regions. 
         FIG. 8  provides a schematic of viral vectors containing fusion proteins of immunogen version 1 (e.g., SEQ ID NOs: 94-101). Fusion polypeptides of immunogen version 1 have twelve conserved regions within HIV-1 Gag, Pol and Nef in the range of 516 to 527 amino acids in length that have been rearranged to reduce or minimize overall junctional responses. A total of four vectors to enable a bi-valent, heterologous prime/boost vaccine regimen. 
         FIG. 9  provides a flow diagram illustrating the basic methodology of the approach for designing the fusion proteins of immunogen version 2 (e.g., SEQ ID NOs: 82-89). A set of 9-mers is selected from conserved regions and combined to form the fusion polypeptides of immunogen version 2, a subset of immunogen version 1. The sequences and gene regions included in immunogen version 2 are provided in Table E. 
         FIGS. 10A-10D  illustrate the regions of HIV encoded proteins Pol (A-B), Gag (C) and Nef (D) that were selected for the immunogen version 2 by combining deep sequencing data and immunogenicity data. Solid horizontal black line=intra-patient conservation (evaluated by coverage of intra-patient 9-mer variants with bi-valent vaccine). Grey horizontal line=inter-patient conservation. Solid vertical black bars=LANL responses. White vertical bars=ELISpot responses. Horizontal bar (diagonal stripes)=regions maintained in immunogen version 2. 
         FIG. 11  provides a schematic of viral vectors containing fusion proteins of immunogen version 2 (e.g., SEQ ID NOs: 82-89). Fusion polypeptides of immunogen version 2 have eight conserved regions within HIV-1 Gag, Pol and Nef in the range of 351 to 365 amino acids in length that have been rearranged to reduce or minimize overall junctional responses. A total of four vectors to enable a bi-valent, heterologous prime/boost vaccine regimen. 
         FIGS. 12A-12B  illustrate that median responses remain stable with size reduction of the fusion polypeptides of immunogen version 1 to the fusion polypeptides of immunogen version 2. 12A. The ability of the fusion polypeptides of immunogen version 1 to induce T-cell responses was tested in vitro for a total of 93 donor PBMCs. The dash line shows the median number of responses recognized. Immune responses are detected in 73/93 (78.49%) participants for immunogen version 1. 12B. The fusion polypeptides of immunogen 2 were assessed in silico for the ability to induce T-cell responses in the same participants. The dash line shows the median number of responses recognized. Immune responses are detected in 71/93 (76.34%) participants for immunogen version 2. 
         FIG. 13  provides a flow diagram illustrating the basic methodology of the approach for designing the fusion proteins of immunogen version 3 (e.g., SEQ ID NOs: 90-93). A set of 9-mers is selected from conserved regions and combined to form the fusion polypeptides of immunogen version 3, a subset of immunogen version 1. The sequences and gene regions included in immunogen version 3 are provided in Table E. 
         FIGS. 14A-14D  illustrate the regions of HIV encoded proteins Pol (A-B), Gag (C) and Nef (D) that were selected for the immunogen version 3 by combining deep sequencing data and immunogenicity data. Solid horizontal black line=intra-patient conservation (evaluated by coverage of intra-patient 9-mer variants with bi-valent vaccine). Grey horizontal line=inter-patient conservation. Solid vertical black bars=LANL responses. Grey vertical bars=ELISpot responses. Horizontal open bar=regions maintain in improved immunogen. 
         FIG. 15  provides a schematic of viral vectors containing the fusion proteins of immunogen version 3 (e.g., SEQ ID NOs: 90-93). Schematic representation of immunogen 3 version constructs. The fusion polypeptides of immunogen version 3 have four conserved regions within HIV-1 Gag, Pol and Nef in the range of 391 to 394 amino acids in length that have been rearranged to minimize overall junctional responses. A total of two vectors to enable a bi-valent, heterologous prime/boost vaccine regimen. 
         FIG. 16  illustrates polypeptide segments encoded by the HIV-1 Gag gene used in the fusion polypeptide constructs described herein. The Gag HIV-1 HXB2 reference polypeptide (SEQ ID NO: 1) sequence is underlined. Amino acid residues corresponding to Gag HIV-1 HXB2 reference polypeptide residues 54-146 and 370-500, and subsequences and fragments thereof, are not included in the herein described polypeptide segments.  FIG. 16  discloses SEQ ID NOs 1 and 4-7, respectively, in order of appearance. 
         FIGS. 17A-17C  illustrate polypeptide segments encoded by the HIV-1 Pol gene used in the fusion polypeptide constructs described herein. The Pol HIV-1 HXB2 reference polypeptide (SEQ ID NO: 2) sequence is underlined. Amino acid residues corresponding to Pol HIV-1 HXB2 reference polypeptide residues 1-55, 118-128, 321-366, 432-541, 607-682, 709-746, 828-839 and 921-931, and subsequences and fragments thereof, are not included in the herein described polypeptide segments.  FIG. 17A-17C  discloses SEQ ID NOs 2, 8-21, 24-25, 189, 23 and 26-27, respectively, in order of appearance. 
         FIG. 18  illustrates polypeptide segments encoded by the HIV-1 Nef gene used in the fusion polypeptide constructs described herein. The Nef HIV-1 HXB2 reference polypeptide, having a tryptophan (W) at position 124 (SEQ ID NO: 3) sequence is underlined. Amino acid residues corresponding to Nef HIV-1 HXB2 reference polypeptide residues 1-63, 100-116 and 149-206, and subsequences and fragments thereof, are not included in the herein described polypeptide segments.  FIG. 18  discloses SEQ ID NOs 3, 30-31, 28-29 and 32-33, respectively, in order of appearance. 
         FIG. 19  illustrates a schematic representation of compound fusion polypeptides containing HIV-1 immunogen version 1 polypeptide sequences (e.g., SEQ ID NOs: 105, 107, 109, 111 and 206-209). The depicted compound fusion polypeptides have 12 conserved regions within HIV-1 Gag, Pol and Nef that have been rearranged to minimize overall junctional responses. All four vectors were used for transduction of monocyte-derived dendritic cells (moDCs) in CD8+ T cell priming assays and are collectively labeled as “post vaccination” in assays corresponding to these polypeptide sequences.  FIG. 19  discloses “AAA” as SEQ ID NO: 48 and “AAY” as SEQ ID NO: 49. 
         FIGS. 20A-20B . Ad5 vectors expressing compound fusion polypeptides of SEQ ID NO: 105, 107, 109 or 111 were used to transduce moDCs to evaluate expression of the transgene and transduction efficiency. Expression efficiency was assessed by Gag p24 ELISA (N=2) ( FIG. 20A ). The y-axis represents Gag p24 concentration (pg/ml) detected in moDC lysates at day 3 post transduction with Ad5 vectors expressing compound fusion polypeptides of SEQ ID NO: 105, 107, 109 or 111 (▪) or empty vector control (▴) at multiplicity of infection (MOI) of 500.  FIG. 20B  illustrates representative moDC transduction efficiency using GFP expressing Ad5 viral vectors at MOI of 500 in N=36 human donors at day 3 post-transduction. Proportion of cells expressing GFP by flow cytometry is shown on the y-axis. The x-axis represents vaccine immunogen constructs of conserved regions of SEQ ID NOs: 105, 107, 109 and 111 (▪) or empty vector control (▴) at multiplicity of infection (MOI) of 500, or untransduced (●). Transduction efficiency was determined by evaluation of percent GFP expression of transduced moDCs by flow cytometry (N=36). The amino acid sequences are provided in Table F. 
         FIG. 21  illustrates a schematic representation of fusion polypeptides containing HIV-1 immunogen version 2 fusion polypeptides (SEQ ID NOs: 82-89). The depicted compound fusion polypeptides have 12 conserved regions within HIV-1 Gag, Pol and Nef that have been rearranged to minimize overall junctional responses. All eight vectors were used for transduction of moDCs in CD8+ T cell priming assays and are collectively labeled as “post vaccination” in assays using these sequences.  FIG. 21  discloses “AAA” as SEQ ID NO: 48, “QEE” as SEQ ID NO: 51, “KILQEE” as SEQ ID NO: 198 and “AAQEE” as SEQ ID NO: 199. 
         FIGS. 22A-22B . Ad5 vectors expressing compound fusion polypeptides of SEQ ID NO: 82-89 were used to transduce moDCs to evaluate expression of the transgene and transduction efficiency. Expression efficiency was assessed by Gag p24 ELISA (N=2) ( FIG. 22A ). The y-axis represents Gag p24 concentration (pg/ml) detected in moDC lysates at day 3 post transduction with Ad5 vectors expressing compound fusion polypeptides of SEQ ID NOs: 82-89 (▪) or empty vector control (▴) at multiplicity of infection (MOI) of 500.  FIG. 22B  illustrates representative moDC transduction efficiency using GFP expressing Ad5 viral vectors at MOI of 500 in N=3 human donors at day 3 post-transduction. Proportion of cells expressing GFP by flow cytometry is shown on the y-axis. The x-axis represents vaccine immunogen constructs of conserved regions of SEQ ID NOs: 82-89 (▪) or empty vector control (▴) at multiplicity of infection (MOI) of 500, or untransduced (●). The amino acid sequences are provided in Table E. 
         FIG. 23  illustrates a schematic representation of fusion polypeptides containing HIV-1 immunogen version 3 fusion polypeptides (SEQ ID NOs: 90-93). All four vectors were used for transduction of moDCs in CD8+ T cell priming assays and are collectively labeled as “post vaccination” in assays using these sequences.  FIG. 23  discloses “QEE” as SEQ ID NO: 51, “AAQEE” as SEQ ID NO: 199 and “AAY” as SEQ ID NO: 49. 
         FIGS. 24A-24B . Ad5 vectors expressing compound fusion polypeptides of SEQ ID NO: 90-93 were used to transduce moDCs to evaluate expression of the transgene and transduction efficiency. Expression efficiency was assessed by Gag p24 ELISA (N=2) ( FIG. 24A ). The y-axis represents Gag p24 concentration (pg/ml) detected in moDC lysates at day 3 post transduction with Ad5 vectors expressing compound fusion polypeptides of SEQ ID NOs: 82-89 (▪) or empty vector control (▴) at multiplicity of infection (MOI) of 500. FIG.  24 B illustrates representative moDC transduction efficiency using GFP expressing Ad5 viral vectors at MOI of 500 in N=3 human donors at day 3 post-transduction. Proportion of cells expressing GFP by flow cytometry is shown on the y-axis. The x-axis represents vaccine immunogen constructs of conserved regions of SEQ ID NOs: 90-93 (▪) or empty vector control (▴) at multiplicity of infection (MOI) of 500, or untransduced (●). The amino acid sequences are provided in Table E. 
         FIG. 25  illustrates a schematic representation of fusion polypeptides containing HIV-1 immunogen version 1 fusion polypeptide sequences. The fusion polypeptides of SEQ ID NOs: 94 and 95 represent bivalent sequences within HIV-1 Gag, Pol and Nef; SEQ ID NOs: 96 and 97 represent bivalent sequences within HIV-1 Pol and Nef. The fusion polypeptides of SEQ ID NOs: 94-97 can be combined to form a priming sequence. The fusion polypeptides of SEQ ID NOs: 98 and 99 represent bivalent sequences within HIV-1 Gag, Pol and Nef. The fusion polypeptides of SEQ ID NOs: 100 and 101 represent bivalent sequences within HIV-1 Pol and Nef. The fusion polypeptides of SEQ ID NOs: 98-101 can be combined to form a boosting sequence that can be used following priming with the fusion polypeptides of SEQ ID NOs: 94-97. Bivalent sequences are designed to cover &gt;80% of inter patient diversity in viral sequences, and gene segments used to generate the polypeptide fusion constructs are rearranged in order to minimize creation of de novo epitopes that react with the human protein and to minimize boosting of junctional responses in prime boost sequences.  FIG. 25  discloses “AAA” as SEQ ID NO: 48 and “AAY” as SEQ ID NO: 49. 
         FIG. 26  illustrates immunization schedule in Balb/c mice. Mice were immunized intramuscularly (IM) in right and left quadriceps at 1×10 9  PFU with Ad5 vectors expressing HIV-1 fusion polypeptide sequences as indicated. Splenocytes were collected at day 16 after immunization and responses against HIV Gag, Pol and Nef antigens were measured by IFN-γ ELISpot Assay. 
         FIGS. 27A-B  illustrate results of immunogenicity testing in Balb/c mice by IFN-γ ELISpot with peptide stimulation with either HIV-1 Gag (i and ii), Nef (vii and viii) ( FIG. 27A ), Pol (protease/RT) (iii and iv), or Pol (integrase) (v and vi) ( FIG. 27B ) peptides. The fusion polypeptides of SEQ ID NOs: 94-95 (Seq 94, Seq 95) were used as bivalent priming sequences. The fusion polypeptides of SEQ ID NOs: 98-99 (Seq 98, Seq 99) were used as boosting sequences. The Y-axis represents magnitude of IFN-γ responses against the specific peptide pool stimulus as number of spot forming colonies (SFC) per 10 6  splenocytes. Peptide specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. The X-axis indicates the individual vaccine constructs used for in vivo priming against which peptide specific responses were studied. All vectors were immunogenic inducing robust responses to HIV-1 Gag responses, with weaker but detectable responses to Pol proteins (Protease, RT and integrase). No responses were detected to HIV-Nef in this model likely due to previously described immunodominance patterns for HIV-1 Gag epitopes in Balb/c mice and reflecting the lack of Nef epitopes that can be presented in Balb/c mice. 
         FIG. 28  illustrates results of immunogenicity testing in Balb/c mice by IFN-γ ELISpot with peptide stimulation with either HIV-1 Pol (protease/RT) (i and ii), Pol (integrase) (iii and iv) or Nef (v and vi) peptides. The fusion polypeptides of SEQ ID NOs: 96-97 (Seq 96, Seq 97) were used as bivalent priming sequences. The fusion polypeptides of SEQ ID NOs: 100-101 (Seq 100, Seq 101) were used as boosting sequences. The Y axis represents magnitude of IFN-γ responses against the specific peptide pool stimulus as number of spot forming colonies (SFC) per 10 6  Splenocytes. Peptide specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. The X-axis indicates the individual vaccine constructs used for in vivo priming against which peptide specific responses were studied. All vectors were immunogenic inducing robust responses to HIV-1 Pol, particularly protease and RT peptides with weaker responses detected to integrase peptides. No responses were detected to HIV-Nef in this model likely due to previously described immunodominance patterns for HIV-1 Gag epitopes in Balb/c mice and reflecting the lack of Nef epitopes that can be presented in Balb/c mice. 
         FIG. 29  illustrates a representative immunization schedule in Balb/c mice. Mice were immunized I.M. in right and left quadriceps at 1×109 PFU with Ad5 vectors expressing HIV-1 sequences as indicated. Individual vectors (i) were tested for immunogenicity as a single dose to prime the response with spleens harvested on Day 16 for analysis. Combination vectors (ii) were tested in a homologous vector prime-boost schedule, with boosting on Day 29 and spleens harvested for analysis on Day 36. Responses against Gag, Pol and Nef antigens were measured by IFN-γ ELISpot Assay and ICS/Flow cytometry. 
         FIGS. 30A-30B  illustrate immunogenicity assessed following immunization either by single Ad5 vector prime alone (A) or in a homologous Ad5 vector prime-boost combination (B). Seq 94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 98-F2A-99 (tPA-SEQ ID NO: 109) were used as a prime-boost pair. Vectors were tested for immunogenicity in Balb/c mice by IFN-γ ELISpot with peptide stimulation with either HIV-1 Gag, (i) and (ii); Pol (protease/RT, (iii) and (iv); Pol (integrase, (v) and (vi); or Nef (vii and viii) peptides. The Y axis represents magnitude of IFN-γ responses against the specific peptide pool stimulus as number of spot forming colonies (SFC) per 10 6  Splenocytes. Peptide specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. The X-axis indicates the individual vaccine constructs used for in vivo priming against which peptide specific responses were studied. All vectors were immunogenic inducing robust responses to HIV-1 Gag responses, with weaker but detectable responses to Pol proteins (protease, RT and integrase). No responses were detected to HIV-Nef in this model likely due to previously described immunodominance patterns for HIV-1 Gag epitopes in Balb/c mice and reflecting the lack of Nef epitopes that can be presented in Balb/c mice. Responses were enhanced by homologous boosting with Ad5 vectors expressing the boost sequence. 
         FIGS. 31A-31B  illustrate immunogenicity is assessed following immunization either by single Ad5 vector prime alone or in a homologous Ad5 vector prime-boost combination. Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) were used as a prime boost pair. Vectors were tested for immunogenicity in Balb/c mice by IFN-γ ELISpot with peptide stimulation with either HIV-1 Pol (protease/RT, (i) and (ii); Pol (integrase, (iii) and (iv); or Nef (v and vi) peptides. The Y-axis represents magnitude of IFN-γ responses against the specific peptide pool stimulus as number of spot forming colonies (SFC) per 10 6  Splenocytes. Peptide specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. The X-axis indicates the individual vaccine constructs used for in vivo priming against which peptide specific responses were studied. All vectors were immunogenic inducing robust responses to HIV-1 Pol, particularly Protease and RT peptides, with weaker responses detected to integrase peptides. The responses observed to the Protease and RT were weaker than previously observed by Seq 96 and Seq 97 when not combined. The immunogenicity responses were boosted in sequential dosing with Seq 96-F2A-97 and Seq 100-F2A-101, however. No responses were detected to HIV-Nef in this model likely due to previously described immunodominance patterns for HIV-1 Gag epitopes in Balb/c mice and reflecting the lack of Nef epitopes that can be presented in Balb/c mice. 
         FIGS. 32A-32C  illustrate HIV-1 Gag immunogenicity by intracellular cytokine staining (ICS) following vaccination with single vectors, Seq 94-F2A-95 (tPA-SEQ ID NO:105) or Seq 98-F2A-99 (tPA-SEQ ID NO: 109), as well as homologous prime-boost. The Y axis represents proportion of CD8+ ( FIG. 32A  i, ii and  FIG. 32C  iii) or CD4+ ( FIG. 32B  iv, v and  FIG. 32C  vi) T cells exhibiting HIV-Gag specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X axis. HIV-Gag specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. Strong CD4+ and CD8+ T cell responses were generated in response to vaccination, with demonstrated polyfunctionality most robust in CD8+ T cells. Homologous prime-boost enhanced polyfunctionality of the CD8+ T cell responses. 
         FIGS. 33A-33C  illustrate HIV-1 Pol (protease and RT) immunogenicity by ICS following vaccination with single vectors, Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq 98-F2A-99 (tPA-SEQ ID NO: 109), as well as homologous prime-boost. The Y axis represents proportion of CD8+ ( FIG. 33A  i, ii and  FIG. 33C  iii) or CD4+ ( FIG. 33B  iv, v and  FIG. 33C  vi) T cells exhibiting HIV-Pol (protease and RT) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X-axis. HIV- Pol (Protease and RT) specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. CD4+ and CD8+ T cell responses were generated in response to vaccination. Responses are weaker than Gag responses and tend to be monofunctional, with limited boosting. 
         FIGS. 34A-34C  illustrate HIV-1 Pol (integrase) immunogenicity by ICS following vaccination with single vectors, Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq 98-F2A-99 (tPA-SEQ ID NO: 109), as well as homologous prime-boost. The Y-axis represents proportion of CD8+ ( FIG. 34A  i, ii and  FIG. 34C  iii) or CD4+ ( FIG. 34B  iv, v and  FIG. 34C  vi) T cells exhibiting HIV-Pol (integrase) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on the X-axis. HIV-Pol (integrase) specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. CD4+ and CD8+ T cell responses were generated in response to vaccination. Responses are weaker than Gag responses and tend to be monofunctional, with limited boosting. 
         FIGS. 35A-35C  illustrate HIV-1 Nef immunogenicity by ICS following vaccination with single vectors, Seq 94-F2A-95 (tPA-SEQ ID NO:105) or Seq 98-F2A-99 (tPA-SEQ ID NO: 109), as well as homologous prime boost. The Y-axis represents proportion of CD8+ ( FIG. 35A  i, ii and  FIG. 35C  iii) or CD4+ ( FIG. 35B  iv, v and  FIG. 35C  vi) T cells exhibiting HIV-Nef specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on the X-axis. HIV-1 Nef specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. Very low proportion of CD4+ and CD8+ T cell responses were generated in response to vaccination. Responses are weaker than Gag responses and tend to be monofunctional, with limited boosting. 
         FIGS. 36A-36C  illustrate HIV-1 Pol (protease and RT) immunogenicity by ICS following vaccination with single vectors, Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111), as well as homologous vector prime-boost. The Y-axis represents proportion of CD8+ ( FIG. 36A  i, ii and  FIG. 36C  iii) or CD4+ ( FIG. 36B  iv, v and  FIG. 36C  vi) T cells exhibiting HIV-Pol (protease and RT) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X-axis. HIV-1 Pol (protease and RT) specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. CD4+ and CD8+ responses were generated in response to vaccination. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) demonstrated strong immunogenicity with polyfunctionality (≥2 cytokines produced). Homologous vector prime-boost with the vectors expressing the fusion polypeptides enhanced both CD4+ and CD8+ T cell responses. 
         FIGS. 37A-37C  illustrate HIV-1 Pol (Integrase) immunogenicity by ICS following vaccination with single vectors, Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111), as well as homologous vector prime boost. The Y-axis represents proportion of CD8+ ( FIG. 37A  i, ii and  FIG. 37C  iii) or CD4+ ( FIG. 37B  iv, v and  FIG. 37C  vi) T cells exhibiting HIV-Pol (integrase) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X-axis. HIV-1 Pol (integrase) specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. CD4+ and CD8+ responses were generated in response to vaccination. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) demonstrated strong immunogenicity with polyfunctionality (≥2 cytokines produced). Homologous vector prime-boost with the vectors expressing the fusion polypeptides enhanced both CD4+ and CD8+ T cell responses. 
         FIGS. 38A-38C  illustrate HIV-1 Nef Immunogenicity by ICS following vaccination with single vectors, Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111), as well as homologous vector prime boost. The Y axis represents proportion of CD8+  FIG. 38A  i, ii and  FIG. 38C  iii) or CD4+ ( FIG. 38B  iv, v and  FIG. 38C  vi) T cells exhibiting HIV-Nef specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X-axis. HIV-1 Nef specific values were obtained by subtracting no peptide stimulated control to exclude nonspecific responses. Low levels of CD4+ and CD8+ T cell responses were generated in response to vaccination and more responses were seen with CD4 T cells. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) demonstrated and induced mostly monokine production. Homologous vector prime-boost with the vectors expressing the fusion polypeptides enhanced both CD4+ and CD8+ T cell responses. 
         FIG. 39  provides a schematic of a protocol established for moDC-T cell priming assays for testing immunogenicity of all conserved regions vaccine constructs followed by individual epitope mapping using 384-well ELISpot assays. 
         FIG. 40  provides a summary of breadth of responses in ex vivo analysis of PBMCs from N=93 participants following in vitro priming with moDCs. Heat map representing the breadth of T cell responses to Gag, Pol and Nef conserved antigens following in vitro priming with moDCs transduced with Ad5-empty vector MOI 500 (pre-vaccine) or Ad5 viral vectors expressing SEQ ID NOs:105, 107, 109 and 111, each at MOI=500 (post-vaccine). Each matched row in the heat map represents responses from a single participant and breadth of responses are categorized as 0, 1-3, 4-6, 7-9, 10-12 or 13-16. Positive ELISpot responses were defined as &gt;3-fold background levels as described in detail in Example 9. 
         FIG. 41  illustrates characterization of the breadth of immune responses targeted to HIV-1 Gag, Pol and Nef antigens post priming with moDCs transduced with Ad5 viral vectors expressing empty vectors (pre-vaccine) or conserved regions vaccines (SEQ ID NOs: 105, 107, 109 and 111, each at MOI=500 (post vaccine) in N=93 participants. Also enumerated is the fraction of participants that exhibited responses to ≥3 or 0 epitopes in each antigen following in vitro priming with vaccine immunogen sequences. Positive ELISpot responses were defined as &gt;3-fold background levels. Each point represents one donor. Wilcoxon matched pairs signed rank test ****p&lt;0.0001. 
         FIG. 42  illustrates breadth of responses to Gag (●), Pol (▴) and Nef (▾) defined as number of de novo recognized peptides (excluding pre-existing baseline responses) assessed by IFN-γ ELISpot assay on day 10 following co-culture of PBMCs with Ad5 vaccine vector transduced autologous moDCs expressing conserved regions constructs (SEQ ID NOs: 105, 107, 109 and 111, each at MOI=500). Each point represents one donor. Median with interquartile range are shown. 
         FIGS. 43A-43B  illustrate results of an in vitro HIV-1 viral inhibition assay staining for Gag-p24 within target cells. Autologous CD4+ T cells were infected in vitro with HIV-1 BaL, cultured alone or in the presence of vaccine or empty vector primed CFSE labeled CD8+ T cells for 3 days and analyzed for infection using flow cytometry. Representative flow cytometry plots illustrating the gating strategy to define Gag p24+ infected CD4+ T cells (HIV-1 Gag+ cells with down-regulated surface CD4 expression) within target cells (CFSE-CD8− cells). 
         FIGS. 44A-44B  illustrate fraction of residual HIV-1 Gag+CD4− T cells after 3 days of co-culture with enriched CD8+ T cells obtained after priming with vaccine (SEQ ID NOs: 105, 107, 109 and 111, or empty vector control each at MOI=500 for N=51 participants normalized to infected CD4+ T cells cultured without CD8+ T cells. Each condition was completed in technical duplicates or triplicates depending on cell availability. Also illustrated correlation between % residual Gag+ cells ( FIG. 44A ) and breadth of total, Gag and Pol responses ( FIG. 44B ). Correlations evaluated by 2-sided Spearman rank-correlation tests without Bonferroni adjustments. 
         FIGS. 45A-45B  illustrates breadth of responses to Gag, Pol and Nef assessed by IFN-γ ELISpot assay on day 10 following co-culture of PBMCs with Ad5 vaccine vector transduced autologous moDCs expressing conserved regions constructs, SEQ ID NO: 82-89 ( FIG. 45A ) and SEQ ID NO: 90-93 ( FIG. 45B ), each at MOI=500). Each point represents one donor. Median with interquartile range are shown. 
         FIG. 46  provides a schematic of immunization schedule prime-boost with arenavirus vectors in non-human primates (NHPs). Indian-origin healthy rhesus macaques were immunized via intramuscular (I.M.) route with the arenavirus vectors. The Gag and Env expressing vectors (TT2 (replication attenuated Pichinde) and TT1 (replication attenuated LCMV)) were administered on the left quadricep whereas the Pol expressing vectors (TT2 and TT1) were administered on the right quadricep. The doses administered are as below: 1×10 6  replication competent virus particles (RCV) of TT2 Gag, Env and Poll/Pol 2 vectors, 4×10 6  RCV of TT1 Gag, Env, and 2×10 6  RCV of TT1 Poll/Pol 2. In the placebo group, NHPs were administered placebo buffer solution composed of 10 mM HEPES, 150 mM NaCl, 20 mM Glycine and 0.1% macaque serum albumin. Responses against Gag, Env and Pol antigens were measured by IFN-γ ELISpot Assay. 
         FIGS. 47A-47B . 47A. Time course of total responses to Gag, Env and Pol was assessed by IFN-γ ELISpot on PBMCs isolated from NHP peripheral blood at two four-week intervals post 1st vaccine dose up to week 32. Median with interquartile range are shown. 47B. The NHP responses in  FIG. 47A  were classified as moderate or high responders depending on whether the magnitude of peak IFN-γ-ELISpot responses was below or above 1000 SFU/10 6  PBMCs, respectively. Each line represents one animal that received the arenavirus vaccine vector. Peak response after each immunization remains constant with subsequent boosting. 
         FIGS. 48A-48D  illustrate magnitude of total responses (A) to Gag (B), Env (C) and Pol (D) assessed by IFN-γ ELISpot on PBMCs isolated from NHP peripheral blood at two weeks post vaccine doses 1, 2, 3 and 4. Threshold for positive response is indicated by dotted line and set to observing at least 50 SFU/10 6  PBMCs for Gag, Env and Pol and to 150 SFU/10 6  PBMCs for the total SIV-specific response. Each symbol represents one NHP. Median with interquartile range are shown. After four doses of the heterologous vaccine, a positive response to Gag, Env and Pol is observed in at least 21 of 24 NHPs (response rate greater or equal to 87.5%). The magnitude of the Gag and Pol responses observed after doses 2 (TT1) and 3 (TT2) remained stable with each subsequent vaccine boost. 
         FIGS. 49A-49D  illustrate the breadth of total SIV (A), Gag (B), Env (C) and Pol (D)-specific IFN-γ responses at 2 weeks post vaccine boost dose 2 (triangles), dose 3 (squares) and dose 4 (diamond). Statistical analysis by Wilcoxon matched-pairs signed rank test was performed. Data are represented as median±interquartile range (IQR). 
         FIGS. 50A-50C  illustrate (A) Time course of plasma SIV viral load over weeks 0-40 post challenge; (B) Peak viral load at week 2 post challenge; (C) Setpoint viral load measured over weeks 10-40 post challenge. Placebo group is shown as closed triangles and TT2/TT1 vaccine group in closed circles. Data are represented as median±SEM. * p&lt;0.05 and ** p&lt;0.01 in B and C by Mann-Whitney t-test. Median viral load (VL) is indicated above each group in figures B and C. 
         FIG. 51  illustrates an immunoblot analysis of replication-attenuated arenavirus vectors. Transgene expression of Gag/Nef/Pol fusion polypeptides from stock material (pl) of replication-attenuated-LCMV and replication-attenuated-PICV vectors, was determined by immunoblot staining of the Gag epitope p24 (mAb anti HIV1 p24; Abcam). Whole cell lysates of three biological replicates (1, 2, 3) were analyzed. TT1=replication-attenuated-LCMV; TT2=replication-attenuated-PICV. GNP=Gag/Nef/Pol; PN=Pol/Nef. TT1-HIV-GNP1/PN1 (SEQ ID NOs: 98 and 100); TT1-HIV-GNP2/PN2 (SEQ ID NOs: 99 and 101); TT2-HIV-GNP1/PN1 (SEQ ID NOs: 82 and 86); TT2-HIV-GNP2/PN2 (SEQ ID NOs: 83 and 87). 
         FIG. 52  illustrates immunoblot analysis of replication-attenuated arenavirus vectors. Transgene expression Gag/Nef/Pol from stock material (p1) of replication attenuated-LCMV and replication attenuated-PICV HIV Immunogen 1 vectors, was determined by immunoblot staining of the Gag epitope p24 (mAb anti HIV1 p24; Abcam). Whole cell lysates of three biological replicates (1, 2, 3) were analyzed. TT1=replication attenuated-LCMV; TT2=replication attenuated-PICV. GNP=Gag/Nef/Pol; PN=Pol/Nef. 
         FIG. 53  illustrates transgene stability analysis of TT1-HIV-GNP1/PN1 (having transgenes encoding fusion polypeptides of SEQ ID NOs: 98 and 100). Shown are transgene PCR results for 4 biological replicates (1-4) and for indicated passaging levels. The last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 54  illustrates transgene stability analysis of TT1-HIV-GNP2/PN2 (having transgenes encoding fusion polypeptides of SEQ ID NOs: 99 and 101). Shown are transgene PCR results for 3 biological replicates (1-3) and for indicated passaging levels. The last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 55  illustrates transgene stability analysis of TT2-HIV-GNP1/PN1 (having transgenes encoding fusion polypeptides SEQ ID NOs: 94 and 95). Shown are transgene PCR results for 3 biological replicates (1-3) and for indicated passaging levels. The last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 56  illustrates transgene Stability analysis of TT2-HIV-GNP2/PN2 (having transgenes encoding fusion polypeptides SEQ ID NOs: 95 and 97). Shown are transgene PCR results for 3 biological replicates (1-3) and for indicated passaging levels. Passaging was discontinued at passage level 4. The (presumably) last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 57  illustrates immunoblot analysis of replication-attenuated arenavirus vectors. Transgene expression Gag/Pol from stock material (P1) and BDS-equivalent passage (P4) of replication-attenuated-LCMV and replication-attenuated-PICV HIV Immunogen 2 vectors, was determined by immunoblot staining of the Gag epitope p24 (mAb anti HIV1 p24; Abcam). Whole cell lysates of biological replicates (1, 2, 3, 4 for TT1-HIV(C2)-GP1/PN1; 1, 2 for TT1-HIV(C2)-GP2/PN2) or representative samples (TT2-HIV(C2)-GP1/PN1 and TT2-HIV(C2)-GP2/PN2) were analyzed. TT1=replication-attenuated-LCMV; TT2=replication-attenuated-PICV. GP=Gag/Pol; PN=Pol/Nef Ctrls=positive (+) control represents TT1-HIV Immunogen 2 or TT2-HIV Immunogen 2 infected cell lysates; negative (−) control represents uninfected cells. 
         FIG. 58  illustrates transgene stability analysis of TT1-HIV(C2)-GP1/PN1. A Shown are transgene PCR results for 5 biological replicates (1-5) and for indicated passaging levels. The expected size of the full-length PCR product is 1359 bp (LCMV-GP1 NP-Segment) and 1366 bp (LCMV-PN1 GP-Segment), respectively. The last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 59  illustrates transgene stability analysis of TT1-HIV(C2)-GNP2/PN2. A Shown are transgene PCR results for 4 biological replicates (1-4) and for indicated passaging levels. The expected size of the full-length PCR product is 1344 bp (LCMV-GP2 NP-Segment) and 1364 bp (LCMV-PN2 GP-Segment), respectively. The last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 60  illustrates transgene stability analysis of TT2-HIV(C2)-GP1/PN1. A Shown are transgene PCR results for 4 biological replicates (1-3 and 9) and for indicated passaging levels. The expected size of the full-length PCR product is 1456 bp (PICV-GP1 NP-Segment) and 1496 bp (PICV-PN1 GP-Segment), respectively. The last passage showing ≥50% full-length transgene was visually assessed. 
         FIG. 61  illustrates transgene stability analysis of TT2-HIV(C2)-GP2/PN2. Shown are transgene PCR results for 3 biological replicates (1-3) and for indicated passaging levels. The expected size of the full-length PCR product is 1450 bp (PICV-GP2 NP-Segment) and 1505 bp (PICV-PN2 GP-Segment), respectively. Passaging was discontinued at passage level 6. The (presumably) last passage showing ≥50% full length transgene was visually assessed. 
         FIG. 62  illustrates a schematic of non-human primate study evaluating combination of TT2/TT1 vaccine replication-attenuated PICV/LCMV arenavirus prime-boost scheme in combination with immune modulators. Each group had 13 rhesus macaques. Vaccine refers to alternating dosing of TT2 (closed circles) and TT1 (open circles). Checkpoint inhibitors αPD1 antibody (triangle) and αCTLA4 antibody (square) were administered immediately after the vaccine. FLT3L-Fc FLT3 agonist (black line) was administered one week before each vaccine dosing. 
         FIG. 63  illustrates the kinetics of total responses to Gag, Env and Pol was assessed by IFN-γ ELISpot in PBMCs isolated from NHP peripheral blood at two week intervals post 1st vaccine dose up to week 16. Median with interquartile range are shown. Statistical analysis by two-way ANOVA with repeated measures and Dunnett&#39;s post-test was performed. * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001 for comparison of combination group with vaccine alone. 
         FIGS. 64A-D  illustrates the breadth of (A) total SIV, (B) Gag, (C) Env and (D) Pol-specific IFN-γ responses at 2 weeks post last vaccine dose in PBMCs. Vector (Vx) only group in circles, Vx+αPD1 in triangles, Vx+αCTLA4 in squares and Vx+Flt3L in diamonds. Statistical analysis by Kruskal-Wallis test with Dunn&#39;s post-test was performed. Data are represented as median±IQR. * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001, **** p&lt;0.0001. 
     
    
    
     DETAILED DESCRIPTION 
     1. Introduction 
     Herein is described an antiviral vaccine immune design approach that incorporates intra-patient diversity by using deep sequence data to evaluate viral quasispecies and determine the level of viral diversity within an individual. We developed an algorithm that considers both the interpatient as well as intrapatient viral diversity in the design of the vaccine immunogen, as well as immunogenicity of vaccine sequences. Understanding host viral diversity and antigen processing and presentation and T cell priming not only ensures that a vaccine immunogen generates a large number of antigen specific T cells, but also generates antigen specific T cells with cytotoxic activity. In the design of the antiviral vaccine immunogen we have combined computational in silico analysis of viral sequences and binding specificities with in vitro experimental immunology. We established an in vitro vaccine trial model that has enabled us to identify conserved regions that generate the strongest response across a large population. The approach has enabled us to identify novel epitopes within the conserved region that had previously not been recognized. This immunogenicity data has enabled the development of highly conserved, highly immunogenic vaccine immunogens that can be delivered to a broad population. 
     Provided herein are fusion polypeptides comprising a plurality of polypeptide or peptide segments and related compositions, including immunogenic compositions and pharmaceutical compositions, as well as methods for making the fusion polypeptides and methods for their use to elicit an immunogenic response to a human immunodeficiency virus (HIV-1) in a subject in need thereof. As used herein, an “immunogen” is a substance, such as an antigen, that elicits an immune response or is capable of eliciting an immune response. Also provided are polynucleotides encoding the fusion polypeptides described herein, as well as vectors comprising same. 
     Provided herein are fusion polypeptides designed to induce an antiviral immune response. The vaccine constructs described herein were designed to provide mathematically-determined improved coverage of predicted T cell epitopes (“PTE”) using the most highly conserved predicted epitopes within a source set of viral proteome sequences. As a paradigm for the methods of designing antiviral immunogens, fusion polypeptides encoded at least two of the HIV-1 genes gag, pol and nef were used. The fusion polypeptides and methods described herein both retain the positional information of the PTE&#39;s within the source set of sequences and construct a bivalent set of sequences to improve coverage of conserved PTEs. Accordingly, described herein are multivalent, e.g., bivalent, vaccine constructs that advantageously improve or increase highly conserved PTEs that are most likely to be highly similar to conserved epitopes in the naturally occurring sequences in proteins expressed by viral species amongst a population of patients and within an individual patient, due to both the retained positional information. In addition, the use of only highly conserved PTE sequences amongst HIV-1 species in interpatient populations reduces the likelihood of escape mutants because the highly conserved sequences are more likely to contribute viral structure and function. 
     Further provided are computational approaches for designing antiviral vaccine immunogens for a highly variable virus, such as HIV-1. The antiviral immunogens can be designed to provide coverage at an individual level, for a group of individuals with a defined set of HLA alleles, or for broad population coverage. In the herein described vaccine immunogen design methods, we define a computational approach for targeting conserved regions within a vaccine sequence using bulk population sequences, e.g., from public databases and internally developed databases. Further, using individual patient deep sequence data we define sequence variability for each potential T cell epitope within the conserved regions. Moreover, we identify regions that may serve as actual epitopes based on likelihood of presentation by the individual host&#39;s set of HLA alleles. The likelihood of binding to host HLA defined by publicly available and internally-developed databases, was used to develop deep learning models that model peptide binding per allele. This can be coupled with in-silico, published and/or experimental in-vitro T cell priming data that can define the potential impact of antigen variants in modulating TCR recognition or identify a peptide as an escape variant. This data is used to design a set of peptide immunogens that contain the epitopes and associated epitope variants. The epitope sequences are concatenated or connected in series into a single fusion polypeptide, either directly fused or linked via a linker sequence. Peptide segments are joined in a computationally determined sequential order from N-terminus to C-terminus that reduces or eliminates the creation of junctional epitopes that may mimic human self-antigens and have undesirable effects (e.g., eliciting an autoimmune response or a tolerogenic response). 
     Unlike similar graph-based approaches to vaccine design, the approaches described herein build segments of connected PTE&#39;s using only adjacent PTE&#39;s that are also adjacent in the natural sequences. In addition, the present methods first build a bivalent construct consisting of two polypeptides matched to improve or increase coverage at each PTE position in the viral proteome. The bivalent construct itself may be used as a vaccine, as in the constructs described in Examples 1 and 2 below. The bivalent constructs designed by analysis of population-based sequences (e.g., interpatient diversity) identifies population-based conserved sequences that may contribute to viral structure. 
     The methods described herein can begin with the identification of conserved region bivalent sequences, using a process referred to herein as the “Conservation Analysis” or “Conservation Algorithm.” The methods further can comprise a step of building a bivalent vaccine construct having maximal epitope coverage while retaining the positional information of the PTE&#39;s from the natural sequences, using a process referred to referred to herein as a “Conserved Walking Algorithm” or “CWA.” 
     2. Fusion Polypeptides Useful to Promote Immune Response Against Human Immunodeficiency Virus-1 (HIV-1) 
     Provided herein are fusion polypeptides comprising a plurality of polypeptide or peptide segments encoded by one or more HIV-1 genes. A ‘segment’ of a fusion polypeptide described herein is a contiguous sequence of at least 25 amino acids with respect to a reference sequence, for example HIV-1 HXB2 reference sequences for Gag, Pol and Nef polypeptides, provided herein as SEQ ID NOs: 1-3, respectively. The polypeptides described herein are ‘fusion’ polypeptides in the sense that they are assembled from connected or concatenated polypeptide or peptide segments of two or more HIV-1 proteins, e.g., at least Pol and Nef. With respect to the HIV-1 protein reference sequences, the polypeptide or peptide segments may correspond to discontinuous sequences of the same HIV-1 protein or different HIV-1 proteins. Generally, the fusion polypeptides are non-naturally occurring, and can be synthetic or recombinantly produced. 
     In various embodiments, immunogenic polypeptides or fusion polypeptides described herein, and/or the polynucleotides encoding such polypeptides, are provided in isolated form. This means that the polypeptide or polynucleotide is at least 50% w/w pure of interfering proteins, cellular and other contaminants arising from its production or purification but does not exclude the possibility that the agent is combined with an excess of pharmaceutical acceptable carrier(s) or other vehicle intended to facilitate its use. The term “isolated,” when applied to a polypeptide or polynucleotide, as described herein, denotes that the polypeptide or polynucleotide is essentially free of cellular components with which it is associated in the natural state. It can be, for example, in a homogeneous state and may be in either a dry or aqueous solution. Purity and homogeneity can be determined using known methods, e.g., analytical chemistry techniques such as polyacrylamide gel electrophoresis, column chromatography, thin layer chromatography, or high-performance liquid chromatography (HPLC) analysis. A protein that is the predominant species present in a preparation is substantially purified. An “isolated” or “purified” polypeptide or polynucleotide is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. In various embodiments, purified polypeptides and/or polynucleotides are at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (w/w), separated from, purified of, or free of interfering proteins and contaminants from production or purification. Often an immunogenic polypeptides or fusion polypeptides described herein, and/or the polynucleotides encoding such polypeptides, is the predominant macromolecular species remaining after its purification. 
     a. Polypeptide Segments 
     With respect to the HIV-1 genes encoding the polypeptide segments used to assemble the herein described fusion polypeptides, in various embodiments, the fusion polypeptides comprise a plurality of polypeptide segments of one or more human immunodeficiency virus-1 (HIV-1) proteins encoded by one or more, e.g. two or more, three or more, HIV-1 genes selected from Gag, Pol and Nef. In some embodiments, the plurality of polypeptide segments is comprised of only polypeptide segments encoded by HIV-1 genes pol and nef e.g., does not comprise polypeptide segments encoded by HIV-1 genes gag, env, tat, rev, vpr, vif and vpu. In some embodiments, the plurality of polypeptide segments is comprised of only polypeptide segments encoded by HIV-1 genes gag, pol and nef and does not comprise polypeptide segments encoded by HIV-1 genes env, tat, rev, vpr, vif and vpu. 
     With respect to the number of polypeptide segments assembled, connected, linked or concatenated into a single fusion polypeptide, in various embodiments, the fusion polypeptides are comprised of at least 4 and up to 6 polypeptide segments, e.g., 4, 5 or 6 polypeptide segments. As appropriate, the polypeptide segments can be arranged in the same order or according to a different order than in the naturally occurring proteins. In various embodiments, the fusion polypeptides comprise from 1 to 4 Pol polypeptide segments, from 1 to 2 Nef polypeptide segments, and optionally, from 1 to 3 Gag polypeptide segments. 
     With respect to the regions of the polypeptides encoded by an HIV-1 gene selected as polypeptide segments to include in the fusion polypeptides, in various embodiments, the polypeptide segments are derived from conserved regions in a population of viral proteome sequences. In some embodiments, the conserved regions are greater than 80%, e.g., greater than 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% conserved amongst HIV-1 species, e.g., as determined in interpatient populations. As used herein, conserved regions in a polypeptide encoded by an HIV-1 gene refers to the percentage of sequences in a population of sequences containing identical amino acid segments or subsequences e.g., segments 9 amino acids in length or 9-mers as the most prevalent one in a predetermined amino acid segment or subsequence position, where an amino acid segment or subsequence position is determined with respect to a reference sequence, e.g., HIV-1 HXB2 polypeptide sequences, e.g., SEQ ID NOs: 1-3. The start and end positions of the HIV polypeptides identified herein are with respect to HIV-1 HXB2 reference polypeptides, GenBank Accession No. K03455 (ncbi.nlm.nih.gov/nuccore/K03455), provided herein as SEQ ID NOs: 1-3 and identified in Table A. As used herein, numbering of a given amino acid polymer or nucleic acid polymer “corresponds to”, is “corresponding to” or is “relative to” the numbering of a selected or reference amino acid polymer or nucleic acid polymer when the position of any given polymer component (e.g., amino acid, nucleotide, also referred to generically as a “residue”) is designated by reference to the same or to an equivalent position (e.g., based on an optimal alignment or a consensus sequence) in the selected amino acid or nucleic acid polymer, rather than by the actual numerical position of the component in the given polymer. In various embodiments, the conserved regions are conserved amongst one or more of HIV-1 clades within Group M, e.g., one or more of HIV-1 clades A-K, e.g., one or more of clades A, B, C, D and G, e.g., amongst HIV-1 Group M, clade B, and recombinant forms thereof, e.g., CRF01_AE. 
     
       
         
           
               
             
               
                 TABLE A 
               
             
            
               
                   
               
               
                 HIV-1 HXB2 reference sequences 
               
            
           
           
               
               
               
            
               
                 SEQ 
                   
                   
               
               
                 ID 
                   
                   
               
               
                 NO: 
                 gene 
                 Amino acid sequence of encoded protein 
               
               
                   
               
               
                 1 
                 gag 
                 MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEG 
               
               
                   
                   
                 CRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSK 
               
               
                   
                   
                 KKAQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEV 
               
               
                   
                   
                 IPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIA 
               
               
                   
                   
                 PGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT 
               
               
                   
                   
                 SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKA 
               
               
                   
                   
                 LGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNERNQRKIVKC 
               
               
                   
                   
                 FNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNF 
               
               
                   
                   
                 LQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLISLRSLFGNDPSSQ 
               
               
                   
               
               
                 2 
                 pol 
                 FFREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNF 
               
               
                   
                   
                 PQVTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKV 
               
               
                   
                   
                 RQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLK 
               
               
                   
                   
                 PGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDST 
               
               
                   
                   
                 KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFR 
               
               
                   
                   
                 KYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIY 
               
               
                   
                   
                 QYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPD 
               
               
                   
                   
                 KWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVI 
               
               
                   
                   
                 PLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNL 
               
               
                   
                   
                 KTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEY 
               
               
                   
                   
                 WQATWIPEWEEVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNR 
               
               
                   
                   
                 GRQKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESEL 
               
               
                   
                   
                 VNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDEHE 
               
               
                   
                   
                 KYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLE 
               
               
                   
                   
                 GKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKIIHTDNGSNFTGAT 
               
               
                   
                   
                 VRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVF 
               
               
                   
                   
                 IHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKG 
               
               
                   
                   
                 PAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED 
               
               
                   
               
               
                 3 
                 nef 
                 MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAATNAACA 
               
               
                   
                   
                 WLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDL 
               
               
                   
                   
                 WIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKIEEANKGENTSLLHPV 
               
               
                   
                   
                 SLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC 
               
               
                   
               
            
           
         
       
     
     In some embodiments, the plurality of polypeptide segments comprises at least 4 polypeptide segments, e.g., at least 4, 5, 6 or more, polypeptide segments selected from SEQ TD NOs: 4-33, e.g., polypeptide segments identified in Table B. 
     
       
         
           
               
             
               
                 TABLE B 
               
             
            
               
                   
               
               
                 polypeptide segments in HIV-1 fusion polypeptides 
               
            
           
           
               
               
               
               
               
               
            
               
                 SEQ ID 
                   
                   
                   
                 Length 
                   
               
               
                 NO:  
                 Gene 
                 Start 
                 End 
                 (aa) 
                 Sequence 
               
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 4 
                 gag 
                 1 
                 53 
                 53 
                 MAARASVLSGGELDRWEKIRLRPGGKKKYRLKH 
               
               
                   
                   
                   
                   
                   
                 IVWASRELERFAVNPGLLET 
               
               
                   
               
               
                 5 
                 gag 
                 1 
                 53 
                 53 
                 MAARASILSGGKLDKWEKIRLRPGGRKKYKLKH 
               
               
                   
                   
                   
                   
                   
                 LVWASRELERFALNPGLLET 
               
               
                   
               
               
                 6 
                 gag 
                 147 
                 369 
                 223 
                 ISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGA 
               
               
                   
                   
                   
                   
                   
                 TPQDLNTMLNTVGGHQAAMQMLKETINEEAAEW 
               
               
                   
                   
                   
                   
                   
                 DRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQE 
               
               
                   
                   
                   
                   
                   
                 QIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYS 
               
               
                   
                   
                   
                   
                   
                 PTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQ 
               
               
                   
                   
                   
                   
                   
                 EVKNWMTETLLVQNANPDCKTILKALGPAATLE 
               
               
                   
                   
                   
                   
                   
                 EMMTACQGVGGPGHKARVLAEAMSQ 
               
               
                   
               
               
                 7 
                 gag 
                 147 
                 369 
                 223 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGA 
               
               
                   
                   
                   
                   
                   
                 TPHDLNTMLNTIGGHQAAMQMLKDTINEEAAEW 
               
               
                   
                   
                   
                   
                   
                 DRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQE 
               
               
                   
                   
                   
                   
                   
                 QIAWMTNNPPIPVGDIYKRWIIMGLNKIVRMYS 
               
               
                   
                   
                   
                   
                   
                 PVSILDIKQGPKEPERDYVDRFYRTLRAEQASQ 
               
               
                   
                   
                   
                   
                   
                 DVKNWMTETLLVQNSNPDCKTILKALGPGATLE 
               
               
                   
                   
                   
                   
                   
                 EMMSACQGVGGPSHKARVLAEAMCQ 
               
               
                   
               
               
                 8 
                 pol 
                 56 
                 117 
                 62 
                 FPQITLWQRPLVTIKIGGQLKEALLDTGADDTV 
               
               
                   
                   
                   
                   
                   
                 LEEMNLPGRWKPKMIGGIGGFIKVRQYDQ 
               
               
                   
               
               
                 9 
                 pol 
                 56 
                 117 
                 62 
                 LPQITLWQRPIVTIKIGGQIKEALLDTGADDTV 
               
               
                   
                   
                   
                   
                   
                 LEDMNLPGKWKPKMIGGIGGFIKVKQYDQ 
               
               
                   
               
               
                 10 
                 pol 
                 129 
                 320 
                 192 
                 GTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIE 
               
               
                   
                   
                   
                   
                   
                 TVPVKLKPGMDGPKVKQWPLTEEKIKALVEICT 
               
               
                   
                   
                   
                   
                   
                 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWR 
               
               
                   
                   
                   
                   
                   
                 KLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKS 
               
               
                   
                   
                   
                   
                   
                 VTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNE 
               
               
                   
                   
                   
                   
                   
                 TPGIRYQYNVLPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 11 
                 pol 
                 129 
                 320 
                 192 
                 GTVLIGPTPVNIIGRNLLTQLGCTLNFPISPID 
               
               
                   
                   
                   
                   
                   
                 TVPVKLKPGMDGPRVKQWPLTEEKIKALIEICT 
               
               
                   
                   
                   
                   
                   
                 EMEKEGKISRIGPENPYNTPIFAIKKKDGTKWR 
               
               
                   
                   
                   
                   
                   
                 KLVDFRELNKKTQDFWEVQLGIPHPSGLKKKKS 
               
               
                   
                   
                   
                   
                   
                 VTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNE 
               
               
                   
                   
                   
                   
                   
                 TPGVRYQYNVLPMGWKGSPAIFQCSMT 
               
               
                   
               
               
                 12 
                 pol 
                 367 
                 431 
                 65 
                 WGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI 
               
               
                   
                   
                   
                   
                   
                 VLPEKDSWTVNDIQKLVGKLNWASQIYPGIKV 
               
               
                   
               
               
                 13 
                 pol 
                 367 
                 431 
                 65 
                 WGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPI 
               
               
                   
                   
                   
                   
                   
                 ELPEKESWTVNDIQKLIGKLNWASQIYAGIKV 
               
               
                   
               
               
                 14 
                 pol 
                 542 
                 606 
                 65 
                 PKFKLPIQKETWETWWTEYWQATWIPEWEFVNT 
               
               
                   
                   
                   
                   
                   
                 PPLVKLWYQLEKEPIVGAETFYVDGAANRETK 
               
               
                   
               
               
                 15 
                 pol 
                 542 
                 606 
                 65 
                 PKFRLPIQKETWDTWWIDYWQATWIPEWEFTNT 
               
               
                   
                   
                   
                   
                   
                 PPLVKLWYQLETEPIAGVETFYVDGASNRETK 
               
               
                   
               
               
                 16 
                 pol 
                 586 
                 606 
                 21 
                 KEPIVGAETFYVDGAANRETK 
               
               
                   
               
               
                 17 
                 pol 
                 586 
                 606 
                 21 
                 TEPIAGVETFYVDGASNRETK 
               
               
                   
               
               
                 18 
                 pol 
                 683 
                 708 
                 26 
                 KEKVYLAWVPAHKGIGGNEQVDKLVS 
               
               
                   
               
               
                 19 
                 pol 
                 683 
                 708 
                 26 
                 KEKIYLAWVPAHKGIGGNEQIDKLVS 
               
               
                   
               
               
                 20 
                 pol 
                 747 
                 827 
                 81 
                 VAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLD 
               
               
                   
                   
                   
                   
                   
                 CTHLEGKIILVAVHVASGYIEAEVIPAETGQET 
               
               
                   
                   
                   
                   
                   
                 AYFLLKLAGRWPVKT 
               
               
                   
               
               
                 21 
                 pol 
                 747 
                 827 
                 81 
                 VAKEIVACCDKCQLKGEAIHGQVDCSPGVWQLD 
               
               
                   
                   
                   
                   
                   
                 CTHLEGKVILVAVHVASGYIEAEIIPTETGQET 
               
               
                   
                   
                   
                   
                   
                 AYFILKLAGRWPVTT 
               
               
                   
               
               
                 22 
                 pol 
                 840 
                 909 
                 69 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKE 
               
               
                   
                   
                   
                   
                   
                 LKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGG 
               
               
                   
                   
                   
                   
                   
                 IGG 
               
               
                   
               
               
                 23 
                 pol 
                 840 
                 909 
                 69 
                 AVKAACWWAGVKQEFGIPYNTQSQGVVESMNNE 
               
               
                   
                   
                   
                   
                   
                 LKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGG 
               
               
                   
                   
                   
                   
                   
                 IGE 
               
               
                   
               
               
                 24 
                 pol 
                 840 
                 920 
                 81 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKE 
               
               
                   
                   
                   
                   
                   
                 LKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGG 
               
               
                   
                   
                   
                   
                   
                 IGGYSAGERIVDIIA 
               
               
                   
               
               
                 25 
                 pol 
                 840 
                 920 
                 81 
                 AVKAACWWAGVKQEFGIPYNTQSQGVVESMNNE 
               
               
                   
                   
                   
                   
                   
                 LKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGG 
               
               
                   
                   
                   
                   
                   
                 IGEYSAGERIIDIIA 
               
               
                   
               
               
                 26 
                 pol 
                 932 
                 1003 
                 72 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAV 
               
               
                   
                   
                   
                   
                   
                 VIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVA 
               
               
                   
                   
                   
                   
                   
                 SRQDED 
               
               
                   
               
               
                 27 
                 pol 
                 932 
                 1003 
                 72 
                 ITKLQNFRVYYRDNRDPLWKGPARLLWKGEGAV 
               
               
                   
                   
                   
                   
                   
                 VIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVA 
               
               
                   
                   
                   
                   
                   
                 GRQDED 
               
               
                   
               
               
                 28 
                 nef 
                 64 
                 76 
                 13 
                 EEVGFPVKPQVPL 
               
               
                   
               
               
                 29 
                 nef 
                 64 
                 76 
                 13 
                 EEVGFPVRPQVPL 
               
               
                   
               
               
                 30 
                 nef 
                 64 
                 99 
                 36 
                 EEVGFPVKPQVPLRPMTFKGALDLSHFLREKGG 
               
               
                   
                   
                   
                   
                   
                 LEG 
               
               
                   
               
               
                 31 
                 nef 
                 64 
                 99 
                 36 
                 EEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGG 
               
               
                   
                   
                   
                   
                   
                 LEG 
               
               
                   
               
               
                 32 
                 nef 
                 117 
                 148 
                 32 
                 TQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPV 
               
               
                   
               
               
                 33 
                 nef 
                 117 
                 148 
                 32 
                 TQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPL 
               
               
                   
               
            
           
         
       
     
     In various embodiments, the fusion polypeptide comprises two, three, four, five, six, or more, of the polypeptide segments comprising or consisting of amino acid residues corresponding to Gag 1-53; Gag 147-369; Pol 56-117; Pol 129-320; Pol 367-431 Pol 542-606; 5 Pol 586-606; Pol 683-708, Pol 747-827; Pol 840-909; Pol 840-920; Pol 932-1003; Nef 64-76; Nef 64-99 or Nef 117-148, wherein the Gag, Pol and Nef amino acid position numbers correspond to HIV-1 HXB2 reference sequences, as set forth in SEQ TD NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more, polypeptide segments selected from SEQ ID NOs: 4-33. 
     In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ TD NOs: 1, 2 and 3, respectively:
         a) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708 and Nef 117-148;   b) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431 and Nef 64-99;   c) amino acid residues corresponding to: Pol 542-606; Pol 747-827; Pol 840-920; Pol 932-1003 and Nef 64-99;   d) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708; Pol 747-827; Pol 840-920 and Nef 117-148;   e) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431; Pol 542-606; Pol 932-1003 and Nef 64-99;   f) amino acid residues corresponding to: Gag 147-369, Pol 586-606, Pol 683-708 and Pol 840-920;   g) amino acid residues corresponding to: Pol 129-320, Pol 747-827, Pol 932-1003 and Nef 64-76; or   h) amino acid residues corresponding to: Gag: 147-369, Pol 747-827, Pol 840-909 and Nef 64-76.       

     In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments:
         a) SEQ ID NOs: 4, 6, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18 and 32, respectively;   b) SEQ ID NOs: 5, 7, 19 and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19 and 33, respectively;   c) SEQ ID NOs: 8, 10, 12 and 30 or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12 and 30, respectively;   d) SEQ ID NOs: 9, 11, 13 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13 and 31, respectively;   e) SEQ ID NOs: 14, 20, 24, 26 and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 20, 24, 26 and 30, respectively;   f) SEQ ID NOs: 15, 21, 25, 27 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 21, 25, 27 and 31, respectively;   g) SEQ ID NOs: 4, 6, 18, 20, 24 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18, 20, 24 and 32, respectively;   h) SEQ ID NOs: 5, 7, 19, 21, 25 and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19, 21, 25 and 33, respectively;   i) SEQ ID NOs: 8, 10, 12, 14, 26 and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12, 14, 26 and 30, respectively;   j) SEQ ID NOs: 9, 11, 13, 15, 27 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13, 15, 27 and 31, respectively;   k) SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively;   l) SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, respectively;   m) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively;   n) SEQ ID NOs: 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively;   o) SEQ ID NOs: 6, 20, 22 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 22 and 28, respectively;   p) SEQ ID NOs: 7, 21, 23 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively;   q) SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively;   r) SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, respectively;   s) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; or   t) SEQ ID NOs: 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively.       

     Modifications may be made in the structure of the fusion polypeptides and polynucleotides encoding such fusion polypeptides, described herein, and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable (e.g., immunogenic) characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, variant or portion of a fusion polypeptide described herein, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence. 
     For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of its ability to bind other polypeptides (e.g., antigens) or cells. Since it is the binding capacity and nature of a protein that defines that protein&#39;s biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the polypeptide sequences of the disclosed fusion polypeptides, or corresponding DNA sequences that encode such fusion polypeptides without appreciable loss of their biological utility or activity. 
     In many instances, a polypeptide variant will contain one or more conservative substitutions. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. 
     When comparing polynucleotide and polypeptide sequences, two sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. 
     Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M. O. (1978) A model of evolutionary change in proteins—Matrices for detecting distant relationships. In Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.; Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5: 151-153; Myers, E. W. and Muller W. (1988) CABIOS 4:11-17; Robinson, E. D. (1971) Comb. Theor 77: 105; Santou, N. Nes, M. (1987) Mol. Biol. Evol. 4:406-425; Sneath, P. H. A. and Sokal, R. R. (1973) Numerical Taxonomy—the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, Calif.; Wilbur, W. J. and Lipman, D. J. (1983) Proc. Natl. Acad., Sci. USA 80:726-730. 
     Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) Add. APL. Math 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity methods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection. 
     One example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides described herein. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (blast.ncbi.nlm.nih.gov/Blast.cgi). 
     In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always &gt;0) and N (penalty score for mismatching residues; always &lt;0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89: 10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=−4 and a comparison of both strands. 
     For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. 
     In one approach, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residues occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity. 
     A “polypeptide variant,” as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the above polypeptide sequences described herein and evaluating one or more biological activities of the polypeptide as described herein and/or using any of a number of techniques well known in the art. The term “variant” may also refer to any naturally occurring or engineered molecule comprising one or more nucleotide or amino acid mutations. 
     In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: 
     a) SEQ ID NOs: 6, 4, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 4, 18 and 32, respectively; 
     b) SEQ ID NOs: 7, 5, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 5, 33 and 19, respectively; 
     c) SEQ ID NOs: 12, 30, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, respectively; 
     d) SEQ ID NOs: 9, 31, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 31, 13 and 11, respectively; 
     e) SEQ ID NOs: 14, 26, 20, 30 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, respectively; 
     f) SEQ ID NOs: 15, 31, 21, 27 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 21, 27 and 25, respectively; 
     g) SEQ ID NOs: 32, 18, 4 and 6, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 32, 18, 4 and 6, respectively; 
     h) SEQ ID NOs: 7, 33, 5 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19, respectively; 
     i) SEQ ID NOs: 8, 30, 12 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 12 and 10, respectively; 
     j) SEQ ID NOs: 13, 31, 9 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11, respectively; 
     k) SEQ ID NOs: 26, 30, 14, 20 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 14, 20 and 24, respectively; 
     l) SEQ ID NOs: 31, 27, 15, 25 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 31, 27, 15, 25 and 21, respectively; 
     m) SEQ ID NOs: 24, 6, 4, 20, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, respectively; 
     n) SEQ ID NOs: 6, 20, 4, 24, 32 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 4, 24, 32 and 18, respectively; 
     o) SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively; 
     p) SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively; 
     q) SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively; 
     r) SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively; 
     s) SEQ ID NOs: 20, 32, 24, 4, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 32, 24, 4, 6 and 18, respectively; 
     t) SEQ ID NOs: 7, 25, 19, 5, 33 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 19, 5, 33 and 21, respectively; 
     u) SEQ ID NOs: 26, 30, 12, 14, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 12, 14, 8 and 10, respectively; 
     v) SEQ ID NOs: 15, 31, 9, 27, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%8, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, respectively; 
     w) SEQ ID NOs: 24, 6, 16 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, respectively; 
     x) SEQ ID NOs: 7, 19, 17 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 19, 17 and 25, respectively; 
     y) SEQ ID NOs: 24, 16, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 16, 6 and 18, respectively; 
     z) SEQ ID NOs: 7, 25, 17 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 17 and 19, respectively; 
     aa) SEQ ID NOs: 26, 20, 10 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 20, 10 and 28, respectively; 
     bb) SEQ ID NOs: 21, 27, 11 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 21, 27, 11 and 29, respectively; 
     cc) SEQ ID NOs: 26, 10, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, respectively; 
     dd) SEQ ID NOs: 11, 27, 21 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 27, 21 and 29, respectively; 
     ee) SEQ ID NOs: 22, 6, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 20 and 28, respectively; 
     ff) SEQ ID NOs: 23, 7, 21 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 23, 7, 21 and 29, respectively; 
     gg) SEQ ID NOs: 22, 20, 6 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 20, 6 and 28, respectively; or 
     hh) SEQ ID NOs: 7, 21, 23 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively. 
     Generally, the fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. Generally, the fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, provided in Table C, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. 
     
       
         
           
               
             
               
                 TABLE C 
               
             
            
               
                   
               
               
                 polypeptide segments NOT in present HIV-1 fusion 
               
               
                 polypeptides 
               
            
           
           
               
               
               
               
               
            
               
                 SEQ ID 
                   
                   
                   
                   
               
               
                 NO:  
                 Gene 
                 Start 
                 End 
                 Sequence 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 35 
                 Gag 
                 54 
                 146 
                 EGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIE 
               
               
                   
                   
                   
                   
                 IKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY 
               
               
                   
                   
                   
                   
                 PIVQNIQGQMVHQA 
               
               
                   
               
               
                 36 
                 Gag 
                 370 
                 500 
                 VTNSATIMMQRGNERNQRKIVKCFNCGKEGHTARNCRAP 
               
               
                   
                   
                   
                   
                 RKKGCWKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGN 
               
               
                   
                   
                   
                   
                 FLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPL 
               
               
                   
                   
                   
                   
                 TSLRSLFGNDPSSQ 
               
               
                   
               
               
                 37 
                 Pol 
                 1 
                 55 
                 FFREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNN 
               
               
                   
                   
                   
                   
                 SPSEAGADRQGTVSFN 
               
               
                   
               
               
                 38 
                 Pol 
                 118 
                 128 
                 ILIEICGHKAI 
               
               
                   
               
               
                 39 
                 Pol 
                 321 
                 366 
                 KILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEE 
               
               
                   
                   
                   
                   
                 LRQHLLR 
               
               
                   
               
               
                 40 
                 Pol 
                 432 
                 541 
                 QLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHG 
               
               
                   
                   
                   
                   
                 VYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYA 
               
               
                   
                   
                   
                   
                 RMRGAHTNDVKQLTEAVQKITTESIVIWGKT 
               
               
                   
               
               
                 41 
                 Pol 
                 607 
                 682 
                 GKAGYVTNRGRQKVVTLTDTTNQKTELQAIYLALQDSGL 
               
               
                   
                   
                   
                   
                 EVNIVTDSQYALGIIQAQPDQSESELVNQIIEQLIK 
               
               
                   
               
               
                 42 
                 Pol 
                 709 
                 746 
                 AGIRKVLFLDGIDKAQDEHEKYHSNWRAMASDFNLPPV 
               
               
                   
               
               
                 43 
                 Pol 
                 828 
                 839 
                 IHTDNGSNFTGA 
               
               
                   
               
               
                 44 
                 Pol 
                 921 
                 931 
                 TDIQTKELQKQ 
               
               
                   
               
               
                 45 
                 Nef 
                 1 
                 63 
                 MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEK 
               
               
                   
                   
                   
                   
                 HGAITSSNTAATNAACAWLEAQEE 
               
               
                   
               
               
                 46 
                 Nef 
                 100 
                 116 
                 LIHSQRRQDILDLWIYH 
               
               
                   
               
               
                 47 
                 Nef 
                 149 
                 206 
                 PDKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSR 
               
               
                   
                   
                   
                   
                 LAFHHVARELHPEYFKNC 
               
               
                   
               
            
           
         
       
     
     With respect to the range of lengths of the individual polypeptide or peptide segments, in various embodiments, each polypeptide segment is at least 25 amino acids in length, and up to about 230 amino acids in length, e.g. from at least 25 amino acids in length up to 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225 or 230 amino acids in length. 
     With respect to the length of the full-length fusion polypeptide, in various embodiments, in some embodiments, the full-length of the fusion polypeptide comprises at least about 330 amino acids and up to about 550 amino acids, e.g., at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545 or 550 amino acids in length. In some embodiments, the full-length of the fusion polypeptide is no longer than 550 amino acids, e.g. no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335 or 330 amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the full-length of the fusion polypeptide comprises at least about 330 amino acids and up to about 505 amino acids, e.g., at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505 amino acids in length. amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the full-length of the fusion polypeptide is no longer than 505 amino acids, e.g. no longer than 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335 or 330 amino acids in length. In various embodiments, in the presence of a signal or leader sequence, the full-length of the fusion polypeptide comprises at least about 350 amino acids and up to about 550 amino acids, e.g., at least about 350 amino acids and up to about 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545 or 550 amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the full-length of the fusion polypeptide is no longer than 550 amino acids, e.g. no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355 or 350 amino acids in length. The inclusion of a signal or leader peptide sequence is described in further detail below. 
     Generally, the fusion polypeptides are immunogenic, in that they are capable of eliciting an immune response in a human, e.g., against HIV-1. In some embodiments, the fusion polypeptides, optionally in combination with one or more additional therapeutic agents, e.g., as described herein, are capable of eliciting a protective or a therapeutically effective immune response in a human against HIV-1, e.g., capable of either preventing HIV-1 infection in an uninfected individual, or in therapeutic contexts, capable of eliciting an immune response sufficient to induce immune mediated control of HIV-1 or eradicate HIV-1 in an infected individual. The immunogenicity of the fusion polypeptides can be evaluated and demonstrated, in in vitro and in vivo assays, as described herein. For example, immunogenicity of the fusion polypeptides can be demonstrated by an in vitro assay, including CD4+ and/or CD8+ T-cell activation (e.g., including cytokine expression and target killing assays) or proliferation assays. The T-cells can be activated by exposure to antigen presenting cells (APCs) (such as dendritic cells, e.g., monocyte-derived dendritic cells) that have been transfected with a polynucleotide encoding the fusion polypeptide. Such assays are known in the art and described herein. The immunogenicity of the fusion polypeptides can also be demonstrated in in vivo animal models, for example, by administering to mice, e.g., BALB/c or BL6, or transgenic for one or more human HLA molecules (available from Jackson Laboratories or Taconic), or non-human primates, and evaluating CD4+ and/or CD8+ T-cell activation (e.g., including serum cytokine levels) or proliferation. In various embodiments, one, two, three, or more, of each polypeptide segment comprises or consists of one or more predicted T cell epitopes, e.g., as computationally or experimentally determined. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by one or more human HLA class I and/or class II alleles (e.g. 1, 2, 3, 4, 5 or 6 alleles), e.g. within a single subject or amongst multiple subjects. 
     Concatenating Polypeptide Segments 
     As appropriate, the one or more of the polypeptide segments can be directly abutted or fused to an adjacent segment, or can be joined, connected or linked to an adjacent segment by one or more peptide linkers. In various embodiments, the one or more peptide linkers is selected from one or more of a polyalanine linker, a polyglycine linker, a cleavable linker, a flexible linker, a rigid linker, a Nef linking sequence, and combinations thereof, e.g., within a linker or within a full-length fusion polypeptide. Illustrative fusion protein linkers that can be used in the present fusion polypeptides to connect one or more polypeptide segments are described, e.g., in Chen, et al.,  Adv Drug Deliv Rev . (2013) 65(10): 1357-1369. In some embodiments, the polyalanine linker comprises or consists of 2 or 3 contiguous alanine residues, e.g. AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49) or AAX, wherein X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y) (SEQ ID NO: 50). In some embodiments, a polyglycine linker is used, e.g., GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58) or GGGS (SEQ ID NO: 59). In some embodiments, the cleavable linker is selected from a 2A cleavable peptide. Illustrative 2A cleavable peptides that can be used in the present fusion polypeptides to connect one or more polypeptide segments are described, e.g., in Donnelly, et al.,  J. Gen. Virol  (2001), 82, 1027-1041 and Chng, et al., mAbs (2015) 7:2, 403-412. Illustrative cleavable peptides that can be used to link one or more polypeptide segments include without limitation 2A cleavage sequences (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), and furin recognition/cleavage sequences (e.g. RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), RRKR (SEQ ID NO: 62)). In certain embodiments, a furin recognition/cleavage sequence (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), RRKR (SEQ ID NO: 62)) is combined or fused with a 2A cleavable peptide (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)) in a single linker. See, e.g., Chng, et al., mAbs (2015) 7:2, 403-412. In various embodiments, the 2A cleavable linker comprises or consists of the amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ TD NO: 65), QCTNYALLKLAGDVESNPGP (SEQ TD NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), or comprises or consists of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ TD NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ TD NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ TD NO: 65), QCTNYALLKLAGDVESNPGP (SEQ TD NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). As appropriate, in certain embodiments, a furin recognition/cleavage sequence can be positioned either at the N-terminus or the C-terminus of a 2A linker. In some embodiments, the cleavable linker comprises or consists of a furin recognition/cleavage site selected from RAKR (SEQ TD NO: 60), REKR (SEQ TD NO: 61) and RRKR (SEQ TD NO: 62). REKR (SEQ TD NO: 61) is a naturally occurring cleavable linker in HIV and SIV envelope glycoprotein precursor (Bahbouhi, et al.,  Biochem. J . (2002) 366, 863-872). Illustrative linkers that can be used to link or connect one or more polypeptide segments in a fusion polypeptide are provided in Table D. 
     
       
         
           
               
             
               
                 TABLE D 
               
             
            
               
                   
               
               
                 illustrative linkers 
               
            
           
           
               
               
               
            
               
                 SEQ 
                   
                   
               
               
                 ID 
                   
                   
               
               
                 NO: 
                 NAME 
                 SEQUENCE 
               
               
                   
               
            
           
           
               
               
               
            
               
                   
                 poly-alanine (2) 
                 AA 
               
               
                   
               
               
                 48 
                 poly-alanine (3) 
                 AAA 
               
               
                   
               
               
                 49 
                 poly-alanine-Tyr 
                 AAY 
               
               
                   
               
               
                 50 
                 poly-alanine-Xaa 
                 AAX (X = any 
               
               
                   
                   
                 amino acid) 
               
               
                   
               
               
                 51 
                 Gln-Glu-Glu 
                 QEE 
               
               
                   
               
               
                   
                 Glu-Glu 
                 EE 
               
               
                   
               
               
                   
                 Isoleucine 
                 I 
               
               
                   
               
               
                   
                 Lysine 
                 K 
               
               
                   
               
               
                   
                 Leu-Ile 
                 LI 
               
               
                   
               
               
                 52 
                 Lys-Ile-Leu 
                 KIL 
               
               
                   
               
               
                 53 
                 Leu-Ile-Lys 
                 LIK 
               
               
                   
               
               
                 54 
                 Pro-Pro-Val 
                 PPV 
               
               
                   
               
               
                 55 
                 Ser-Glu-Gly 
                 SEG 
               
               
                   
               
               
                   
                 poly-glycine (2) 
                 GG 
               
               
                   
               
               
                 57 
                 poly-glycine 
                 GGS 
               
               
                   
               
               
                 58 
                 poly-glycine 
                 GSG 
               
               
                   
               
               
                 59 
                 Gly3Ser 
                 GGGS 
               
               
                   
               
               
                 60 
                 furin recognition site 
                 RAKR 
               
               
                   
               
               
                 61 
                 furin recognition site 
                 REKR 
               
               
                   
               
               
                 62 
                 furin recognition site 
                 RRKR 
               
               
                   
               
               
                 63 
                 P2A 
                 ATNFSLLKQAGDVEENPGP 
               
               
                   
               
               
                 64 
                 F2A 
                 APVKQTLNFDLLKLAGDVE 
               
               
                   
                   
                 SNPGP 
               
               
                 65 
                 F2A + N-terminal 
                 RAKRAPVKQTLNFDLLKLAG 
               
               
                   
                 furin recognition site 
                 DVESNPGP 
               
               
                 66 
                 E2A 
                 QCTNYALLKLAGDVESNPGP 
               
               
                   
               
               
                 67 
                 T2A 
                 EGRGSLLTCGDVEENPGP 
               
               
                   
               
            
           
         
       
     
     Illustrative fusion polypeptides, without signal sequences, which have been designed and assembled according to the herein described methods, are provided in Table E. Table E discloses “AAA” as SEQ ID NO: 48, “LIK” as SEQ ID NO: 53, “AAY” as SEQ ID NO: 49, “SEG” as SEQ ID NO: 55, “QEE” as SEQ ID NO: 51, “KIL” as SEQ ID NO: 52 and “PPV” as SEQ ID NO: 54. 
     In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 82. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 83, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 83. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 85. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 86, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 86. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 87, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 87. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 98, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 98. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 99, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 99. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 100, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 100. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 101, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 101. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 227. As appropriate or desired, the fusion polypeptide can have an N-terminal methionine residue. 
     
       
         
           
               
             
               
                 TABLE E 
               
             
            
               
                   
               
               
                 Illustrative Fusion Polypeptides 
               
            
           
           
               
               
               
               
            
               
                   
                 Polypeptide 
                   
                   
               
               
                 SEQ 
                 segments 
                   
                   
               
               
                 ID 
                 (N-term to 
                 Length 
                   
               
               
                 NO: 
                 C-term) 
                 (aa) 
                 Amino Acid Sequence 
               
               
                   
               
            
           
           
               
               
               
               
            
               
                 70 
                 Gag: 147-369 
                 337 
                 ISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINE 
               
               
                   
                 Gag: 1-53 
                   
                 EAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIIL 
               
               
                   
                 AAA 
                   
                 GLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPD 
               
               
                   
                 Pol: 683-708 
                   
                 CKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQMAARASVLSGGELDRWEKIRL 
               
               
                   
                 Nef: 117-148 
                   
                 RPGGKKKYRLKHIVWASRELERFAVNPGLLETAAAKEKVYLAWVPAHKGIGGNEQVDKLVS 
               
               
                   
                   
                   
                 TQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPV 
               
               
                   
               
               
                 71 
                 Gag: 147-369 
                 339 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 AA 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Gag: 1-53 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 Nef: 117-148 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQAAMAARASILSGGKLDKWEKI 
               
               
                   
                 LIK 
                   
                 RLRPGGRKKYKLKHLVWASRELERFALNPGLLETTQGFFPDWQNYTPGPGIRFPLTFGWCF 
               
               
                   
                 Pol: 683-708 
                   
                 KLVPLLIKKEKIYLAWVPAHKGIGGNEQIDKLVS 
               
               
                   
               
               
                 72 
                 Pol: 367-431 
                 360 
                 WGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYP 
               
               
                   
                 AA 
                   
                 GIKVAAQEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGFPQITLWQRPLVTIKI 
               
               
                   
                 QEE 
                   
                 GGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQGTVLVGPTPVNIIGR 
               
               
                   
                 Nef: 64-99 
                   
                 NLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISK 
               
               
                   
                 Pol: 56-117 
                   
                 IGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLD 
               
               
                   
                 Pol: 129-320 
                   
                 VGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 73 
                 Pol: 56-117 
                 356 
                 LPQITLWQRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYD 
               
               
                   
                 Nef: 64-99 
                   
                 QEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGWGLTTPDKKHQKDPPFLWMGYELH 
               
               
                   
                 Pol: 367-431 
                   
                 PDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYAGIKVKGTVLIGPTPVNIIGRNLLT 
               
               
                   
                 K 
                   
                 QLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISRIGPE 
               
               
                   
                 Pol: 129-320 
                   
                 NPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDA 
               
               
                   
                   
                   
                 YFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNVLPMGWKGSPAIFQCSMT 
               
               
                   
               
               
                 74 
                 Pol: 542-606 
                 335 
                 PKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAAN 
               
               
                   
                 Pol: 932-1003 
                   
                 RETKITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGK 
               
               
                   
                 Pol: 747-827 
                   
                 QMAGDDCVASRQDEDVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAV 
               
               
                   
                 Nef: 64-99 
                   
                 HVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTEEVGFPVKPQVPLRPMTFKGALDLSH 
               
               
                   
                 Pol: 840-920 
                   
                 FLREKGGLEGTVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTA 
               
               
                   
                   
                   
                 VQMAVFIHNFKRKGGIGGYSAGERIVDIIA 
               
               
                   
               
               
                 75 
                 Pol: 542-606 
                 335 
                 PKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASN 
               
               
                   
                 Nef: 64-99 
                   
                 RETKEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGVAKEIVACCDKCQLKGEAIHG 
               
               
                   
                 Pol: 747-827 
                   
                 QVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLAGRWPVTTI 
               
               
                   
                 Pol: 932-1003 
                   
                 TKLQNFRVYYRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGD 
               
               
                   
                 Pol: 840-920 
                   
                 DCVAGRQDEDAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTA 
               
               
                   
                   
                   
                 VQMAVLIHNFKRKGGIGEYSAGERIIDIIA 
               
               
                   
               
               
                 76 
                 Nef: 117-148 
                 340 
                 TQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPVKEKVYLAWVPAHKGIGGNEQVDKLVSAAY 
               
               
                   
                 Pol: 683-708 
                   
                 MAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPGLLETSEGISPRT 
               
               
                   
                 AY 
                   
                 LNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEW 
               
               
                   
                 Gag: 1-53 
                   
                 DRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKI 
               
               
                   
                 SEG 
                   
                 VRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTIL 
               
               
                   
                 Gag: 147-369 
                   
                 KALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQ 
               
               
                   
               
               
                 77 
                 Gag: 147-369 
                 334 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 Nef: 117-148 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Gag: 1-53 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 Pol: 683-708 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQTQGFFPDWQNYTPGPGIRFPL 
               
               
                   
                   
                   
                 TFGWCFKLVPLMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGL 
               
               
                   
                   
                   
                 LETKEKIYLAWVPAHKGIGGNEQIDKLVS 
               
               
                   
               
               
                 78 
                 Pol: 56-117 
                 360 
                 FPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD 
               
               
                   
                 AAY 
                   
                 QAAYEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGAAWGFTTPDKKHQKEPPFLWM 
               
               
                   
                 Nef: 64-99 
                   
                 GYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVGTVLVGPTPVNIIGR 
               
               
                   
                 AA 
                   
                 NLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISK 
               
               
                   
                 Pol: 367-431 
                   
                 IGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLD 
               
               
                   
                 Pol: 129-320 
                   
                 VGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 79 
                 Pol: 367-431 
                 358 
                 WGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYA 
               
               
                   
                 Nef: 64-99 
                   
                 GIKVEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGLPQITLWQRPIVTIKIGGQIK 
               
               
                   
                 Pol: 56-117 
                   
                 EALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQAAAGTVLIGPTPVNIIGRNL 
               
               
                   
                 AAA 
                   
                 LTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISRIG 
               
               
                   
                 Pol: 129-320 
                   
                 PENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIG 
               
               
                   
                   
                   
                 DAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNVLPMGWKGSPAIFQCSMT 
               
               
                   
               
               
                 80 
                 Pol: 932-1003 
                 342 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAG 
               
               
                   
                 AAY 
                   
                 DDCVASRQDEDAAYEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPI 
               
               
                   
                 EE 
                   
                 QKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKVAK 
               
               
                   
                 Nef: 64-99 
                   
                 EIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQ 
               
               
                   
                 LI 
                   
                 ETAYFLLKLAGRWPVKTTVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQ 
               
               
                   
                 Pol: 542-606 
                   
                 AEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIA 
               
               
                   
                 Pol: 747-827 
                   
                   
               
               
                   
                 Pol: 840-920 
                   
                   
               
               
                   
               
               
                 81 
                 Nef: 64-99 
                 335 
                 EEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRVYYRDNRDPLWKGPARL 
               
               
                   
                 Pol: 932-1003 
                   
                 LWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDPKFRLPIQKETWDT 
               
               
                   
                 Pol: 542-606 
                   
                 WWITYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASNRETKAVKAACWWAG 
               
               
                   
                 Pol: 840-920 
                   
                 VKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIGEYS 
               
               
                   
                 Pol: 747-827 
                   
                 AGERIIDIIAVAKEIVACCDKCQLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASG 
               
               
                   
                   
                   
                 YIEAEIIPTETGQETAYFILKLAGRWPVTT 
               
               
                   
               
               
                 82 
                 Pol: 840-920 
                 353 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNF 
               
               
                   
                 Gag: 147-369 
                   
                 KRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTM 
               
               
                   
                 Pol: 586-606 
                   
                 LNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIG 
               
               
                   
                 AA 
                   
                 WMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQA 
               
               
                   
                 Pol: 683-708 
                   
                 SQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQK 
               
               
                   
                   
                   
                 EPIVGAETFYVDGAANRETKAAKEKVYLAWVPAHKGIGGNEQVDKLVS 
               
               
                   
               
               
                 83 
                 Gag: 147-369 
                 351 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 Pol: 683-708 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Pol: 586-606 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 Pol: 840-920 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQKEKIYLAWVPAHKGIGGNEQI 
               
               
                   
                   
                   
                 DKLVSTEPIAGVETFYVDGASNRETKAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELK 
               
               
                   
                   
                   
                 KIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIGEYSAGERIIDIIA 
               
               
                   
               
               
                 84 
                 Pol: 840-920 
                 358 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNF 
               
               
                   
                 Pol: 586-606 
                   
                 KRKGGIGGYSAGERIVDIIAKEPIVGAETFYVDGAANRETKAAAISPRTLNAWVKVVEEKA 
               
               
                   
                 AAA 
                   
                 FSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIA 
               
               
                   
                 Gag: 147-369 
                   
                 PGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDI 
               
               
                   
                 AAA 
                   
                 RQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEM 
               
               
                   
                 Pol: 683-708 
                   
                 MTACQGVGGPGHKARVLAEAMSQAAAKEKVYLAWVPAHKGIGGNEQVDKLVSL 
               
               
                   
               
               
                 85 
                 Gag: 147-369 
                 353 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 Pol: 840-920 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Pol: 586-606 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 AA 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQAVKAACWWAGVKQEFGIPYNT 
               
               
                   
                 Pol: 683-708 
                   
                 QSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIGEYSAGERIIDIIAT 
               
               
                   
                   
                   
                 EPIAGVETFYVDGASNRETKAAKEKIYLAWVPAHKGIGGNEQIDKLVS 
               
               
                   
               
               
                 86 
                 Pol: 932-1003 
                 361 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAG 
               
               
                   
                 Pol: 747-827 
                   
                 DDCVASRQDEDVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVAS 
               
               
                   
                 Pol: 129-320 
                   
                 GYIEAEVIPAETGQETAYFLLKLAGRWPVKTGTVLVGPTPVNIIGRNLLTQIGCTLNFPIS 
               
               
                   
                 QEE 
                   
                 PIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIK 
               
               
                   
                 Nef: 64-76 
                   
                 KKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFR 
               
               
                   
                   
                   
                 KYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTQEEEEVGFPVKPQVPL 
               
               
                   
               
               
                 87 
                 Pol: 747-827 
                 364 
                 VAKEIVACCDKCQLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTE 
               
               
                   
                 Pol: 932-1003 
                   
                 TGQETAYFILKLAGRWPVTTITKLQNFRVYYRDNRDPLWKGPARLLWKGEGAVVIQDNSEI 
               
               
                   
                 Pol: 129-320 
                   
                 KVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDGTVLIGPTPVNIIGRNLLTQLGCTLNFPIS 
               
               
                   
                 KIL 
                   
                 PIDTVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIK 
               
               
                   
                 QEE 
                   
                 KKDGTKWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFR 
               
               
                   
                 Nef: 64-76 
                   
                 KYTAFTVPSTNNETPGVRYQYNVLPMGWKGSPAIFQCSMTKILQEEEEVGFPVRPQVPL 
               
               
                   
               
               
                 88 
                 Pol: 932-1003 
                 365 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAG 
               
               
                   
                 AAA 
                   
                 DDCVASRQDEDAAAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGP 
               
               
                   
                 I 
                   
                 KVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFREL 
               
               
                   
                 Pol: 129-320 
                   
                 NKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPG 
               
               
                   
                 Pol: 747-827 
                   
                 IRYQYNVLPQGWKGSPAIFQSSMTVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHL 
               
               
                   
                 QEE 
                   
                 EGKIILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTQEEEEVGFPVKPQVPL 
               
               
                   
                 Nef: 64-76 
                   
                   
               
               
                   
               
               
                 89 
                 Pol: 129-320 
                 363 
                 GTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKAL 
               
               
                   
                 Pol: 932-1003 
                   
                 IEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWEVQLGIP 
               
               
                   
                 Pol: 747-827 
                   
                 HPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNVLPMGWKGS 
               
               
                   
                 AA 
                   
                 PAIFQCSMTITKLQNFRVYYRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKII 
               
               
                   
                 QEE 
                   
                 RDYGKRMAGDDCVAGRQDEDVAKEIVACCDKCQLKGEAIHGQVDCSPGVWQLDCTHLEGKV 
               
               
                   
                 Nef: 64-76 
                   
                 ILVAVHVASGYIEAEIIPTETGQETAYFILKLAGRWPVTTAAQEEEEVGFPVRPQVPL 
               
               
                   
               
               
                 90 
                 Pol: 840-909 
                 391 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNF 
               
               
                   
                 AA 
                   
                 KRKGGIGGAAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAA 
               
               
                   
                 Gag: 147-369 
                   
                 MQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPV 
               
               
                   
                 Pol: 747-827 
                   
                 GEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTE 
               
               
                   
                 QEE 
                   
                 TLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVAKEIVASCDK 
               
               
                   
                 Nef: 64-76 
                   
                 CQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFLLK 
               
               
                   
                   
                   
                 LAGRWPVKTQEEEEVGFPVKPQVPL 
               
               
                   
               
               
                 91 
                 Pol: 840-909 
                 393 
                 AVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNF 
               
               
                   
                 Gag: 147-369 
                   
                 KRKGGIGELSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQ 
               
               
                   
                 VT 
                   
                 MLKDTINEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGD 
               
               
                   
                 Pol: 747-827 
                   
                 IYKRWIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETL 
               
               
                   
                 AA 
                   
                 LVQNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVTVAKEIVACCDK 
               
               
                   
                 QEE 
                   
                 CQLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILK 
               
               
                   
                 Nef: 64-76 
                   
                 LAGRWPVTTAAQEEEEVGFPVRPQVPL 
               
               
                   
               
               
                 92 
                 Pol: 840-909 
                 391 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNF 
               
               
                   
                 Pol: 747-827 
                   
                 KRKGGIGGVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYI 
               
               
                   
                 AA 
                   
                 EAEVIPAETGQETAYFLLKLAGRWPVKTAAISPRTLNAWVKVVEEKAFSPEVIPMFSALSE 
               
               
                   
                 Gag: 147-369 
                   
                 GATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAG 
               
               
                   
                 QEE 
                   
                 TTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDR 
               
               
                   
                 Nef: 64-76 
                   
                 FYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKA 
               
               
                   
                   
                   
                 RVLAEAMSQQEEEEVGFPVKPQVPL 
               
               
                   
               
               
                 93 
                 Gag: 147-369 
                 394 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 PV 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Pol: 747-827 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 AAY 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQPVVAKEIVACCDKCQLKGEAI 
               
               
                   
                 Pol: 840-909 
                   
                 HGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLAGRWPVT 
               
               
                   
                 QEE 
                   
                 TAAYAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVL 
               
               
                   
                 Nef: 64-76 
                   
                 IHNFKRKGGIGEQEEEEVGFPVRPQVPL 
               
               
                   
               
               
                 94 
                 Pol: 840-920 
                 499 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNF 
               
               
                   
                 Gag: 147-369 
                   
                 KRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTM 
               
               
                   
                 Gag: 1-53 
                   
                 LNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIG 
               
               
                   
                 PPV 
                   
                 WMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQA 
               
               
                   
                 Pol: 747-827 
                   
                 SQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQM 
               
               
                   
                 Pol: 683-708 
                   
                 AARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPGLLETPPVVAKEIV 
               
               
                   
                 Nef: 117-148 
                   
                 ASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETA 
               
               
                   
                   
                   
                 YFLLKLAGRWPVKTKEKVYLAWVPAHKGIGGNEQVDKLVSTQGYFPDWQNYTPGPGTRYPL 
               
               
                   
                   
                   
                 TFGWCFKLVPV 
               
               
                   
               
               
                 95 
                 Gag: 147-369 
                 501 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 Pol: 747-827 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Gag: 1-53 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 AA 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQLKGEAIHG 
               
               
                   
                 Pol: 840-920 
                   
                 QVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLAGRWPVTTM 
               
               
                   
                 Nef: 117-148 
                   
                 AARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGLLETAAAVKAACW 
               
               
                   
                 LIK 
                   
                 WAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIG 
               
               
                   
                 Pol: 683-708 
                   
                 EYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPLLIKKEKIYLAWVPAHK 
               
               
                   
                   
                   
                 GIGGNEQIDKLVS 
               
               
                   
               
               
                 220 
                 Gag: 147-369 
                 501 
                 ISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINE 
               
               
                   
                 Pol: 747-827 
                   
                 EAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIIL 
               
               
                   
                 Gag: 1-53 
                   
                 GLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPD 
               
               
                   
                 AA 
                   
                 CKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQPPVVAKEIVASCDKCQLKGEA 
               
               
                   
                 Pol: 840-920 
                   
                 MHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPV 
               
               
                   
                 Nef: 117-148 
                   
                 KTMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPGLLETAATVKA 
               
               
                   
                 LIK 
                   
                 ACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKG 
               
               
                   
                 Pol: 683-708 
                   
                 GIGGYSAGERIVDIIATQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPVKEKVYLAWVPAHK 
               
               
                   
                   
                   
                 GIGGNEQVDKLVS 
               
               
                   
               
               
                 96 
                 Pol: 56-117 
                 494 
                 FPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD 
               
               
                   
                 Nef: 64-99 
                   
                 QEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPIQKETWETWWTEYWQA 
               
               
                   
                 LI 
                   
                 TWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKWGFTTPDKKHQKEPPFLW 
               
               
                   
                 Pol: 542-606 
                   
                 MGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVITKIQNFRVYYRDS 
               
               
                   
                 Pol: 367-431 
                   
                 RDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDEDGTV 
               
               
                   
                 Pol: 932-1003 
                   
                 LVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEI 
               
               
                   
                 Pol: 129-320 
                   
                 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPA 
               
               
                   
                   
                   
                 GLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAI 
               
               
                   
                   
                   
                 FQSSMT 
               
               
                   
               
               
                 97 
                 Pol: 56-117 
                 499 
                 LPQITLWQRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYD 
               
               
                   
                 Pol: 367-431 
                   
                 QWGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIY 
               
               
                   
                 AA 
                   
                 AGIKVAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRVYYRDNR 
               
               
                   
                 QEE 
                   
                 DPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDPKFR 
               
               
                   
                 Nef: 64-99 
                   
                 LPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASNRETK 
               
               
                   
                 Pol: 932-1003 
                   
                 AAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEKIK 
               
               
                   
                 Pol: 542-606 
                   
                 ALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWEVQLG 
               
               
                   
                 AA 
                   
                 IPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNVLPMGWK 
               
               
                   
                 Pol: 129-320 
                   
                 GSPAIFQCSMT 
               
               
                   
               
               
                 221 
                 Pol: 56-117 
                 501 
                 FPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD 
               
               
                   
                 Pol: 367-431 
                   
                 QWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIY 
               
               
                   
                 AA 
                   
                 PGIKVAAQEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIITKIQNFRVYYRD 
               
               
                   
                 QEE 
                   
                 SRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDEDPK 
               
               
                   
                 Nef: 64-99 
                   
                 FKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRE 
               
               
                   
                 Pol: 932-1003 
                   
                 TKAAGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEK 
               
               
                   
                 Pol: 542-606 
                   
                 IKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQ 
               
               
                   
                 AA 
                   
                 LGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQG 
               
               
                   
                 Pa1: 129-320 
                   
                 WKGSPAIFQSSMT 
               
               
                   
               
               
                 98 
                 Pol: 747-827 
                 504 
                 VAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAE 
               
               
                   
                 Nef: 117-148 
                   
                 TGQETAYFLLKLAGRWPVKTTQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPVTVKAACWWA 
               
               
                   
                 Pol: 840-920 
                   
                 GIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGY 
               
               
                   
                 AA 
                   
                 SAGERIVDIIAAAMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNP 
               
               
                   
                 Gag: 1-53 
                   
                 GLLETSEGISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQ 
               
               
                   
                 SEG 
                   
                 MLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGE 
               
               
                   
                 Gag: 147-369 
                   
                 IYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETL 
               
               
                   
                 AAA 
                   
                 LVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQAAAKEKVYLAWVP 
               
               
                   
                 Pol: 683-708 
                   
                 AHKGIGGNEQVDKLVS 
               
               
                   
               
               
                 99 
                 Gag: 147-369 
                 499 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 Pol: 840-920 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Pol: 683-708 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSNPD 
               
               
                   
                 AAY 
                   
                 CKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQAVKAACWWAGVKQEFGIPYNT 
               
               
                   
                 Gag: 1-53 
                   
                 QSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIGEYSAGERIIDIIAK 
               
               
                   
                 Nef: 117-148 
                   
                 EKIYLAWVPAHKGIGGNEQIDKLVSAAYMAARASILSGGKLDKWEKIRLRPGGRKKYKLKH 
               
               
                   
                 Pol: 747-827 
                   
                 LVWASRELERFALNPGLLETTQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPLVAKEIVACC 
               
               
                   
                   
                   
                 DKCQLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFI 
               
               
                   
                   
                   
                 LKLAGRWPVTT 
               
               
                   
               
               
                 100 
                 Pol: 932-1003 
                 499 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAG 
               
               
                   
                 AAY 
                   
                 DDCVASRQDEDAAYEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGAAWGFTTPD 
               
               
                   
                 EE 
                   
                 KKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVPKF 
               
               
                   
                 Nef: 64-99 
                   
                 KLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRET 
               
               
                   
                 AA 
                   
                 KFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQY 
               
               
                   
                 Pol: 367-431 
                   
                 DQGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIK 
               
               
                   
                 Pol: 542-606 
                   
                 ALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLG 
               
               
                   
                 Pol: 56-117 
                   
                 IPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWK 
               
               
                   
                 Pol: 129-320 
                   
                 GSPAIFQSSMT 
               
               
                   
               
               
                 101 
                 Pol: 542-606 
                 493 
                 PKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASN 
               
               
                   
                 Nef: 64-99 
                   
                 RETKEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGLPQITLWQRPIVTIKIGGQIK 
               
               
                   
                 Pol: 56-117 
                   
                 EALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQITKLQNFRVYYRDNRDPLWK 
               
               
                   
                 Pol: 932-1003 
                   
                 GPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDWGLTTPDKK 
               
               
                   
                 Pol: 367-431 
                   
                 HQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYAGIKVKGTVL 
               
               
                   
                 K 
                   
                 IGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALIEIC 
               
               
                   
                 Pol: 129-320 
                   
                 TEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWEVQLGIPHPSG 
               
               
                   
                   
                   
                 LKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNVLPMGWKGSPAIF 
               
               
                   
                   
                   
                 QCSMT 
               
               
                   
               
            
           
         
       
     
     Compound Fusion Polypeptides 
     In various embodiments, provided are compound fusion polypeptides comprising two or more fusion polypeptides, as described herein. Such compound fusion polypeptides can be delivered in viral vectors that can express a polypeptide having at least about 750 amino acids in length, e.g., at least about 800, 850, 900, 950, 1000, 1050, 1100 amino acids in length, or longer. As appropriate, the two or more fusion polypeptides can be directly fused, or joined or connected by one or more linkers. In some embodiments, provided are compound fusion polypeptides comprising at least a first fusion polypeptide and a second fusion polypeptide, as described herein, the first and second fusion polypeptides optionally joined or connected by one or more linkers, as described herein, e.g., a cleavable linker such as a 2A cleavable peptide linker. 
     In various embodiments, the first fusion polypeptide and the second fusion polypeptide in the compound fusion polypeptide comprises the same polypeptide segments, e.g., same amino acid residue position ranges. In some embodiments, the first fusion polypeptide and the second fusion polypeptide in the compound fusion polypeptide are bivalent. For example, in some embodiments, the first fusion polypeptide and the second fusion polypeptide comprise or consist of the following polypeptide segments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively: 
     a) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708 and Nef 117-148; 
     b) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431 and Nef 64-99; 
     c) amino acid residues corresponding to: Pol 542-606; Pol 747-827; Pol 840-920; Pol 932-1003 and Nef 64-99; 
     d) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708; Pol 747-827; Pol 840-920 and Nef 117-148; 
     e) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431; Pol 542-606; Pol 932-1003 and Nef 64-99; 
     f) amino acid residues corresponding to: Gag 147-369, Pol 586-606, Pol 683-708 and Pol 840-920; 
     g) amino acid residues corresponding to: Pol 129-320, Pol 747-827, Pol 932-1003 and Nef 64-76; or 
     h) amino acid residues corresponding to: Gag:147-369, Pol 747-827, Pol 840-909 and Nef 64-76. 
     In various embodiments, the first fusion polypeptide and the second fusion polypeptide in the compound fusion polypeptide comprises different polypeptide segments, e.g., same amino acid residue position ranges. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bivalent. For example, in some embodiments, the compound fusion polypeptide (inclusive of the first fusion polypeptide and the second fusion polypeptide) comprises or consists of the following polypeptide segments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively: 
     a) amino acid residues corresponding to: Gag 147-369, Pol 129-320, Pol 586-606, Pol 683-708, Pol 747-827, Pol 840-920, Pol 932-1003 and Nef 64-76; or 
     b) Gag 1-53, Gag 147-369, Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 683-708, Pol 747-827, Pol 840-920, Pol 932-1003, Nef 64-99 and Nef 117-148. 
     In some embodiments, the compound fusion polypeptide comprises the following polypeptide segments comprising in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         a) SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17, respectively;   b) SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11, respectively;   c) SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21, respectively;   d) SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17, respectively;   e) SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11, respectively;   f) SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19, respectively;   g) SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29, respectively;   h) SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28, respectively;   i) SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29, respectively;   j) SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10, respectively;   k) SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11, respectively;   l) SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19, respectively;   m) SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17, respectively;   n) SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11, respectively;   o) SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 18, 26, 20, 4, 6 and 16, SEQ ID NOs: 7, 21, 17, 5, 27 and 19, respectively;   p) SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18, and 32, SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively;   q) SEQ ID NOs: 6, 20, 4, 24, 32, 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 4, 24, 32, 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively;   r) SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively;   s) SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively;   t) SEQ ID NOs: 6, 20, 4, 24, 32, 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 4, 24, 32, 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively; or   u) SEQ ID NOs: 7, 21, 5, 25, 33 and 19, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively.       

     In various embodiments, the compound fusion polypeptide comprises or consists of the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.       

     In various embodiments, the compound fusion polypeptide comprises or consists of the following first fusion polypeptide and second fusion polypeptide in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively;   SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively;   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or   SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.       

     In some embodiments of the compound fusion polypeptide, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a cleavable linker. In various embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a cleavable linker selected from a 2A cleavable peptide (e.g. foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), a furin recognition/cleavage sequence (e.g. RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a furin recognition/cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a 2A cleavable peptide comprising or consisting of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), or having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). 
     Illustrative compound fusion polypeptides, without signal sequences, which have been designed and assembled according to the herein described methods, are provided in Table F. Table F discloses “AAA” as SEQ ID NO: 48, “LIK” as SEQ ID NO: 53, “AAY” as SEQ ID NO: 49, “SEG” as SEQ ID NO: 55, “QEE” as SEQ ID NO: 51, “RAKR” as SEQ ID NO: 60 and “PPV” as SEQ ID NO: 54. 
     In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 209. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 222. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 223. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of SEQ ID NO: 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 227. As appropriate or desired, the compound fusion polypeptide can have an N-terminal methionine residue. 
     
       
         
           
               
             
               
                 TABLE F 
               
             
            
               
                   
               
               
                 Illustrative Compound Fusion Polypeptides 
               
            
           
           
               
               
               
               
            
               
                 SEQ ID 
                 Polypeptide 
                 Length 
                   
               
               
                 NO: 
                 segments 
                 (aa) 
                 Amino Acid Sequence 
               
               
                   
               
               
                 105 
                 Pol:840-920 
                 1028 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH 
               
               
                   
                 Gag:147-369 
                   
                 NFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQD 
               
               
                   
                 Gag:1-53 
                   
                 LNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTST 
               
               
                   
                 PPV 
                   
                 LQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFY 
               
               
                   
                 Pol:747-827 
                   
                 KTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKA 
               
               
                   
                 Pol:683-708 
                   
                 RVLAEAMSQMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPGL 
               
               
                   
                 Nef:117-148 
                   
                 LETPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYI 
               
               
                   
                 RAKR 
                   
                 EAEVIPAETGQETAYFLLKLAGRWPVKTKEKVYLAWVPAHKGIGGNEQVDKLVSTQGYF 
               
               
                   
                 F2A linker 
                   
                 PDWQNYTPGPGTRYPLTFGWCFKLVPVRAKRAPVKQTLNFDLLKLAGDVESNPGPLSPR 
               
               
                   
                 Gag:147-369 
                   
                 TLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINEEA 
               
               
                   
                 Pol:747-827 
                   
                 AEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWIIM 
               
               
                   
                 Gag:1-53 
                   
                 GLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQNSN 
               
               
                   
                 AA 
                   
                 PDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQLKGE 
               
               
                   
                 Pol:840-920 
                   
                 AIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLAGR 
               
               
                   
                 Nef:117-148 
                   
                 WPVTTMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGLLETA 
               
               
                   
                 LIK 
                   
                 AAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLI 
               
               
                   
                 Pol:683-708 
                   
                 HNFKRKGGIGEYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPLLIKK 
               
               
                   
                   
                   
                 EKIYLAWVPAHKGIGGNEQIDKLVS 
               
               
                   
               
               
                 206 
                 M 
                 1030 
                 MTVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFI 
               
               
                   
                 Pol:840-920 
                   
                 HNFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQ 
               
               
                   
                 Gag:147-369 
                   
                 DLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTS 
               
               
                   
                 Gag:1-53 
                   
                 TLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRF 
               
               
                   
                 PPV 
                   
                 YKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHK 
               
               
                   
                 Pol:747-827 
                   
                 ARVLAEAMSQMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPG 
               
               
                   
                 Pol:683-708 
                   
                 LLETPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGY 
               
               
                   
                 Nef:117-148 
                   
                 IEAEVIPAETGQETAYFLLKLAGRWPVKTKEKVYLAWVPAHKGIGGNEQVDKLVSTQGY 
               
               
                   
                 RAKR 
                   
                 FPDWQNYTPGPGTRYPLTFGWCFKLVPVRAKRAPVKQTLNFDLLKLAGDVESNPGPMLS 
               
               
                   
                 F2A linker 
                   
                 PRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTINE 
               
               
                   
                 M 
                   
                 EAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKRWI 
               
               
                   
                 Gag:147-369 
                   
                 IMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLVQN 
               
               
                   
                 Pol:747-827 
                   
                 SNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQLK 
               
               
                   
                 Gag:1-53 
                   
                 GEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLA 
               
               
                   
                 AA 
                   
                 GRWPVTTMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGLLE 
               
               
                   
                 Pol:840-920 
                   
                 TAAAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAV 
               
               
                   
                 Nef:117-148 
                   
                 LIHNFKRKGGIGEYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPLLI 
               
               
                   
                 LIK 
                   
                 KKEKIYLAWVPAHKGIGGNEQIDKLVS 
               
               
                   
                 Pol:683-708 
                   
                   
               
               
                   
               
               
                 106 
                 Gag:147-369 
                 1028 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTI 
               
               
                   
                 Pol:747-827 
                   
                 NEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKR 
               
               
                   
                 Gag:1-53 
                   
                 WIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLV 
               
               
                   
                 AA 
                   
                 QNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQ 
               
               
                   
                 Pol:840-920 
                   
                 LKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILK 
               
               
                   
                 Nef:117-148 
                   
                 LAGRWPVTTMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGL 
               
               
                   
                 LIK 
                   
                 LETAAAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQM 
               
               
                   
                 Pol:683-708 
                   
                 AVLIHNFKRKGGIGEYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPL 
               
               
                   
                 RAKR 
                   
                 LIKKEKIYLAWVPAHKGIGGNEQIDKLVSRAKRAPVKQTLNFDLLKLAGDVESNPGPTV 
               
               
                   
                 F2A linker 
                   
                 KAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNF 
               
               
                   
                 Pol:840-920 
                   
                 KRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLN 
               
               
                   
                 Gag:147-369 
                   
                 TMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQ 
               
               
                   
                 Gag:1-53 
                   
                 EQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKT 
               
               
                   
                 PPV 
                   
                 LRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARV 
               
               
                   
                 Pol:747-827 
                   
                 LAEAMSQMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPGLLE 
               
               
                   
                 Pol:683-708 
                   
                 TPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEA 
               
               
                   
                 Nef:117-148 
                   
                 EVIPAETGQETAYFLLKLAGRWPVKTKEKVYLAWVPAHKGIGGNEQVDKLVSTQGYFPD 
               
               
                   
                   
                   
                 WQNYTPGPGTRYPLTFGWCFKLVPV 
               
               
                   
               
               
                 107 
                 Pol:56-117 
                 1022 
                 FPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQ 
               
               
                   
                 Nef:64-99 
                   
                 YDQEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPIQKETWETWWTE 
               
               
                   
                 LI 
                   
                 YWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKWGFTTPDKKHQK 
               
               
                   
                 Pol:542-606 
                   
                 EPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQTYPGIKVITKIQN 
               
               
                   
                 Pol:367-431 
                   
                 FRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCV 
               
               
                   
                 Pol:932-1003 
                   
                 ASRQDEDGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWP 
               
               
                   
                 Pol:129-320 
                   
                 LTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRT 
               
               
                   
                 RAKR 
                   
                 QDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIR 
               
               
                   
                 F2A linker 
                   
                 YQYNVLPQGWKGSPAIFQSSMTRAKRAPVKQTLNFDLLKLAGDVESNPGPNLPQITLWQ 
               
               
                   
                 Pol:56-117 
                   
                 RPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQWGLTT 
               
               
                   
                 Pol:367-431 
                   
                 PDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYAGIK 
               
               
                   
                 AA 
                   
                 VAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRVYYRDNRDP 
               
               
                   
                 QEE 
                   
                 LWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDPKFR 
               
               
                   
                 Nef:64-99 
                   
                 LPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASNRE 
               
               
                   
                 Pol:932-1003 
                   
                 TKAAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTE 
               
               
                   
                 Pol:542-606 
                   
                 EKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDF 
               
               
                   
                 AA 
                   
                 WEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQY 
               
               
                   
                 Pol:129-320 
                   
                 NVLPMGWKGSPAIFQCSMT 
               
               
                   
               
               
                 207 
                 M 
                 1023 
                 MFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVR 
               
               
                   
                 Pol:56-117 
                   
                 QYDQEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPIQKETWETWWT 
               
               
                   
                 Nef:64-99 
                   
                 EYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKWGFTTPDKKHQ 
               
               
                   
                 LI 
                   
                 KEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVITKIQ 
               
               
                   
                 Pol:542-606 
                   
                 NFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDC 
               
               
                   
                 Pol:367-431 
                   
                 VASRQDEDGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQW 
               
               
                   
                 Pol:932-1003 
                   
                 PLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKR 
               
               
                   
                 Pol:129-320 
                   
                 TQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGI 
               
               
                   
                 RAKR 
                   
                 RYQYNVLPQGWKGSPAIFQSSMTRAKRAPVKQTLNFDLLKLAGDVESNPGPMLPQITLW 
               
               
                   
                 F2A linker 
                   
                 QRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQWGLT 
               
               
                   
                 M 
                   
                 TPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYAGI 
               
               
                   
                 Pol:56-117 
                   
                 KVAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRVYYRDNRD 
               
               
                   
                 Pol:367-431 
                   
                 PLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDPKF 
               
               
                   
                 AA 
                   
                 RLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASNR 
               
               
                   
                 QEE 
                   
                 ETKAAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLT 
               
               
                   
                 Nef:64-99 
                   
                 EEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQD 
               
               
                   
                 Pol:932-1003 
                   
                 FWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQ 
               
               
                   
                 Pol:542-606 
                   
                 YNVLPMGWKGSPAIFQCSMT 
               
               
                   
                 AA 
                   
                   
               
               
                   
                 Pol:129-320 
                   
                   
               
               
                   
               
               
                 108 
                 Pol:56-117 
                 1022 
                 LPQITLWQRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQ 
               
               
                   
                 Pol:367-431 
                   
                 YDQWGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWA 
               
               
                   
                 AA 
                   
                 SQIYAGIKVAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRV 
               
               
                   
                 QEE 
                   
                 YYRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGR 
               
               
                   
                 Nef:64-99 
                   
                 QDEDPKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFY 
               
               
                   
                 Pol:932-1003 
                   
                 VDGASNRETKAAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPR 
               
               
                   
                 Pol:542-606 
                   
                 VKQWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRE 
               
               
                   
                 AA 
                   
                 LNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNE 
               
               
                   
                 Pol:129-320 
                   
                 TPGVRYQYNVLPMGWKGSPAIFQCSMTRAKRAPVKQTLNFDLLKLAGDVESNPGPFPQI 
               
               
                   
                 RAKR 
                   
                 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQE 
               
               
                   
                 F2A linker 
                   
                 EVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPIQKETWETWWTEYWQA 
               
               
                   
                 Pol:56-117 
                   
                 TWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKWGFTTPDKKHQKEPPF 
               
               
                   
                 Nef:64-99 
                   
                 LWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVITKIQNFRVY 
               
               
                   
                 LI 
                   
                 YRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQ 
               
               
                   
                 Pol:542-606 
                   
                 DEDGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEE 
               
               
                   
                 Pol:367-431 
                   
                 KIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFW 
               
               
                   
                 Pol:932-1003 
                   
                 EVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYN 
               
               
                   
                 Pol:129-320 
                   
                 VLPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 109 
                 Pol:747-827 
                 1034 
                 VAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIP 
               
               
                   
                 Nef:117-148 
                   
                 AETGQETAYFLLKLAGRWPVKTTQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPVTVKAA 
               
               
                   
                 Pol:840-920 
                   
                 CWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRK 
               
               
                   
                 AA 
                   
                 GGIGGYSAGERIVDIIAAAMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRE 
               
               
                   
                 Gag:1-53 
                   
                 LERFAVNPGLLETSEGISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLN 
               
               
                   
                 SEG 
                   
                 TVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIG 
               
               
                   
                 Gag:147-369 
                   
                 WMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAE 
               
               
                   
                 AAA 
                   
                 QASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEA 
               
               
                   
                 Pol:683-708 
                   
                 MSQAAAKEKVYLAWVPAHKGIGGNEQVDKLVSRAKRAPVKQTLNFDLLKLAGDVESNPG 
               
               
                   
                 RAKR 
                   
                 PHQALSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQML 
               
               
                   
                 F2A linker 
                   
                 KDTINEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGD 
               
               
                   
                 Gag:147-369 
                   
                 IYKRWIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTE 
               
               
                   
                 Pol:840-920 
                   
                 TLLVQNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQAVKAACWWA 
               
               
                   
                 Pol:683-708 
                   
                 GVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIG 
               
               
                   
                 AAY 
                   
                 EYSAGERIIDIIAKEKIYLAWVPAHKGIGGNEQIDKLVSAAYMAARASILSGGKLDKWE 
               
               
                   
                 Gag:1-53 
                   
                 KIRLRPGGRKKYKLKHLVWASRELERFALNPGLLETTQGFFPDWQNYTPGPGIRFPLTF 
               
               
                   
                 Nef:117-148 
                   
                 GWCFKLVPLVAKEIVACCDKCQLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVAS 
               
               
                   
                 Pol:747-827 
                   
                 GYIEAEIIPTETGQETAYFILKLAGRWPVTT 
               
               
                   
               
               
                 110 
                 Gag:147-369 
                 1031 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTI 
               
               
                   
                 Pol:840-920 
                   
                 NEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKR 
               
               
                   
                 Pol:683-708 
                   
                 WIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLV 
               
               
                   
                 AAY 
                   
                 QNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQAVKAACWWAGVKQ 
               
               
                   
                 Gag:1-53 
                   
                 EFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIGEYSA 
               
               
                   
                 Nef:117-148 
                   
                 GERIIDIIAKEKIYLAWVPAHKGIGGNEQIDKLVSAAYMAARASILSGGKLDKWEKIRL 
               
               
                   
                 Pol:747-827 
                   
                 RPGGRKKYKLKHLVWASRELERFALNPGLLETTQGFFPDWQNYTPGPGIRFPLTFGWCF 
               
               
                   
                 RAKR 
                   
                 KLVPLVAKEIVACCDKCQLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIE 
               
               
                   
                 F2A linker 
                   
                 AEIIPTETGQETAYFILKLAGRWPVTTRAKRAPVKQTLNFDLLKLAGDVESNPGPVAKE 
               
               
                   
                 Pol:747-827 
                   
                 IVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETG 
               
               
                   
                 Nef:117-148 
                   
                 QETAYFLLKLAGRWPVKTTQGYFPDWQNYTPGPGTRYPLTFGWCFKLVPVTVKAACWWA 
               
               
                   
                 Pol:840-920 
                   
                 GIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIG 
               
               
                   
                 AA 
                   
                 GYSAGERIVDIIAAAMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERF 
               
               
                   
                 Gag:1-53 
                   
                 AVNPGLLETSEGISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGG 
               
               
                   
                 SEG 
                   
                 HQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTN 
               
               
                   
                 Gag:147-369 
                   
                 NPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQ 
               
               
                   
                 AAA 
                   
                 EVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQA 
               
               
                   
                 Pol:683-708 
                   
                 AAKEKVYLAWVPAHKGIGGNEQVDKLVS 
               
               
                   
               
               
                 111 
                 Pol:932-1003 
                 1020 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQM 
               
               
                   
                 AAY 
                   
                 AGDDCVASRQDEDAAYEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGAAWGF 
               
               
                   
                 EE 
                   
                 TTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPG 
               
               
                   
                 Nef:64-99 
                   
                 IKVPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYV 
               
               
                   
                 AA 
                   
                 DGAANRETKFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGG 
               
               
                   
                 Pol:367-431 
                   
                 IGGFIKVRQYDQGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPK 
               
               
                   
                 Pol:542-606 
                   
                 VKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRE 
               
               
                   
                 Pol:56-117 
                   
                 LNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNE 
               
               
                   
                 Pol:129-320 
                   
                 TPGIRYQYNVLPQGWKGSPAIFQSSMTRAKRAPVKQTLNFDLLKLAGDVESNPGPPKFR 
               
               
                   
                 RAKR 
                   
                 LPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGASNRE 
               
               
                   
                 F2A linker 
                   
                 TKEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGLPQITLWQRPIVTIKIGGQIK 
               
               
                   
                 Pol:542-606 
                   
                 EALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQITKLQNFRVYYRDNRDPL 
               
               
                   
                 Nef:64-99 
                   
                 WKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDWGLTT 
               
               
                   
                 Pol:56-117 
                   
                 PDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYAGIK 
               
               
                   
                 Pol:932-1003 
                   
                 VKGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEK 
               
               
                   
                 Pol:367-431 
                   
                 IKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWE 
               
               
                   
                 K 
                   
                 VQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNV 
               
               
                   
                 Pol:129-320 
                   
                 LPMGWKGSPAIFQCSMT 
               
               
                   
               
               
                 112 
                 Pol:542-606 
                 1020 
                 PKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVDGA 
               
               
                   
                 Nef:64-99 
                   
                 SNRETKEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGLPQITLWQRPIVTIKIG 
               
               
                   
                 Pol:56-117 
                   
                 GQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQITKLQNFRVYYRDN 
               
               
                   
                 Pol:932-1003 
                   
                 RDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQDEDW 
               
               
                   
                 Pol:367-431 
                   
                 GLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQIY 
               
               
                   
                 K 
                   
                 AGIKVKGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPL 
               
               
                   
                 Pol:129-320 
                   
                 TEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQ 
               
               
                   
                 RAKR 
                   
                 DFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRY 
               
               
                   
                 F2A linker 
                   
                 QYNVLPMGWKGSPAIFQCSMTRAKRAPVKQTLNFDLLKLAGDVESNPGPITKIQNFRVY 
               
               
                   
                 Pol:932-1003 
                   
                 YRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQ 
               
               
                   
                 AAY 
                   
                 DEDAAYEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGAAWGFTTPDKKHQKE 
               
               
                   
                 EE 
                   
                 PPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVPKFKLPI 
               
               
                   
                 Nef:64-99 
                   
                 QKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKF 
               
               
                   
                 AA 
                   
                 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQY 
               
               
                   
                 Pol:367-431 
                   
                 DQGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEK 
               
               
                   
                 Pol:542-606 
                   
                 IKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWE 
               
               
                   
                 Pol:56-117 
                   
                 VQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNV 
               
               
                   
                 Pol:129-320 
                   
                 LPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 208 
                 M 
                 1023 
                 MTVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFI 
               
               
                   
                 Pol:840-920 
                   
                 HNFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQ 
               
               
                   
                 Gag:147-369 
                   
                 DLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTS 
               
               
                   
                 Gag:1-53 
                   
                 TLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRF 
               
               
                   
                 PPV 
                   
                 YKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHK 
               
               
                   
                 Pol:747-827 
                   
                 ARVLAEAMSQMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPG 
               
               
                   
                 Pol:683-708 
                   
                 LLETPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGY 
               
               
                   
                 Nef:117-148 
                   
                 IEAEVIPAETGQETAYFLLKLAGRWPVKTKEKVYLAWVPAHKGIGGNEQVDKLVSTQGY 
               
               
                   
                 RAKR 
                   
                 FPDWQNYTPGPGTRYPLTFGWCFKLVPVRAKRAPVKQTLNFDLLKLAGDVESNPGPMFP 
               
               
                   
                 F2A linker 
                   
                 QITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD 
               
               
                   
                 M 
                   
                 QEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPIQKETWETWWTEYW 
               
               
                   
                 Pol:56-117 
                   
                 QATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKWGFTTPDKKHQKEP 
               
               
                   
                 Nef:64-99 
                   
                 PFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVITKIQNFR 
               
               
                   
                 LI 
                   
                 VYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVAS 
               
               
                   
                 Pol:542-606 
                   
                 RQDEDGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLT 
               
               
                   
                 Pol:367-431 
                   
                 EEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQD 
               
               
                   
                 Pol:932-1003 
                   
                 FWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQ 
               
               
                   
                 Pol:129-320 
                   
                 YNVLPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 224 
                 Pol:840-920 
                 1021 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH 
               
               
                   
                 Gag:147-369 
                   
                 NFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQD 
               
               
                   
                 Gag:1-53 
                   
                 LNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTST 
               
               
                   
                 PPV 
                   
                 LQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFY 
               
               
                   
                 Pol:747-827 
                   
                 KTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKA 
               
               
                   
                 Pol:683-708 
                   
                 RVLAEAMSQMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVNPGL 
               
               
                   
                 Nef:117-148 
                   
                 LETPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYI 
               
               
                   
                 RAKR 
                   
                 EAEVIPAETGQETAYFLLKLAGRWPVKTKEKVYLAWVPAHKGIGGNEQVDKLVSTQGYF 
               
               
                   
                 F2A linker 
                   
                 PDWQNYTPGPGTRYPLTFGWCFKLVPVRAKRAPVKQTLNFDLLKLAGDVESNPGPFPQI 
               
               
                   
                 Pol:56-117 
                   
                 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQE 
               
               
                   
                 Nef:64-99 
                   
                 EVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIPKFKLPIQKETWETWWTEYWQA 
               
               
                   
                 LI 
                   
                 TWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKWGFTTPDKKHQKEPPF 
               
               
                   
                 Pol:542-606 
                   
                 LWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVITKIQNFRVY 
               
               
                   
                 Pol:367-431 
                   
                 YRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQ 
               
               
                   
                 Pol:932-1003 
                   
                 DEDGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEE 
               
               
                   
                 Pol:129-320 
                   
                 KIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFW 
               
               
                   
                   
                   
                 EVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYN 
               
               
                   
                   
                   
                 VLPQGWKGSPAIFQSSMT 
               
               
                   
               
               
                 209 
                 M 
                 1030 
                 MLSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDT 
               
               
                   
                 Gag:147-369 
                   
                 INEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYK 
               
               
                   
                 Pol:747-827 
                   
                 RWIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLL 
               
               
                   
                 Gag:1-53 
                   
                 VQNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKC 
               
               
                   
                 AA 
                   
                 QLKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFIL 
               
               
                   
                 Pol:840-920 
                   
                 KLAGRWPVTTMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPG 
               
               
                   
                 Nef:117-148 
                   
                 LLETAAAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQ 
               
               
                   
                 LIK 
                   
                 MAVLIHNFKRKGGIGEYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVP 
               
               
                   
                 Pol:683-708 
                   
                 LLIKKEKIYLAWVPAHKGIGGNEQIDKLVSRAKRAPVKQTLNFDLLKLAGDVESNPGPM 
               
               
                   
                 RAKR 
                   
                 LPQITLWQRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQ 
               
               
                   
                 F2A linker 
                   
                 YDQWGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWA 
               
               
                   
                 M 
                   
                 SQIYAGIKVAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRV 
               
               
                   
                 Pol:56-117 
                   
                 YYRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGR 
               
               
                   
                 Pol:367-431 
                   
                 QDEDPKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFY 
               
               
                   
                 AA 
                   
                 VDGASNRETKAAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPR 
               
               
                   
                 QEE 
                   
                 VKQWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRE 
               
               
                   
                 Nef:64-99 
                   
                 LNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNE 
               
               
                   
                 Pol:932-1003 
                   
                 TPGVRYQYNVLPMGWKGSPAIFQCSMT 
               
               
                   
                 Pol:542-606 
                   
                   
               
               
                   
                 AA 
                   
                   
               
               
                   
                 Pol:129-320 
                   
                   
               
               
                   
               
               
                 227 
                 Gag:147-369 
                 1029 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTI 
               
               
                   
                 Pol:747-827 
                   
                 NEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKR 
               
               
                   
                 Gag:1-53 
                   
                 WIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLV 
               
               
                   
                 AA 
                   
                 QNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQ 
               
               
                   
                 Pol:840-920 
                   
                 LKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILK 
               
               
                   
                 Nef:117-148 
                   
                 LAGRWPVTTMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGL 
               
               
                   
                 LIK 
                   
                 LETAAAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQM 
               
               
                   
                 Pol:683-708 
                   
                 AVLIHNFKRKGGIGEYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPL 
               
               
                   
                 RAKR 
                   
                 LIKKEKIYLAWVPAHKGIGGNEQIDKLVSRAKRAPVKQTLNFDLLKLAGDVESNPGPML 
               
               
                   
                 F2A linker 
                   
                 PQITLWQRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQY 
               
               
                   
                 M 
                   
                 DQWGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWAS 
               
               
                   
                 Pol:56-117 
                   
                 QIYAGIKVAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRVY 
               
               
                   
                 Pol:367-431 
                   
                 YRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQ 
               
               
                   
                 AA 
                   
                 DEDPKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYV 
               
               
                   
                 QEE 
                   
                 DGASNRETKAAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRV 
               
               
                   
                 Nef:64-99 
                   
                 KQWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFREL 
               
            
           
           
               
               
               
               
               
            
               
                   
                 Pol:932-1003 
                   
                 NKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNET 
                   
               
               
                   
                 Pol:542-606 
                   
                 PGVRYQYNVLPMGWKGSPAIFQCSMT 
                   
               
               
                   
                 AA 
                   
                   
                   
               
               
                   
                 Pol:129-320 
                   
                   
                   
               
               
                   
               
               
                 223 
                 Gag:147-369 
                 1028 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTI 
                   
               
               
                   
                 Pol:747-827 
                   
                 NEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKR 
                   
               
               
                   
                 Gag:1-53 
                   
                 WIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLV 
                   
               
               
                   
                 AA 
                   
                 QNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQ 
                   
               
               
                   
                 Pol:840-920 
                   
                 LKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILK 
                   
               
               
                   
                 Nef:117-148 
                   
                 LAGRWPVTTMAARASILSGGKLDKWEKIRLRPGGRKKYKLKHLVWASRELERFALNPGL 
                   
               
               
                   
                 LIK 
                   
                 LETAAAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQM 
                   
               
               
                   
                 Pol:683-708 
                   
                 AVLIHNFKRKGGIGEYSAGERIIDIIATQGFFPDWQNYTPGPGIRFPLTFGWCFKLVPL 
                   
               
               
                   
                 RAKR 
                   
                 LIKKEKIYLAWVPAHKGIGGNEQIDKLVSRAKRAPVKQTLNFDLLKLAGDVESNPGPLP 
                   
               
               
                   
                 F2A linker 
                   
                 QITLWQRPIVTIKIGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYD 
                   
               
               
                   
                 Pol:56-117 
                   
                 QWGLTTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKESWTVNDIQKLIGKLNWASQ 
                   
               
               
                   
                 Pol:367-431 
                   
                 IYAGIKVAAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGITKLQNFRVYY 
                   
               
               
                   
                 AA 
                   
                 RDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQD 
                   
               
               
                   
                 QEE 
                   
                 EDPKFRLPIQKETWDTWWTDYWQATWIPEWEFTNTPPLVKLWYQLETEPIAGVETFYVD 
                   
               
               
                   
                 Nef:64-99 
                   
                 GASNRETKAAGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVK 
                   
               
               
                   
                 Pol:932-1003 
                   
                 QWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELN 
                   
               
               
                   
                 Pol:542-606 
                   
                 KKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETP 
                   
               
               
                   
                 AA 
                   
                 GVRYQYNVLPMGWKGSPAIFQCSMT 
                   
               
               
                   
                 Pol:129-320 
                   
                   
                   
               
               
                   
               
               
                 222 
                 Gag:147-369 
                 1030 
                 ISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETI 
                   
               
               
                   
                 Pol:747-827 
                   
                 NEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKR 
                   
               
               
                   
                 Gag:1-53 
                   
                 WIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLV 
                   
               
               
                   
                 AA 
                   
                 QNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQPPVVAKEIVASCD 
                   
               
               
                   
                 Pol:840-920 
                   
                 KCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYF 
                   
               
               
                   
                 Nef:117-148 
                   
                 LLKLAGRWPVKTMAARASVLSGGELDRWEKIRLRPGGKKKYRLKHIVWASRELERFAVN 
                   
               
               
                   
                 LIK 
                   
                 PGLLETAATVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTA 
                   
               
               
                   
                 Pol:683-708 
                   
                 VQMAVFIHNFKRKGGIGGYSAGERIVDIIATQGYFPDWQNYTPGPGTRYPLTFGWCFKL 
                   
               
               
                   
                 F2A 
                   
                 VPVKEKVYLAWVPAHKGIGGNEQVDKLVSRAKRAPVKQTLNFDLLKLAGDVESNPGPFP 
                   
               
               
                   
                 Pol:56-117 
                   
                 QITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD 
                   
               
               
                   
                 Pol:367-431 
                   
                 QWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQ 
                   
               
               
                   
                 AA 
                   
                 IYPGIKVAAQEEEEVGFPVKPQVPLRPMTFKGALDLSHFLREKGGLEGLIITKIQNFRV 
                   
               
               
                   
                 QEE 
                   
                 YYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASR 
                   
               
               
                   
                 Nef:64-99 
                   
                 QDEDPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFY 
                   
               
               
                   
                 Pol:932-1003 
                   
                 VDGAANRETKAAGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPK 
                   
               
               
                   
                 Pol:542-606 
                   
                 VKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRE 
                   
               
               
                   
                 AA 
                   
                 LNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNE 
                   
               
               
                   
                 Pol:129-320 
                   
                 TPGIRYQYNVLPQGWKGSPAIFQSSMT 
                   
               
               
                   
               
               
                 200 
                 Pol:840-920 
                  735 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH 
                   
               
               
                   
                 Gag:147-369 
                   
                 NFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQD 
                   
               
               
                   
                 Pol:586-606 
                   
                 LNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTST 
                   
               
               
                   
                 AA 
                   
                 LQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFY 
                   
               
               
                   
                 Pol:683-708 
                   
                 KTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKA 
                   
               
               
                   
                 RAKR 
                   
                 RVLAEAMSQKEPIVGAETFYVDGAANRETKAAKEKVYLAWVPAHKGIGGNEQVDKLVSR 
                   
               
               
                   
                 F2A linker 
                   
                 AKRAPVKQTLNFDLLKLAGDVESNPGPLSPRTLNAWVKVIEEKAFSPEVIPMFTALSEG 
                   
               
               
                   
                 Gag:147-369 
                   
                 ATPHDLNTMLNTIGGHQAAMQMLKDTINEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIA 
                   
               
               
                   
                 Pol:840-920 
                   
                 GSTSTLQEQIAWMTNNPPIPVGDIYKRWIIMGLNKIVRMYSPVSILDIKQGPKEPFRDY 
                   
               
               
                   
                 Pol:586-606 
                   
                 VDRFYRTLRAEQASQDVKNWMTETLLVQNSNPDCKTILKALGPGATLEEMMSACQGVGG 
                   
               
               
                   
                 AA 
                   
                 PSHKARVLAEAMCQAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQA 
                   
               
               
                   
                 Pol:683-708 
                   
                 EHLKTAVQMAVLIHNFKRKGGIGEYSAGERIIDIIATEPIAGVETFYVDGASNRETKAA 
                   
               
               
                   
                   
                   
                 KEKIYLAWVPAHKGIGGNEQIDKLVS 
                   
               
               
                   
               
               
                 201 
                 Pol:932-1003 
                  758 
                 ITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQM 
                   
               
               
                   
                 AAA 
                   
                 AGDDCVASRQDEDAAAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPG 
                   
               
               
                   
                 I 
                   
                 MDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKL 
                   
               
               
                   
                 Pol:129-320 
                   
                 VDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIP 
                   
               
               
                   
                 Pol:747-827 
                   
                 SINNETPGIRYQYNVLPQGWKGSPAIFQSSMTVAKEIVASCDKCQLKGEAMHGQVDCSP 
                   
               
               
                   
                 QEE 
                   
                 GIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTQEEEE 
                   
               
               
                   
                 Nef:64-76 
                   
                 VGFPVKPQVPLRAKRAPVKQTLNFDLLKLAGDVESNPGPVAKEIVACCDKCQLKGEAIH 
                   
               
               
                   
                 RAKR 
                   
                 GQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLAGRWPV 
                   
               
               
                   
                 F2A linker 
                   
                 TTITKLQNFRVYYRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGK 
                   
               
               
                   
                 Pol:747-827 
                   
                 RMAGDDCVAGRQDEDGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMD 
                   
               
               
                   
                 Pol:932-1003 
                   
                 GPRVKQWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVD 
                   
               
               
                   
                 Pol:129-320 
                   
                 FRELNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPST 
                   
               
               
                   
                 KIL 
                   
                 NNETPGVRYQYNVLPMGWKGSPAIFQCSMTKILQEEEEVGFPVRPQVPL 
                   
               
               
                   
                 QEE 
                   
                   
                   
               
               
                   
                 Nef:64-76 
                   
                   
                   
               
               
                   
               
               
                 202 
                 Pol:840-920 
                  747 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH 
                   
               
               
                   
                 Gag:147-369 
                   
                 NFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQD 
                   
               
               
                   
                 Pol:586-606 
                   
                 LNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTST 
                   
               
               
                   
                 AA 
                   
                 LQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFY 
                   
               
               
                   
                 Pol:683-708 
                   
                 KTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKA 
                   
               
               
                   
                 RAKR 
                   
                 RVLAEAMSQKEPIVGAETFYVDGAANRETKAAKEKVYLAWVPAHKGIGGNEQVDKLVSR 
                   
               
               
                   
                 F2A linker 
                   
                 AKRAPVKQTLNFDLLKLAGDVESNPGPITKIQNFRVYYRDSRDPLWKGPAKLLWKGEGA 
                   
               
               
                   
                 Pol:932-1003 
                   
                 VVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDEDAAAIGTVLVGPTPVNIIGR 
                   
               
               
                   
                 AAA 
                   
                 NLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKI 
                   
               
               
                   
                 I 
                   
                 SKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSV 
                   
               
               
                   
                 Pol:129-320 
                   
                 TVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMT 
                   
               
               
                   
                 Pol:747-827 
                   
                 VAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIP 
                   
               
               
                   
                 QEE 
                   
                 AETGQETAYFLLKLAGRWPVKTQEEEEVGFPVKPQVPL 
                   
               
               
                   
                 Nef:64-76 
                   
                   
                   
               
               
                   
               
               
                 203 
                 Gag:147-369 
                  746 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTI 
                   
               
               
                   
                 Pol:840-920 
                   
                 NEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKR 
                   
               
               
                   
                 Pol:586-606 
                   
                 WIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLV 
                   
               
               
                   
                 AA 
                   
                 QNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQAVKAACWWAGVKQ 
                   
               
               
                   
                 Pol:683-708 
                   
                 EFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLKTAVQMAVLIHNFKRKGGIGEYSA 
                   
               
               
                   
                 RAKR 
                   
                 GERIIDIIATEPIAGVETFYVDGASNRETKAAKEKIYLAWVPAHKGIGGNEQIDKLVSR 
                   
               
               
                   
                 F2A linker 
                   
                 AKRAPVKQTLNFDLLKLAGDVESNPGPVAKEIVACCDKCQLKGEAIHGQVDCSPGVWQL 
                   
               
               
                   
                 Pol:747-827 
                   
                 DCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILKLAGRWPVTTITKLQNFRVY 
                   
               
               
                   
                 Pol:932-1003 
                   
                 YRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGDDCVAGRQ 
                   
               
               
                   
                 Pol:129-320 
                   
                 DEDGTVLIGPTPVNIIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEE 
                   
               
               
                   
                 KIL 
                   
                 KIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFW 
                   
               
               
                   
                 QEE 
                   
                 EVQLGIPHPSGLKKKKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYN 
                   
               
               
                   
                 Nef:64-76 
                   
                 VLPMGWKGSPAIFQCSMTKILQEEEEVGFPVRPQVPL 
                   
               
               
                   
               
               
                 204 
                 Pol:840-920 
                  717 
                 TVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH 
                   
               
               
                   
                 Gag:147-369 
                   
                 NFKRKGGIGGYSAGERIVDIIAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQD 
                   
               
               
                   
                 Pol:586-606 
                   
                 LNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTST 
                   
               
               
                   
                 Pol:747-827 
                   
                 LQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFY 
                   
               
               
                   
                 Pol:683-708 
                   
                 KTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKA 
                   
               
               
                   
                 Nef:64-76 
                   
                 RVLAEAMSQKEPIVGAETFYVDGAANRETKVAKEIVASCDKCQLKGEAMHGQVDCSPGI 
                   
               
               
                   
                 Pol:932-1003 
                   
                 WQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTKEKVYLA 
                   
               
               
                   
                 AAA 
                   
                 WVPAHKGIGGNEQVDKLVSQEEEEVGFPVKPQVPLITKIQNFRVYYRDSRDPLWKGPAK 
                   
               
               
                   
                 Pol:129-320 
                   
                 LLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDEDAAAIGTVLVGP 
                   
               
               
                   
                   
                   
                 TPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICT 
                   
               
               
                   
                   
                   
                 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPA 
                   
               
               
                   
                   
                   
                 GLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSP 
                   
               
               
                   
                   
                   
                 AIFQSSMT 
                   
               
               
                   
               
               
                 205 
                 Gag:147-369 
                  716 
                 LSPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPHDLNTMLNTIGGHQAAMQMLKDTI 
                   
               
               
                   
                 Pol:747-827 
                   
                 NEEAAEWDRVHPVHAGPVAPGQMRDPRGSDIAGSTSTLQEQIAWMTNNPPIPVGDIYKR 
                   
               
               
                   
                 Pol:683-708 
                   
                 WIIMGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFYRTLRAEQASQDVKNWMTETLLV 
                   
               
               
                   
                 Pol:586-606 
                   
                 QNSNPDCKTILKALGPGATLEEMMSACQGVGGPSHKARVLAEAMCQVAKEIVACCDKCQ 
                   
               
               
                   
                 Pol:932-1003 
                   
                 LKGEAIHGQVDCSPGVWQLDCTHLEGKVILVAVHVASGYIEAEIIPTETGQETAYFILK 
                   
               
               
                   
                 Pol:840-920 
                   
                 LAGRWPVTTKEKIYLAWVPAHKGIGGNEQIDKLVSTEPIAGVETFYVDGASNRETKITK 
                   
               
               
                   
                 Nef:64-76 
                   
                 LQNFRVYYRDNRDPLWKGPARLLWKGEGAVVIQDNSEIKVVPRRKVKIIRDYGKRMAGD 
                   
               
               
                   
                 Pol:129-320 
                   
                 DCVAGRQDEDAVKAACWWAGVKQEFGIPYNTQSQGVVESMNNELKKIIGQIRDQAEHLK 
                   
               
               
                   
                   
                   
                 TAVQMAVLIHNFKRKGGIGEYSAGERIIDIIAQEEEEVGFPVRPQVPLGTVLIGPTPVN 
                   
               
               
                   
                   
                   
                 IIGRNLLTQLGCTLNFPISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEK 
                   
               
               
                   
                   
                   
                 EGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKK 
                   
               
               
                   
                   
                   
                 KKSVTVLDIGDAYFSVPLDKEFRKYTAFTVPSTNNETPGVRYQYNVLPMGWKGSPAIFQ 
                   
               
               
                   
                   
                   
                 CSMTKIL 
               
               
                   
               
            
           
         
       
     
     Signal or Leader Sequences 
     In various embodiments, the fusion polypeptides and/or compound fusion polypeptides comprise a signal sequence or signal peptide, e.g., to direct intracellular trafficking of the fusion polypeptide or compound fusion polypeptide to a proteasomal or lysosomal compartment. In various embodiments, fusion polypeptide or compound fusion polypeptide comprises a signal sequence at the N-terminus and/or the C-terminus. In some embodiments, the fusion polypeptide or compound fusion polypeptide comprises an N-terminal signal peptide or leader sequence. In various embodiments, the signal peptide or leader sequence is from a source protein selected from a serum protein, a cytokine, a chemokine, a chaperone protein, an invariant protein, and a protein that directs proteins to the lysosomal compartment. In some embodiments, the signal peptide or leader sequence is from a source protein selected from colony stimulating factor 2 (CSF2, GM-CSF), tissue type plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-GAMMA, invariant chain), serum albumin (ALB), polyubiquitin B/C (UBB/UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosomal associated membrane protein 1 (LAMP-1) and lysosomal associated membrane protein 2 (LAMP-2). In certain embodiments, the fusion polypeptide comprises N-terminal and C-terminal signal sequences from LAMP-1, e.g., SEQ ID NOs: 125 and 126, respectively. In various embodiments, the signal peptide or leader sequence is selected from an amino acid sequence of any one of SEQ ID NOs: 115-126, or a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 115-126. Illustrative signal sequences that can be used in the present fusion polypeptides and compound fusion polypeptides are provided in Table G. 
     
       
         
           
               
             
               
                 TABLE G 
               
             
            
               
                   
               
               
                 signal sequences 
               
            
           
           
               
               
               
            
               
                 SEQ 
                 source 
                   
               
               
                 ID 
                 protein 
                   
               
               
                 NO: 
                 name 
                 SEQUENCE 
               
               
                   
               
               
                 115 
                 CD74 
                 MHRRRSRSCREDQKPV 
               
               
                   
               
               
                 116 
                 VSV-G 
                 MKCLLYLAFLFIGVNC 
               
               
                   
               
               
                 117 
                 albumin 
                 KWVTFISLLFLFSSAYS 
               
               
                   
               
               
                 118 
                 calret- 
                 MLLSVPLLLGLLGLAVA 
               
               
                   
                 iculin 
                   
               
               
                   
               
               
                 119 
                 CSF2,  
                 MWLQSLLLLGTVACSISV 
               
               
                   
                 GM-CSF 
                   
               
               
                   
               
               
                 120 
                 CXCL10,  
                 MNQTAILICCLIFLTLSGIQG 
               
               
                   
                 IP-10 
                   
               
               
                   
               
               
                 121 
                 PLAT,  
                 MDAMKRGLCCVLLLCGAVFVSAR 
               
               
                   
                 t-PA 
                   
               
               
                   
               
               
                 122 
                 β- 
                 MRKAAVSHWQQQSYLDSGIHSGATTTAPSLS 
               
               
                   
                 catenin 
                   
               
               
                   
               
               
                 123 
                 ubi- 
                 MQIFVKILIGKTITLEVEPSDTIENVKAKIQDKE 
               
               
                   
                 quitin 
                 GIPPDQQRLIFAGKQLEDGRILSDYNIQKESTLH 
               
               
                   
                   
                 LVLRLRGG 
               
               
                   
               
               
                 124 
                 CCL7,  
                 MKASAALLCLLLTAAAFSPQGLA 
               
               
                   
                 MCP-3 
                   
               
               
                   
               
               
                 125 
                 LAMP-1 
                 MAPRSARRPLLLLLLLLLLGLMHCASAAMFMVKN 
               
               
                   
                 N- 
                 GNGTACIMANFSAAFSVNYDTKSGPKNMTLDLPS 
               
               
                   
                 terminal 
                 DATVVLNRSSCGKENTSDPSLVIAFGRGHTLTLN 
               
               
                   
                   
                 FTRNATRYSVQLMSFVYNLSDTHLFPNASSKEIK 
               
               
                   
                   
                 TVESITDIRADIDKKYRCVSGTQVHMNNVTVTLH 
               
               
                   
                   
                 DATIQAYLSNSSFSRGETRCEQDRPSPTTAPPAP 
               
               
                   
                   
                 PSPSPSPVPKSPSVDKYNVSGTNGTCLLASMGLQ 
               
               
                   
                   
                 LNLTYERKDNTTVTRLLNINPNKTSASGSCGAHL 
               
               
                   
                   
                 VTLELHSEGTTVLLFQFGMNASSSRFFLQGIQLN 
               
               
                   
                   
                 TlLPDARDPAFKAANGSLRALQATVGNSYKCNAE 
               
               
                   
                   
                 EHVRVTKAFSVNIFKVWVQAFKVEGGQFGSVEEC 
               
               
                   
                   
                 LLDENSLEDI 
               
               
                   
               
               
                 126 
                 LAMP-1 
                 GSEFTLIPIAVGGALAGLVIVLIAYLVGRKRSHA 
               
               
                   
                 C- 
                 GYQTI 
               
               
                   
                 terminal 
               
               
                   
               
            
           
         
       
     
     3. Polynucleotides Encoding the Fusion Polypeptides or Compound Fusion Polypeptides 
     Provided are polynucleotides encoding the fusion polypeptides or the compound fusion polypeptides, described herein, vectors comprising such polynucleotides, and host cells (e.g., human cells, mammalian cells, yeast cells, plant cells, insect cells, bacterial cells, e.g.,  E. coli ) comprising such polynucleotides or expression vectors. Provided herein are polynucleotides comprising nucleotide sequence(s) encoding any of the fusion polypeptides or compound fusion polypeptides provided herein, as well as expression cassettes and vector(s) comprising such polynucleotide sequences, e.g., expression vectors for their efficient expression in host cells, e.g., mammalian cells. In various embodiments, the polynucleotide is a DNA, a cDNA, an mRNA, a self-amplifying RNA (SAM), a self-replicating RNA, or a self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotide comprises an alphavirus self-replicating or self-amplifying replicon RNA (RepRNA). Self-replicating RNA and self-amplifying replicon RNA as modes of vaccine delivery are described, e.g., by Ballesteros-Briones, et al.,  Curr Opin Virol . (2020) 44:145-153; Bloom, et al.,  Gene Ther . (2020) 22:1-13; Lundstrom,  Int. J. Mol. Sci . (2020) 21:5130; Moyo, et al.,  Mol Ther Methods Clin Dev . (2018) 12:32-46; Tews, et al.,  Methods Mol Biol . (2017) 1499:15-35; Démoulins, et al.,  Methods Mol Biol . (2017) 1499:37-75; Englezou, et al.,  Mol Ther Nucleic Acids . (2018) 12:118-134; McCollough, et al.,  Vaccines  (Basel). (2014) 2(4):735-54; and McCollough, et al.,  Mol Ther Nucleic Acids . (2014) 3:e173. 
     The terms “polynucleotide” and “nucleic acid molecule” interchangeably refer to a polymeric form of nucleotides and includes both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. As used herein, the term nucleic acid molecule may be interchangeable with the term polynucleotide. In some embodiments, a nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide, and combinations thereof. The terms also include without limitation, single- and double-stranded forms of DNA. In addition, a polynucleotide, e.g., a cDNA or mRNA, may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages. The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analogue, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.). The above term is also intended to include any topological conformation, including single-stranded, double-stranded, partially duplexed, triplex, hairpinned, circular and padlocked conformations. A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The term also includes codon-biased polynucleotides for improved expression in a desired viral expression vector or host cell. 
     A “substitution,” as used herein, denotes the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively. 
     An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. “Isolated nucleic acid” encoding a polypeptide segment or a fusion polypeptide or a compound fusion polypeptide refers to one or more nucleic acid molecules encoding such polypeptide segments or fusion polypeptides or compound fusion polypeptides, including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell. 
     A “polynucleotide variant,” as the term is used herein, is a polynucleotide that typically differs from a polynucleotide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the polynucleotide sequences described herein and evaluating one or more biological activities of the encoded polypeptide as described herein and/or using any of a number of techniques well known in the art. 
     In some embodiments, the nucleic acid molecule is codon-biased to enhance expression in a desired host cell, e.g., in human cells, mammalian cells, yeast cells, plant cells, insect cells, or bacterial cells, e.g.,  E. coli  cells. Accordingly, provided are polynucleotides encoding a fusion polypeptide or a compound fusion polypeptide, described herein, wherein the polynucleotides are codon-biased, comprise replacement heterologous signal sequences, and/or have mRNA instability elements eliminated. Methods to generate codon-biased nucleic acids can be carried out by adapting the methods described in, e.g., U.S. Pat. Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498. Preferred codon usage for expression of the fusion polypeptides or compound fusion polypeptides comprising HIV-1 polypeptide segments from desired viral expression vectors and/or in desired host cells is provided, e.g., at kazusa.or.jp/codon/; and genscript.com/tools/codon-frequency-table. 
     In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 130-167, 210-219 and 225-226, as provided in Table H. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, as provided in Table H. Table H discloses “AAA” as SEQ ID NO: 48, “LIK” as SEQ ID NO: 53, “AAY” as SEQ ID NO: 49, “SEG” as SEQ ID NO: 55, “QEE” as SEQ ID NO: 51, “RAKR” as SEQ ID NO: 60, “KIL” as SEQ ID NO: 52 and “PPV” as SEQ ID NO: 54. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 139, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 139. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 142. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 145. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 148. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 150, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 150. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 152, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 152. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 155, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 155. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 158, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 158. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 225, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 225. In some embodiments, the polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 226. 
     
       
         
           
               
             
               
                 TABLE H 
               
             
            
               
                   
               
               
                 Illustrative Polynucleotides Encoding Fusion Polypeptides 
               
            
           
           
               
               
               
            
               
                 SEQ 
                 Encoded 
                   
               
               
                 ID 
                 Polypeptide 
                   
               
               
                 NO: 
                 Segments 
                 Nucleic Acid Sequences 
               
               
                   
               
               
                 130 
                 Pol:840-920 
                 ACAGTGAAGGCAGCTTGTTGGTGGGCCGGAATTAAACAGGAGTTTGGCATCCCTTATAATCCTCAGTCTCAG 
               
               
                   
                 Gag:147-369 
                 GGAGTGGTGGAGTCTATGAACAAGGAGCTGAAGAAGATCATCGGCCAGGTGAGAGATCAGGCAGAACATCTG 
               
               
                   
                 Gag:1-53 
                 AAGACAGCAGTGCAGATGGCCGTGTTTATCCACAACTTCAAGAGGAAGGGCGGCATTGGAGGATATAGCGCA 
               
               
                   
                 PPV 
                 GGAGAAAGAATCGTGGACATCATCGCCATCTCTCCTAGAACACTGAACGCTTGGGTGAAAGTGGTGGAGGAG 
               
               
                   
                 Pol:747-827 
                 AAAGCCTTTAGCCCAGAAGTGATCCCTATGTTCTCAGCTCTGTCAGAAGGAGCTACACCTCAGGATCTGAAC 
               
               
                   
                 Pol:683-708 
                 ACCATGCTGAATACCGTGGGAGGACATCAGGCAGCTATGCAGATGCTGAAGGAGACAATTAACGAGGAAGCA 
               
               
                   
                 Nef:117-148 
                 GCCGAGTGGGATAGACTGCATCCAGTGCACGCAGGACCTATTGCTCCAGGACAGATGAGAGAGCCTAGAGGA 
               
               
                   
                   
                 AGCGATATTGCCGGCACAACATCTACACTGCAGGAACAGATCGGTTGGATGACCAACAATCCTCCTATCCCA 
               
               
                   
                   
                 GTGGGCGAAATCTACAAACGCTGGATCATCCTGGGCCTGAATAAGATCGTGAGAATGTACAGCCCCACAAGC 
               
               
                   
                   
                 ATCCTGGATATCAGACAGGGACCTAAGGAACCTTTCAGGGATTACGTGGACCGGTTCTACAAGACACTGAGA 
               
               
                   
                   
                 GCAGAACAGGCATCTCAGGAGGTGAAGAATTGGATGACCGAGACACTGCTGGTGCAGAACGCTAATCCAGAT 
               
               
                   
                   
                 TGCAAGACCATTCTGAAAGCTCTGGGACCAGCAGCTACACTGGAAGAGATGATGACAGCTTGTCAGGGAGTG 
               
               
                   
                   
                 GGAGGACCAGGACATAAAGCTAGAGTGCTGGCAGAAGCTATGTCTCAGATGGCAGCTAGAGCTTCAGTGCTG 
               
               
                   
                   
                 TCAGGAGGAGAACTCGATAGGTGGGAGAAGATCAGACTGAGACCAGGAGGCAAGAAGAAGTACAGACTGAAG 
               
               
                   
                   
                 CACATCGTGTGGGCTTCTAGAGAACTGGAGAGATTTGCCGTGAATCCAGGACTCCTGGAAACACCTCCAGTG 
               
               
                   
                   
                 GTGGCTAAAGAGATTGTGGCTTCTTGCGATAAGTGCCAGCTGAAAGGAGAGGCTATGCACGGACAGGTGGAT 
               
               
                   
                   
                 TGTTCTCCAGGAATTTGGCAGCTGGATTGTACACACCTGGAGGGAAAGATTATTCTGGTGGCAGTGCACGTG 
               
               
                   
                   
                 GCATCAGGATATATTGAGGCCGAAGTGATTCCAGCAGAAACAGGACAGGAGACAGCTTACTTTCTGCTCAAA 
               
               
                   
                   
                 CTGGCAGGTCGCTGGCCAGTGAAAACCAAGGAGAAGGTGTACCTGGCTTGGGTGCCAGCTCATAAAGGAATT 
               
               
                   
                   
                 GGCGGAAACGAGCAGGTGGATAAACTGGTGTCTACACAGGGCTACTTCCCAGATTGGCAGAATTACACACCA 
               
               
                   
                   
                 GGACCAGGCACAAGATATCCTCTGACATTCGGTTGGTGTTTCAAGCTGGTGCCCGTG 
               
               
                   
               
               
                 131 
                 Pol:840-920 
                 ACAGTGAAAGCAGCTTGTTGGTGGGCAGGAATCAAGCAGGAGTTTGGCATCCCTTACAATCCTCAGTCTCAG 
               
               
                   
                 Gag:147-369 
                 GGAGTGGTGGAATCTATGAACAAGGAGCTGAAGAAGATCATCGGCCAGGTGAGAGATCAGGCAGAACATCTG 
               
               
                   
                 Gag:1-53 
                 AAGACAGCAGTGCAGATGGCAGTGTTTATCCACAATTTCAAGAGAAAGGGCGGCATTGGCGGATATAGCGCC 
               
               
                   
                 PPV 
                 GGAGAGAGAATCGTGGATATCATCGCCATCTCTCCTAGAACACTGAACGCTTGGGTGAAAGTGGTGGAAGAG 
               
               
                   
                 Pol:747-827 
                 AAAGCCTTCTCTCCAGAGGTGATCCCTATGTTTAGCGCTCTGTCAGAAGGAGCTACACCTCAGGATCTGAAT 
               
               
                   
                 Pol:683-708 
                 ACCATGCTGAATACCGTGGGCGGACATCAGGCAGCTATGCAGATGCTGAAAGAGACAATCAACGAAGAAGCA 
               
               
                   
                 Nef:117-148 
                 GCCGAGTGGGATAGACTGCATCCAGTGCACGCAGGACCTATTGCTCCAGGACAGATGAGAGAACCTAGAGGA 
               
               
                   
                   
                 TCAGACATTGCCGGAACAACATCTACACTGCAGGAGCAGATCGGTTGGATGACAAACAACCCTCCAATCCCA 
               
               
                   
                   
                 GTGGGAGAGATCTACAAGAGATGGATCATCCTGGGCCTGAATAAGATCGTGAGAATGTACAGCCCCACAAGC 
               
               
                   
                   
                 ATCCTGGATATCAGACAGGGACCTAAGGAGCCTTTCAGAGATTACGTGGACAGGTTCTACAAGACCCTGAGA 
               
               
                   
                   
                 GCAGAACAGGCTTCTCAGGAGGTGAAAAATTGGATGACCGAAACACTGCTGGTGCAGAACGCTAATCCCGAT 
               
               
                   
                   
                 TGCAAGACCATCCTGAAAGCTCTGGGACCAGCAGCTACACTGGAAGAGATGATGACAGCTTGTCAGGGAGTG 
               
               
                   
                   
                 GGAGGACCAGGACATAAAGCTAGAGTGCTGGCAGAAGCTATGTCTCAGATGGCAGCTAGAGCTTCAGTGCTG 
               
               
                   
                   
                 TCAGGAGGAGAACTCGATAGATGGGAAAAGATCAGACTGAGACCAGGAGGAAAGAAGAAGTACAGGCTGAAG 
               
               
                   
                   
                 CACATCGTCTGGGCTTCTAGAGAACTGGAGAGATTTGCCGTGAATCCAGGACTCCTGGAAACACCTCCAGTG 
               
               
                   
                   
                 GTGGCTAAAGAGATTGTGGCTTCTTGCGACAAGTGTCAGCTGAAAGGAGAGGCTATGCACGGACAGGTGGAT 
               
               
                   
                   
                 TGTTCTCCAGGAATTTGGCAGCTGGATTGCACACATCTGGAAGGAAAGATTATTCTGGTGGCAGTGCACGTG 
               
               
                   
                   
                 GCATCTGGATATATCGAGGCCGAGGTGATTCCAGCCGAAACAGGACAGGAAACAGCCTACTTTCTCCTGAAA 
               
               
                   
                   
                 CTGGCAGGTAGGTGGCCAGTGAAGACAAAGGAGAAGGTGTACCTGGCTTGGGTGCCAGCCCATAAAGGAATT 
               
               
                   
                   
                 GGAGGCAATGAGCAGGTGGATAAACTGGTGTCAACACAGGGCTACTTCCCAGATTGGCAGAATTACACCCCA 
               
               
                   
                   
                 GGACCAGGAACAAGATATCCTCTGACATTCGGTTGGTGCTTTAAACTGGTGCCCGTG 
               
               
                   
               
               
                 132 
                 Gag:147-369 
                 CTGTCTCCTAGAACACTGAACGCTTGGGTGAAGGTGATCGAAGAGAAGGCCTTTAGCCCAGAAGTGATCCCT 
               
               
                   
                 Pol:747-827 
                 ATGTTCACAGCTCTGTCAGAAGGAGCTACACCTCATGACCTGAACACCATGCTGAATACCATCGGAGGACAT 
               
               
                   
                 Gag:1-53 
                 CAGGCAGCTATGCAGATGCTGAAGGATACCATCAACGAAGAAGCAGCCGAGTGGGATAGAGTGCATCCAGTG 
               
               
                   
                 AA 
                 CACGCAGGACCAGTGGCTCCAGGACAGATGAGAGATCCTAGAGGAAGCGATATTGCCGGCTCTACATCTACA 
               
               
                   
                 Pol:840-920 
                 CTGCAGGAACAGATCGCTTGGATGACCAACAATCCTCCTATCCCAGTGGGCGATATCTACAAACGCTGGATC 
               
               
                   
                 Nef:117-148 
                 ATCATGGGCCTGAACAAGATCGTGAGGATGTACAGCCCAGTGTCTATCCTGGATATCAAGCAGGGCCCTAAA 
               
               
                   
                 LIK 
                 GAACCTTTCAGGGATTACGTGGACCGGTTCTACAGAACACTGAGAGCAGAACAGGCCTCACAGGATGTGAAG 
               
               
                   
                 Pol:683-708 
                 AATTGGATGACCGAGACACTGCTGGTGCAGAACAGCAACCCCGATTGCAAGACCATTCTGAAAGCTCTGGGA 
               
               
                   
                   
                 CCAGGAGCTACACTGGAAGAGATGATGTCAGCTTGTCAGGGAGTGGGAGGACCATCTCATAAAGCTAGAGTG 
               
               
                   
                   
                 CTGGCCGAAGCTATGTGTCAGGTGGCTAAAGAGATCGTGGCTTGTTGCGACAAGTGTCAGCTGAAAGGAGAG 
               
               
                   
                   
                 GCTATTCACGGACAGGTGGATTGTTCTCCAGGAGTCTGGCAGCTGGATTGTACACACCTGGAGGGAAAGGTG 
               
               
                   
                   
                 ATTCTGGTGGCAGTGCACGTGGCATCAGGATATATTGAGGCCGAGATCATTCCTACAGAAACAGGACAGGAG 
               
               
                   
                   
                 ACCGCTTACTTCATCCTGAAACTGGCAGGTAGGTGGCCAGTGACAACAATGGCAGCTAGAGCTTCTATCCTG 
               
               
                   
                   
                 AGCGGAGGAAAACTCGACAAGTGGGAGAAGATCAGACTGAGACCAGGAGGCAGAAAGAAGTACAAGCTGAAG 
               
               
                   
                   
                 CATCTCGTCTGGGCTTCTAGAGAGCTGGAAAGATTCGCTCTGAATCCAGGTCTGCTGGAAACAGCAGCAGCA 
               
               
                   
                   
                 GTGAAAGCAGCTTGTTGGTGGGCAGGAGTGAAACAGGAATTTGGCATCCCTTACAATACACAGTCTCAGGGA 
               
               
                   
                   
                 GTGGTGGAGAGCATGAACAACGAGCTGAAGAAGATCATCGGCCAGATCAGAGATCAGGCAGAACATCTGAAG 
               
               
                   
                   
                 ACAGCAGTGCAGATGGCAGTGCTGATCCACAACTTCAAGAGGAAGGGCGGAATCGGAGAATATAGCGCCGGC 
               
               
                   
                   
                 GAGAGAATTATCGATATCATCGCCACACAGGGCTTTTTCCCAGATTGGCAGAACTATACACCAGGACCAGGA 
               
               
                   
                   
                 ATCAGGTTCCCTCTGACATTCGGTTGGTGTTTCAAGCTGGTGCCTCTGCTGATCAAGAAGGAGAAAATCTAT 
               
               
                   
                   
                 CTGGCTTGGGTGCCAGCTCACAAAGGAATTGGCGGAAACGAGCAGATCGATAAGCTGGTGTCT 
               
               
                   
               
               
                 133 
                 Gag:147-369 
                 CTGTCTCCTAGAACACTGAACGCTTGGGTGAAGGTGATTGAGGAGAAAGCCTTCAGCCCAGAAGTGATCCCT 
               
               
                   
                 Pol:747-827 
                 ATGTTTACAGCCCTGAGCGAAGGAGCTACACCTCACGATCTGAATACCATGCTGAATACAATCGGCGGACAT 
               
               
                   
                 Gag:1-53 
                 CAGGCAGCCATGCAGATGCTGAAGGATACAATCAACGAAGAAGCAGCCGAGTGGGATAGAGTGCATCCAGTG 
               
               
                   
                 AA 
                 CACGCAGGACCAGTGGCTCCAGGACAGATGAGAGATCCTAGAGGAAGCGATATCGCCGGATCTACATCTACA 
               
               
                   
                 Pol:840-920 
                 CTGCAGGAACAGATCGCTTGGATGACAAATAACCCCCCTATCCCAGTGGGAGATATCTATAAGCGCTGGATC 
               
               
                   
                 Nef:117-148 
                 ATCATGGGCCTGAACAAGATCGTGAGGATGTACAGCCCAGTGAGCATCCTGGATATCAAGCAGGGACCTAAG 
               
               
                   
                 LIK 
                 GAGCCTTTCAGAGATTACGTGGACAGGTTCTACAGAACCCTGAGAGCAGAACAGGCTTCTCAGGACGTGAAG 
               
               
                   
                 Pol:683-708 
                 AATTGGATGACCGAAACACTGCTGGTGCAGAATAGCAACCCCGATTGCAAGACCATCCTGAAAGCTCTGGGA 
               
               
                   
                   
                 CCAGGAGCTACACTGGAAGAAATGATGAGCGCTTGTCAGGGAGTGGGAGGACCATCTCATAAGGCTAGAGTG 
               
               
                   
                   
                 CTGGCAGAAGCTATGTGTCAGGTGGCTAAGGAGATTGTGGCTTGTTGCGACAAGTGTCAGCTGAAAGGAGAG 
               
               
                   
                   
                 GCTATTCACGGACAGGTGGATTGTTCTCCAGGAGTCTGGCAGCTGGATTGTACACATCTGGAGGGAAAAGTG 
               
               
                   
                   
                 ATTCTGGTGGCAGTGCACGTGGCATCAGGATATATTGAGGCCGAAATCATCCCTACAGAGACAGGACAGGAG 
               
               
                   
                   
                 ACAGCCTACTTTATCCTGAAACTGGCAGGCAGATGGCCAGTGACAACAATGGCAGCTAGAGCTTCTATCCTG 
               
               
                   
                   
                 AGCGGAGGAAAGCTGGATAAGTGGGAAAAGATCAGACTGAGACCAGGAGGAAGGAAGAAGTACAAGCTGAAG 
               
               
                   
                   
                 CACCTGGTCTGGGCTTCTAGAGAACTGGAAAGATTCGCCCTGAATCCAGGTCTGCTGGAAACAGCAGCAGCA 
               
               
                   
                   
                 GTGAAAGCAGCTTGTTGGTGGGCAGGAGTGAAACAGGAGTTCGGAATCCCCTACAACACACAGTCTCAGGGA 
               
               
                   
                   
                 GTGGTGGAATCTATGAACAACGAGCTGAAGAAGATCATCGGCCAGATCAGAGACCAGGCCGAACATCTGAAG 
               
               
                   
                   
                 ACAGCAGTGCAGATGGCAGTGCTGATTCACAATTTCAAGAGAAAGGGCGGCATCGGAGAGTATAGCGCCGGA 
               
               
                   
                   
                 GAGAGAATCATCGATATCATCGCTACACAGGGCTTCTTCCCCGATTGGCAGAATTACACCCCAGGCCCAGGC 
               
               
                   
                   
                 ATTAGATTCCCTCTGACATTCGGTTGGTGCTTCAAACTGGTGCCTCTGCTGATCAAGAAGGAGAAGATCTAC 
               
               
                   
                   
                 CTGGCTTGGGTGCCAGCTCATAAAGGAATCGGAGGAAACGAGCAGATCGATAAGCTGGTGTCT 
               
               
                   
               
               
                 134 
                 Pol:56-117 
                 TTTCCTCAGATCACTCTCTGGCAGAGACCACTGGTGACAATCAAGATCGGAGGACAGCTGAAAGAAGCTCTG 
               
               
                   
                 Nef:64-99 
                 CTGGATACAGGAGCAGACGATACAGTGCTGGAAGAGATGAATCTGCCAGGTCGCTGGAAACCTAAGATGATT 
               
               
                   
                 LI 
                 GGAGGCATTGGCGGCTTTATCAAGGTGAGACAGTACGACCAGGAGGAAGTGGGATTTCCAGTGAAACCTCAG 
               
               
                   
                 Pol:542-606 
                 GTGCCTCTGAGACCTATGACATTTAAGGGCGCTCTGGACCTGTCTCACTTTCTGAGAGAGAAGGGAGGACTG 
               
               
                   
                 Pol:367-431 
                 GAAGGACTGATCCCTAAGTTCAAGCTGCCTATCCAGAAGGAGACTTGGGAAACTTGGTGGACAGAGTATTGG 
               
               
                   
                 Pol:932-1003 
                 CAGGCTACTTGGATTCCCGAGTGGGAATTTGTGAACACACCTCCTCTGGTGAAGCTGTGGTATCAGCTGGAA 
               
               
                   
                 Pol:129-320 
                 AAGGAGCCTATTGTGGGCGCAGAAACATTCTACGTGGACGGAGCAGCTAACAGAGAAACTAAGTGGGGATTC 
               
               
                   
                   
                 ACCACCCCAGATAAGAAGCACCAGAAGGAGCCACCATTTCTCTGGATGGGATACGAACTGCACCCAGATAAG 
               
               
                   
                   
                 TGGACAGTCCAGCCTATTGTGCTGCCAGAAAAGGACTCTTGGACCGTGAACGATATCCAGAAGCTGGTGGGA 
               
               
                   
                   
                 AAGCTGAATTGGGCTTCTCAGATCTACCCAGGAATCAAGGTGATCACCAAGATCCAGAACTTCAGGGTGTAC 
               
               
                   
                   
                 TACAGAGACAGCAGAGATCCTCTCTGGAAGGGACCAGCTAAACTCCTCTGGAAAGGAGAAGGAGCAGTGGTG 
               
               
                   
                   
                 ATCCAGGATAACAGCGACATCAAGGTGGTGCCTAGAAGAAAGGCCAAGATCATCAGGGACTACGGCAAACAG 
               
               
                   
                   
                 ATGGCAGGAGACGATTGCGTGGCTTCTAGACAGGACGAAGACGGAACAGTCCTGGTGGGACCTACACCAGTG 
               
               
                   
                   
                 AATATCATCGGCAGAAATCTCCTGACACAGATCGGTTGTACCCTGAACTTCCCTATCAGCCCTATCGAGACA 
               
               
                   
                   
                 GTGCCAGTGAAACTGAAGCCAGGAATGGACGGACCTAAAGTCAAGCAGTGGCCTCTGACAGAAGAGAAGATC 
               
               
                   
                   
                 AAGGCCCTGGTGGAGATTTGCACAGAGATGGAGAAGGAGGGAAAGATCAGCAAGATCGGCCCAGAGAATCCT 
               
               
                   
                   
                 TACAACACCCCAGTGTTCGCCATCAAGAAGAAGGATAGCACCAAGTGGAGAAAGCTGGTGGATTTCAGGGAG 
               
               
                   
                   
                 CTGAACAAGAGAACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCATCCAGCAGGACTGAAGAAGAAG 
               
               
                   
                   
                 AAGAGCGTGACAGTGCTGGACGTGGGAGACGCTTATTTTAGCGTGCCTCTGGACAAGGACTTCAGAAAGTAC 
               
               
                   
                   
                 ACCGCCTTCACCATCCCTTCTATCAACAACGAGACCCCAGGCATCAGATACCAGTATAACGTGCTGCCTCAG 
               
               
                   
                   
                 GGTTGGAAAGGATCTCCAGCAATCTTTCAGTCTAGCATGACC 
               
               
                   
               
               
                 135 
                 Pol:56-117 
                 TTCCCTCAGATTACTCTCTGGCAGAGGCCACTGGTGACAATTAAGATCGGAGGACAGCTGAAAGAAGCTCTG 
               
               
                   
                 Nef:64-99 
                 CTGGATACAGGAGCAGACGATACAGTGCTGGAGGAAATGAACCTGCCAGGTCGCTGGAAACCTAAAATGATC 
               
               
                   
                 LI 
                 GGAGGAATCGGCGGCTTTATTAAGGTGAGACAGTACGATCAGGAGGAAGTGGGATTTCCAGTGAAACCTCAG 
               
               
                   
                 Pol:542-606 
                 GTGCCTCTGAGACCTATGACATTTAAGGGCGCTCTGGATCTGAGCCACTTTCTGAGAGAGAAAGGAGGACTG 
               
               
                   
                 Pol:367-431 
                 GAAGGACTGATCCCTAAGTTCAAGCTGCCCATCCAGAAGGAGACTTGGGAAACTTGGTGGACCGAGTATTGG 
               
               
                   
                 Pol:932-1003 
                 CAGGCAACTTGGATTCCCGAGTGGGAATTTGTGAACACACCTCCTCTGGTGAAGCTGTGGTATCAGCTGGAA 
               
               
                   
                 Pol:129-320 
                 AAGGAGCCTATCGTGGGAGCCGAAACATTTTACGTGGACGGAGCAGCCAACAGAGAAACTAAGTGGGGATTC 
               
               
                   
                   
                 ACCACCCCAGATAAGAAGCACCAGAAAGAGCCTCCCTTTCTCTGGATGGGATACGAACTGCACCCAGATAAG 
               
               
                   
                   
                 TGGACAGTCCAGCCTATTGTGCTGCCAGAAAAGGACTCTTGGACAGTGAACGACATCCAGAAGCTGGTGGGA 
               
               
                   
                   
                 AAGCTGAATTGGGCCTCTCAGATTTACCCAGGAATCAAGGTGATCACCAAGATCCAGAACTTCAGGGTGTAC 
               
               
                   
                   
                 TACAGGGATAGCAGAGATCCTCTCTGGAAGGGACCAGCTAAACTCCTCTGGAAAGGAGAAGGAGCAGTGGTG 
               
               
                   
                   
                 ATCCAGGATAATAGCGACATCAAGGTGGTGCCTAGAAGAAAGGCTAAGATCATCCGGGACTACGGCAAACAG 
               
               
                   
                   
                 ATGGCAGGAGACGATTGCGTGGCTTCTAGACAGGATGAAGACGGAACAGTCCTGGTGGGACCTACACCAGTG 
               
               
                   
                   
                 AACATCATCGGCAGAAACCTGCTGACACAGATCGGTTGTACCCTGAACTTCCCTATCTCTCCTATCGAAACA 
               
               
                   
                   
                 GTGCCAGTGAAGCTGAAGCCAGGAATGGACGGACCTAAAGTCAAGCAGTGGCCTCTGACAGAAGAGAAGATC 
               
               
                   
                   
                 AAGGCTCTGGTGGAGATTTGCACCGAAATGGAGAAGGAGGGCAAGATCAGCAAGATCGGACCAGAGAATCCT 
               
               
                   
                   
                 TACAATACCCCAGTGTTCGCCATCAAGAAGAAGGACAGCACCAAGTGGAGAAAGCTGGTGGATTTCAGGGAA 
               
               
                   
                   
                 CTGAACAAGAGGACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCATCCAGCAGGACTGAAGAAGAAG 
               
               
                   
                   
                 AAGAGCGTGACAGTGCTGGACGTGGGAGACGCTTATTTTAGCGTGCCTCTGGACAAGGACTTCAGAAAGTAC 
               
               
                   
                   
                 ACCGCCTTCACCATCCCTAGCATCAATAACGAGACCCCAGGCATCAGATACCAGTATAACGTGCTGCCACAG 
               
               
                   
                   
                 GGCTGGAAAGGATCTCCAGCAATCTTTCAGAGCTCTATGACA 
               
               
                   
               
               
                 136 
                 Pol:56-117 
                 CTGCCTCAGATTACCCTGTGGCAGAGACCTATCGTGACCATCAAGATCGGAGGACAGATCAAAGAAGCTCTG 
               
               
                   
                 Pol:367-431 
                 CTGGATACAGGAGCAGACGATACAGTGCTGGAGGATATGAACCTGCCAGGTAAGTGGAAGCCTAAGATGATC 
               
               
                   
                 AA 
                 GGCGGAATTGGCGGCTTTATCAAGGTCAAGCAGTACGATCAGTGGGGACTGACAACACCAGACAAGAAGCAC 
               
               
                   
                 QEE 
                 CAGAAGGACCCCCCTTTCCTCTGGATGGGATACGAACTGCATCCAGATAGGTGGACAGTGCAGCCAATTGAG 
               
               
                   
                 Nef:64-99 
                 CTGCCAGAAAAGGAGTCTTGGACAGTGAACGACATCCAGAAGCTGATCGGCAAGCTGAATTGGGCTTCTCAG 
               
               
                   
                 Pol:932-1003 
                 ATCTACGCCGGAATTAAGGTGGCAGCTCAGGAAGAAGAAGAAGTGGGATTTCCAGTGAGACCTCAGGTGCCT 
               
               
                   
                 Pol:542-606 
                 CTGAGACCTATGACATACAAGGGAGCTCTGGATCTGAGCCACTTTCTGAAAGAGAAGGGAGGACTGGAGGGA 
               
               
                   
                 AA 
                 ATTACCAAGCTGCAGAACTTCAGGGTGTACTACAGGGACAACAGAGATCCTCTGTGGAAAGGACCAGCTAGA 
               
               
                   
                 Pol:129-320 
                 CTCCTCTGGAAAGGAGAAGGAGCAGTGGTGATTCAGGACAATAGCGAGATCAAGGTGGTGCCTAGAAGAAAG 
               
               
                   
                   
                 GTGAAGATCATCCGGGACTACGGCAAAAGAATGGCAGGAGACGATTGCGTGGCAGGAAGACAGGACGAGGAC 
               
               
                   
                   
                 CCCAAATTCAGACTGCCTATCCAGAAGGAGACTTGGGACACTTGGTGGACAGATTATTGGCAGGCAACTTGG 
               
               
                   
                   
                 ATTCCCGAGTGGGAATTTACCAATACCCCTCCTCTGGTCAAGCTCTGGTATCAGCTGGAAACAGAGCCTATC 
               
               
                   
                   
                 GCAGGAGTGGAAACATTCTACGTGGACGGAGCCTCTAATAGAGAGACAAAAGCCGCAGGAACAGTGCTGATT 
               
               
                   
                   
                 GGACCTACACCAGTGAACATCATCGGGAGAAACCTGCTGACACAGCTGGGTTGTACACTGAACTTCCCTATC 
               
               
                   
                   
                 AGCCCTATCGATACAGTGCCAGTGAAACTGAAGCCAGGAATGGACGGACCTAGAGTGAAACAGTGGCCTCTG 
               
               
                   
                   
                 ACAGAAGAGAAGATCAAGGCCCTGATCGAGATTTGTACAGAGATGGAGAAGGAGGGCAAGATCTCTAGAATT 
               
               
                   
                   
                 GGCCCAGAGAACCCCTACAATACCCCTATCTTTGCCATCAAGAAGAAGGACGGCACCAAGTGGAGAAAGCTG 
               
               
                   
                   
                 GTGGATTTCAGGGAGCTGAACAAGAAGACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCACCCTAGC 
               
               
                   
                   
                 GGACTGAAAAAGAAGAAGAGCGTGACCGTGCTGGATATTGGAGACGCCTATTTTAGCGTGCCACTGGATAAG 
               
               
                   
                   
                 GAGTTCAGAAAGTACACCGCCTTTACCGTGCCTTCTACCAATAACGAGACACCAGGAGTGAGATACCAGTAC 
               
               
                   
                   
                 AACGTGCTGCCTATGGGTTGGAAGGGATCACCAGCCATCTTTCAGTGTAGCATGACA 
               
               
                   
               
               
                 137 
                 Pol:56-117 
                 CTGCCTCAGATTACTCTCTGGCAGAGGCCTATTGTGACAATCAAGATCGGCGGACAGATCAAAGAAGCCCTG 
               
               
                   
                 Pol:367-431 
                 CTGGATACAGGAGCAGACGATACAGTGCTGGAGGATATGAACCTGCCAGGCAAGTGGAAACCTAAGATGATC 
               
               
                   
                 AA 
                 GGAGGAATCGGCGGATTTATCAAGGTGAAGCAGTACGATCAGTGGGGACTGACAACACCAGATAAGAAGCAC 
               
               
                   
                 QEE 
                 CAGAAGGACCCCCCATTCCTGTGGATGGGATACGAACTGCATCCAGATAGGTGGACAGTGCAGCCAATCGAA 
               
               
                   
                 Nef:64-99 
                 CTGCCAGAAAAGGAGTCTTGGACCGTGAACGACATCCAGAAACTGATCGGCAAGCTGAATTGGGCCAGCCAG 
               
               
                   
                 Pol:932-1003 
                 ATTTACGCCGGAATCAAAGTGGCAGCTCAGGAAGAAGAGGAAGTGGGATTTCCAGTGAGACCTCAGGTGCCT 
               
               
                   
                 Pol:542-606 
                 CTGAGACCTATGACATACAAAGGCGCTCTGGATCTGAGCCACTTTCTGAAAGAGAAGGGAGGACTGGAGGGA 
               
               
                   
                 AA 
                 ATTACAAAGCTGCAGAACTTCCGGGTGTACTACAGAGACAACAGAGACCCTCTCTGGAAAGGACCAGCTAGA 
               
               
                   
                 Pol:129-320 
                 CTCCTCTGGAAAGGAGAAGGAGCAGTGGTGATCCAGGATAATAGCGAGATCAAGGTGGTGCCTAGGAGAAAG 
               
               
                   
                   
                 GTGAAGATCATCAGGGATTACGGCAAAAGAATGGCCGGAGACGATTGCGTGGCAGGAAGACAGGACGAAGAT 
               
               
                   
                   
                 CCCAAGTTCAGACTGCCTATCCAGAAGGAGACTTGGGACACTTGGTGGACCGATTATTGGCAGGCAACTTGG 
               
               
                   
                   
                 ATTCCCGAGTGGGAATTTACCAACACACCTCCTCTGGTGAAGCTGTGGTATCAGCTGGAAACAGAGCCTATT 
               
               
                   
                   
                 GCCGGAGTGGAAACATTCTACGTGGACGGAGCCAGCAACAGAGAGACAAAAGCCGCCGGAACAGTGCTGATT 
               
               
                   
                   
                 GGACCTACACCCGTGAATATCATCGGAAGAAATCTGCTGACACAGCTGGGTTGTACCCTGAATTTCCCTATC 
               
               
                   
                   
                 AGCCCCATCGATACAGTGCCAGTGAAACTGAAGCCAGGAATGGACGGACCTAGAGTCAAACAGTGGCCTCTG 
               
               
                   
                   
                 ACAGAAGAGAAGATCAAGGCCCTGATCGAGATTTGTACCGAGATGGAGAAGGAGGGAAAGATCAGCAGAATC 
               
               
                   
                   
                 GGCCCAGAGAATCCTTACAACACCCCCATCTTCGCCATCAAGAAGAAAGACGGAACCAAGTGGAGAAAGCTG 
               
               
                   
                   
                 GTGGATTTCAGGGAGCTGAACAAGAAGACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCACCCTAGC 
               
               
                   
                   
                 GGCCTGAAGAAGAAAAAGAGCGTGACAGTGCTGGACATTGGAGACGCTTATTTCAGCGTGCCACTGGATAAG 
               
               
                   
                   
                 GAGTTCAGAAAGTACACCGCCTTTACCGTGCCTTCTACAAACAACGAGACACCAGGCGTGAGATATCAGTAC 
               
               
                   
                   
                 AACGTGCTGCCTATGGGTTGGAAAGGATCTCCCGCCATCTTTCAGTGTAGCATGACA 
               
               
                   
               
               
                 138 
                 Pol:747-827 
                 GTGGCCAAAGAAATTGTGGCCTCTTGCGATAAGTGCCAGCTGAAAGGAGAGGCTATGCACGGACAGGTGGAT 
               
               
                   
                 Nef:117-148 
                 TGTTCTCCAGGAATTTGGCAGCTGGATTGTACACACCTGGAGGGAAAGATTATTCTGGTGGCAGTGCACGTG 
               
               
                   
                 Pol:840-920 
                 GCATCAGGATATATTGAGGCCGAAGTGATTCCAGCAGAAACAGGACAGGAGACAGCTTACTTTCTGCTCAAA 
               
               
                   
                 AA 
                 CTGGCAGGTCGCTGGCCAGTGAAGACAACACAGGGCTACTTTCCTGATTGGCAGAATTACACACCAGGACCA 
               
               
                   
                 Gag:1-53 
                 GGAACAAGATACCCTCTGACCTTTGGTTGGTGCTTCAAACTGGTGCCCGTGACAGTGAAAGCAGCTTGTTGG 
               
               
                   
                 SEG 
                 TGGGCAGGAATTAAGCAGGAGTTCGGCATCCCTTACAATCCTCAGTCTCAGGGAGTGGTGGAATCTATGAAC 
               
               
                   
                 Gag:147-369 
                 AAGGAGCTGAAGAAGATCATCGGCCAGGTGAGAGATCAGGCAGAACATCTGAAGACAGCAGTGCAGATGGCA 
               
               
                   
                 AAA 
                 GTGTTCATCCACAACTTCAAGCGGAAGGGAGGAATTGGAGGATATAGCGCAGGAGAGAGAATCGTGGATATC 
               
               
                   
                 Pol:683-708 
                 ATTGCCGCCGCTATGGCAGCTAGAGCCAGCGTGCTGAGCGGAGGAGAACTCGATCGCTGGGAAAAGATCAGA 
               
               
                   
                   
                 CTGAGACCAGGAGGCAAGAAGAAGTACAGACTGAAGCACATCGTCTGGGCTTCTAGAGAACTGGAGAGATTT 
               
               
                   
                   
                 GCCGTGAATCCAGGACTGCTGGAAACAAGCGAGGGCATTTCTCCTAGAACCCTGAACGCTTGGGTGAAAGTG 
               
               
                   
                   
                 GTGGAAGAAAAAGCCTTCTCTCCAGAGGTGATCCCTATGTTTAGCGCTCTGTCAGAAGGAGCTACACCTCAG 
               
               
                   
                   
                 GATCTGAACACCATGCTGAACACAGTGGGAGGACATCAGGCAGCTATGCAGATGCTGAAGGAGACAATTAAC 
               
               
                   
                   
                 GAAGAAGCCGCCGAGTGGGATAGACTGCATCCAGTGCACGCAGGACCTATTGCTCCAGGACAGATGAGAGAG 
               
               
                   
                   
                 CCTAGAGGAAGCGATATTGCCGGAACAACAAGCACACTGCAGGAACAGATCGGTTGGATGACCAATAATCCC 
               
               
                   
                   
                 CCTATTCCAGTGGGCGAGATCTATAAGCGCTGGATTATCCTGGGCCTGAACAAGATCGTGAGAATGTACAGC 
               
               
                   
                   
                 CCCACCTCTATCCTGGATATCAGACAGGGCCCTAAGGAACCTTTCAGAGACTACGTGGACAGGTTCTACAAG 
               
               
                   
                   
                 ACACTGAGAGCAGAACAGGCATCTCAGGAGGTGAAGAATTGGATGACCGAGACACTGCTGGTGCAGAACGCC 
               
               
                   
                   
                 AATCCAGATTGCAAGACAATTCTGAAAGCCCTGGGACCAGCAGCTACACTGGAAGAGATGATGACCGCTTGT 
               
               
                   
                   
                 CAGGGAGTGGGAGGACCAGGACATAAAGCTAGAGTGCTGGCAGAAGCTATGTCTCAGGCAGCAGCTAAGGAG 
               
               
                   
                   
                 AAAGTGTATCTGGCTTGGGTGCCAGCCCATAAAGGAATTGGAGGAAACGAGCAGGTGGATAAACTGGTGTCT 
               
               
                   
               
               
                 139 
                 Pol:747-827 
                 GTGGCTAAGGAAATTGTGGCCTCTTGCGACAAGTGTCAGCTGAAAGGAGAGGCTATGCACGGACAGGTGGAT 
               
               
                   
                 Nef:117-148 
                 TGTTCTCCAGGAATTTGGCAGCTGGATTGCACACATCTGGAAGGAAAGATTATTCTGGTGGCAGTGCACGTG 
               
               
                   
                 Pol:840-920 
                 GCATCTGGATATATCGAGGCCGAGGTGATTCCAGCCGAAACAGGACAGGAAACAGCCTACTTTCTCCTGAAA 
               
               
                   
                 AA 
                 CTGGCAGGTAGGTGGCCAGTGAAGACAACACAGGGCTACTTCCCAGATTGGCAGAATTACACCCCAGGACCA 
               
               
                   
                 Gag:1-53 
                 GGAACAAGATACCCTCTGACCTTTGGTTGGTGCTTCAAGCTCGTCCCAGTGACAGTGAAAGCAGCTTGTTGG 
               
               
                   
                 SEG 
                 TGGGCAGGAATTAAACAGGAGTTCGGAATCCCTTACAATCCTCAGTCTCAGGGAGTGGTGGAAAGCATGAAC 
               
               
                   
                 Gag:147-369 
                 AAGGAGCTGAAGAAGATCATCGGACAGGTGAGAGATCAGGCAGAACATCTGAAGACAGCAGTGCAGATGGCA 
               
               
                   
                 AAA 
                 GTGTTCATCCACAACTTCAAGAGGAAGGGCGGAATTGGAGGATATAGCGCCGGAGAGAGAATCGTGGATATC 
               
               
                   
                 Pol:683-708 
                 ATTGCAGCAGCTATGGCAGCTAGAGCTTCAGTGCTGTCAGGAGGAGAACTCGATAGGTGGGAGAAGATCAGA 
               
               
                   
                   
                 CTGAGACCAGGAGGCAAGAAGAAGTACAGACTGAAGCACATCGTGTGGGCTTCTAGAGAACTGGAGAGATTC 
               
               
                   
                   
                 GCAGTGAATCCAGGACTGCTGGAAACAAGCGAGGGAATTAGCCCTAGAACCCTGAATGCTTGGGTGAAAGTG 
               
               
                   
                   
                 GTGGAAGAGAAGGCCTTCAGCCCAGAGGTGATCCCTATGTTTAGCGCTCTGTCAGAAGGAGCTACACCTCAG 
               
               
                   
                   
                 GATCTGAACACCATGCTGAATACAGTGGGAGGACATCAGGCAGCTATGCAGATGCTGAAGGAGACCATCAAC 
               
               
                   
                   
                 GAAGAAGCAGCCGAGTGGGATAGACTGCATCCAGTGCACGCAGGACCTATTGCTCCAGGACAGATGAGAGAA 
               
               
                   
                   
                 CCTAGAGGAAGCGATATCGCCGGAACAACATCTACACTGCAGGAACAGATCGGTTGGATGACCAACAACCCT 
               
               
                   
                   
                 CCTATTCCAGTGGGCGAGATTTACAAGCGCTGGATTATCCTGGGCCTGAATAAGATCGTGAGAATGTACAGC 
               
               
                   
                   
                 CCTACCAGCATTCTGGACATCAGACAGGGACCTAAGGAGCCTTTTAGAGACTACGTGGACAGGTTCTACAAG 
               
               
                   
                   
                 ACCCTGAGAGCAGAACAGGCATCTCAGGAGGTGAAGAATTGGATGACCGAGACACTGCTGGTGCAGAACGCT 
               
               
                   
                   
                 AATCCCGATTGCAAGACCATCCTGAAAGCTCTGGGACCAGCAGCTACACTGGAAGAGATGATGACAGCTTGT 
               
               
                   
                   
                 CAGGGAGTGGGAGGACCAGGACATAAAGCTAGAGTGCTGGCAGAAGCTATGTCTCAGGCAGCAGCTAAAGAG 
               
               
                   
                   
                 AAAGTGTATCTGGCTTGGGTGCCAGCTCACAAAGGAATTGGAGGAAACGAGCAGGTGGATAAACTGGTGAGC 
               
               
                   
               
               
                 140 
                 Pol:747-827 
                 GTGGCCAAAGAGATTGTGGCCTCCTGTGACAAGTGCCAGCTGAAAGGAGAGGCAATGCATGGACAGGTGGAT 
               
               
                   
                 Nef:117-148 
                 TGTTCTCCAGGAATCTGGCAGCTGGATTGCACACACCTGGAGGGAAAGATCATCCTGGTGGCAGTGCATGTT 
               
               
                   
                 Pol:840-920 
                 GCATCAGGATACATTGAGGCAGAAGTGATTCCAGCAGAAACAGGACAGGAGACTGCTTACTTTCTGCTGAAA 
               
               
                   
                 AA 
                 CTGGCAGGAAGGTGGCCAGTGAAGACAACACAGGGTTATTTCCCTGATTGGCAGAACTACACCCCAGGCCCT 
               
               
                   
                 Gag:1-53 
                 GGCACAAGATACCCTCTGACCTTTGGTTGGTGCTTCAAACTGGTCCCTGTGACAGTGAAAGCAGCTTGTTGG 
               
               
                   
                 SEG 
                 TGGGCAGGCATCAAGCAGGAGTTTGGCATCCCTTACAACCCTCAGTCTCAGGGAGTTGTGGAATCCATGAAC 
               
               
                   
                 Gag:147-369 
                 AAGGAGCTGAAGAAGATCATTGGTCAGGTGAGGGATCAGGCAGAACATCTGAAGACAGCAGTGCAGATGGCA 
               
               
                   
                 AAA 
                 GTGTTCATCCACAATTTCAAGAGGAAGGGAGGAATTGGAGGATACAGTGCAGGAGAGAGAATTGTGGACATC 
               
               
                   
                 Pol:683-708 
                 ATTGCAGCTGCAATGGCAGCAAGAGCCAGTGTGCTCAGTGGAGGAGAACTTGACAGGTGGGAAAAGATCAGA 
               
               
                   
                   
                 CTGAGACCAGGAGGCAAGAAGAAGTACAGACTGAAGCACATTGTCTGGGCTTCCAGAGAACTGGAGAGATTT 
               
               
                   
                   
                 GCTGTGAATCCAGGGCTGCTGGAAACAAGTGAGGGCATTTCTCCCAGAACTCTGAATGCTTGGGTGAAGGTG 
               
               
                   
                   
                 GTGGAAGAAAAAGCCTTCTCTCCAGAGGTGATCCCCATGTTCAGTGCACTGTCTGAAGGAGCCACACCTCAG 
               
               
                   
                   
                 GACCTCAACACCATGCTGAACACAGTGGGAGGACATCAGGCAGCCATGCAGATGCTGAAGGAGACCATCAAT 
               
               
                   
                   
                 GAAGAAGCTGCAGAGTGGGACAGGCTGCATCCAGTTCATGCAGGACCAATTGCTCCTGGACAGATGAGAGAG 
               
               
                   
                   
                 CCCAGAGGAAGTGACATTGCTGGCACAACCAGCACACTGCAGGAACAGATTGGTTGGATGACCAACAATCCC 
               
               
                   
                   
                 CCCATTCCAGTGGGAGAGATCTACAAGAGGTGGATCATCCTTGGCCTGAACAAGATTGTGAGAATGTACAGC 
               
               
                   
                   
                 CCCACTTCAATCCTGGACATCAGACAGGGCCCCAAGGAACCTTTCAGAGACTATGTGGACAGGTTCTACAAG 
               
               
                   
                   
                 ACACTGAGAGCAGAACAGGCCTCACAGGAGGTGAAGAATTGGATGACTGAGACACTGCTGGTGCAGAATGCC 
               
               
                   
                   
                 AATCCAGATTGCAAGACAATTCTGAAAGCCCTGGGTCCAGCAGCCACACTGGAAGAGATGATGACAGCTTGC 
               
               
                   
                   
                 CAGGGAGTGGGTGGACCAGGACACAAAGCAAGAGTGCTGGCAGAAGCAATGTCTCAGGCTGCAGCCAAGGAG 
               
               
                   
                   
                 AAAGTTTATCTGGCTTGGGTCCCAGCGCACAAAGGAATTGGAGGAAATGAGCAGGTGGACAAACTTGTGTCC 
               
               
                   
               
               
                 141 
                 Gag:147-369 
                 CTGTCTCCTAGAACACTGAACGCTTGGGTGAAAGTGATCGAGGAAAAGGCCTTTAGCCCAGAAGTGATCCCT 
               
               
                   
                 Pol:840-920 
                 ATGTTTACCGCCCTGTCAGAAGGAGCTACACCTCACGATCTGAACACCATGCTGAACACAATCGGAGGACAT 
               
               
                   
                 Pol:683-708 
                 CAGGCAGCTATGCAGATGCTGAAGGATACAATCAACGAAGAAGCCGCCGAGTGGGATAGAGTGCATCCAGTG 
               
               
                   
                 AAY 
                 CACGCAGGACCAGTGGCTCCAGGACAGATGAGAGATCCTAGAGGAAGCGATATCGCAGGATCTACAAGCACA 
               
               
                   
                 Gag:1-53 
                 CTGCAGGAACAGATCGCTTGGATGACCAATAATCCCCCTATTCCAGTGGGCGATATCTACAAGCGCTGGATC 
               
               
                   
                 Nef:117-148 
                 ATCATGGGCCTGAACAAGATCGTGAGGATGTACAGCCCAGTGAGCATCCTGGATATCAAGCAGGGACCTAAG 
               
               
                   
                 Pol:747-827 
                 GAGCCTTTCAGAGATTACGTGGACAGGTTCTACAGAACACTGAGAGCCGAACAGGCATCTCAGGACGTGAAG 
               
               
                   
                   
                 AATTGGATGACCGAGACACTGCTGGTGCAGAACAGCAATCCCGATTGCAAGACAATCCTGAAAGCTCTGGGA 
               
               
                   
                   
                 CCAGGAGCTACACTGGAGGAAATGATGAGCGCTTGTCAGGGAGTGGGAGGACCATCTCATAAAGCTAGAGTG 
               
               
                   
                   
                 CTGGCCGAAGCTATGTGTCAGGCAGTGAAAGCAGCTTGTTGGTGGGCAGGAGTGAAACAGGAGTTCGGCATC 
               
               
                   
                   
                 CCTTACAACACCCAGTCTCAGGGAGTGGTGGAATCTATGAACAACGAGCTGAAGAAGATCATCGGCCAGATC 
               
               
                   
                   
                 AGAGACCAGGCAGAACATCTGAAGACAGCAGTGCAGATGGCAGTGCTGATTCACAACTTCAAGAGAAAGGGC 
               
               
                   
                   
                 GGCATTGGAGAGTATAGCGCCGGAGAGAGAATTATCGATATCATCGCCAAGGAGAAGATCTATCTGGCTTGG 
               
               
                   
                   
                 GTGCCAGCTCATAAAGGAATCGGAGGAAACGAGCAGATCGATAAGCTGGTGTCAGCCGCCTATATGGCAGCT 
               
               
                   
                   
                 AGAGCTTCTATTCTGAGCGGAGGAAAGCTCGACAAGTGGGAAAAGATCAGGCTGAGACCAGGAGGCAGAAAG 
               
               
                   
                   
                 AAGTACAAGCTGAAGCATCTCGTCTGGGCTTCTAGAGAACTGGAAAGATTCGCTCTGAATCCAGGACTGCTG 
               
               
                   
                   
                 GAAACAACCCAGGGCTTCTTCCCCGATTGGCAGAATTACACCCCAGGACCAGGAATCAGATTCCCTCTGACC 
               
               
                   
                   
                 TTCGGTTGGTGTTTCAAGCTGGTGCCTCTGGTGGCTAAAGAGATTGTGGCTTGTTGCGACAAGTGTCAGCTG 
               
               
                   
                   
                 AAAGGAGAGGCTATTCACGGACAGGTGGATTGTTCTCCAGGAGTCTGGCAGCTGGATTGTACACATCTGGAG 
               
               
                   
                   
                 GGAAAAGTGATTCTGGTGGCAGTGCACGTGGCATCAGGATATATTGAGGCCGAAATCATCCCTACAGAGACA 
               
               
                   
                   
                 GGACAGGAGACAGCCTACTTTATCCTGAAGCTGGCAGGAAGATGGCCAGTGACAACA 
               
               
                   
               
               
                 142 
                 Gag:147-369 
                 CTGTCTCCTAGAACACTGAACGCTTGGGTGAAGGTGATTGAGGAGAAAGCCTTCAGCCCAGAAGTGATCCCT 
               
               
                   
                 Pol:840-920 
                 ATGTTTACAGCCCTGAGCGAAGGAGCTACACCTCACGATCTGAATACCATGCTGAATACAATCGGCGGACAT 
               
               
                   
                 Pol:683-708 
                 CAGGCAGCCATGCAGATGCTGAAGGATACAATCAACGAAGAAGCAGCCGAGTGGGATAGAGTGCATCCAGTG 
               
               
                   
                 AAY 
                 CACGCAGGACCAGTGGCTCCAGGACAGATGAGAGATCCTAGAGGAAGCGATATCGCCGGATCTACATCTACA 
               
               
                   
                 Gag:1-53 
                 CTGCAGGAACAGATCGCTTGGATGACAAATAACCCCCCTATCCCAGTGGGAGATATCTATAAGCGCTGGATC 
               
               
                   
                 Nef:117-148 
                 ATCATGGGCCTGAACAAGATCGTGAGGATGTACAGCCCAGTGAGCATCCTGGATATCAAGCAGGGACCTAAG 
               
               
                   
                 Pol:747-827 
                 GAGCCTTTCAGAGATTACGTGGACAGGTTCTACAGAACCCTGAGAGCAGAACAGGCTTCTCAGGACGTGAAG 
               
               
                   
                   
                 AATTGGATGACCGAAACACTGCTGGTGCAGAATAGCAACCCCGATTGCAAGACCATCCTGAAAGCTCTGGGA 
               
               
                   
                   
                 CCAGGAGCTACACTGGAAGAAATGATGAGCGCTTGTCAGGGAGTGGGAGGACCATCTCATAAGGCTAGAGTG 
               
               
                   
                   
                 CTGGCAGAAGCTATGTGTCAGGCAGTGAAAGCAGCTTGTTGGTGGGCAGGAGTGAAACAGGAGTTTGGCATC 
               
               
                   
                   
                 CCTTACAATACCCAGTCTCAGGGAGTGGTGGAAAGCATGAACAACGAGCTGAAGAAGATCATCGGCCAGATT 
               
               
                   
                   
                 AGAGATCAGGCCGAACATCTGAAAACAGCAGTGCAGATGGCCGTGCTGATCCACAATTTCAAGAGGAAGGGC 
               
               
                   
                   
                 GGAATTGGCGAATATAGCGCCGGAGAGAGAATCATCGACATCATCGCCAAGGAGAAGATCTACCTGGCTTGG 
               
               
                   
                   
                 GTGCCAGCTCATAAAGGAATCGGAGGAAACGAGCAGATCGATAAACTGGTGTCTGCCGCTTATATGGCAGCT 
               
               
                   
                   
                 AGAGCTTCTATCCTGTCAGGAGGAAAGCTCGATAAGTGGGAAAAGATCAGACTGAGACCAGGCGGAAGAAAG 
               
               
                   
                   
                 AAGTACAAGCTGAAGCACCTCGTCTGGGCTTCTAGAGAACTGGAAAGATTCGCCCTGAATCCAGGACTGCTG 
               
               
                   
                   
                 GAAACAACACAGGGATTCTTCCCCGATTGGCAGAACTACACACCAGGACCAGGCATCAGATTTCCTCTGACC 
               
               
                   
                   
                 TTTGGTTGGTGCTTTAAACTGGTGCCTCTGGTGGCTAAGGAGATTGTGGCTTGTTGCGACAAGTGTCAGCTG 
               
               
                   
                   
                 AAAGGAGAGGCTATTCACGGACAGGTGGATTGTTCTCCAGGAGTCTGGCAGCTGGATTGTACACACCTGGAG 
               
               
                   
                   
                 GGAAAAGTGATTCTGGTGGCAGTGCACGTGGCATCAGGATATATCGAGGCCGAGATCATCCCTACAGAGACA 
               
               
                   
                   
                 GGACAGGAAACCGCCTACTTTATCCTGAAACTGGCAGGTAGGTGGCCAGTGACAACA 
               
               
                   
               
               
                 143 
                 Gag:147-369 
                 CTGAGCCCCAGAACCCTCAATGCCTGGGTCAAAGTGATTGAGGAAAAGGCCTTCAGCCCAGAGGTGATCCCC 
               
               
                   
                 Pol:840-920 
                 ATGTTCACAGCCCTCAGTGAGGGGGCCACCCCCCATGACCTGAACACCATGCTCAACACCATTGGGGGCCAC 
               
               
                   
                 Pol:683-708 
                 CAGGCTGCCATGCAGATGCTGAAGGACACCATCAATGAGGAAGCTGCTGAGTGGGACAGAGTCCACCCAGTG 
               
               
                   
                 AAY 
                 CATGCTGGCCCAGTGGCCCCAGGCCAGATGAGGGACCCCAGGGGCTCTGACATTGCTGGCAGCACCAGCACC 
               
               
                   
                 Gag:1-53 
                 CTGCAGGAGCAGATAGCCTGGATGACCAACAACCCCCCCATCCCTGTGGGAGACATCTACAAAAGATGGATC 
               
               
                   
                 Nef:117-148 
                 ATCATGGGCCTCAACAAGATTGTCAGGATGTACTCCCCTGTGTCCATCCTGGACATCAAGCAGGGCCCCAAG 
               
               
                   
                 Pol:747-827 
                 GAACCCTTCAGGGACTATGTGGACAGATTCTACAGAACCCTGAGAGCTGAGCAGGCCTCCCAGGATGTGAAA 
               
               
                   
                   
                 AACTGGATGACAGAGACCCTCCTGGTCCAGAACAGCAACCCAGACTGCAAGACCATCCTCAAGGCCTTGGGC 
               
               
                   
                   
                 CCAGGAGCCACCCTGGAAGAGATGATGAGTGCCTGCCAGGGAGTTGGAGGCCCCAGCCACAAGGCCAGAGTG 
               
               
                   
                   
                 CTGGCAGAGGCCATGTGCCAGGCTGTGAAGGCTGCCTGCTGGTGGGCAGGAGTCAAGCAGGAGTTTGGCATC 
               
               
                   
                   
                 CCATACAACACCCAGAGCCAGGGTGTGGTGGAAAGCATGAACAATGAGCTGAAAAAGATCATTGGCCAGATC 
               
               
                   
                   
                 AGAGACCAGGCTGAGCACCTGAAGACAGCAGTGCAGATGGCTGTGCTCATCCACAACTTCAAGAGGAAAGGT 
               
               
                   
                   
                 GGCATAGGGGAATACAGTGCTGGGGAGAGGATCATTGACATCATTGCCAAGGAGAAGATCTACCTGGCCTGG 
               
               
                   
                   
                 GTGCCTGCCCACAAGGGCATTGGTGGCAATGAGCAGATTGACAAGCTGGTCTCAGCAGCCTACATGGCTGCC 
               
               
                   
                   
                 AGAGCCTCCATCCTCTCAGGGGGCAAGCTGGACAAGTGGGAGAAAATCAGACTGAGGCCTGGTGGCAGAAAG 
               
               
                   
                   
                 AAGTACAAGCTGAAGCACCTGGTGTGGGCCTCCAGGGAACTGGAAAGATTTGCCCTGAACCCTGGCCTGCTG 
               
               
                   
                   
                 GAAACCACCCAGGGCTTCTTCCCTGACTGGCAGAACTACACCCCAGGCCCAGGCATCAGGTTCCCCCTGACC 
               
               
                   
                   
                 TTTGGCTGGTGCTTCAAGCTGGTGCCCCTGGTGGCCAAGGAAATAGTGGCCTGCTGTGACAAGTGCCAGCTG 
               
               
                   
                   
                 AAAGGGGAGGCCATCCATGGCCAAGTGGACTGCAGCCCTGGTGTGTGGCAGCTGGACTGCACCCACCTGGAA 
               
               
                   
                   
                 GGCAAGGTCATCCTGGTTGCAGTGCATGTGGCCAGTGGCTACATTGAGGCTGAGATCATCCCCACAGAGACA 
               
               
                   
                   
                 GGCCAGGAGACTGCCTACTTCATCCTGAAACTTGCAGGCAGGTGGCCTGTGACCACC 
               
               
                   
               
               
                 144 
                 Pol:932-1003 
                 ATCACCAAGATCCAGAACTTCAGGGTGTACTACAGAGACAGCAGAGATCCTCTCTGGAAGGGACCAGCTAAA 
               
               
                   
                 AAY 
                 CTCCTCTGGAAAGGAGAAGGAGCAGTGGTGATCCAGGATAACAGCGACATCAAGGTGGTGCCTAGAAGAAAG 
               
               
                   
                 EE 
                 GCCAAGATCATCAGGGACTACGGCAAACAGATGGCAGGAGACGATTGCGTGGCTTCTAGACAGGACGAAGAC 
               
               
                   
                 Nef:64-99 
                 GCAGCTTACGAAGAGGAAGAGGTGGGATTTCCAGTGAAACCTCAGGTGCCTCTGAGACCTATGACATTCAAG 
               
               
                   
                 AA 
                 GGAGCTCTGGATCTGTCTCACTTCCTGAGAGAAAAGGGAGGACTGGAAGGAGCAGCTTGGGGATTTACCACC 
               
               
                   
                 Pol:367-431 
                 CCAGACAAGAAGCACCAGAAGGAACCACCATTCCTCTGGATGGGATACGAACTGCACCCAGATAAGTGGACA 
               
               
                   
                 Pol:542-606 
                 GTCCAGCCTATTGTGCTGCCAGAAAAGGACTCTTGGACCGTGAACGATATCCAGAAGCTGGTGGGAAAGCTG 
               
               
                   
                 Pol:56-117 
                 AATTGGGCTTCTCAGATCTACCCAGGAATCAAGGTGCCCAAGTTCAAGCTGCCTATCCAGAAGGAGACTTGG 
               
               
                   
                 Pol:129-320 
                 GAAACTTGGTGGACAGAGTATTGGCAGGCTACTTGGATTCCCGAGTGGGAATTTGTGAACACACCTCCTCTG 
               
               
                   
                   
                 GTGAAGCTGTGGTATCAGCTGGAAAAGGAGCCTATCGTGGGCGCAGAAACATTTTACGTGGACGGAGCCGCC 
               
               
                   
                   
                 AATAGAGAAACCAAGTTTCCTCAGATCACTCTCTGGCAGAGACCTCTGGTGACAATCAAGATCGGCGGACAG 
               
               
                   
                   
                 CTGAAAGAGGCTCTGCTGGATACAGGAGCAGACGATACCGTGCTGGAAGAAATGAATCTGCCAGGTAGGTGG 
               
               
                   
                   
                 AAGCCTAAGATGATTGGCGGAATTGGCGGCTTCATCAAGGTGAGACAGTACGATCAGGGAACAGTGCTGGTG 
               
               
                   
                   
                 GGACCTACTCCAGTGAACATCATCGGAAGGAACCTGCTGACACAGATCGGCTGTACACTGAACTTCCCTATC 
               
               
                   
                   
                 AGCCCTATCGAGACAGTGCCAGTGAAACTGAAGCCAGGAATGGACGGACCTAAAGTCAAACAGTGGCCTCTG 
               
               
                   
                   
                 ACAGAGGAGAAAATCAAAGCCCTGGTGGAGATTTGTACCGAGATGGAGAAGGAGGGCAAGATTTCTAAGATC 
               
               
                   
                   
                 GGACCAGAGAACCCCTACAATACCCCAGTGTTTGCCATCAAGAAGAAGGACAGCACCAAGTGGAGGAAGCTG 
               
               
                   
                   
                 GTGGATTTTAGGGAGCTGAACAAGAGGACACAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCACCCAGCC 
               
               
                   
                   
                 GGACTGAAAAAGAAGAAGTCAGTGACAGTGCTGGACGTGGGAGATGCCTATTTTAGCGTGCCTCTGGATAAG 
               
               
                   
                   
                 GACTTCAGGAAGTACACCGCCTTCACAATCCCTAGCATCAACAACGAGACCCCAGGAATCAGATACCAGTAC 
               
               
                   
                   
                 AACGTGCTGCCTCAGGGTTGGAAAGGAAGCCCAGCCATCTTTCAGTCTAGCATGACC 
               
               
                   
               
               
                 145 
                 Pol:932-1003 
                 ATCACCAAGATCCAGAACTTCCGGGTGTACTACAGGGATAGCAGAGATCCTCTCTGGAAGGGACCAGCTAAA 
               
               
                   
                 AAY 
                 CTCCTCTGGAAAGGAGAAGGAGCAGTGGTGATCCAGGATAATAGCGACATCAAGGTGGTGCCTAGAAGAAAG 
               
               
                   
                 EE 
                 GCTAAGATCATCCGGGACTACGGCAAACAGATGGCAGGAGACGATTGCGTGGCTTCTAGACAGGATGAAGAC 
               
               
                   
                 Nef:64-99 
                 GCAGCCTACGAAGAAGAGGAAGTGGGATTTCCAGTGAAACCTCAGGTGCCTCTGAGACCTATGACATTCAAG 
               
               
                   
                 AA 
                 GGAGCTCTGGACCTGTCTCACTTTCTGAGAGAGAAGGGAGGACTGGAAGGAGCAGCTTGGGGATTTACCACA 
               
               
                   
                 Pol:367-431 
                 CCAGATAAGAAGCACCAGAAGGAGCCACCATTTCTCTGGATGGGATACGAACTGCACCCAGATAAGTGGACA 
               
               
                   
                 Pol:542-606 
                 GTCCAGCCTATTGTGCTGCCAGAAAAGGACTCTTGGACAGTGAACGACATCCAGAAGCTGGTGGGAAAGCTG 
               
               
                   
                 Pol:56-117 
                 AATTGGGCCTCTCAGATTTACCCAGGAATCAAGGTGCCCAAGTTTAAGCTGCCTATCCAGAAGGAGACTTGG 
               
               
                   
                 Pol:129-320 
                 GAAACTTGGTGGACCGAGTATTGGCAGGCAACTTGGATTCCCGAGTGGGAATTTGTGAACACACCTCCTCTG 
               
               
                   
                   
                 GTGAAGCTGTGGTATCAGCTGGAAAAGGAGCCTATCGTGGGAGCCGAAACATTTTACGTGGACGGAGCAGCC 
               
               
                   
                   
                 AACAGAGAGACAAAGTTCCCTCAGATCACTCTCTGGCAGAGACCACTGGTGACAATTAAGATCGGAGGACAG 
               
               
                   
                   
                 CTGAAAGAAGCTCTGCTGGATACAGGAGCAGACGATACAGTGCTGGAGGAAATGAACCTGCCAGGTCGCTGG 
               
               
                   
                   
                 AAACCTAAAATGATCGGCGGCATTGGCGGATTTATCAAGGTGAGGCAGTACGATCAGGGAACAGTGCTGGTG 
               
               
                   
                   
                 GGACCTACACCCGTGAATATTATCGGAAGGAATCTGCTGACACAGATTGGCTGTACCCTGAACTTCCCTATC 
               
               
                   
                   
                 AGCCCTATCGAAACCGTGCCAGTGAAACTGAAACCAGGAATGGACGGACCTAAAGTCAAGCAGTGGCCTCTG 
               
               
                   
                   
                 ACAGAAGAGAAGATCAAAGCCCTGGTGGAGATTTGTACCGAGATGGAGAAGGAGGGAAAGATCAGCAAGATC 
               
               
                   
                   
                 GGCCCAGAGAATCCTTACAACACCCCAGTGTTCGCCATCAAGAAGAAGGATAGCACCAAGTGGAGAAAGCTG 
               
               
                   
                   
                 GTGGATTTCAGGGAGCTGAACAAGAGAACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCACCCTGCC 
               
               
                   
                   
                 GGCCTGAAGAAGAAGAAAAGCGTGACAGTGCTGGACGTGGGAGACGCTTATTTTAGCGTGCCTCTGGACAAG 
               
               
                   
                   
                 GACTTCAGAAAGTACACCGCCTTCACCATCCCTTCTATCAATAACGAGACCCCAGGCATCAGATACCAGTAT 
               
               
                   
                   
                 AACGTGCTGCCTCAGGGTTGGAAAGGAAGCCCAGCCATTTTTCAGAGCAGCATGACA 
               
               
                   
               
               
                 146 
                 Pol:932-1003 
                 ATCACCAAGATCCAGAACTTCAGGGTCTACTACAGAGACAGCAGAGATCCACTCTGGAAGGGCCCAGCCAAA 
               
               
                   
                 AAY 
                 CTCCTTTGGAAAGGAGAAGGAGCAGTGGTGATCCAGGACAACAGTGACATCAAGGTGGTTCCCAGAAGAAAG 
               
               
                   
                 EE 
                 GCCAAGATCATCAGGGACTATGGCAAACAGATGGCAGGAGATGACTGTGTGGCTTCCAGACAGGATGAAGAT 
               
               
                   
                 Nef:64-99 
                 GCAGCTTATGAAGAGGAAGAGGTGGGATTCCCAGTGAAACCCCAGGTGCCTCTGAGGCCAATGACATTCAAG 
               
               
                   
                 AA 
                 GGAGCTCTGGATCTGTCCCACTTCCTGAGAGAAAAGGGAGGACTGGAAGGAGCAGCTTGGGGATTCACCACC 
               
               
                   
                 Pol:367-431 
                 CCAGACAAGAAGCATCAGAAGGAACCTCCCTTCCTCTGGATGGGTTATGAACTGCACCCAGACAAGTGGACA 
               
               
                   
                 Pol:542-606 
                 GTCCAGCCCATTGTGCTGCCAGAAAAGGATTCTTGGACAGTGAATGACATCCAGAAGCTGGTGGGCAAGCTG 
               
               
                   
                 Pol:56-117 
                 AATTGGGCCTCCCAGATCTACCCAGGAATCAAGGTGCCCAAGTTCAAGCTCCCCATCCAGAAGGAGACTTGG 
               
               
                   
                 Pol:129-320 
                 GAAACTTGGTGGACAGAGTATTGGCAGGCAACTTGGATTCCTGAGTGGGAATTTGTGAACACCCCCCCTCTG 
               
               
                   
                   
                 GTGAAGCTGTGGTATCAGCTGGAAAAGGAGCCCATTGTGGGGGCAGAAACATTTTATGTGGATGGAGCAGCC 
               
               
                   
                   
                 AACAGAGAAACCAAGTTTCCCCAGATCACTCTTTGGCAGAGACCACTGGTGACAATCAAGATTGGGGGACAG 
               
               
                   
                   
                 CTGAAAGAGGCTCTGCTGGACACAGGAGCTGATGACACAGTGCTGGAAGAAATGAATCTGCCAGGCAGGTGG 
               
               
                   
                   
                 AAGCCCAAGATGATTGGAGGCATTGGGGGTTTCATCAAGGTGAGACAGTATGACCAGGGAACTGTGCTGGTG 
               
               
                   
                   
                 GGACCCACTCCAGTGAACATCATTGGCAGGAACCTGCTGACACAGATTGGCTGCACACTGAACTTCCCCATC 
               
               
                   
                   
                 AGCCCCATTGAGACAGTCCCAGTGAAACTGAAGCCAGGAATGGATGGCCCAAAAGTCAAACAATGGCCCCTG 
               
               
                   
                   
                 ACAGAGGAGAAAATCAAAGCTCTGGTGGAGATTTGCACAGAGATGGAGAAGGAGGGCAAGATCTCTAAGATT 
               
               
                   
                   
                 GGCCCAGAGAACCCATACAACACTCCAGTGTTTGCAATCAAGAAGAAGGACAGCACCAAGTGGAGGAAGCTG 
               
               
                   
                   
                 GTGGACTTCAGGGAGCTCAACAAGAGGACACAGGACTTTTGGGAAGTGCAGCTGGGCATTCCCCACCCAGCA 
               
               
                   
                   
                 GGACTGAAAAAGAAGAAGTCAGTGACAGTGCTGGATGTGGGGGATGCTTATTTCAGTGTGCCTCTGGACAAG 
               
               
                   
                   
                 GACTTCAGGAAGTACACAGCCTTCACAATCCCCAGCATCAACAATGAGACCCCAGGAATCAGATATCAGTAC 
               
               
                   
                   
                 AATGTGCTGCCTCAGGGTTGGAAAGGAAGCCCAGCCATTTTCCAGTCGAGCATGACC 
               
               
                   
               
               
                 147 
                 Pol:542-606 
                 CCTAAATTCAGACTGCCTATCCAGAAGGAGACTTGGGATACTTGGTGGACCGATTATTGGCAGGCAACTTGG 
               
               
                   
                 Nef:64-99 
                 ATTCCCGAGTGGGAATTTACCAATACCCCTCCTCTGGTGAAGCTGTGGTATCAGCTGGAAACAGAGCCTATT 
               
               
                   
                 Pol:56-117 
                 GCCGGAGTGGAAACATTCTACGTGGACGGAGCCTCTAATAGAGAGACCAAGGAGGAAGTGGGATTTCCAGTG 
               
               
                   
                 Pol:932-1003 
                 AGACCTCAGGTGCCTCTGAGACCTATGACATACAAGGGAGCTCTGGACCTGTCTCACTTTCTGAAGGAGAAG 
               
               
                   
                 Pol:367-431 
                 GGAGGACTGGAAGGACTGCCTCAGATTACTCTCTGGCAGAGACCTATCGTGACCATCAAGATCGGAGGACAG 
               
               
                   
                 K 
                 ATCAAAGAAGCTCTGCTGGATACAGGAGCAGACGATACAGTGCTGGAGGATATGAACCTGCCAGGTAAGTGG 
               
               
                   
                 Pol:129-320 
                 AAGCCTAAGATGATCGGCGGAATTGGCGGCTTTATCAAGGTCAAGCAGTACGACCAGATCACCAAGCTGCAG 
               
               
                   
                   
                 AACTTCAGGGTGTACTACAGGGACAACAGAGACCCCCTCTGGAAAGGACCAGCTAGACTCCTCTGGAAAGGA 
               
               
                   
                   
                 GAAGGAGCAGTGGTGATCCAGGACAATAGCGAGATCAAGGTGGTGCCTAGAAGGAAGGTGAAGATCATCAGG 
               
               
                   
                   
                 GACTACGGAAAAAGAATGGCCGGAGACGATTGCGTGGCAGGAAGACAGGACGAAGATTGGGGACTGACAACA 
               
               
                   
                   
                 CCAGACAAGAAGCACCAGAAGGACCCCCCATTCCTCTGGATGGGATACGAACTGCATCCAGATAGGTGGACA 
               
               
                   
                   
                 GTGCAGCCAATTGAACTGCCAGAGAAGGAGTCTTGGACCGTGAACGATATCCAGAAGCTGATCGGCAAGCTG 
               
               
                   
                   
                 AATTGGGCTTCTCAGATCTACGCAGGAATCAAGGTGAAGGGCACAGTGCTGATTGGACCTACACCAGTGAAC 
               
               
                   
                   
                 ATCATCGGCAGAAACCTCCTGACACAGCTGGGTTGTACACTGAATTTCCCTATCAGCCCTATCGATACAGTG 
               
               
                   
                   
                 CCAGTGAAGCTGAAACCAGGAATGGACGGACCTAGAGTCAAACAGTGGCCTCTGACAGAAGAGAAGATCAAG 
               
               
                   
                   
                 GCCCTGATCGAGATTTGCACCGAGATGGAGAAGGAGGGAAAGATCTCTAGGATCGGCCCAGAGAATCCTTAC 
               
               
                   
                   
                 AATACCCCTATCTTCGCCATCAAGAAGAAGGACGGAACCAAGTGGAGAAAGCTGGTGGATTTCAGGGAGCTG 
               
               
                   
                   
                 AACAAGAAGACCCAGGACTTTTGGGAGGTGCAGCTGGGCATCCCCCATCCTTCAGGACTGAAGAAGAAGAAG 
               
               
                   
                   
                 AGCGTGACAGTGCTGGATATCGGAGACGCTTACTTTAGCGTGCCACTGGACAAGGAGTTCAGAAAGTACACC 
               
               
                   
                   
                 GCTTTCACCGTGCCTTCTACCAATAACGAGACCCCAGGAGTGAGATACCAGTATAACGTGCTGCCCATGGGT 
               
               
                   
                   
                 TGGAAAGGATCTCCAGCAATTTTTCAGTGTAGCATGACA 
               
               
                   
               
               
                 148 
                 Pol:542-606 
                 CCCAAGTTCAGGCTGCCTATCCAGAAAGAGACTTGGGACACTTGGTGGACCGATTATTGGCAGGCAACTTGG 
               
               
                   
                 Nef:64-99 
                 ATTCCCGAGTGGGAATTTACCAACACACCTCCTCTGGTGAAGCTGTGGTATCAGCTGGAAACAGAGCCTATT 
               
               
                   
                 Pol:56-117 
                 GCCGGAGTGGAAACATTCTACGTGGACGGAGCCAGCAACAGAGAGACCAAGGAGGAAGTGGGATTTCCAGTG 
               
               
                   
                 Pol:932-1003 
                 AGACCTCAGGTGCCTCTGAGACCTATGACATACAAGGGAGCTCTGGATCTGAGCCACTTTCTGAAGGAGAAA 
               
               
                   
                 Pol:367-431 
                 GGAGGACTGGAAGGACTGCCTCAGATTACTCTCTGGCAGAGACCTATCGTGACAATCAAGATCGGCGGACAG 
               
               
                   
                 K 
                 ATCAAGGAAGCTCTGCTGGATACAGGAGCCGACGATACAGTGCTGGAAGATATGAACCTGCCAGGCAAGTGG 
               
               
                   
                 Pol:129-320 
                 AAACCTAAGATGATCGGAGGCATTGGCGGCTTTATCAAGGTGAAACAGTACGACCAGATCACCAAGCTGCAG 
               
               
                   
                   
                 AACTTCAGGGTGTACTACAGGGACAACAGAGACCCCCTCTGGAAAGGACCAGCTAGACTGCTGTGGAAAGGA 
               
               
                   
                   
                 GAAGGAGCAGTGGTGATCCAGGATAATAGCGAGATCAAGGTGGTGCCTAGGAGAAAGGTGAAGATCATCAGG 
               
               
                   
                   
                 GACTACGGCAAGAGAATGGCAGGAGACGATTGCGTGGCAGGAAGACAGGACGAAGATTGGGGACTGACAACA 
               
               
                   
                   
                 CCAGACAAGAAGCACCAGAAGGACCCCCCTTTCCTCTGGATGGGATACGAACTGCATCCAGATAGGTGGACA 
               
               
                   
                   
                 GTGCAGCCAATTGAGCTGCCAGAAAAGGAGTCTTGGACAGTGAACGACATCCAGAAGCTGATCGGCAAGCTG 
               
               
                   
                   
                 AATTGGGCTTCTCAGATCTACGCCGGAATTAAGGTGAAGGGAACAGTGCTGATTGGACCTACACCAGTGAAC 
               
               
                   
                   
                 ATCATCGGAAGAAACCTGCTGACACAGCTGGGTTGTACACTGAACTTCCCTATCAGCCCTATCGATACCGTG 
               
               
                   
                   
                 CCAGTGAAACTGAAACCAGGAATGGACGGACCTAGAGTCAAGCAGTGGCCTCTGACAGAAGAGAAGATCAAG 
               
               
                   
                   
                 GCCCTGATCGAGATTTGCACCGAGATGGAGAAGGAGGGAAAGATCAGCAGAATTGGCCCCGAGAATCCTTAC 
               
               
                   
                   
                 AACACCCCTATCTTCGCCATCAAGAAGAAGGACGGAACTAAGTGGAGAAAGCTGGTGGACTTCAGAGAGCTG 
               
               
                   
                   
                 AACAAGAAGACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCATCCTTCAGGACTGAAGAAGAAGAAG 
               
               
                   
                   
                 AGCGTGACAGTGCTGGACATCGGAGACGCTTATTTTAGCGTGCCTCTGGATAAGGAGTTCCGGAAATACACC 
               
               
                   
                   
                 GCCTTTACCGTGCCTTCTACCAATAACGAGACACCAGGAGTGAGGTACCAGTATAACGTGCTGCCAATGGGC 
               
               
                   
                   
                 TGGAAAGGATCTCCAGCAATCTTTCAGTGTAGCATGACA 
               
               
                   
               
               
                 149 
                 Pol:542-606 
                 CCCAAGTTCAGGCTGCCCATCCAGAAAGAAACCTGGGACACCTGGTGGACTGACTACTGGCAGGCCACCTGG 
               
               
                   
                 Nef:64-99 
                 ATCCCAGAGTGGGAGTTCACCAACACCCCTCCCCTGGTGAAGCTGTGGTACCAGCTGGAAACTGAGCCCATA 
               
               
                   
                 Pol:56-117 
                 GCAGGAGTGGAAACCTTTTATGTGGATGGAGCCAGCAACAGGGAAACCAAGGAAGAGGTGGGCTTCCCAGTG 
               
               
                   
                 Pol:932-1003 
                 AGGCCCCAGGTGCCCCTGAGACCCATGACCTACAAGGGAGCCCTGGATCTGAGCCACTTCCTGAAAGAGAAG 
               
               
                   
                 Pol:367-431 
                 GGGGGCCTGGAAGGCCTGCCCCAGATCACCCTGTGGCAGAGACCCATTGTGACCATCAAGATTGGGGGCCAG 
               
               
                   
                 K 
                 ATCAAAGAGGCCCTCCTGGACACTGGAGCTGATGACACAGTCCTGGAAGACATGAACCTCCCAGGAAAGTGG 
               
               
                   
                 Pol:129-320 
                 AAGCCCAAGATGATTGGGGGCATTGGAGGCTTCATCAAGGTCAAGCAGTATGACCAGATCACCAAGCTCCAG 
               
               
                   
                   
                 AATTTCAGAGTCTACTACAGAGACAACAGAGACCCCCTGTGGAAAGGCCCAGCCAGACTTCTCTGGAAGGGG 
               
               
                   
                   
                 GAGGGAGCAGTGGTGATCCAAGACAACTCTGAGATCAAAGTGGTCCCCAGGAGAAAGGTGAAGATCATCAGG 
               
               
                   
                   
                 GACTATGGCAAAAGGATGGCAGGGGATGACTGTGTGGCAGGCAGACAGGATGAGGACTGGGGCCTGACCACC 
               
               
                   
                   
                 CCTGACAAGAAGCACCAGAAGGACCCCCCCTTCCTGTGGATGGGCTATGAGCTGCACCCAGACAGATGGACT 
               
               
                   
                   
                 GTCCAACCCATTGAGCTGCCTGAGAAGGAGAGCTGGACAGTCAATGACATCCAGAAGCTGATTGGGAAGCTG 
               
               
                   
                   
                 AATTGGGCCTCCCAGATCTATGCAGGCATCAAGGTCAAGGGCACTGTCCTGATTGGCCCCACCCCTGTGAAC 
               
               
                   
                   
                 ATCATAGGCAGAAACCTGCTGACCCAGCTGGGCTGCACACTGAACTTCCCCATCAGCCCCATTGACACAGTG 
               
               
                   
                   
                 CCTGTGAAGCTCAAGCCTGGCATGGATGGCCCCAGAGTGAAACAGTGGCCCTTGACAGAGGAAAAAATCAAG 
               
               
                   
                   
                 GCCCTGATTGAGATCTGCACTGAGATGGAAAAAGAGGGCAAGATCTCAAGAATTGGCCCTGAGAACCCCTAC 
               
               
                   
                   
                 AACACCCCCATTTTTGCCATCAAGAAAAAGGATGGCACAAAGTGGAGAAAGCTGGTGGACTTCAGAGAGCTC 
               
               
                   
                   
                 AACAAGAAGACCCAGGACTTCTGGGAGGTGCAGCTGGGCATCCCCCACCCCTCTGGCCTCAAGAAGAAGAAA 
               
               
                   
                   
                 AGTGTGACTGTGCTGGACATTGGTGATGCCTACTTCAGTGTCCCCCTGGACAAGGAATTCAGGAAGTACACA 
               
               
                   
                   
                 GCCTTCACAGTGCCCAGCACCAACAATGAGACCCCTGGTGTCAGGTACCAGTACAATGTGCTGCCCATGGGC 
               
               
                   
                   
                 TGGAAGGGCAGCCCAGCCATCTTCCAGTGCAGCATGACC 
               
               
                   
               
               
                 150 
                 Pol:840-920 
                 ACTGTAAAGGCCGCCTGTTGGTGGGCTGGGATCAAACAGGAGTTCGGAATCCCATACAATCCCCAAAGCCAG 
               
               
                   
                 Gag:147-369 
                 GGAGTAGTGGAATCCATGAATAAGGAGCTCAAGAAGATCATTGGGCAAGTCAGGGACCAGGCTGAGCACCTC 
               
               
                   
                 Pol:586-606 
                 AAGACGGCCGTTCAAATGGCGGTATTTATCCATAACTTTAAACGCAAAGGCGGTATTGGCGGTTACTCCGCA 
               
               
                   
                 AA 
                 GGTGAGCGGATAGTTGACATTATCGCAATAAGCCCTAGGACGCTTAACGCTTGGGTCAAGGTAGTGGAGGAA 
               
               
                   
                 Pol:683-708 
                 AAAGCCTTCTCACCGGAGGTCATCCCTATGTTTAGCGCCCTGAGCGAAGGAGCGACGCCACAAGACTTGAAC 
               
               
                   
                   
                 ACCATGCTTAATACGGTGGGGGGTCACCAAGCTGCAATGCAAATGTTGAAGGAAACGATAAACGAAGAGGCC 
               
               
                   
                   
                 GCCGAATGGGACAGGTTGCATCCCGTTCATGCAGGTCCCATAGCTCCCGGTCAAATGAGGGAACCACGCGGA 
               
               
                   
                   
                 TCAGACATCGCGGGAACGACGTCCACGTTGCAGGAACAAATTGGATGGATGACCAATAACCCTCCTATCCCA 
               
               
                   
                   
                 GTCGGTGAAATCTATAAGAGGTGGATCATCCTCGGCCTCAATAAAATAGTGAGGATGTATTCTCCAACTAGC 
               
               
                   
                   
                 ATTCTGGATATACGCCAAGGCCCTAAAGAACCATTTCGCGATTACGTAGACCGATTTTACAAGACACTCCGG 
               
               
                   
                   
                 GCTGAGCAGGCCTCCCAAGAGGTAAAGAATTGGATGACCGAAACGTTGCTGGTGCAGAATGCCAACCCCGAC 
               
               
                   
                   
                 TGTAAGACCATTTTGAAGGCGCTTGGGCCAGCAGCAACACTGGAAGAGATGATGACTGCGTGTCAAGGTGTA 
               
               
                   
                   
                 GGTGGCCCCGGCCACAAAGCCAGAGTGTTGGCCGAGGCAATGAGCCAAAAAGAACCCATTGTAGGAGCTGAG 
               
               
                   
                   
                 ACCTTTTACGTTGATGGCGCAGCTAACAGAGAAACTAAGGCGGCAAAAGAGAAAGTTTATCTTGCATGGGTG 
               
               
                   
                   
                 CCTGCGCACAAAGGAATCGGCGGAAATGAGCAAGTTGATAAACTCGTAAGT 
               
               
                   
               
               
                 151 
                 Pol:840-920 
                 ACCGTGAAGGCGGCGTGTTGGTGGGCAGGGATAAAGCAAGAATTTGGCATACCTTATAACCCGCAGAGTCAG 
               
               
                   
                 Pol:586-606 
                 GGAGTTGTCGAATCCATGAATAAGGAGCTTAAGAAGATCATCGGTCAGGTGCGCGATCAGGCAGAGCACCTC 
               
               
                   
                 AAA 
                 AAAACTGCGGTCCAAATGGCCGTGTTCATCCACAACTTCAAGCGCAAAGGCGGAATCGGTGGATACAGTGCT 
               
               
                   
                 Gag:147-369 
                 GGGGAAAGGATCGTCGATATTATCGCCAAAGAGCCAATCGTGGGAGCGGAAACATTCTACGTAGACGGTGCG 
               
               
                   
                 AAA 
                 GCCAACAGGGAGACAAAAGCCGCTGCGATCTCACCCCGAACCCTTAATGCTTGGGTGAAGGTGGTGGAAGAA 
               
               
                   
                 Pol:683-708 
                 AAAGCCTTCAGTCCCGAAGTTATCCCGATGTTCTCCGCCCTCAGTGAAGGTGCAACGCCGCAGGACCTTAAT 
               
               
                   
                   
                 ACTATGTTGAACACCGTTGGTGGTCATCAGGCCGCCATGCAGATGCTTAAAGAAACCATTAACGAAGAAGCC 
               
               
                   
                   
                 GCAGAATGGGACAGGTTGCACCCAGTCCACGCTGGGCCCATCGCGCCTGGGCAGATGCGAGAGCCACGAGGG 
               
               
                   
                   
                 TCCGATATCGCGGGCACAACAAGCACTTTGCAAGAACAGATTGGGTGGATGACTAATAACCCGCCGATACCT 
               
               
                   
                   
                 GTTGGGGAAATATATAAACGCTGGATAATTCTGGGACTCAATAAGATAGTGAGAATGTACTCCCCTACATCC 
               
               
                   
                   
                 ATTCTTGATATACGACAAGGTCCAAAAGAACCCTTTCGCGACTACGTGGATAGATTTTATAAGACCCTCAGG 
               
               
                   
                   
                 GCCGAACAGGCAAGTCAGGAGGTCAAGAACTGGATGACGGAGACGCTTCTTGTTCAGAATGCAAATCCCGAT 
               
               
                   
                   
                 TGCAAAACTATCTTGAAAGCGCTCGGACCAGCAGCGACGCTGGAAGAAATGATGACCGCCTGCCAGGGCGTA 
               
               
                   
                   
                 GGCGGCCCAGGTCATAAAGCAAGGGTATTGGCAGAAGCGATGAGTCAAGCAGCGGCAAAGGAGAAAGTATAT 
               
               
                   
                   
                 CTTGCGTGGGTACCAGCGCACAAAGGGATAGGTGGAAACGAGCAAGTTGATAAGCTGGTCTCCCTT 
               
               
                   
               
               
                 152 
                 Pol:932-1003 
                 ATAACGAAAATTCAGAACTTTCGAGTGTACTACAGAGATAGTAGAGACCCGCTGTGGAAGGGCCCAGCTAAA 
               
               
                   
                 Pol:747-827 
                 CTCCTTTGGAAAGGTGAAGGGGCTGTGGTCATACAGGATAACTCAGACATAAAGGTCGTCCCAAGGAGAAAA 
               
               
                   
                 Pol:129-320 
                 GCCAAAATAATTAGAGACTACGGCAAGCAGATGGCAGGGGATGACTGTGTTGCGAGCCGGCAGGATGAGGAT 
               
               
                   
                 QEE 
                 GTCGCGAAGGAAATCGTGGCGAGTTGTGATAAATGTCAACTGAAGGGTGAGGCAATGCACGGCCAAGTAGAT 
               
               
                   
                 Nef:64-76 
                 TGCAGTCCAGGTATCTGGCAACTCGATTGCACCCACCTGGAGGGTAAGATTATCCTGGTGGCTGTGCATGTT 
               
               
                   
                   
                 GCATCCGGCTACATCGAAGCTGAAGTGATTCCGGCTGAAACGGGGCAGGAAACCGCCTACTTCCTGTTGAAG 
               
               
                   
                   
                 TTGGCTGGTCGATGGCCAGTCAAGACCGGTACAGTACTCGTTGGCCCGACGCCAGTGAATATCATAGGTCGG 
               
               
                   
                   
                 AACCTGCTGACACAAATCGGGTGCACTCTTAATTTTCCGATTTCACCTATCGAAACCGTTCCAGTAAAACTC 
               
               
                   
                   
                 AAGCCTGGGATGGATGGCCCGAAGGTTAAGCAATGGCCACTGACCGAAGAGAAAATCAAAGCGCTCGTGGAG 
               
               
                   
                   
                 ATATGTACTGAAATGGAGAAAGAAGGAAAAATCTCTAAAATCGGGCCAGAAAATCCCTATAATACTCCGGTA 
               
               
                   
                   
                 TTTGCTATCAAAAAAAAAGACTCAACCAAGTGGCGAAAGCTCGTTGACTTCCGAGAGTTGAATAAAAGGACC 
               
               
                   
                   
                 CAGGATTTTTGGGAGGTTCAGCTGGGCATACCGCACCCCGCTGGCTTGAAAAAAAAGAAGTCTGTTACCGTC 
               
               
                   
                   
                 CTGGATGTGGGCGACGCCTACTTCAGTGTACCTCTTGACAAAGACTTTAGAAAGTATACTGCTTTCACGATC 
               
               
                   
                   
                 CCGAGTATAAACAACGAGACTCCAGGAATTAGGTACCAGTACAATGTATTGCCGCAGGGATGGAAGGGATCA 
               
               
                   
                   
                 CCCGCAATCTTCCAATCTAGTATGACGCAAGAGGAGGAGGAAGTAGGTTTCCCAGTCAAACCACAAGTGCCG 
               
               
                   
                   
                 CTC 
               
               
                   
               
               
                 153 
                 Pol:932-1003 
                 ATTACTAAAATACAAAACTTCCGAGTATATTATAGGGATAGCCGGGACCCTCTCTGGAAAGGGCCCGCGAAA 
               
               
                   
                 Pol:747-827 
                 CTGCTTTGGAAGGGCGAGGGCGCTGTTGTCATACAGGACAATAGCGATATAAAAGTAGTCCCGCGACGCAAA 
               
               
                   
                 Pol:129-320 
                 GCAAAAATAATAAGAGATTATGGAAAACAAATGGCGGGCGACGATTGTGTCGCCTCACGGCAGGACGAGGAT 
               
               
                   
                 QEE 
                 GCTGCAGCCATCGGAACAGTACTCGTGGGGCCAACTCCCGTCAACATAATAGGACGAAATCTTCTGACTCAA 
               
               
                   
                 Nef:64-76 
                 ATAGGTTGCACGCTCAACTTCCCAATTAGCCCTATAGAGACAGTGCCCGTAAAGTTGAAGCCTGGCATGGAC 
               
               
                   
                   
                 GGCCCAAAAGTAAAGCAGTGGCCCCTTACTGAAGAGAAGATCAAGGCCCTGGTGGAGATCTGTACAGAGATG 
               
               
                   
                   
                 GAGAAAGAAGGGAAAATCTCCAAAATCGGTCCAGAAAACCCATACAACACACCTGTTTTTGCGATAAAAAAA 
               
               
                   
                   
                 AAGGATTCCACCAAGTGGAGGAAACTGGTGGATTTTCGAGAGTTGAATAAGCGAACCCAGGACTTCTGGGAA 
               
               
                   
                   
                 GTACAGCTTGGGATACCACATCCAGCGGGTCTCAAGAAAAAGAAATCAGTTACGGTCCTCGATGTTGGCGAC 
               
               
                   
                   
                 GCGTATTTTAGTGTTCCTCTCGATAAAGATTTCCGAAAATATACGGCATTCACCATACCCAGTATTAACAAC 
               
               
                   
                   
                 GAGACACCGGGAATCAGGTATCAGTATAATGTACTTCCACAAGGTTGGAAGGGAAGCCCCGCGATTTTTCAG 
               
               
                   
                   
                 AGCTCAATGACGGTTGCCAAGGAGATTGTAGCTAGCTGTGACAAATGTCAGCTGAAGGGCGAAGCGATGCAC 
               
               
                   
                   
                 GGCCAGGTAGATTGCAGCCCCGGTATTTGGCAGCTCGACTGTACACATTTGGAAGGAAAAATTATACTTGTG 
               
               
                   
                   
                 GCTGTCCACGTTGCAAGTGGATACATAGAGGCGGAGGTCATTCCCGCAGAAACTGGGCAAGAAACTGCTTAC 
               
               
                   
                   
                 TTTCTCTTGAAGTTGGCCGGTAGGTGGCCAGTGAAAACCCAAGAGGAAGAGGAGGTTGGTTTTCCCGTCAAA 
               
               
                   
                   
                 CCTCAAGTCCCCCTC 
               
               
                   
               
               
                 154 
                 Gag:147-369 
                 CTGAGCCCCAGGACCCTGAATGCATGGGTCAAAGTGATTGAAGAGAAGGCTTTCTCTCCTGAAGTCATCCCA 
               
               
                   
                 Pol:683-708 
                 ATGTTCACAGCACTTTCTGAGGGGGCCACACCACATGATTTGAACACCATGCTCAACACCATTGGTGGTCAT 
               
               
                   
                 Pol:586-606 
                 CAGGCTGCTATGCAGATGCTCAAGGACACCATCAATGAGGAAGCAGCAGAGTGGGACAGAGTCCACCCAGTC 
               
               
                   
                 Pol:840-920 
                 CATGCAGGGCCTGTTGCACCAGGGCAAATGAGGGACCCCAGAGGCTCAGACATTGCAGGTTCCACATCAACC 
               
               
                   
                   
                 CTTCAAGAACAAATTGCCTGGATGACAAACAATCCCCCAATCCCAGTGGGGGACATCTACAAGAGATGGATC 
               
               
                   
                   
                 ATCATGGGCCTGAACAAAATTGTGAGGATGTACAGCCCTGTGTCAATTCTGGACATCAAGCAAGGCCCAAAA 
               
               
                   
                   
                 GAACCTTTCAGGGACTATGTTGACAGGTTTTACAGGACCCTCAGGGCAGAACAGGCCTCCCAGGATGTGAAG 
               
               
                   
                   
                 AATTGGATGACAGAGACATTGCTTGTTCAGAACAGCAACCCAGACTGCAAGACCATTCTGAAAGCCCTGGGT 
               
               
                   
                   
                 CCAGGAGCAACCCTGGAAGAGATGATGTCAGCCTGTCAGGGGGTGGGGGGGCCATCACACAAAGCCAGGGTG 
               
               
                   
                   
                 TTGGCTGAGGCCATGTGCCAGAAAGAAAAAATCTATCTGGCATGGGTGCCAGCCCACAAGGGGATTGGAGGC 
               
               
                   
                   
                 AATGAGCAAATTGACAAGCTGGTGTCAACTGAACCCATTGCTGGGGTAGAGACTTTTTATGTGGATGGTGCC 
               
               
                   
                   
                 AGCAACAGGGAAACCAAGGCTGTGAAGGCTGCTTGTTGGTGGGCTGGAGTCAAGCAGGAGTTTGGCATTCCC 
               
               
                   
                   
                 TACAACACCCAAAGCCAAGGTGTTGTTGAATCCATGAACAATGAGTTGAAAAAGATCATAGGCCAGATCAGG 
               
               
                   
                   
                 GATCAAGCTGAGCATCTGAAAACTGCAGTTCAGATGGCAGTCCTGATTCACAATTTCAAGAGAAAGGGAGGG 
               
               
                   
                   
                 ATAGGAGAGTACAGTGCAGGGGAAAGGATCATTGACATCATTGCA 
               
               
                   
               
               
                 155 
                 Gag:147-369 
                 CTGAGCCCCCGAACCCTCAACGCATGGGTCAAGGTGATCGAAGAGAAGGCGTTCTCTCCTGAAGTTATTCCT 
               
               
                   
                 Pol:683-708 
                 ATGTTTACGGCTCTGTCTGAGGGCGCCACACCCCATGATTTGAACACGATGCTCAACACGATAGGCGGTCAT 
               
               
                   
                 Pol:586-606 
                 CAAGCCGCGATGCAGATGCTCAAGGATACGATCAACGAGGAAGCTGCAGAGTGGGACCGAGTTCACCCAGTC 
               
               
                   
                 Pol:840-920 
                 CATGCAGGGCCTGTTGCACCAGGGCAAATGCGGGACCCACGCGGTTCAGATATTGCCGGTTCCACGTCTACC 
               
               
                   
                   
                 CTGCAAGAACAAATAGCGTGGATGACAAATAATCCACCGATCCCGGTGGGCGATATATACAAGAGATGGATT 
               
               
                   
                   
                 ATCATGGGCCTGAACAAAATAGTTAGGATGTACAGCCCGGTGTCAATACTTGATATAAAACAAGGACCGAAA 
               
               
                   
                   
                 GAACCCTTTCGCGACTATGTAGACCGGTTCTACAGGACGCTTAGGGCAGAACAGGCCTCCCAAGATGTGAAG 
               
               
                   
                   
                 AATTGGATGACAGAGACATTGCTTGTTCAGAACAGCAACCCTGACTGCAAGACCATACTTAAAGCTCTGGGT 
               
               
                   
                   
                 CCAGGAGCCACTCTGGAAGAGATGATGTCAGCATGTCAGGGGGTAGGCGGGCCATCACATAAAGCCCGGGTT 
               
               
                   
                   
                 TTGGCGGAAGCAATGTGCCAGAAAGAAAAAATTTATCTGGCGTGGGTGCCCGCCCACAAGGGGATAGGTGGT 
               
               
                   
                   
                 AACGAGCAGATCGACAAGCTGGTCTCAACAGAACCTATAGCTGGAGTAGAGACGTTTTATGTGGATGGTGCA 
               
               
                   
                   
                 AGCAATCGGGAAACCAAGGCGGTAAAGGCCGCTTGCTGGTGGGCCGGAGTCAAGCAGGAGTTCGGCATCCCG 
               
               
                   
                   
                 TATAACACCCAAAGTCAAGGTGTCGTCGAATCCATGAATAACGAGTTGAAAAAGATCATAGGTCAAATAAGG 
               
               
                   
                   
                 GATCAAGCTGAACATCTGAAGACGGCTGTTCAGATGGCGGTCCTTATCCACAACTTTAAGCGCAAAGGAGGT 
               
               
                   
                   
                 ATAGGAGAGTACAGCGCAGGTGAACGGATAATAGACATTATAGCA 
               
               
                   
               
               
                 156 
                 Gag:147-369 
                 CTGTCTCCTAGAACATTGAACGCTTGGGTTAAGGTTATAGAAGAGAAAGCCTTCAGTCCTGAGGTGATTCCC 
               
               
                   
                 Pol:840-920 
                 ATGTTTACCGCCCTGAGCGAGGGCGCTACACCACATGATCTGAATACCATGCTGAATACTATCGGGGGACAT 
               
               
                   
                 Pol:586-606 
                 CAGGCTGCCATGCAGATGCTTAAAGATACAATAAATGAGGAGGCTGCAGAGTGGGACAGGGTCCATCCTGTA 
               
               
                   
                 AA 
                 CACGCGGGACCTGTTGCGCCGGGACAGATGAGAGATCCGCGGGGGAGCGATATTGCAGGAAGCACCTCAACT 
               
               
                   
                 Pol:683-708 
                 CTTCAGGAGCAGATTGCCTGGATGACGAACAACCCTCCGATTCCTGTGGGAGACATTTATAAGAGGTGGATA 
               
               
                   
                   
                 ATTATGGGGTTGAACAAGATAGTCAGGATGTATTCTCCTGTTAGCATCCTGGACATAAAACAGGGCCCTAAA 
               
               
                   
                   
                 GAGCCTTTTCGCGATTATGTTGACAGGTTTTATAGGACACTTCGCGCGGAGCAAGCCTCCCAGGATGTTAAA 
               
               
                   
                   
                 AACTGGATGACCGAGACGCTCCTGGTTCAAAACAGTAACCCCGATTGTAAGACCATCCTTAAAGCACTTGGA 
               
               
                   
                   
                 CCTGGCGCTACCCTGGAGGAAATGATGAGCGCCTGTCAGGGGGTAGGAGGCCCATCACATAAGGCACGGGTG 
               
               
                   
                   
                 CTCGCAGAGGCGATGTGTCAAGCGGTGAAGGCAGCCTGCTGGTGGGCAGGTGTGAAGCAGGAATTTGGGATT 
               
               
                   
                   
                 CCTTATAATACACAATCCCAAGGTGTTGTCGAATCTATGAACAATGAACTGAAGAAAATTATAGGGCAAATC 
               
               
                   
                   
                 CGGGACCAAGCTGAGCACCTCAAAACCGCGGTTCAAATGGCTGTACTTATTCATAATTTCAAGCGCAAAGGG 
               
               
                   
                   
                 GGAATCGGTGAGTACAGTGCTGGGGAACGGATAATAGATATTATCGCCACCGAGCCTATCGCAGGTGTTGAA 
               
               
                   
                   
                 ACTTTTTACGTGGACGGTGCATCAAACAGAGAGACCAAAGCGGCCAAGGAGAAGATATATTTGGCCTGGGTT 
               
               
                   
                   
                 CCTGCTCACAAGGGAATTGGCGGAAATGAGCAAATTGATAAGCTCGTAAGT 
               
               
                   
               
               
                 157 
                 Pol:747-827 
                 GTTGCCAAGGAGATTGTGGCCTGCTGTGACAAGTGCCAATTGAAGGGGGAGGCAATTCATGGACAGGTGGAT 
               
               
                   
                 Pol:932-1003 
                 TGCAGTCCAGGAGTCTGGCAGCTGGATTGCACACACCTGGAAGGGAAGGTCATCCTTGTTGCAGTTCATGTT 
               
               
                   
                 Pol:129-320 
                 GCCTCAGGATACATTGAAGCAGAGATCATCCCCACAGAAACTGGTCAGGAAACAGCTTACTTCATTCTCAAA 
               
               
                   
                 KIL 
                 CTGGCTGGCAGGTGGCCAGTCACCACAATCACCAAGCTTCAAAATTTCAGGGTTTACTACAGGGACAACAGA 
               
               
                   
                 QEE 
                 GATCCTCTCTGGAAGGGACCTGCAAGACTTCTTTGGAAGGGTGAAGGGGCAGTTGTCATTCAGGACAACAGT 
               
               
                   
                 Nef:64-76 
                 GAGATCAAGGTTGTTCCCAGGAGAAAGGTCAAGATCATCAGGGACTATGGGAAAAGGATGGCAGGGGATGAC 
               
               
                   
                   
                 TGTGTTGCAGGGAGACAAGATGAGGATGGCACTGTGCTGATAGGCCCCACACCTGTCAACATCATTGGCAGG 
               
               
                   
                   
                 AACCTCTTGACTCAGCTGGGCTGCACTCTCAATTTTCCCATTTCCCCCATTGACACAGTGCCAGTGAAACTG 
               
               
                   
                   
                 AAGCCTGGAATGGATGGCCCAAGGGTCAAACAGTGGCCCCTGACAGAGGAGAAGATCAAGGCTCTCATTGAG 
               
               
                   
                   
                 ATCTGCACTGAAATGGAAAAGGAAGGCAAGATCAGCAGGATTGGCCCTGAGAACCCTTACAACACTCCTATT 
               
               
                   
                   
                 TTTGCAATCAAGAAGAAGGATGGGACCAAGTGGAGGAAGTTGGTTGACTTCAGGGAACTCAACAAGAAAACA 
               
               
                   
                   
                 CAAGACTTTTGGGAAGTCCAACTTGGCATTCCCCATCCCAGTGGGTTGAAAAAGAAAAAGTCAGTGACAGTG 
               
               
                   
                   
                 TTGGACATTGGGGATGCTTATTTCTCAGTTCCCCTTGACAAGGAGTTCAGAAAATACACAGCATTCACTGTG 
               
               
                   
                   
                 CCTTCCACAAACAATGAAACCCCTGGGGTCAGGTACCAGTACAATGTCCTTCCAATGGGTTGGAAAGGCAGT 
               
               
                   
                   
                 CCTGCAATCTTTCAATGCAGCATGACAAAAATCCTTCAAGAAGAAGAGGAAGTTGGCTTTCCTGTGAGGCCT 
               
               
                   
                   
                 CAGGTCCCCCTT 
               
               
                   
               
               
                 158 
                 Pol:747-827 
                 GTTGCCAAGGAGATCGTGGCGTGCTGCGATAAGTGCCAATTGAAAGGGGAGGCGATTCATGGACAGGTCGAT 
               
               
                   
                 Pol:932-1003 
                 TGTAGTCCCGGAGTCTGGCAGCTGGATTGCACTCACCTGGAAGGTAAGGTCATCCTTGTGGCTGTACATGTT 
               
               
                   
                 Pol:129-320 
                 GCCTCCGGGTATATTGAAGCCGAGATAATCCCTACCGAAACTGGTCAGGAAACCGCTTACTTCATTCTCAAA 
               
               
                   
                 KIL 
                 CTTGCTGGAAGGTGGCCCGTTACTACAATTACCAAGCTGCAAAATTTCAGGGTGTACTACAGGGATAACCGC 
               
               
                   
                 QEE 
                 GACCCTCTCTGGAAGGGCCCAGCACGACTGCTTTGGAAGGGTGAGGGGGCTGTTGTTATTCAGGATAACAGT 
               
               
                   
                 Nef:64-76 
                 GAGATTAAGGTAGTCCCCAGGCGAAAGGTTAAAATAATACGGGACTACGGTAAAAGAATGGCGGGGGATGAC 
               
               
                   
                   
                 TGTGTTGCAGGGAGACAAGACGAAGACGGAACGGTACTTATAGGCCCAACTCCGGTAAACATAATTGGTAGA 
               
               
                   
                   
                 AACCTCTTGACGCAGCTGGGCTGTACTCTTAATTTTCCAATATCACCTATTGACACTGTCCCAGTCAAGCTG 
               
               
                   
                   
                 AAGCCTGGAATGGATGGACCTCGGGTTAAACAGTGGCCCCTCACCGAGGAGAAGATCAAGGCGCTGATCGAA 
               
               
                   
                   
                 ATCTGCACCGAAATGGAAAAGGAAGGTAAGATTAGCCGGATCGGCCCCGAGAACCCTTATAACACGCCTATA 
               
               
                   
                   
                 TTCGCTATCAAGAAGAAGGACGGAACAAAGTGGAGGAAGTTGGTTGACTTCCGGGAACTTAACAAGAAAACA 
               
               
                   
                   
                 CAAGACTTTTGGGAAGTCCAACTCGGCATCCCACACCCAAGTGGGTTGAAAAAGAAAAAGTCCGTAACTGTA 
               
               
                   
                   
                 TTGGACATAGGTGACGCTTATTTTTCAGTACCACTTGATAAGGAATTTCGAAAATACACAGCGTTCACTGTG 
               
               
                   
                   
                 CCGTCCACGAACAACGAAACCCCCGGGGTACGCTACCAATATAACGTACTGCCAATGGGTTGGAAAGGTAGT 
               
               
                   
                   
                 CCTGCGATCTTTCAATGCAGTATGACTAAAATCCTTCAAGAAGAAGAGGAAGTCGGATTTCCTGTGCGGCCC 
               
               
                   
                   
                 CAGGTCCCCCTG 
               
               
                   
               
               
                 159 
                 Pol:129-320 
                 GGGACGGTGCTTATTGGGCCCACTCCAGTCAATATTATCGGACGAAACCTGCTGACTCAGCTGGGTTGCACT 
               
               
                   
                 Pol:932-1003 
                 CTCAATTTCCCTATTAGTCCTATAGACACGGTGCCCGTAAAACTCAAGCCAGGCATGGATGGTCCGCGCGTG 
               
               
                   
                 Pol:747-827 
                 AAGCAATGGCCTTTGACTGAAGAAAAAATTAAGGCACTCATTGAGATATGTACGGAGATGGAGAAAGAAGGG 
               
               
                   
                 AA 
                 AAAATCTCTCGAATTGGACCAGAAAACCCGTACAATACTCCGATTTTTGCGATTAAGAAGAAGGATGGCACG 
               
               
                   
                 QEE 
                 AAGTGGCGCAAACTCGTCGATTTTAGGGAGCTTAACAAGAAGACCCAAGATTTTTGGGAGGTCCAGCTGGGC 
               
               
                   
                 Nef:64-76 
                 ATTCCGCATCCGTCCGGCTTGAAAAAGAAAAAATCAGTTACTGTGCTTGATATAGGAGACGCCTATTTTAGT 
               
               
                   
                   
                 GTGCCGTTGGACAAGGAATTTCGCAAATATACAGCATTTACCGTCCCTTCAACGAACAATGAGACTCCGGGC 
               
               
                   
                   
                 GTACGCTACCAATATAATGTGTTGCCTATGGGGTGGAAGGGGTCTCCTGCGATCTTCCAATGCTCTATGACG 
               
               
                   
                   
                 ATTACCAAGCTGCAAAATTTTCGCGTATACTACCGCGACAATCGAGATCCATTGTGGAAGGGGCCGGCGAGG 
               
               
                   
                   
                 CTCCTTTGGAAGGGAGAAGGTGCCGTAGTTATCCAAGATAATAGCGAGATCAAAGTTGTGCCCCGAAGAAAG 
               
               
                   
                   
                 GTGAAAATTATAAGGGATTACGGGAAGAGAATGGCGGGAGACGACTGTGTTGCCGGTCGCCAAGACGAGGAT 
               
               
                   
                   
                 GTTGCGAAGGAAATCGTTGCGTGTTGTGATAAATGTCAGCTGAAAGGCGAAGCAATTCACGGACAGGTAGAT 
               
               
                   
                   
                 TGTTCTCCTGGCGTGTGGCAGCTTGACTGTACCCATTTGGAGGGAAAAGTGATCCTGGTAGCAGTCCACGTT 
               
               
                   
                   
                 GCCAGTGGCTACATAGAAGCTGAGATAATTCCTACTGAGACGGGACAGGAGACGGCTTATTTTATTCTCAAG 
               
               
                   
                   
                 CTGGCAGGCAGATGGCCCGTGACCACCGCGGCGCAGGAAGAGGAGGAAGTTGGTTTTCCCGTACGCCCTCAG 
               
               
                   
                   
                 GTTCCCTTG 
               
               
                   
               
               
                 160 
                 Pol:840-909 
                 ACAGTCAAAGCCGCTTGCTGGTGGGCGGGCATAAAGCAAGAATTTGGGATACCCTATAACCCTCAATCTCAA 
               
               
                   
                 AA 
                 GGGGTAGTTGAATCTATGAACAAGGAACTCAAAAAGATCATAGGACAGGTCCGCGATCAGGCTGAGCATTTG 
               
               
                   
                 Gag:147-369 
                 AAGACGGCTGTGCAAATGGCGGTTTTTATCCATAACTTCAAGCGGAAGGGTGGGATCGGCGGAGCAGCAATC 
               
               
                   
                 Pol:747-827 
                 AGTCCACGAACTCTTAATGCTTGGGTGAAGGTTGTTGAGGAGAAAGCGTTCAGTCCTGAGGTGATCCCCATG 
               
               
                   
                 QEE 
                 TTCTCTGCACTTAGCGAAGGAGCAACACCCCAGGACCTTAACACGATGTTGAACACAGTGGGGGGTCATCAA 
               
               
                   
                 Nef:64-76 
                 GCCGCCATGCAGATGCTCAAAGAAACTATAAATGAGGAGGCTGCCGAGTGGGACAGACTGCATCCTGTGCAC 
               
               
                   
                   
                 GCCGGACCAATAGCACCGGGGCAGATGCGAGAACCGCGAGGTTCCGACATCGCTGGGACCACTTCTACTCTG 
               
               
                   
                   
                 CAGGAGCAGATTGGTTGGATGACTAACAACCCCCCGATACCGGTGGGTGAGATCTATAAGCGCTGGATCATA 
               
               
                   
                   
                 CTTGGCCTTAACAAAATAGTTCGCATGTACTCACCAACAAGCATTCTCGACATCCGACAGGGGCCTAAGGAG 
               
               
                   
                   
                 CCTTTTCGAGACTATGTGGATAGATTTTATAAAACTTTGCGGGCGGAGCAAGCATCCCAGGAGGTTAAGAAC 
               
               
                   
                   
                 TGGATGACAGAGACACTTCTGGTCCAGAATGCCAACCCCGACTGTAAAACGATACTTAAAGCACTTGGGCCG 
               
               
                   
                   
                 GCTGCAACTCTGGAGGAAATGATGACAGCGTGTCAAGGTGTGGGGGGTCCTGGCCATAAGGCTCGCGTGTTG 
               
               
                   
                   
                 GCGGAAGCAATGTCACAAGTTGCCAAAGAAATAGTTGCCAGTTGCGACAAGTGCCAACTCAAAGGTGAAGCG 
               
               
                   
                   
                 ATGCATGGACAGGTGGATTGCTCACCAGGCATCTGGCAGCTTGACTGTACACACCTGGAGGGCAAGATAATT 
               
               
                   
                   
                 TTGGTCGCGGTGCATGTAGCAAGTGGTTATATCGAAGCTGAGGTAATACCCGCCGAGACGGGGCAAGAGACA 
               
               
                   
                   
                 GCCTACTTCCTCTTGAAGTTGGCCGGTCGATGGCCGGTTAAGACGCAAGAGGAGGAAGAGGTTGGCTTCCCC 
               
               
                   
                   
                 GTTAAGCCTCAAGTACCGCTT 
               
               
                   
               
               
                 161 
                 Pol:840-909 
                 GCGGTGAAGGCCGCATGTTGGTGGGCGGGTGTTAAACAAGAGTTCGGTATACCGTACAATACGCAGAGTCAA 
               
               
                   
                 Gag:147-369 
                 GGAGTCGTAGAATCTATGAATAATGAGCTGAAAAAAATCATTGGGCAAATTCGGGACCAGGCTGAGCATCTC 
               
               
                   
                 VT 
                 AAAACGGCCGTTCAGATGGCCGTCCTGATTCATAACTTTAAGAGAAAAGGCGGCATAGGGGAGCTCAGTCCA 
               
               
                   
                 Pol:747-827 
                 AGGACTCTCAACGCCTGGGTGAAGGTTATTGAAGAAAAAGCGTTTAGCCCGGAGGTAATTCCAATGTTTACA 
               
               
                   
                 AA 
                 GCTCTCAGCGAGGGGGCGACACCTCATGATCTCAATACAATGCTCAATACAATAGGGGGGCACCAGGCCGCT 
               
               
                   
                 QEE 
                 ATGCAAATGCTGAAAGACACGATCAATGAAGAAGCGGCTGAATGGGATAGAGTTCATCCTGTTCATGCAGGA 
               
               
                   
                 Nef:64-76 
                 CCGGTCGCCCCGGGACAGATGAGAGACCCGCGCGGTTCCGACATAGCTGGGAGCACGTCTACGTTGCAGGAG 
               
               
                   
                   
                 CAGATCGCTTGGATGACTAATAATCCCCCTATCCCTGTCGGTGATATTTATAAACGGTGGATTATTATGGGT 
               
               
                   
                   
                 TTGAACAAAATTGTGAGAATGTACAGCCCAGTTTCCATACTTGATATTAAGCAGGGGCCGAAAGAACCCTTT 
               
               
                   
                   
                 AGGGACTATGTAGACCGCTTCTATCGCACACTTAGAGCCGAGCAGGCGAGTCAGGACGTAAAGAACTGGATG 
               
               
                   
                   
                 ACAGAAACCCTCCTTGTCCAAAACTCCAATCCCGATTGCAAAACCATTTTGAAAGCACTCGGTCCTGGAGCC 
               
               
                   
                   
                 ACTTTGGAAGAAATGATGTCCGCGTGTCAGGGGGTGGGAGGGCCAAGCCACAAAGCGAGAGTATTGGCGGAG 
               
               
                   
                   
                 GCGATGTGCCAGGTTACCGTAGCGAAGGAGATAGTCGCATGCTGTGACAAATGCCAACTTAAAGGCGAGGCG 
               
               
                   
                   
                 ATCCATGGTCAGGTTGACTGCAGTCCGGGGGTATGGCAACTTGACTGTACACATTTGGAGGGTAAGGTTATT 
               
               
                   
                   
                 CTCGTTGCAGTTCATGTAGCTTCAGGATACATCGAGGCCGAAATCATCCCGACGGAGACGGGCCAAGAGACT 
               
               
                   
                   
                 GCCTACTTCATCTTGAAACTGGCGGGTCGCTGGCCGGTAACTACCGCCGCCCAGGAGGAAGAAGAAGTTGGG 
               
               
                   
                   
                 TTCCCTGTCCGACCCCAAGTGCCACTC 
               
               
                   
               
               
                 162 
                 Pol:840-909 
                 ACGGTGAAAGCGGCCTGTTGGTGGGCGGGAATTAAGCAGGAATTTGGGATACCGTATAACCCTCAAAGCCAA 
               
               
                   
                 Pol:747-827 
                 GGCGTCGTAGAATCCATGAACAAAGAGCTGAAGAAGATTATTGGCCAGGTTCGGGACCAGGCAGAACACCTT 
               
               
                   
                 AA 
                 AAAACAGCCGTGCAGATGGCAGTGTTCATCCATAATTTTAAGCGGAAGGGCGGGATTGGCGGAGTTGCGAAG 
               
               
                   
                 Gag:147-369 
                 GAAATTGTTGCGAGTTGTGATAAATGCCAACTTAAAGGGGAGGCAATGCACGGACAAGTTGATTGCTCACCT 
               
               
                   
                 QEE 
                 GGCATATGGCAGCTGGATTGTACCCACCTTGAGGGTAAAATAATCCTGGTGGCCGTTCATGTCGCATCTGGC 
               
               
                   
                 Nef:64-76 
                 TATATAGAAGCGGAAGTCATTCCAGCAGAGACGGGTCAAGAAACTGCTTACTTTCTCCTTAAACTTGCGGGA 
               
               
                   
                   
                 AGGTGGCCTGTTAAAACCGCCGCTATTAGCCCCAGGACGTTGAATGCCTGGGTAAAGGTTGTGGAGGAGAAG 
               
               
                   
                   
                 GCATTCTCCCCTGAGGTAATTCCCATGTTCTCAGCACTGAGTGAAGGGGCTACACCTCAAGATCTGAACACG 
               
               
                   
                   
                 ATGCTCAACACGGTTGGCGGACATCAAGCGGCCATGCAAATGCTCAAAGAAACCATCAATGAAGAAGCGGCT 
               
               
                   
                   
                 GAGTGGGACCGCCTTCATCCAGTCCATGCTGGCCCAATCGCACCTGGTCAAATGAGAGAGCCGAGGGGTAGT 
               
               
                   
                   
                 GATATAGCCGGGACGACTAGCACATTGCAGGAACAGATAGGGTGGATGACAAATAACCCTCCTATACCTGTG 
               
               
                   
                   
                 GGGGAAATATATAAACGCTGGATTATTCTCGGTCTGAACAAGATTGTCAGGATGTACTCCCCGACCAGTATC 
               
               
                   
                   
                 CTTGACATAAGACAAGGGCCTAAGGAGCCCTTTCGGGACTACGTTGATCGGTTCTATAAGACGCTTCGGGCC 
               
               
                   
                   
                 GAGCAGGCGTCTCAAGAGGTGAAAAATTGGATGACTGAAACTTTGCTGGTGCAAAATGCTAACCCCGACTGC 
               
               
                   
                   
                 AAGACAATATTGAAGGCTCTCGGTCCAGCAGCAACTTTGGAAGAGATGATGACAGCGTGTCAAGGCGTAGGT 
               
               
                   
                   
                 GGGCCAGGACACAAGGCTAGGGTCCTTGCAGAGGCTATGTCTCAGCAGGAGGAGGAAGAGGTAGGTTTCCCC 
               
               
                   
                   
                 GTCAAGCCTCAAGTCCCACTC 
               
               
                   
               
               
                 163 
                 Gag:147-369 
                 CTTAGTCCGAGAACTCTCAACGCTTGGGTCAAAGTCATAGAGGAGAAAGCCTTTTCACCCGAAGTAATACCT 
               
               
                   
                 PV 
                 ATGTTCACTGCGTTGAGCGAGGGCGCGACACCTCATGACCTGAATACTATGCTGAACACCATCGGGGGCCAC 
               
               
                   
                 Pol:747-827 
                 CAAGCAGCTATGCAGATGCTGAAGGACACAATTAACGAAGAAGCGGCAGAATGGGATAGGGTTCACCCTGTA 
               
               
                   
                 AAY 
                 CATGCCGGACCAGTTGCACCTGGCCAAATGAGAGACCCACGAGGGAGCGACATCGCAGGCTCAACTAGTACC 
               
               
                   
                 Pol:840-909 
                 CTGCAAGAGCAGATAGCGTGGATGACCAATAATCCTCCTATTCCTGTTGGTGACATTTACAAACGATGGATA 
               
               
                   
                 QEE 
                 ATAATGGGCCTCAATAAGATCGTCAGAATGTACAGCCCAGTGAGCATCCTGGATATAAAGCAGGGACCGAAA 
               
               
                   
                 Nef:64-76 
                 GAACCCTTCCGGGACTATGTTGACCGCTTCTACCGGACTCTTAGGGCGGAACAGGCCAGCCAGGACGTAAAA 
               
               
                   
                   
                 AACTGGATGACTGAAACGTTGTTGGTTCAAAATTCAAATCCAGACTGCAAAACCATTCTCAAAGCACTCGGA 
               
               
                   
                   
                 CCAGGCGCTACCCTGGAAGAGATGATGTCTGCCTGTCAAGGTGTCGGGGGGCCGAGTCACAAGGCACGCGTA 
               
               
                   
                   
                 CTGGCGGAGGCCATGTGTCAACCAGTAGTTGCCAAAGAGATTGTCGCGTGCTGTGATAAGTGTCAGCTCAAA 
               
               
                   
                   
                 GGGGAAGCGATACATGGACAAGTAGACTGTAGTCCTGGCGTGTGGCAGTTGGACTGTACCCATTTGGAGGGC 
               
               
                   
                   
                 AAGGTAATATTGGTAGCTGTCCATGTCGCGTCTGGTTATATCGAAGCAGAAATCATTCCGACTGAGACTGGT 
               
               
                   
                   
                 CAAGAGACGGCCTACTTCATACTGAAACTTGCAGGTAGGTGGCCGGTAACAACGGCGGCTTATGCCGTAAAA 
               
               
                   
                   
                 GCTGCTTGTTGGTGGGCTGGAGTCAAGCAAGAATTTGGAATCCCTTACAACACACAGAGTCAAGGCGTCGTC 
               
               
                   
                   
                 GAGTCTATGAATAACGAGCTGAAAAAGATCATAGGCCAAATCAGAGACCAAGCCGAACACTTGAAGACAGCC 
               
               
                   
                   
                 GTTCAAATGGCAGTTCTTATCCACAACTTCAAGCGCAAAGGGGGCATAGGTGAACAGGAGGAGGAGGAGGTA 
               
               
                   
                   
                 GGCTTCCCTGTCCGGCCGCAAGTGCCGCTC 
               
               
                   
               
               
                 164 
                 Pol:840-920 
                 ACAGTGAAGGCAGCTTGTTGGTGGGCCGGAATTAAACAGGAGTTTGGCATCCCTTATAATCCTCAGTCTCAG 
               
               
                   
                 Gag:147-369 
                 GGAGTGGTGGAGTCTATGAACAAGGAGCTGAAGAAGATCATCGGCCAGGTGAGAGATCAGGCAGAACATCTG 
               
               
                   
                 Gag:1-53 
                 AAGACAGCAGTGCAGATGGCCGTGTTTATCCACAACTTCAAGAGGAAGGGCGGCATTGGAGGATATAGCGCA 
               
               
                   
                 PPV 
                 GGAGAAAGAATCGTGGACATCATCGCCATCTCTCCTAGAACACTGAACGCTTGGGTGAAAGTGGTGGAGGAG 
               
               
                   
                 Pol:747-827 
                 AAAGCCTTTAGCCCAGAAGTGATCCCTATGTTCTCAGCTCTGTCAGAAGGAGCTACACCTCAGGATCTGAAC 
               
               
                   
                 Pol:683-708 
                 ACCATGCTGAATACCGTGGGAGGACATCAGGCAGCTATGCAGATGCTGAAGGAGACAATTAACGAGGAAGCA 
               
               
                   
                 Nef:117-148 
                 GCCGAGTGGGATAGACTGCATCCAGTGCACGCAGGACCTATTGCTCCAGGACAGATGAGAGAGCCTAGAGGA 
               
               
                   
                 RAKR 
                 AGCGATATTGCCGGCACAACATCTACACTGCAGGAACAGATCGGTTGGATGACCAACAATCCTCCTATCCCA 
               
               
                   
                 F2A linker 
                 GTGGGCGAAATCTACAAACGCTGGATCATCCTGGGCCTGAATAAGATCGTGAGAATGTACAGCCCCACAAGC 
               
               
                   
                 Gag:147-369 
                 ATCCTGGATATCAGACAGGGACCTAAGGAACCTTTCAGGGATTACGTGGACCGGTTCTACAAGACACTGAGA 
               
               
                   
                 Pol:747-827 
                 GCAGAACAGGCATCTCAGGAGGTGAAGAATTGGATGACCGAGACACTGCTGGTGCAGAACGCTAATCCAGAT 
               
               
                   
                 Gag:1-53 
                 TGCAAGACCATTCTGAAAGCTCTGGGACCAGCAGCTACACTGGAAGAGATGATGACAGCTTGTCAGGGAGTG 
               
               
                   
                 AA 
                 GGAGGACCAGGACATAAAGCTAGAGTGCTGGCAGAAGCTATGTCTCAGATGGCAGCTAGAGCTTCAGTGCTG 
               
               
                   
                 Pol:840-920 
                 TCAGGAGGAGAACTCGATAGGTGGGAGAAGATCAGACTGAGACCAGGAGGCAAGAAGAAGTACAGACTGAAG 
               
               
                   
                 Nef:117-148 
                 CACATCGTGTGGGCTTCTAGAGAACTGGAGAGATTTGCCGTGAATCCAGGACTCCTGGAAACACCTCCAGTG 
               
               
                   
                 LIK 
                 GTGGCTAAAGAGATTGTGGCTTCTTGCGATAAGTGCCAGCTGAAAGGAGAGGCTATGCACGGACAGGTGGAT 
               
               
                   
                 Pol:683-708 
                 TGTTCTCCAGGAATTTGGCAGCTGGATTGTACACACCTGGAGGGAAAGATTATTCTGGTGGCAGTGCACGTG 
               
               
                   
                   
                 GCATCAGGATATATTGAGGCCGAAGTGATTCCAGCAGAAACAGGACAGGAGACAGCTTACTTTCTGCTCAAA 
               
               
                   
                   
                 CTGGCAGGTCGCTGGCCAGTGAAAACCAAGGAGAAGGTGTACCTGGCTTGGGTGCCAGCTCATAAAGGAATT 
               
               
                   
                   
                 GGCGGAAACGAGCAGGTGGATAAACTGGTGTCTACACAGGGCTACTTCCCAGATTGGCAGAATTACACACCA 
               
               
                   
                   
                 GGACCAGGCACAAGATATCCTCTGACATTCGGTTGGTGTTTCAAGCTCGTGCCAGTGAGAGCTAAAAGAGCT 
               
               
                   
                   
                 CCAGTGAAGCAGACCCTGAATTTCGATCTGCTGAAGCTCGCAGGAGACGTGGAATCTAATCCAGGACCTCTG 
               
               
                   
                   
                 TCTCCTAGAACACTGAACGCTTGGGTGAAGGTGATCGAAGAGAAGGCCTTTAGCCCAGAAGTGATCCCTATG 
               
               
                   
                   
                 TTTACAGCCCTGAGCGAAGGAGCTACACCTCACGATCTGAATACCATGCTGAACACAATTGGAGGACATCAG 
               
               
                   
                   
                 GCCGCTATGCAGATGCTGAAGGACACCATCAACGAAGAAGCAGCCGAGTGGGATAGAGTGCATCCAGTGCAC 
               
               
                   
                   
                 GCAGGACCAGTGGCTCCAGGACAGATGAGAGATCCTAGAGGAAGCGACATCGCAGGATCTACATCTACACTG 
               
               
                   
                   
                 CAGGAACAGATCGCCTGGATGACAAATAACCCCCCTATCCCAGTGGGAGATATCTATAAGCGCTGGATCATC 
               
               
                   
                   
                 ATGGGCCTGAACAAGATCGTGAGGATGTACAGCCCAGTGTCTATCCTGGACATCAAGCAGGGACCTAAGGAG 
               
               
                   
                   
                 CCTTTTAGAGACTACGTGGACAGATTCTACAGAACACTGAGAGCCGAACAGGCATCTCAGGACGTGAAGAAT 
               
               
                   
                   
                 TGGATGACCGAGACACTGCTGGTGCAGAACAGCAACCCCGATTGCAAGACAATCCTGAAAGCCCTGGGACCA 
               
               
                   
                   
                 GGAGCTACACTGGAAGAGATGATGTCAGCTTGTCAGGGAGTGGGAGGACCATCTCATAAGGCTAGAGTGCTG 
               
               
                   
                   
                 GCAGAAGCTATGTGTCAGGTGGCTAAGGAGATTGTGGCTTGTTGCGACAAGTGCCAGCTGAAAGGAGAAGCT 
               
               
                   
                   
                 ATCCACGGACAGGTGGATTGTTCTCCAGGAGTCTGGCAGCTGGATTGTACACACCTGGAAGGAAAAGTGATT 
               
               
                   
                   
                 CTGGTGGCAGTGCACGTGGCCAGCGGCTATATTGAAGCCGAGATCATTCCTACAGAGACAGGACAGGAGACA 
               
               
                   
                   
                 GCTTACTTCATTCTGAAACTGGCAGGTCGCTGGCCAGTGACAACAATGGCAGCTAGAGCTTCTATCCTGTCA 
               
               
                   
                   
                 GGAGGAAAGCTCGATAAGTGGGAAAAGATCAGACTGAGACCAGGCGGAAGAAAGAAGTACAAGCTGAAGCAC 
               
               
                   
                   
                 CTCGTCTGGGCTTCTAGAGAACTGGAAAGATTCGCCCTGAATCCAGGTCTGCTGGAAACAGCAGCAGCAGTG 
               
               
                   
                   
                 AAAGCAGCTTGTTGGTGGGCAGGAGTGAAACAGGAGTTCGGCATCCCTTACAACACCCAGTCTCAGGGAGTG 
               
               
                   
                   
                 GTGGAATCTATGAACAACGAGCTGAAGAAGATCATCGGCCAGATCAGAGACCAGGCAGAACATCTGAAGACA 
               
               
                   
                   
                 GCAGTGCAGATGGCAGTGCTGATTCACAACTTCAAGAGAAAGGGCGGCATTGGAGAGTATAGCGCCGGAGAG 
               
               
                   
                   
                 AGAATCATCGATATCATTGCCACACAGGGCTTCTTCCCAGATTGGCAGAATTACACCCCAGGACCAGGCATT 
               
               
                   
                   
                 AGATTTCCTCTGACCTTCGGTTGGTGTTTCAAACTGGTGCCCCTGCTGATCAAGAAGGAGAAGATCTACCTG 
               
               
                   
                   
                 GCTTGGGTGCCAGCTCATAAAGGAATCGGAGGAAACGAGCAGATCGATAAACTGGTGTCT 
               
               
                   
               
               
                 165 
                 Pol:56-117 
                 TTTCCTCAGATCACTCTCTGGCAGAGACCACTGGTGACAATCAAGATCGGAGGACAGCTGAAAGAAGCTCTG 
               
               
                   
                 Nef:64-99 
                 CTGGATACAGGAGCAGACGATACAGTGCTGGAAGAGATGAATCTGCCAGGTCGCTGGAAACCTAAGATGATT 
               
               
                   
                 LI 
                 GGAGGCATTGGCGGCTTTATCAAGGTGAGACAGTACGACCAGGAGGAAGTGGGATTTCCAGTGAAACCTCAG 
               
               
                   
                 Pol:542-606 
                 GTGCCTCTGAGACCTATGACATTTAAGGGCGCTCTGGACCTGTCTCACTTTCTGAGAGAGAAGGGAGGACTG 
               
               
                   
                 Pol:367-431 
                 GAAGGACTGATCCCTAAGTTCAAGCTGCCTATCCAGAAGGAGACTTGGGAAACTTGGTGGACAGAGTATTGG 
               
               
                   
                 Pol:932-1003 
                 CAGGCTACTTGGATTCCCGAGTGGGAATTTGTGAACACACCTCCTCTGGTGAAGCTGTGGTATCAGCTGGAA 
               
               
                   
                 Pol:129-320 
                 AAGGAGCCTATTGTGGGCGCAGAAACATTCTACGTGGACGGAGCAGCTAACAGAGAAACTAAGTGGGGATTC 
               
               
                   
                 RAKR 
                 ACCACCCCAGATAAGAAGCACCAGAAGGAGCCACCATTTCTCTGGATGGGATACGAACTGCACCCAGATAAG 
               
               
                   
                 F2A linker 
                 TGGACAGTCCAGCCTATTGTGCTGCCAGAAAAGGACTCTTGGACCGTGAACGATATCCAGAAGCTGGTGGGA 
               
               
                   
                 Pol:56-117 
                 AAGCTGAATTGGGCTTCTCAGATCTACCCAGGAATCAAGGTGATCACCAAGATCCAGAACTTCAGGGTGTAC 
               
               
                   
                 Pol:367-431 
                 TACAGAGACAGCAGAGATCCTCTCTGGAAGGGACCAGCTAAACTCCTCTGGAAAGGAGAAGGAGCAGTGGTG 
               
               
                   
                 AA 
                 ATCCAGGATAACAGCGACATCAAGGTGGTGCCTAGAAGAAAGGCCAAGATCATCAGGGACTACGGCAAACAG 
               
               
                   
                 QEE 
                 ATGGCAGGAGACGATTGCGTGGCTTCTAGACAGGACGAAGACGGAACAGTCCTGGTGGGACCTACACCAGTG 
               
               
                   
                 Nef:64-99 
                 AATATCATCGGCAGAAATCTCCTGACACAGATCGGTTGTACCCTGAACTTCCCTATCAGCCCTATCGAGACA 
               
               
                   
                 Pol:932-1003 
                 GTGCCAGTGAAACTGAAGCCAGGAATGGACGGACCTAAAGTCAAGCAGTGGCCTCTGACAGAAGAGAAGATC 
               
               
                   
                 Pol:542-606 
                 AAGGCCCTGGTGGAGATTTGCACAGAGATGGAGAAGGAGGGAAAGATCAGCAAGATCGGCCCAGAGAATCCT 
               
               
                   
                 AA 
                 TACAACACCCCAGTGTTCGCCATCAAGAAGAAGGATAGCACCAAGTGGAGAAAGCTGGTGGATTTCAGGGAG 
               
               
                   
                 Pol:129-320 
                 CTGAACAAGAGAACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCATCCAGCAGGACTGAAGAAGAAG 
               
               
                   
                   
                 AAGAGCGTGACAGTGCTGGACGTGGGAGACGCTTATTTTAGCGTGCCTCTGGACAAGGACTTCAGAAAGTAC 
               
               
                   
                   
                 ACCGCCTTCACCATCCCTTCTATCAACAACGAGACCCCAGGCATCAGATACCAGTATAACGTGCTGCCTCAG 
               
               
                   
                   
                 GGTTGGAAAGGATCTCCAGCAATCTTCCAGAGCAGCATGACCAGAGCTAAGAGAGCTCCAGTGAAACAGACC 
               
               
                   
                   
                 CTGAACTTCGATCTGCTCAAACTGGCAGGAGACGTGGAAAGCAATCCAGGACCTAATCTGCCTCAGATCACA 
               
               
                   
                   
                 CTGTGGCAGAGACCTATTGTGACCATCAAGATTGGCGGCCAGATTAAAGAAGCCCTGCTGGATACAGGAGCA 
               
               
                   
                   
                 GACGATACAGTGCTGGAGGATATGAACCTGCCAGGTAAGTGGAAGCCTAAGATGATTGGCGGAATTGGCGGC 
               
               
                   
                   
                 TTTATCAAGGTCAAGCAGTACGATCAGTGGGGACTGACAACACCAGACAAGAAGCACCAGAAGGACCCCCCA 
               
               
                   
                   
                 TTCCTCTGGATGGGATACGAACTGCATCCAGATAGGTGGACAGTGCAGCCAATTGAACTGCCAGAGAAGGAG 
               
               
                   
                   
                 TCTTGGACCGTGAACGATATCCAGAAGCTGATCGGCAAGCTGAATTGGGCTTCTCAGATCTACGCAGGAATT 
               
               
                   
                   
                 AAGGTGGCCGCTCAGGAAGAAGAGGAAGTGGGATTTCCAGTGAGACCTCAGGTGCCTCTGAGACCTATGACA 
               
               
                   
                   
                 TACAAGGGAGCTCTGGACCTGTCTCACTTTCTGAAGGAGAAGGGAGGACTGGAAGGAATCACCAAGCTGCAG 
               
               
                   
                   
                 AATTTCCGGGTGTACTACAGGGACAATAGAGACCCTCTCTGGAAAGGACCAGCTAGACTGCTGTGGAAAGGA 
               
               
                   
                   
                 GAAGGAGCAGTGGTGATCCAGGATAATAGCGAGATCAAGGTGGTGCCTAGGAGAAAGGTGAAGATCATCAGG 
               
               
                   
                   
                 GACTACGGCAAGAGAATGGCAGGAGACGATTGCGTGGCAGGAAGACAGGACGAGGACCCCAAGTTCAGACTG 
               
               
                   
                   
                 CCTATCCAGAAGGAGACTTGGGATACTTGGTGGACCGATTATTGGCAGGCAACTTGGATTCCCGAGTGGGAG 
               
               
                   
                   
                 TTTACAAATACCCCTCCTCTGGTCAAGCTCTGGTATCAGCTGGAAACAGAGCCTATTGCCGGAGTGGAAACC 
               
               
                   
                   
                 TTTTACGTGGACGGAGCCAGCAACAGAGAGACAAAAGCCGCAGGAACAGTGCTGATTGGACCTACCCCAGTG 
               
               
                   
                   
                 AACATCATCGGAAGAAACCTGCTGACACAGCTGGGTTGTACACTGAACTTCCCTATCAGCCCTATTGATACA 
               
               
                   
                   
                 GTGCCAGTGAAGCTGAAACCAGGAATGGACGGACCTAGAGTCAAGCAGTGGCCTCTGACAGAAGAGAAGATC 
               
               
                   
                   
                 AAGGCCCTGATCGAGATTTGCACCGAAATGGAGAAGGAGGGCAAGATTAGCAGGATCGGCCCAGAGAATCCT 
               
               
                   
                   
                 TACAATACCCCTATCTTCGCCATCAAGAAGAAGGACGGCACCAAGTGGAGAAAACTGGTGGATTTCAGGGAG 
               
               
                   
                   
                 CTGAACAAGAAGACCCAGGACTTTTGGGAGGTGCAGCTGGGCATCCCCCATCCTTCAGGACTGAAGAAGAAG 
               
               
                   
                   
                 AAGAGCGTGACAGTGCTGGACATTGGAGACGCTTACTTTAGCGTGCCACTGGACAAGGAGTTCAGAAAGTAC 
               
               
                   
                   
                 ACCGCCTTCACAGTGCCTAGCACAAATAACGAGACCCCAGGAGTGAGATACCAGTATAACGTGCTGCCAATG 
               
               
                   
                   
                 GGCTGGAAAGGAAGCCCAGCTATCTTTCAGTGTAGCATGACA 
               
               
                   
               
               
                 166 
                 Pol:747-827 
                 GTGGCCAAAGAAATTGTGGCCTCTTGCGATAAGTGCCAGCTGAAAGGAGAGGCTATGCACGGACAGGTGGAT 
               
               
                   
                 Nef:117-148 
                 TGTTCTCCAGGAATTTGGCAGCTGGATTGTACACACCTGGAGGGAAAGATTATTCTGGTGGCAGTGCACGTG 
               
               
                   
                 Pol:840-920 
                 GCATCAGGATATATTGAGGCCGAAGTGATTCCAGCAGAAACAGGACAGGAGACAGCTTACTTTCTGCTCAAA 
               
               
                   
                 AA 
                 CTGGCAGGTCGCTGGCCAGTGAAGACAACACAGGGCTACTTTCCTGATTGGCAGAATTACACACCAGGACCA 
               
               
                   
                 Gag:1-53 
                 GGAACAAGATACCCTCTGACCTTTGGTTGGTGCTTCAAACTGGTGCCCGTGACAGTGAAAGCAGCTTGTTGG 
               
               
                   
                 SEG 
                 TGGGCAGGAATTAAGCAGGAGTTCGGCATCCCTTACAATCCTCAGTCTCAGGGAGTGGTGGAATCTATGAAC 
               
               
                   
                 Gag:147-369 
                 AAGGAGCTGAAGAAGATCATCGGCCAGGTGAGAGATCAGGCAGAACATCTGAAGACAGCAGTGCAGATGGCA 
               
               
                   
                 AAA 
                 GTGTTCATCCACAACTTCAAGCGGAAGGGAGGAATTGGAGGATATAGCGCAGGAGAGAGAATCGTGGATATC 
               
               
                   
                 Pol:683-708 
                 ATTGCCGCCGCTATGGCAGCTAGAGCCAGCGTGCTGAGCGGAGGAGAACTCGATCGCTGGGAAAAGATCAGA 
               
               
                   
                 RAKR 
                 CTGAGACCAGGAGGCAAGAAGAAGTACAGACTGAAGCACATCGTCTGGGCTTCTAGAGAACTGGAGAGATTT 
               
               
                   
                 F2A linker 
                 GCCGTGAATCCAGGACTGCTGGAAACAAGCGAGGGCATTTCTCCTAGAACCCTGAACGCTTGGGTGAAAGTG 
               
               
                   
                 Gag:147-369 
                 GTGGAAGAAAAAGCCTTCTCTCCAGAGGTGATCCCTATGTTTAGCGCTCTGTCAGAAGGAGCTACACCTCAG 
               
               
                   
                 Pol:840-920 
                 GATCTGAACACCATGCTGAACACAGTGGGAGGACATCAGGCAGCTATGCAGATGCTGAAGGAGACAATTAAC 
               
               
                   
                 Pol:683-708 
                 GAAGAAGCCGCCGAGTGGGATAGACTGCATCCAGTGCACGCAGGACCTATTGCTCCAGGACAGATGAGAGAG 
               
               
                   
                 AAY 
                 CCTAGAGGAAGCGATATTGCCGGAACAACAAGCACACTGCAGGAACAGATCGGTTGGATGACCAATAATCCC 
               
               
                   
                 Gag:1-53 
                 CCTATTCCAGTGGGCGAGATCTATAAGCGCTGGATTATCCTGGGCCTGAACAAGATCGTGAGAATGTACAGC 
               
               
                   
                 Nef:117-148 
                 CCCACCTCTATCCTGGATATCAGACAGGGCCCTAAGGAACCTTTCAGAGACTACGTGGACAGGTTCTACAAG 
               
               
                   
                 Pol:747-827 
                 ACACTGAGAGCAGAACAGGCATCTCAGGAGGTGAAGAATTGGATGACCGAGACACTGCTGGTGCAGAACGCC 
               
               
                   
                   
                 AATCCAGATTGCAAGACAATTCTGAAAGCCCTGGGACCAGCAGCTACACTGGAAGAGATGATGACCGCTTGT 
               
               
                   
                   
                 CAGGGAGTGGGAGGACCAGGACATAAAGCTAGAGTGCTGGCAGAAGCTATGTCTCAGGCAGCAGCTAAGGAG 
               
               
                   
                   
                 AAAGTGTATCTGGCTTGGGTGCCAGCCCATAAAGGAATTGGAGGAAACGAGCAGGTGGATAAGCTGGTGTCT 
               
               
                   
                   
                 AGAGCTAAGAGAGCTCCAGTGAAGCAGACCCTGAACTTTGATCTGCTCAAGCTGGCAGGAGACGTGGAATCT 
               
               
                   
                   
                 AATCCAGGACCTCATCAGGCTCTGTCTCCTAGAACACTGAACGCTTGGGTGAAGGTGATCGAAGAGAAGGCC 
               
               
                   
                   
                 TTTAGCCCAGAAGTGATCCCTATGTTTACAGCCCTGAGCGAAGGAGCTACACCTCACGATCTGAATACCATG 
               
               
                   
                   
                 CTGAACACAATTGGAGGACATCAGGCCGCTATGCAGATGCTGAAGGACACCATCAACGAGGAAGCAGCAGAG 
               
               
                   
                   
                 TGGGATAGAGTGCATCCAGTGCATGCAGGACCAGTGGCTCCAGGACAGATGAGAGATCCTAGAGGAAGCGAT 
               
               
                   
                   
                 ATCGCAGGATCTACAAGCACACTGCAGGAACAGATCGCTTGGATGACCAATAACCCACCTATCCCAGTGGGA 
               
               
                   
                   
                 GACATCTACAAGCGCTGGATCATCATGGGACTGAACAAGATCGTGAGGATGTACAGCCCAGTGTCTATCCTG 
               
               
                   
                   
                 GATATCAAGCAGGGACCTAAGGAGCCTTTCAGAGATTACGTGGACAGGTTTTACAGAACCCTGAGAGCCGAA 
               
               
                   
                   
                 CAGGCATCTCAGGACGTGAAGAATTGGATGACCGAAACACTGCTGGTGCAGAATAGCAACCCAGATTGCAAG 
               
               
                   
                   
                 ACAATCCTGAAAGCCCTGGGACCAGGAGCTACACTGGAAGAAATGATGAGCGCTTGTCAGGGAGTGGGAGGA 
               
               
                   
                   
                 CCATCTCATAAGGCTAGAGTGCTGGCAGAAGCTATGTGTCAGGCAGTGAAAGCAGCTTGTTGGTGGGCAGGA 
               
               
                   
                   
                 GTGAAACAGGAGTTTGGCATCCCTTACAACACACAGTCTCAGGGAGTGGTGGAATCTATGAACAACGAGCTG 
               
               
                   
                   
                 AAGAAGATCATCGGCCAGATCAGAGACCAGGCAGAACATCTGAAGACAGCAGTGCAGATGGCAGTGCTGATT 
               
               
                   
                   
                 CACAACTTCAAGAGAAAGGGCGGCATTGGAGAGTATAGCGCCGGCGAGAGAATTATCGACATCATCGCCAAG 
               
               
                   
                   
                 GAGAAGATCTATCTGGCTTGGGTGCCAGCCCATAAAGGAATTGGAGGCAATGAGCAGATCGATAAACTGGTG 
               
               
                   
                   
                 TCAGCAGCTTATATGGCCGCTAGAGCCTCTATTCTGAGCGGAGGAAAGCTCGATAAGTGGGAGAAGATCAGA 
               
               
                   
                   
                 CTGAGACCAGGAGGCAGAAAGAAGTACAAGCTGAAGCATCTCGTCTGGGCTTCTAGAGAACTGGAGAGATTC 
               
               
                   
                   
                 GCTCTGAATCCAGGACTGCTGGAAACAACACAGGGCTTCTTCCCCGATTGGCAGAATTACACACCAGGACCA 
               
               
                   
                   
                 GGAATCAGATTCCCTCTGACCTTCGGTTGGTGTTTTAAGCTGGTGCCTCTGGTGGCTAAGGAAATTGTGGCT 
               
               
                   
                   
                 TGTTGCGACAAGTGCCAGCTGAAAGGAGAAGCTATCCACGGACAGGTGGATTGTTCTCCAGGAGTCTGGCAG 
               
               
                   
                   
                 CTGGATTGTACACACCTGGAGGGAAAAGTGATTCTGGTGGCAGTGCACGTGGCATCAGGATATATTGAGGCC 
               
               
                   
                   
                 GAGATCATTCCTACAGAAACAGGACAGGAGACAGCCTACTTTATCCTGAAGCTGGCTGGTAGGTGGCCAGTG 
               
               
                   
                   
                 ACAACA 
               
               
                   
               
               
                 167 
                 Pol:932-1003 
                 ATCACCAAGATCCAGAACTTCAGGGTGTACTACAGAGACAGCAGAGATCCTCTCTGGAAGGGACCAGCTAAA 
               
               
                   
                 AAY 
                 CTCCTCTGGAAAGGAGAAGGAGCAGTGGTGATCCAGGATAACAGCGACATCAAGGTGGTGCCTAGAAGAAAG 
               
               
                   
                 EE 
                 GCCAAGATCATCAGGGACTACGGCAAACAGATGGCAGGAGACGATTGCGTGGCTTCTAGACAGGACGAAGAC 
               
               
                   
                 Nef:64-99 
                 GCAGCTTACGAAGAGGAAGAGGTGGGATTTCCAGTGAAACCTCAGGTGCCTCTGAGACCTATGACATTCAAG 
               
               
                   
                 AA 
                 GGAGCTCTGGATCTGTCTCACTTCCTGAGAGAAAAGGGAGGACTGGAAGGAGCAGCTTGGGGATTTACCACC 
               
               
                   
                 Pol:367-431 
                 CCAGACAAGAAGCACCAGAAGGAACCACCATTCCTCTGGATGGGATACGAACTGCACCCAGATAAGTGGACA 
               
               
                   
                 Pol:542-606 
                 GTCCAGCCTATTGTGCTGCCAGAAAAGGACTCTTGGACCGTGAACGATATCCAGAAGCTGGTGGGAAAGCTG 
               
               
                   
                 Pol:56-117 
                 AATTGGGCTTCTCAGATCTACCCAGGAATCAAGGTGCCCAAGTTCAAGCTGCCTATCCAGAAGGAGACTTGG 
               
               
                   
                 Pol:129-320 
                 GAAACTTGGTGGACAGAGTATTGGCAGGCTACTTGGATTCCCGAGTGGGAATTTGTGAACACACCTCCTCTG 
               
               
                   
                 RAKR 
                 GTGAAGCTGTGGTATCAGCTGGAAAAGGAGCCTATCGTGGGCGCAGAAACATTTTACGTGGACGGAGCCGCC 
               
               
                   
                 F2A linker 
                 AATAGAGAAACCAAGTTTCCTCAGATCACTCTCTGGCAGAGACCTCTGGTGACAATCAAGATCGGCGGACAG 
               
               
                   
                 Pol:542-606 
                 CTGAAAGAGGCTCTGCTGGATACAGGAGCAGACGATACCGTGCTGGAAGAAATGAATCTGCCAGGTAGGTGG 
               
               
                   
                 Nef:64-99 
                 AAGCCTAAGATGATTGGCGGAATTGGCGGCTTCATCAAGGTGAGACAGTACGATCAGGGAACAGTGCTGGTG 
               
               
                   
                 Pol:56-117 
                 GGACCTACTCCAGTGAACATCATCGGAAGGAACCTGCTGACACAGATCGGCTGTACACTGAACTTCCCTATC 
               
               
                   
                 Pol:932-1003 
                 AGCCCTATCGAGACAGTGCCAGTGAAACTGAAGCCAGGAATGGACGGACCTAAAGTCAAACAGTGGCCTCTG 
               
               
                   
                 Pol:367-431 
                 ACAGAGGAGAAAATCAAAGCCCTGGTGGAGATTTGTACCGAGATGGAGAAGGAGGGCAAGATTTCTAAGATC 
               
               
                   
                 K 
                 GGACCAGAGAACCCCTACAATACCCCAGTGTTTGCCATCAAGAAGAAGGACAGCACCAAGTGGAGGAAGCTG 
               
               
                   
                 Pol:129-320 
                 GTGGATTTTAGGGAGCTGAACAAGAGGACACAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCACCCAGCC 
               
               
                   
                   
                 GGACTGAAAAAGAAGAAGTCAGTGACAGTGCTGGACGTGGGAGATGCCTATTTTAGCGTGCCTCTGGATAAG 
               
               
                   
                   
                 GACTTCAGGAAGTACACCGCCTTCACAATCCCTAGCATCAACAACGAGACCCCAGGAATCAGATACCAGTAC 
               
               
                   
                   
                 AACGTGCTGCCTCAGGGTTGGAAAGGATCTCCAGCCATCTTTCAGAGCAGCATGACAAGAGCCAAGAGAGCT 
               
               
                   
                   
                 CCAGTGAAGCAGACCCTGAATTTCGATCTGCTGAAGCTCGCAGGAGACGTGGAATCTAATCCAGGACCTCCC 
               
               
                   
                   
                 AAGTTCAGACTGCCTATTCAGAAGGAGACTTGGGACACTTGGTGGACCGATTATTGGCAGGCAACTTGGATT 
               
               
                   
                   
                 CCCGAGTGGGAGTTCACAAATACACCTCCTCTGGTCAAGCTCTGGTATCAGCTGGAAACAGAGCCTATCGCA 
               
               
                   
                   
                 GGAGTGGAAACATTCTACGTGGACGGAGCTTCTAACAGAGAGACCAAGGAGGAGGTGGGATTTCCAGTGAGA 
               
               
                   
                   
                 CCTCAGGTGCCTCTGAGACCTATGACATACAAGGGAGCCCTGGATCTGTCTCACTTTCTGAAGGAGAAAGGC 
               
               
                   
                   
                 GGACTGGAAGGACTGCCTCAGATTACTCTCTGGCAGAGGCCTATTGTGACAATCAAGATCGGCGGACAGATC 
               
               
                   
                   
                 AAAGAAGCCCTGCTGGATACAGGAGCAGACGATACAGTGCTGGAGGATATGAACCTGCCAGGCAAGTGGAAA 
               
               
                   
                   
                 CCTAAGATGATCGGAGGAATCGGCGGATTTATCAAGGTGAAGCAGTACGACCAGATCACCAAGCTGCAGAAC 
               
               
                   
                   
                 TTCAGGGTGTACTACAGAGACAACAGAGACCCTCTCTGGAAAGGACCAGCTAGACTCCTCTGGAAAGGAGAA 
               
               
                   
                   
                 GGAGCAGTGGTGATCCAGGATAATAGCGAGATCAAGGTGGTGCCTAGGAGAAAGGTGAAGATCATCCGGGAC 
               
               
                   
                   
                 TACGGCAAAAGAATGGCAGGAGACGATTGCGTGGCAGGAAGACAGGACGAAGATTGGGGACTGACAACCCCA 
               
               
                   
                   
                 GATAAGAAGCACCAGAAGGACCCCCCATTCCTCTGGATGGGATACGAACTGCATCCAGATAGGTGGACAGTG 
               
               
                   
                   
                 CAGCCAATTGAACTGCCAGAAAAGGAGTCTTGGACAGTGAACGACATCCAGAAGCTGATCGGCAAGCTGAAT 
               
               
                   
                   
                 TGGGCTTCTCAGATCTACGCCGGAATTAAGGTGAAGGGAACAGTGCTGATTGGACCTACACCAGTGAACATC 
               
               
                   
                   
                 ATCGGGAGAAACCTGCTGACACAGCTGGGTTGTACACTGAACTTCCCTATCAGCCCTATCGATACAGTGCCA 
               
               
                   
                   
                 GTGAAACTGAAGCCAGGAATGGACGGACCTAGAGTGAAACAGTGGCCTCTGACAGAAGAGAAGATCAAGGCC 
               
               
                   
                   
                 CTGATCGAGATTTGTACAGAGATGGAGAAGGAGGGCAAGATCTCTAGAATTGGCCCAGAGAACCCCTACAAT 
               
               
                   
                   
                 ACCCCTATCTTTGCCATCAAGAAGAAGGACGGCACCAAGTGGAGAAAGCTGGTGGATTTCAGGGAGCTGAAC 
               
               
                   
                   
                 AAGAAGACCCAGGACTTTTGGGAAGTGCAGCTGGGCATCCCCCACCCTAGCGGACTGAAAAAGAAGAAGAGC 
               
               
                   
                   
                 GTGACCGTGCTGGATATTGGAGACGCCTATTTTAGCGTGCCACTGGATAAGGAGTTCAGAAAGTACACCGCC 
               
               
                   
                   
                 TTTACCGTGCCTTCTACCAATAACGAGACACCAGGAGTGAGATACCAGTACAACGTGCTGCCTATGGGTTGG 
               
               
                   
                   
                 AAGGGATCACCAGCCATCTTTCAGTGTAGCATGACA 
               
               
                   
               
               
                 210 
                 Pol:840-920 
                 ACGGTGAAGGCTGCGTGTTGGTGGGCCGGCATAAAACAAGAATTTGGAATACCATACAATCCACAATCTCAA 
               
               
                   
                 Gag:147-369 
                 GGCGTTGTGGAATCCATGAATAAAGAATTGAAAAAAATTATCGGGCAAGTTCGAGACCAGGCTGAGCATCTC 
               
               
                   
                 Pol:586-606 
                 AAAACGGCCGTACAGATGGCGGTGTTTATTCACAACTTCAAAAGAAAAGGAGGAATCGGTGGTTACAGTGCA 
               
               
                   
                 AA 
                 GGCGAACGAATAGTTGACATTATAGCGATATCTCCTCGGACTCTGAATGCGTGGGTAAAGGTAGTCGAGGAG 
               
               
                   
                 Pol:683-708 
                 AAAGCATTTAGCCCCGAAGTCATCCCCATGTTTTCAGCCCTTTCAGAGGGCGCTACACCACAGGATCTGAAT 
               
               
                   
                 RAKR 
                 ACCATGCTGAACACAGTAGGGGGGCACCAAGCGGCGATGCAGATGCTGAAGGAGACAATAAATGAGGAGGCG 
               
               
                   
                 F2A linker 
                 GCGGAATGGGATAGATTGCATCCCGTCCACGCGGGGCCGATAGCGCCTGGCCAGATGAGGGAGCCACGAGGT 
               
               
                   
                 Gag:147-369 
                 TCCGACATCGCGGGAACAACCTCAACCCTGCAGGAACAAATAGGGTGGATGACGAATAACCCTCCTATTCCA 
               
               
                   
                 Pol:840-920 
                 GTTGGTGAAATTTATAAACGATGGATAATACTCGGTCTCAATAAAATAGTAAGGATGTATTCTCCGACAAGC 
               
               
                   
                 Pol:586-606 
                 ATACTTGACATCAGACAGGGGCCGAAAGAACCTTTCCGCGATTATGTGGACAGATTCTACAAAACGCTCAGG 
               
               
                   
                 AA 
                 GCCGAACAGGCCAGCCAAGAGGTTAAAAACTGGATGACTGAAACCCTGCTGGTCCAGAATGCTAACCCCGAC 
               
               
                   
                 Pol:683-708 
                 TGCAAGACAATCTTGAAGGCACTTGGGCCGGCCGCAACGTTGGAAGAAATGATGACGGCTTGTCAAGGGGTT 
               
               
                   
                   
                 GGCGGTCCGGGCCATAAGGCCCGAGTCCTGGCAGAAGCTATGAGTCAGAAAGAACCAATAGTTGGAGCCGAA 
               
               
                   
                   
                 ACATTCTACGTCGACGGTGCTGCAAATCGCGAGACGAAGGCTGCTAAGGAAAAGGTCTATCTGGCGTGGGTT 
               
               
                   
                   
                 CCGGCACACAAGGGCATAGGCGGGAATGAGCAAGTCGACAAATTGGTCTCACGAGCTAAACGCGCCCCGGTT 
               
               
                   
                   
                 AAACAAACCCTGAACTTCGACTTGCTTAAACTCGCAGGGGACGTTGAATCAAATCCGGGCCCACTTAGTCCC 
               
               
                   
                   
                 CGAACGCTGAACGCATGGGTAAAAGTAATAGAAGAGAAAGCGTTTTCCCCGGAGGTTATTCCCATGTTTACA 
               
               
                   
                   
                 GCCCTCAGCGAGGGCGCGACGCCACATGATCTCAACACAATGCTTAACACGATTGGGGGGCATCAGGCTGCG 
               
               
                   
                   
                 ATGCAAATGCTCAAGGATACGATAAACGAAGAGGCCGCAGAATGGGACCGAGTACATCCGGTCCACGCCGGG 
               
               
                   
                   
                 CCCGTCGCACCAGGACAGATGCGAGACCCCCGAGGGTCAGACATCGCCGGTTCTACGTCAACCTTGCAAGAA 
               
               
                   
                   
                 CAAATTGCATGGATGACTAACAATCCACCTATCCCCGTGGGAGATATCTATAAGAGATGGATCATCATGGGG 
               
               
                   
                   
                 CTTAATAAAATAGTCAGGATGTATTCACCAGTTTCAATTCTTGATATTAAACAGGGTCCTAAGGAGCCCTTT 
               
               
                   
                   
                 CGAGATTATGTGGATAGGTTTTATAGAACCCTTCGCGCAGAACAGGCTTCACAAGACGTCAAAAATTGGATG 
               
               
                   
                   
                 ACAGAAACTCTTCTCGTACAGAATTCAAACCCGGATTGTAAGACGATCTTGAAAGCACTCGGTCCGGGTGCC 
               
               
                   
                   
                 ACGTTGGAAGAGATGATGTCAGCCTGCCAAGGGGTGGGTGGCCCAAGCCATAAGGCCAGGGTATTGGCAGAG 
               
               
                   
                   
                 GCAATGTGTCAAGCTGTCAAGGCAGCATGCTGGTGGGCTGGCGTAAAGCAGGAATTCGGCATACCGTACAAT 
               
               
                   
                   
                 ACACAGTCACAAGGTGTTGTCGAGAGTATGAATAATGAACTTAAAAAAATCATAGGACAGATCCGAGATCAA 
               
               
                   
                   
                 GCTGAACATCTGAAGACTGCTGTACAAATGGCAGTGCTTATACATAACTTCAAACGCAAGGGAGGAATTGGG 
               
               
                   
                   
                 GAGTATTCAGCGGGAGAGCGGATTATTGATATCATAGCAACCGAACCCATAGCGGGCGTCGAGACTTTCTAT 
               
               
                   
                   
                 GTGGACGGAGCCAGCAATAGGGAGACTAAGGCGGCGAAAGAAAAGATTTATCTGGCATGGGTTCCGGCTCAT 
               
               
                   
                   
                 AAGGGGATCGGAGGCAATGAGCAGATTGACAAACTGGTATCC 
               
               
                   
               
               
                 211 
                 Pol:932-1003 
                 TTGAGCCCCCGAACCCTTAACGCCTGGGTGAAGGTAATTGAGGAAAAAGCTTTTTCACCCGAAGTGATCCCG 
               
               
                   
                 AAA 
                 ATGTTTACAGCACTGTCTGAAGGTGCAACCCCACACGATCTCAACACTATGCTCAATACCATAGGGGGCCAC 
               
               
                   
                 I 
                 CAAGCAGCGATGCAGATGCTCAAAGATACCATTAACGAGGAAGCGGCCGAGTGGGACAGGGTACACCCCGTG 
               
               
                   
                 Pol:129-320 
                 CATGCCGGACCTGTCGCCCCGGGTCAAATGCGAGATCCACGCGGAAGTGATATCGCTGGGAGTACGTCCACC 
               
               
                   
                 Pol:747-827 
                 CTCCAAGAACAAATCGCGTGGATGACAAATAATCCTCCTATCCCCGTAGGAGATATTTATAAAAGGTGGATT 
               
               
                   
                 QEE 
                 ATCATGGGGCTTAATAAAATCGTTCGAATGTATAGTCCTGTCTCAATACTGGACATCAAACAAGGCCCAAAA 
               
               
                   
                 Nef:64-76 
                 GAACCATTCAGGGACTACGTTGACAGATTCTATCGCACACTCCGAGCGGAACAAGCAAGCCAGGACGTCAAA 
               
               
                   
                 RAKR 
                 AATTGGATGACCGAGACGTTGCTTGTACAAAATAGCAACCCCGACTGTAAAACGATACTCAAAGCCTTGGGG 
               
               
                   
                 F2A linker 
                 CCAGGCGCGACCTTGGAGGAGATGATGTCCGCTTGTCAGGGAGTAGGCGGACCATCACACAAAGCACGCGTT 
               
               
                   
                 Pol:747-827 
                 TTGGCGGAAGCTATGTGTCAGGCGGTAAAGGCAGCCTGTTGGTGGGCTGGAGTCAAACAAGAATTTGGCATC 
               
               
                   
                 Pol:932-1003 
                 CCCTATAATACACAGTCCCAGGGTGTCGTCGAGTCTATGAATAATGAGCTGAAGAAAATCATTGGGCAGATA 
               
               
                   
                 Pol:129-320 
                 AGAGACCAAGCCGAACATCTTAAAACGGCTGTCCAAATGGCGGTTTTGATCCATAATTTTAAGCGAAAAGGG 
               
               
                   
                 KIL 
                 GGGATTGGTGAGTACTCAGCAGGAGAGAGAATCATAGACATCATAGCAACAGAACCAATTGCTGGTGTCGAG 
               
               
                   
                 QEE 
                 ACTTTTTACGTAGATGGGGCGAGCAATAGGGAAACTAAAGCAGCGAAGGAAAAGATTTACCTCGCGTGGGTA 
               
               
                   
                 Nef:64-76 
                 CCGGCCCACAAGGGAATCGGCGGGAACGAGCAAATCGATAAACTTGTATCCAGAGCCAAACGGGCTCCAGTA 
               
               
                   
                   
                 AAACAGACACTCAATTTCGATCTTTTGAAGCTTGCTGGAGACGTTGAGAGCAATCCTGGGCCGGTAGCAAAG 
               
               
                   
                   
                 GAGATTGTAGCTTGTTGCGACAAGTGCCAGTTGAAGGGTGAAGCGATACACGGTCAGGTCGATTGCTCTCCG 
               
               
                   
                   
                 GGAGTTTGGCAACTTGACTGTACCCATCTCGAGGGCAAAGTTATCCTCGTAGCTGTGCATGTAGCATCAGGA 
               
               
                   
                   
                 TATATAGAGGCCGAGATCATTCCGACGGAAACGGGTCAAGAAACTGCTTACTTCATTCTCAAACTTGCCGGG 
               
               
                   
                   
                 CGGTGGCCAGTCACAACTATCACGAAACTCCAAAACTTTCGAGTTTACTATAGGGACAATCGAGACCCACTG 
               
               
                   
                   
                 TGGAAAGGACCTGCCAGGCTTCTGTGGAAAGGGGAGGGTGCCGTTGTCATACAGGATAACTCCGAGATAAAA 
               
               
                   
                   
                 GTTGTGCCAAGGCGAAAAGTTAAGATTATTCGGGATTACGGGAAACGCATGGCAGGGGATGACTGCGTTGCG 
               
               
                   
                   
                 GGGCGACAAGATGAGGATGGTACTGTACTTATTGGCCCAACACCCGTGAACATTATAGGACGGAATCTGCTG 
               
               
                   
                   
                 ACACAGTTGGGGTGTACGCTCAACTTTCCGATAAGTCCGATAGATACGGTTCCGGTAAAGCTGAAGCCCGGC 
               
               
                   
                   
                 ATGGATGGTCCGCGCGTGAAGCAATGGCCACTCACAGAAGAGAAAATCAAAGCTTTGATAGAAATCTGCACC 
               
               
                   
                   
                 GAAATGGAAAAAGAGGGGAAGATCAGCAGGATCGGCCCGGAGAATCCTTACAACACCCCTATTTTCGCGATT 
               
               
                   
                   
                 AAGAAAAAAGATGGTACAAAATGGAGGAAACTCGTTGATTTTCGGGAGCTCAACAAGAAAACGCAAGACTTC 
               
               
                   
                   
                 TGGGAGGTCCAGCTTGGCATACCCCACCCCTCTGGACTTAAAAAGAAAAAAAGCGTAACCGTACTTGATATT 
               
               
                   
                   
                 GGTGACGCGTATTTCTCCGTTCCCTTGGATAAAGAATTTAGGAAGTACACGGCCTTTACTGTCCCCTCCACT 
               
               
                   
                   
                 AACAACGAAACTCCGGGCGTGCGATATCAATATAATGTGCTTCCGATGGGATGGAAAGGCTCACCAGCGATT 
               
               
                   
                   
                 TTTCAATGCAGTATGACCAAGATTCTTCAGGAAGAAGAGGAAGTGGGGTTTCCGGTAAGACCACAGGTGCCC 
               
               
                   
                   
                 CTC 
               
               
                   
               
               
                 212 
                 Pol:840-920 
                 ACGGTTAAGGCGGCGTGTTGGTGGGCGGGGATAAAGCAAGAGTTCGGAATCCCATATAATCCACAATCCCAA 
               
               
                   
                 Gag:147-369 
                 GGTGTGGTGGAAAGCATGAACAAGGAATTGAAGAAGATTATAGGACAAGTCAGAGATCAGGCCGAGCATCTG 
               
               
                   
                 Pol:586-606 
                 AAAACTGCAGTTCAGATGGCTGTGTTCATCCACAATTTTAAACGCAAAGGAGGAATTGGTGGATATAGCGCT 
               
               
                   
                 AA 
                 GGCGAGAGGATTGTAGACATTATTGCCATATCACCTCGCACTCTGAACGCCTGGGTGAAGGTTGTTGAAGAA 
               
               
                   
                 Pol:683-708 
                 AAGGCTTTTTCACCGGAGGTAATCCCAATGTTCAGTGCTCTTAGCGAGGGGGCAACTCCGCAGGACCTTAAT 
               
               
                   
                 RAKR 
                 ACAATGTTGAACACTGTAGGGGGACATCAAGCCGCTATGCAAATGCTGAAGGAGACGATTAACGAGGAAGCT 
               
               
                   
                 F2A linker 
                 GCGGAATGGGATAGACTTCACCCCGTCCACGCTGGACCTATTGCACCGGGACAGATGCGCGAACCAAGAGGT 
               
               
                   
                 Pol:932-1003 
                 TCCGATATAGCGGGAACAACTAGCACACTCCAGGAACAGATAGGATGGATGACCAACAACCCTCCGATACCA 
               
               
                   
                 AAA 
                 GTAGGCGAAATCTACAAGCGCTGGATAATATTGGGGCTGAACAAAATCGTCAGGATGTACAGCCCAACTTCA 
               
               
                   
                 I 
                 ATATTGGACATTCGCCAAGGACCTAAAGAGCCGTTCCGGGATTACGTGGATAGGTTTTACAAGACTTTGCGA 
               
               
                   
                 Pol:129-320 
                 GCTGAACAAGCCAGTCAAGAGGTGAAAAACTGGATGACCGAGACTCTGCTCGTCCAAAATGCTAATCCAGAT 
               
               
                   
                 Pol:747-827 
                 TGCAAAACAATACTTAAGGCACTGGGTCCCGCCGCAACGCTCGAGGAGATGATGACTGCCTGCCAAGGTGTC 
               
               
                   
                 QEE 
                 GGTGGTCCGGGTCACAAAGCACGAGTCCTGGCGGAAGCCATGTCTCAGAAAGAGCCTATAGTGGGTGCCGAG 
               
               
                   
                 Nef:64-76 
                 ACGTTCTACGTTGATGGAGCCGCTAATCGAGAGACGAAAGCGGCCAAGGAAAAGGTGTATCTCGCTTGGGTG 
               
               
                   
                   
                 CCTGCTCATAAGGGCATCGGAGGTAATGAACAAGTTGATAAACTGGTGAGTCGGGCGAAGCGCGCACCAGTA 
               
               
                   
                   
                 AAGCAGACCCTTAATTTCGATTTGCTCAAACTCGCTGGTGATGTCGAATCTAACCCCGGTCCGATTACAAAA 
               
               
                   
                   
                 ATCCAGAATTTTAGGGTTTACTATCGAGATTCCCGAGATCCACTCTGGAAAGGCCCCGCGAAATTGCTCTGG 
               
               
                   
                   
                 AAGGGCGAAGGGGCTGTAGTAATTCAAGACAATTCTGATATCAAGGTAGTCCCTCGGAGGAAAGCTAAAATA 
               
               
                   
                   
                 ATACGAGACTATGGAAAACAGATGGCGGGGGATGACTGTGTAGCAAGCCGGCAAGATGAAGACGCGGCAGCT 
               
               
                   
                   
                 ATAGGAACAGTGCTGGTGGGGCCGACCCCCGTAAACATTATCGGCAGGAATCTGTTGACGCAAATAGGTTGT 
               
               
                   
                   
                 ACGCTCAATTTTCCTATCTCACCGATCGAAACGGTGCCCGTCAAGTTGAAGCCGGGCATGGACGGCCCAAAG 
               
               
                   
                   
                 GTAAAACAATGGCCCTTGACGGAGGAGAAAATCAAAGCTCTTGTCGAAATCTGTACCGAAATGGAAAAGGAA 
               
               
                   
                   
                 GGTAAGATAAGTAAAATCGGACCAGAAAACCCGTATAACACTCCAGTTTTCGCGATAAAGAAGAAAGACTCC 
               
               
                   
                   
                 ACAAAGTGGAGAAAACTTGTAGATTTCAGGGAGCTGAATAAAAGGACCCAGGATTTTTGGGAAGTCCAGTTG 
               
               
                   
                   
                 GGCATACCACATCCCGCGGGGCTCAAAAAGAAGAAGTCAGTCACGGTACTCGACGTTGGCGACGCATATTTC 
               
               
                   
                   
                 TCTGTTCCGCTCGATAAGGACTTCAGAAAATATACCGCTTTCACTATTCCAAGTATCAACAATGAAACTCCC 
               
               
                   
                   
                 GGGATACGCTATCAATACAACGTTCTGCCACAGGGATGGAAGGGGAGTCCGGCTATTTTTCAGTCTTCAATG 
               
               
                   
                   
                 ACAGTGGCAAAAGAGATCGTTGCAAGCTGTGATAAATGCCAACTGAAAGGTGAGGCCATGCACGGACAGGTT 
               
               
                   
                   
                 GACTGCTCTCCCGGGATATGGCAGCTGGATTGCACGCATTTGGAGGGTAAGATAATTCTCGTCGCGGTCCAC 
               
               
                   
                   
                 GTGGCTAGTGGCTACATCGAGGCCGAAGTAATCCCCGCAGAGACGGGCCAAGAAACTGCGTACTTCCTCCTG 
               
               
                   
                   
                 AAGCTGGCAGGACGATGGCCTGTCAAAACACAGGAGGAAGAAGAAGTGGGATTCCCGGTTAAGCCCCAGGTT 
               
               
                   
                   
                 CCGCTG 
               
               
                   
               
               
                 213 
                 Gag:147-369 
                 CTTAGCCCACGGACACTTAATGCATGGGTCAAGGTGATTGAGGAGAAGGCGTTTTCCCCAGAGGTGATCCCA 
               
               
                   
                 Pol:840-920 
                 ATGTTCACAGCCCTCTCTGAGGGCGCAACACCTCACGACCTGAATACAATGCTCAACACTATCGGAGGGCAC 
               
               
                   
                 Pol:586-606 
                 CAAGCAGCCATGCAAATGCTGAAAGACACCATCAACGAGGAGGCTGCTGAGTGGGATCGAGTACACCCTGTA 
               
               
                   
                 AA 
                 CACGCGGGGCCGGTTGCTCCTGGTCAAATGAGGGATCCCCGCGGCTCCGACATAGCCGGCTCAACAAGCACT 
               
               
                   
                 Pol:683-708 
                 CTGCAGGAACAGATAGCATGGATGACCAACAACCCCCCTATTCCCGTAGGGGACATTTACAAGAGGTGGATT 
               
               
                   
                 RAKR 
                 ATAATGGGTCTGAACAAGATCGTACGAATGTATTCACCGGTCAGCATACTTGATATAAAACAAGGCCCGAAA 
               
               
                   
                 F2A linker 
                 GAACCTTTCAGGGACTATGTCGATCGATTTTACCGCACGCTGCGCGCCGAGCAGGCCTCCCAGGACGTGAAG 
               
               
                   
                 Pol:747-827 
                 AACTGGATGACTGAAACACTGCTTGTGCAAAATTCAAATCCAGATTGTAAAACCATACTTAAGGCTCTTGGT 
               
               
                   
                 Pol:932-1003 
                 CCGGGGGCTACCCTGGAAGAGATGATGAGCGCGTGTCAAGGGGTAGGAGGTCCTTCTCACAAGGCCAGGGTT 
               
               
                   
                 Pol:129-320 
                 TTGGCTGAAGCTATGTGCCAGGCCGTTAAGGCGGCCTGTTGGTGGGCAGGAGTCAAGCAAGAATTCGGCATC 
               
               
                   
                 KIL 
                 CCCTACAACACGCAATCACAGGGTGTCGTTGAATCAATGAACAACGAGCTGAAAAAAATTATAGGTCAAATA 
               
               
                   
                 QEE 
                 CGCGATCAAGCGGAACATCTTAAGACCGCAGTGCAGATGGCTGTGCTTATACATAATTTCAAGCGAAAAGGA 
               
               
                   
                 Nef:64-76 
                 GGCATCGGAGAATACTCAGCCGGAGAAAGAATCATCGACATTATCGCAACGGAGCCAATCGCCGGTGTGGAA 
               
               
                   
                   
                 ACGTTCTATGTAGACGGAGCATCAAATAGGGAAACGAAGGCCGCCAAGGAGAAAATTTATCTGGCGTGGGTC 
               
               
                   
                   
                 CCGGCCCACAAGGGAATTGGCGGCAATGAACAGATCGACAAGCTTGTTTCTCGGGCTAAACGGGCTCCCGTT 
               
               
                   
                   
                 AAGCAGACGCTCAACTTCGATCTTCTCAAGCTGGCCGGTGATGTCGAGAGCAATCCGGGGCCGGTAGCTAAG 
               
               
                   
                   
                 GAAATCGTCGCTTGTTGTGATAAATGTCAACTTAAGGGTGAAGCAATTCATGGCCAAGTTGACTGTTCACCG 
               
               
                   
                   
                 GGAGTATGGCAACTCGATTGTACCCATCTCGAAGGAAAAGTCATCTTGGTTGCAGTGCACGTAGCTTCTGGC 
               
               
                   
                   
                 TACATTGAAGCGGAGATTATCCCGACAGAGACCGGGCAGGAGACCGCTTATTTTATCCTCAAGCTCGCAGGA 
               
               
                   
                   
                 CGATGGCCCGTCACTACTATCACGAAGCTCCAAAATTTTAGAGTGTACTACCGCGATAACAGAGATCCTTTG 
               
               
                   
                   
                 TGGAAAGGCCCCGCCAGACTTTTGTGGAAGGGTGAGGGAGCGGTGGTTATTCAGGACAATTCTGAGATAAAA 
               
               
                   
                   
                 GTTGTACCCCGACGGAAGGTCAAGATAATTAGAGATTATGGTAAAAGGATGGCGGGCGACGACTGTGTAGCT 
               
               
                   
                   
                 GGAAGGCAGGATGAGGACGGCACAGTGCTGATTGGCCCGACGCCCGTAAACATTATCGGTCGCAACCTTCTC 
               
               
                   
                   
                 ACCCAGCTGGGGTGCACTTTGAATTTCCCGATTTCCCCGATTGATACTGTTCCAGTAAAGCTCAAACCCGGG 
               
               
                   
                   
                 ATGGACGGCCCACGAGTAAAACAATGGCCATTGACAGAGGAGAAGATTAAGGCGCTTATCGAAATATGTACT 
               
               
                   
                   
                 GAAATGGAGAAGGAAGGGAAAATTAGTCGGATAGGGCCTGAGAATCCCTACAACACGCCCATTTTTGCTATC 
               
               
                   
                   
                 AAGAAGAAAGATGGCACCAAGTGGCGGAAGCTGGTCGATTTTCGGGAACTTAACAAGAAAACACAAGACTTC 
               
               
                   
                   
                 TGGGAAGTACAGCTTGGGATCCCGCACCCGTCAGGATTGAAGAAGAAAAAGAGCGTCACGGTACTCGACATA 
               
               
                   
                   
                 GGCGACGCTTACTTCTCAGTTCCGCTGGACAAAGAGTTCAGAAAATATACAGCTTTCACGGTACCCTCCACT 
               
               
                   
                   
                 AACAATGAGACACCTGGAGTTCGCTACCAGTACAATGTGCTTCCAATGGGATGGAAGGGCTCACCGGCTATT 
               
               
                   
                   
                 TTCCAATGCTCTATGACTAAAATACTTCAAGAGGAAGAAGAGGTTGGGTTTCCCGTCAGACCGCAGGTTCCA 
               
               
                   
                   
                 CTT 
               
               
                   
               
               
                 214 
                 Pol:840-920 
                 ACGGTGAAAGCAGCTTGCTGGTGGGCGGGGATCAAACAGGAGTTTGGAATACCTTATAATCCTCAATCACAG 
               
               
                   
                 Gag:147-369 
                 GGGGTTGTCGAAAGCATGAACAAGGAGCTCAAGAAGATCATCGGACAGGTGCGCGATCAGGCTGAACATCTT 
               
               
                   
                 Pol:586-606 
                 AAGACCGCAGTTCAGATGGCAGTCTTTATTCACAATTTTAAACGGAAAGGAGGTATAGGTGGCTACAGCGCG 
               
               
                   
                 Pol:747-827 
                 GGCGAGCGCATTGTAGATATTATAGCGATTTCTCCGCGGACGCTGAATGCATGGGTTAAAGTAGTTGAAGAG 
               
               
                   
                 Pol:683-708 
                 AAGGCCTTTTCTCCCGAAGTAATACCCATGTTCAGTGCACTGTCTGAAGGTGCTACTCCTCAGGATCTCAAC 
               
               
                   
                 Nef:64-76 
                 ACGATGCTCAACACGGTCGGTGGGCATCAGGCAGCAATGCAGATGCTGAAGGAAACGATAAACGAGGAGGCA 
               
               
                   
                 Pol:932-1003 
                 GCAGAATGGGATCGACTGCACCCAGTACACGCAGGCCCTATAGCCCCAGGTCAAATGCGGGAACCAAGAGGT 
               
               
                   
                 AAA 
                 AGTGATATAGCTGGGACTACCTCAACGTTGCAGGAGCAAATTGGTTGGATGACGAATAATCCTCCTATACCA 
               
               
                   
                 Pol:129-320 
                 GTTGGCGAAATATACAAAAGATGGATTATCTTGGGACTGAATAAAATCGTGCGAATGTATTCTCCGACCTCT 
               
               
                   
                   
                 ATACTGGACATTCGACAGGGACCAAAAGAGCCGTTCCGCGACTACGTCGATCGGTTTTATAAAACTTTGCGG 
               
               
                   
                   
                 GCCGAACAGGCAAGCCAGGAGGTAAAGAACTGGATGACAGAGACCCTGTTGGTGCAAAATGCGAACCCTGAT 
               
               
                   
                   
                 TGCAAGACCATACTGAAAGCACTCGGGCCAGCTGCCACCCTTGAGGAAATGATGACAGCTTGCCAGGGTGTG 
               
               
                   
                   
                 GGGGGGCCGGGGCATAAAGCACGCGTCCTCGCCGAAGCCATGTCACAGAAAGAACCAATTGTGGGTGCCGAA 
               
               
                   
                   
                 ACTTTTTACGTGGACGGCGCAGCCAACCGAGAGACTAAAGTGGCTAAAGAGATAGTTGCATCATGTGATAAG 
               
               
                   
                   
                 TGCCAATTGAAAGGTGAGGCCATGCACGGTCAGGTAGATTGTTCACCTGGTATATGGCAGTTGGACTGTACT 
               
               
                   
                   
                 CACCTTGAAGGAAAGATTATCCTGGTCGCGGTACACGTCGCATCCGGTTATATAGAGGCGGAAGTTATACCT 
               
               
                   
                   
                 GCGGAGACTGGTCAAGAAACTGCCTACTTCCTTCTTAAATTGGCTGGTCGATGGCCAGTAAAAACTAAAGAG 
               
               
                   
                   
                 AAAGTGTACCTTGCGTGGGTTCCAGCCCACAAGGGTATAGGAGGAAATGAGCAAGTAGACAAACTCGTAAGC 
               
               
                   
                   
                 CAAGAGGAAGAAGAAGTGGGTTTCCCAGTTAAGCCACAGGTACCCCTCATTACCAAAATACAGAATTTCCGG 
               
               
                   
                   
                 GTTTATTATCGCGATTCAAGGGACCCCCTGTGGAAAGGTCCAGCAAAACTGCTGTGGAAGGGCGAAGGGGCA 
               
               
                   
                   
                 GTTGTTATACAAGACAACTCAGATATCAAGGTCGTGCCAAGACGCAAAGCTAAAATTATAAGGGATTATGGT 
               
               
                   
                   
                 AAACAGATGGCTGGAGACGACTGCGTGGCCAGCAGACAAGACGAGGATGCAGCTGCAATTGGAACAGTCCTG 
               
               
                   
                   
                 GTCGGACCAACTCCCGTTAACATCATAGGTAGAAACTTGCTCACTCAAATCGGATGCACACTTAATTTTCCG 
               
               
                   
                   
                 ATTTCACCTATCGAGACCGTTCCCGTTAAGCTGAAACCTGGGATGGACGGTCCCAAGGTGAAGCAATGGCCC 
               
               
                   
                   
                 TTGACTGAGGAAAAGATAAAGGCGTTGGTAGAGATCTGCACCGAAATGGAGAAGGAAGGCAAGATATCTAAG 
               
               
                   
                   
                 ATCGGGCCAGAAAACCCATATAATACACCTGTCTTCGCGATAAAAAAAAAGGACTCTACTAAATGGAGAAAA 
               
               
                   
                   
                 CTGGTCGACTTCAGAGAGCTTAATAAGCGAACTCAAGACTTTTGGGAAGTGCAGCTTGGTATACCTCACCCT 
               
               
                   
                   
                 GCTGGTCTGAAGAAGAAAAAATCTGTTACTGTTCTTGATGTCGGTGACGCATACTTCAGTGTGCCCCTCGAT 
               
               
                   
                   
                 AAAGATTTCAGGAAATACACCGCGTTCACTATACCCAGCATTAATAACGAGACCCCCGGGATACGCTACCAA 
               
               
                   
                   
                 TACAATGTCCTCCCCCAGGGCTGGAAAGGGTCTCCAGCAATTTTTCAGTCATCAATGACG 
               
               
                   
               
               
                 215 
                 Gag:147-369 
                 TTGTCCCCTCGGACGCTCAATGCATGGGTTAAAGTTATCGAGGAGAAGGCCTTCAGTCCCGAGGTTATACCT 
               
               
                   
                 Pol:747-827 
                 ATGTTCACCGCTCTGTCTGAAGGAGCAACGCCCCATGATCTCAATACTATGCTCAATACAATTGGAGGTCAC 
               
               
                   
                 Pol:683-708 
                 CAAGCGGCTATGCAAATGCTCAAAGATACCATTAATGAGGAGGCTGCTGAATGGGATAGGGTCCACCCAGTT 
               
               
                   
                 Pol:586-606 
                 CATGCCGGACCGGTGGCTCCGGGACAGATGCGCGACCCCCGGGGGTCAGACATCGCCGGAAGTACCTCTACT 
               
               
                   
                 Pol:932-1003 
                 CTGCAGGAACAAATTGCATGGATGACAAATAATCCACCTATTCCGGTCGGAGACATCTACAAACGATGGATC 
               
               
                   
                 Pol:840-920 
                 ATAATGGGTCTCAACAAGATAGTCCGGATGTATAGTCCGGTAAGTATACTCGACATCAAGCAAGGCCCTAAG 
               
               
                   
                 Nef:64-76 
                 GAGCCGTTCCGGGATTACGTAGACCGATTCTACCGGACGCTCAGAGCCGAACAGGCCTCCCAAGATGTTAAG 
               
               
                   
                 Pol:129-320 
                 AACTGGATGACCGAAACGTTGTTGGTTCAAAATTCCAATCCTGATTGCAAAACGATACTCAAAGCTCTTGGT 
               
               
                   
                   
                 CCTGGTGCAACACTGGAGGAAATGATGTCAGCCTGCCAAGGGGTCGGCGGGCCTTCACACAAAGCAAGGGTT 
               
               
                   
                   
                 TTGGCGGAGGCAATGTGCCAAGTAGCGAAGGAAATAGTGGCCTGTTGTGACAAATGTCAGCTGAAAGGAGAG 
               
               
                   
                   
                 GCAATACATGGACAAGTTGACTGTTCTCCCGGTGTGTGGCAACTCGACTGTACCCACTTGGAAGGAAAAGTT 
               
               
                   
                   
                 ATACTGGTGGCCGTTCACGTCGCGTCTGGCTACATCGAGGCTGAGATCATACCTACAGAGACCGGGCAGGAG 
               
               
                   
                   
                 ACCGCGTACTTCATCCTTAAGCTCGCGGGCCGCTGGCCAGTCACGACTAAAGAGAAAATTTATCTGGCGTGG 
               
               
                   
                   
                 GTACCCGCGCATAAAGGTATTGGCGGCAATGAACAAATAGACAAATTGGTATCAACAGAGCCGATTGCAGGA 
               
               
                   
                   
                 GTCGAAACATTCTATGTTGATGGTGCGTCAAACAGGGAAACGAAGATAACAAAGTTGCAAAACTTTCGAGTC 
               
               
                   
                   
                 TACTATCGCGACAATCGGGATCCCCTCTGGAAGGGCCCAGCAAGGTTGCTGTGGAAGGGCGAGGGAGCAGTA 
               
               
                   
                   
                 GTCATTCAAGACAACAGTGAGATTAAGGTAGTTCCGCGACGGAAGGTCAAAATAATACGGGATTACGGCAAA 
               
               
                   
                   
                 AGGATGGCAGGGGATGATTGCGTGGCTGGGCGCCAGGATGAGGACGCTGTCAAAGCCGCGTGTTGGTGGGCA 
               
               
                   
                   
                 GGGGTTAAGCAGGAGTTCGGAATACCATACAACACCCAGTCTCAAGGAGTTGTTGAAAGCATGAACAATGAG 
               
               
                   
                   
                 CTTAAAAAAATAATCGGACAAATAAGGGATCAGGCCGAACACTTGAAGACAGCAGTTCAGATGGCCGTGCTG 
               
               
                   
                   
                 ATCCATAACTTCAAACGGAAGGGCGGCATAGGAGAATACTCCGCAGGCGAGAGAATAATCGACATTATAGCT 
               
               
                   
                   
                 CAAGAAGAAGAGGAAGTCGGCTTTCCTGTACGACCTCAGGTCCCTCTTGGTACGGTGTTGATAGGGCCGACC 
               
               
                   
                   
                 CCCGTCAACATCATCGGTCGGAACCTGCTTACACAACTTGGTTGCACTCTTAACTTTCCTATTTCCCCCATA 
               
               
                   
                   
                 GATACCGTCCCAGTCAAGTTGAAGCCGGGGATGGATGGCCCGCGCGTCAAGCAGTGGCCCCTGACTGAAGAA 
               
               
                   
                   
                 AAGATTAAAGCTCTGATTGAAATATGCACAGAAATGGAAAAAGAGGGTAAGATCAGCAGAATCGGTCCAGAA 
               
               
                   
                   
                 AATCCCTATAACACGCCGATATTCGCCATTAAGAAGAAGGACGGAACAAAGTGGCGGAAACTCGTCGATTTT 
               
               
                   
                   
                 AGGGAGCTGAATAAGAAAACGCAGGATTTCTGGGAAGTTCAACTTGGCATACCTCACCCCTCTGGTCTTAAA 
               
               
                   
                   
                 AAAAAAAAGTCAGTCACCGTTCTCGACATTGGGGACGCGTATTTTTCCGTTCCGCTCGACAAAGAGTTTCGG 
               
               
                   
                   
                 AAGTACACGGCGTTCACGGTACCTTCTACAAACAATGAAACCCCCGGGGTCAGGTATCAGTATAATGTGCTG 
               
               
                   
                   
                 CCAATGGGGTGGAAGGGTAGCCCTGCTATTTTTCAATGCTCAATGACAAAGATCCTT 
               
               
                   
               
               
                 216 
                 M 
                 ATGACAGTAAAAGCGGCTTGCTGGTGGGCGGGTATTAAGCAAGAGTTTGGTATCCCCTACAACCCCCAGTCC 
               
               
                   
                 Pol:840-920 
                 CAAGGAGTCGTCGAGTCTATGAACAAAGAACTGAAGAAGATCATTGGGCAGGTGCGCGATCAGGCTGAGCAC 
               
               
                   
                 Gag:147-369 
                 TTGAAAACAGCGGTCCAGATGGCTGTGTTTATCCATAACTTTAAGAGGAAGGGGGGGATAGGGGGCTATTCA 
               
               
                   
                 Gag:1-53 
                 GCAGGGGAGAGAATTGTAGACATCATCGCCATATCCCCTCGAACGCTCAATGCGTGGGTTAAAGTAGTTGAG 
               
               
                   
                 PPV 
                 GAAAAGGCATTTAGTCCTGAAGTCATCCCAATGTTTAGCGCACTTTCCGAGGGCGCTACGCCCCAGGACCTG 
               
               
                   
                 Pol:747-827 
                 AATACCATGCTTAACACCGTTGGGGGCCACCAGGCGGCCATGCAGATGCTCAAGGAAACTATTAACGAGGAG 
               
               
                   
                 Pol:683-708 
                 GCGGCGGAGTGGGATCGGCTGCACCCTGTCCACGCAGGACCGATCGCCCCGGGGCAAATGAGAGAACCCAGA 
               
               
                   
                 Nef:117-148 
                 GGTTCTGATATTGCTGGAACTACTAGTACTCTTCAGGAGCAAATCGGGTGGATGACTAATAACCCACCAATT 
               
               
                   
                 RAKR 
                 CCCGTAGGTGAAATTTACAAGAGATGGATCATACTGGGCTTGAACAAAATAGTCCGAATGTATAGTCCCACC 
               
               
                   
                 F2A linker 
                 TCAATCCTCGACATCCGGCAAGGACCGAAGGAGCCTTTCCGCGACTATGTGGATCGCTTTTATAAGACTCTG 
               
               
                   
                 M 
                 CGAGCAGAACAAGCATCACAAGAGGTTAAAAACTGGATGACCGAAACACTCTTGGTGCAGAACGCAAATCCC 
               
               
                   
                 Gag:147-369 
                 GACTGCAAAACCATCCTGAAGGCATTGGGCCCTGCAGCAACTTTGGAGGAGATGATGACTGCATGTCAAGGC 
               
               
                   
                 Pol:747-827 
                 GTAGGAGGGCCCGGCCATAAAGCCAGAGTTTTGGCAGAGGCTATGTCTCAAATGGCGGCACGAGCTTCAGTT 
               
               
                   
                 Gag:1-53 
                 CTGTCAGGGGGCGAACTTGATCGGTGGGAAAAGATACGGCTTCGGCCCGGAGGCAAGAAAAAGTACAGGCTG 
               
               
                   
                 AA 
                 AAGCACATAGTATGGGCGTCCCGCGAACTGGAGAGGTTTGCAGTGAACCCCGGCCTGCTCGAGACGCCCCCG 
               
               
                   
                 Pol:840-920 
                 GTGGTTGCTAAAGAAATAGTCGCCTCTTGTGATAAATGCCAACTCAAGGGAGAAGCTATGCATGGCCAGGTT 
               
               
                   
                 Nef:117-148 
                 GACTGCTCACCGGGTATATGGCAGCTGGATTGTACACATTTGGAAGGTAAAATCATACTCGTTGCTGTGCAT 
               
               
                   
                 LIK 
                 GTAGCAAGCGGGTATATTGAGGCGGAAGTAATTCCGGCGGAAACCGGGCAAGAAACTGCCTATTTCCTTCTT 
               
               
                   
                 Pol:683-708 
                 AAACTCGCGGGGCGGTGGCCGGTTAAGACCAAGGAGAAAGTCTATCTCGCATGGGTTCCGGCCCATAAAGGC 
               
               
                   
                   
                 ATCGGCGGTAATGAACAAGTAGATAAACTCGTTAGCACTCAAGGATATTTTCCGGATTGGCAGAATTATACA 
               
               
                   
                   
                 CCCGGACCTGGTACAAGATATCCCTTGACGTTCGGATGGTGTTTCAAGCTCGTCCCAGTCCGCGCTAAAAGA 
               
               
                   
                   
                 GCACCAGTAAAGCAGACCTTGAACTTCGACTTGCTCAAGCTTGCTGGGGATGTCGAAAGTAACCCCGGCCCG 
               
               
                   
                   
                 ATGTTGTCCCCCAGGACTTTGAATGCATGGGTCAAAGTGATTGAGGAGAAGGCCTTCTCCCCCGAAGTTATT 
               
               
                   
                   
                 CCGATGTTTACCGCGCTTAGTGAAGGGGCCACACCTCATGATCTGAATACGATGCTTAACACTATAGGGGGT 
               
               
                   
                   
                 CACCAGGCAGCGATGCAAATGCTGAAGGATACCATCAATGAAGAAGCAGCTGAATGGGACAGGGTACATCCA 
               
               
                   
                   
                 GTGCATGCAGGACCGGTTGCACCCGGACAAATGCGCGACCCGCGAGGTTCCGACATCGCGGGGTCAACGTCC 
               
               
                   
                   
                 ACCCTGCAAGAACAAATTGCATGGATGACCAATAATCCCCCTATCCCAGTGGGCGACATATATAAGCGCTGG 
               
               
                   
                   
                 ATAATCATGGGTCTCAATAAAATTGTAAGGATGTATAGTCCGGTGTCAATCCTGGACATAAAGCAAGGTCCC 
               
               
                   
                   
                 AAGGAACCGTTTCGCGACTATGTAGACAGATTTTATCGAACGCTGAGAGCCGAGCAAGCGAGCCAGGATGTC 
               
               
                   
                   
                 AAAAACTGGATGACCGAAACACTTCTCGTTCAGAATTCAAACCCGGATTGTAAGACAATACTTAAGGCGCTC 
               
               
                   
                   
                 GGTCCCGGGGCGACCCTTGAAGAGATGATGTCTGCTTGTCAAGGTGTTGGGGGTCCATCCCACAAAGCTCGC 
               
               
                   
                   
                 GTCCTGGCGGAAGCAATGTGCCAAGTCGCCAAAGAAATCGTCGCGTGCTGTGACAAGTGCCAACTCAAGGGT 
               
               
                   
                   
                 GAGGCGATCCATGGGCAAGTGGACTGTAGTCCAGGCGTATGGCAATTGGACTGTACGCATCTCGAAGGGAAG 
               
               
                   
                   
                 GTGATCTTGGTGGCCGTCCATGTGGCGAGCGGATATATTGAAGCCGAAATCATCCCTACCGAAACGGGACAA 
               
               
                   
                   
                 GAAACGGCGTATTTCATTTTGAAACTGGCGGGTCGGTGGCCGGTCACCACCATGGCCGCGCGAGCGAGCATA 
               
               
                   
                   
                 CTTAGCGGGGGTAAATTGGACAAGTGGGAGAAGATCCGGCTTCGGCCCGGGGGTCGGAAAAAATATAAGCTG 
               
               
                   
                   
                 AAGCACCTGGTCTGGGCATCACGAGAACTGGAGCGGTTCGCACTTAATCCAGGGTTGCTTGAAACCGCAGCC 
               
               
                   
                   
                 GCGGTGAAGGCCGCCTGCTGGTGGGCGGGAGTAAAGCAGGAGTTCGGAATTCCTTACAACACGCAGAGCCAA 
               
               
                   
                   
                 GGTGTAGTGGAAAGCATGAACAATGAGCTTAAGAAAATCATTGGTCAGATCAGAGACCAAGCGGAACACCTC 
               
               
                   
                   
                 AAGACAGCTGTGCAAATGGCTGTACTTATTCACAACTTCAAGAGAAAAGGCGGTATAGGAGAATATAGCGCG 
               
               
                   
                   
                 GGGGAAAGAATAATAGACATCATCGCTACTCAAGGGTTTTTCCCCGACTGGCAGAATTATACACCTGGCCCC 
               
               
                   
                   
                 GGTATACGGTTTCCACTTACTTTCGGCTGGTGTTTCAAGTTGGTGCCTCTCCTGATAAAAAAGGAGAAAATA 
               
               
                   
                   
                 TATCTTGCGTGGGTGCCTGCACACAAAGGTATAGGCGGTAACGAACAAATCGACAAATTGGTTAGC 
               
               
                   
               
               
                 217 
                 M 
                 ATGTTCCCCCAGATTACACTGTGGCAGCGACCTCTGGTCACCATCAAGATTGGGGGACAGCTTAAGGAAGCG 
               
               
                   
                 Pol:56-117 
                 CTGCTTGACACTGGTGCTGATGACACTGTACTGGAGGAGATGAATCTCCCGGGTCGCTGGAAGCCTAAAATG 
               
               
                   
                 Nef:64-99 
                 ATAGGCGGTATCGGGGGGTTCATTAAGGTCAGGCAGTACGACCAAGAAGAGGTCGGATTCCCGGTAAAGCCA 
               
               
                   
                 LI 
                 CAAGTGCCTCTTCGCCCGATGACGTTCAAGGGTGCGTTGGACCTCAGCCACTTTCTTCGAGAAAAGGGCGGA 
               
               
                   
                 Pol:542-606 
                 CTGGAAGGTCTGATACCTAAATTTAAGCTCCCTATTCAGAAGGAAACATGGGAGACATGGTGGACGGAGTAT 
               
               
                   
                 Pol:367-431 
                 TGGCAGGCGACATGGATCCCCGAGTGGGAATTTGTAAACACCCCGCCACTCGTAAAACTCTGGTACCAACTG 
               
               
                   
                 Pol:932-1003 
                 GAAAAGGAACCCATCGTCGGTGCTGAAACCTTCTACGTCGATGGTGCGGCTAATAGGGAAACGAAGTGGGGT 
               
               
                   
                 Pol:129-320 
                 TTCACTACCCCAGACAAAAAACATCAAAAAGAACCACCCTTTCTCTGGATGGGATATGAATTGCATCCCGAT 
               
               
                   
                 RAKR 
                 AAATGGACCGTGCAACCCATCGTTCTGCCGGAAAAGGACAGCTGGACCGTTAATGATATTCAGAAGCTTGTT 
               
               
                   
                 F2A linker 
                 GGGAAACTCAACTGGGCTTCCCAAATTTACCCGGGAATAAAGGTGATAACGAAAATTCAGAATTTTAGGGTG 
               
               
                   
                 M_ 
                 TACTATAGGGACTCACGCGATCCTCTTTGGAAAGGTCCAGCAAAGTTGTTGTGGAAAGGTGAGGGGGCTGTC 
               
               
                   
                 Pol:56-117 
                 GTCATCCAAGACAATAGTGATATTAAGGTCGTGCCTAGAAGAAAGGCAAAGATTATTAGGGATTACGGCAAG 
               
               
                   
                 Pol:367-431 
                 CAGATGGCTGGTGACGACTGTGTTGCAAGTCGCCAAGACGAAGATGGCACGGTGTTGGTCGGGCCCACACCA 
               
               
                   
                 AA 
                 GTAAACATTATAGGCCGAAATCTGCTTACTCAAATCGGATGTACTCTTAATTTTCCGATCTCCCCTATAGAA 
               
               
                   
                 QEE 
                 ACGGTTCCTGTAAAATTGAAACCTGGAATGGATGGTCCGAAAGTTAAACAGTGGCCGCTCACCGAGGAAAAG 
               
               
                   
                 Nef:64-99 
                 ATTAAAGCGCTTGTCGAGATCTGTACTGAAATGGAAAAAGAAGGAAAGATCTCCAAAATAGGGCCAGAAAAT 
               
               
                   
                 Pol:932-1003 
                 CCGTACAATACTCCAGTCTTTGCTATAAAGAAGAAGGATTCTACGAAGTGGAGGAAGCTGGTAGACTTTCGC 
               
               
                   
                 Pol:542-606 
                 GAGCTCAACAAACGCACGCAAGATTTTTGGGAAGTCCAGTTGGGCATCCCTCATCCAGCTGGACTCAAGAAA 
               
               
                   
                 AA 
                 AAAAAATCCGTCACAGTATTGGATGTGGGCGACGCCTACTTTTCAGTGCCATTGGACAAAGATTTTCGAAAA 
               
               
                   
                 Pol:129-320 
                 TACACCGCGTTCACAATTCCTAGTATCAATAACGAGACTCCCGGAATAAGGTACCAGTACAACGTGCTCCCT 
               
               
                   
                   
                 CAAGGGTGGAAAGGTTCTCCCGCGATATTTCAGTCCAGTATGACTCGCGCGAAACGAGCTCCAGTTAAACAG 
               
               
                   
                   
                 ACCCTCAACTTTGATTTGTTGAAGCTTGCTGGGGATGTTGAGAGTAATCCAGGCCCTATGCTGCCGCAAATC 
               
               
                   
                   
                 ACACTCTGGCAAAGGCCGATAGTGACCATTAAAATTGGCGGGCAGATCAAGGAGGCATTGCTTGATACGGGA 
               
               
                   
                   
                 GCAGACGATACAGTGTTGGAGGACATGAACCTGCCCGGAAAATGGAAACCAAAGATGATCGGTGGGATTGGC 
               
               
                   
                   
                 GGTTTCATAAAGGTCAAGCAGTATGACCAGTGGGGTCTGACAACCCCTGACAAAAAACATCAGAAGGATCCC 
               
               
                   
                   
                 CCCTTTCTTTGGATGGGTTATGAGTTGCATCCAGATCGCTGGACGGTGCAGCCTATTGAGCTTCCGGAAAAG 
               
               
                   
                   
                 GAGTCTTGGACAGTTAATGATATTCAAAAACTTATTGGGAAATTGAATTGGGCCAGCCAGATATACGCAGGT 
               
               
                   
                   
                 ATAAAAGTTGCGGCGCAGGAGGAGGAAGAAGTGGGGTTCCCCGTCCGACCCCAGGTGCCGCTCAGACCAATG 
               
               
                   
                   
                 ACGTATAAAGGTGCGTTGGATCTGAGTCATTTTTTGAAGGAAAAAGGCGGGTTGGAAGGCATTACCAAACTC 
               
               
                   
                   
                 CAAAACTTCCGGGTGTATTATCGGGACAACAGAGATCCACTCTGGAAGGGTCCCGCAAGATTGCTTTGGAAG 
               
               
                   
                   
                 GGAGAAGGAGCAGTTGTTATACAAGACAACTCCGAAATTAAGGTAGTGCCTAGACGGAAGGTTAAAATTATT 
               
               
                   
                   
                 AGGGACTACGGAAAACGGATGGCGGGGGATGACTGCGTCGCGGGCCGCCAGGACGAGGACCCGAAATTCCGC 
               
               
                   
                   
                 CTGCCTATACAAAAGGAGACGTGGGACACGTGGTGGACAGACTACTGGCAAGCAACGTGGATCCCGGAATGG 
               
               
                   
                   
                 GAATTTACTAACACACCTCCTTTGGTGAAACTCTGGTATCAACTCGAGACGGAGCCGATTGCAGGGGTCGAG 
               
               
                   
                   
                 ACATTTTACGTCGATGGAGCATCCAATAGGGAAACTAAAGCAGCTGGTACAGTTCTGATAGGTCCGACCCCG 
               
               
                   
                   
                 GTGAATATAATAGGCAGGAATCTCCTCACACAACTTGGCTGCACTTTGAATTTCCCAATTTCCCCAATTGAC 
               
               
                   
                   
                 ACCGTACCCGTAAAGTTGAAGCCTGGAATGGACGGACCACGAGTGAAGCAGTGGCCTCTCACGGAAGAAAAG 
               
               
                   
                   
                 ATCAAAGCGCTTATTGAAATTTGTACAGAAATGGAGAAGGAGGGTAAAATCTCCAGGATAGGTCCTGAAAAC 
               
               
                   
                   
                 CCGTACAACACGCCCATCTTCGCTATCAAAAAAAAAGATGGAACGAAATGGCGCAAGCTGGTGGACTTCAGA 
               
               
                   
                   
                 GAACTTAACAAAAAGACGCAGGATTTTTGGGAAGTCCAGTTGGGAATCCCTCACCCGAGCGGACTTAAAAAA 
               
               
                   
                   
                 AAGAAAAGTGTCACAGTTCTTGATATAGGCGACGCTTATTTTTCCGTCCCACTTGACAAGGAATTTAGGAAG 
               
               
                   
                   
                 TACACGGCGTTTACAGTGCCATCAACGAACAACGAAACCCCGGGGGTGCGCTACCAGTACAACGTACTGCCA 
               
               
                   
                   
                 ATGGGATGGAAAGGTTCACCCGCAATCTTTCAATGCTCAATGACT 
               
               
                   
               
               
                 218 
                 M 
                 ATGACGGTAAAGGCAGCATGCTGGTGGGCAGGTATAAAACAGGAATTCGGCATTCCGTATAACCCACAAAGT 
               
               
                   
                 Pol:840-920 
                 CAAGGAGTTGTCGAGTCCATGAACAAAGAATTGAAAAAGATAATTGGTCAAGTGCGAGACCAAGCAGAACAC 
               
               
                   
                 Gag:147-369 
                 CTGAAAACCGCGGTTCAAATGGCCGTGTTTATACACAACTTTAAGAGAAAAGGGGGCATCGGGGGCTACTCC 
               
               
                   
                 Gag:1-53 
                 GCGGGTGAACGCATAGTCGATATAATAGCCATCTCCCCTCGCACTCTCAACGCATGGGTGAAAGTCGTAGAG 
               
               
                   
                 PPV 
                 GAGAAAGCTTTCTCACCTGAAGTAATTCCGATGTTTAGTGCACTGAGTGAAGGCGCTACGCCTCAAGATCTG 
               
               
                   
                 Pol:747-827 
                 AACACGATGCTTAATACCGTCGGGGGTCACCAAGCCGCGATGCAGATGTTGAAGGAAACAATAAATGAGGAA 
               
               
                   
                 Pol:683-708 
                 GCAGCAGAGTGGGACAGACTTCACCCGGTCCACGCGGGACCAATCGCACCAGGACAAATGCGAGAACCGAGA 
               
               
                   
                 Nef:117-148 
                 GGTAGTGACATCGCCGGAACAACCTCCACCCTCCAGGAACAGATTGGTTGGATGACAAATAATCCTCCGATA 
               
               
                   
                 RAKR 
                 CCCGTCGGTGAGATCTACAAACGCTGGATCATCCTGGGTCTTAACAAGATCGTACGGATGTACAGCCCAACC 
               
               
                   
                 F2A linker 
                 AGTATCCTTGACATTAGGCAGGGACCGAAGGAGCCGTTTCGCGACTACGTCGATCGGTTTTACAAGACGCTT 
               
               
                   
                 M 
                 AGAGCGGAACAAGCGTCACAGGAAGTTAAAAATTGGATGACAGAAACCTTGCTTGTCCAGAATGCTAATCCC 
               
               
                   
                 Pol:56-117 
                 GATTGCAAAACTATTCTGAAGGCACTGGGTCCTGCGGCGACTTTGGAGGAGATGATGACGGCCTGTCAAGGT 
               
               
                   
                 Nef:64-99 
                 GTTGGAGGCCCTGGTCATAAGGCACGAGTCCTGGCTGAAGCAATGTCTCAAATGGCGGCTAGAGCCTCTGTG 
               
               
                   
                 LI 
                 CTGTCCGGAGGGGAGCTTGACCGCTGGGAAAAGATCCGATTGCGACCAGGTGGGAAAAAGAAGTACAGGCTC 
               
               
                   
                 Pol:542-606 
                 AAGCATATTGTGTGGGCATCACGGGAACTTGAGCGCTTCGCAGTCAATCCTGGACTTCTTGAAACGCCACCG 
               
               
                   
                 Pol:367-431 
                 GTGGTCGCTAAAGAGATCGTTGCGAGCTGTGATAAATGTCAACTTAAAGGCGAGGCTATGCATGGCCAGGTC 
               
               
                   
                 Pol:932-1003 
                 GACTGTAGCCCGGGCATCTGGCAGCTGGATTGCACTCACCTGGAGGGTAAGATCATTCTCGTGGCGGTCCAT 
               
               
                   
                 Pol:129-320 
                 GTTGCCAGTGGCTACATTGAGGCGGAGGTGATTCCTGCGGAAACTGGTCAGGAGACAGCCTATTTCTTGCTG 
               
               
                   
                   
                 AAGCTCGCGGGACGCTGGCCTGTCAAAACTAAGGAAAAGGTTTATTTGGCCTGGGTTCCCGCACATAAAGGA 
               
               
                   
                   
                 ATTGGTGGCAATGAACAGGTAGACAAACTTGTAAGTACTCAGGGATATTTTCCCGATTGGCAGAATTACACT 
               
               
                   
                   
                 CCAGGGCCGGGGACTAGGTACCCTTTGACATTTGGTTGGTGTTTTAAGCTTGTGCCTGTTCGGGCGAAGAGG 
               
               
                   
                   
                 GCGCCAGTCAAACAGACTCTGAATTTCGACCTGCTGAAGCTGGCAGGAGACGTCGAGTCCAACCCTGGTCCT 
               
               
                   
                   
                 ATGTTCCCACAGATTACTCTGTGGCAGCGCCCGCTTGTGACTATTAAAATCGGCGGACAACTCAAAGAGGCA 
               
               
                   
                   
                 CTCCTTGACACCGGAGCGGACGACACGGTGCTGGAAGAAATGAACTTGCCCGGCCGGTGGAAGCCAAAGATG 
               
               
                   
                   
                 ATCGGAGGTATCGGCGGCTTTATAAAGGTGCGCCAGTATGACCAAGAAGAAGTCGGCTTCCCAGTAAAGCCT 
               
               
                   
                   
                 CAAGTTCCACTGAGACCTATGACTTTTAAGGGTGCGCTTGATCTGTCACACTTCCTCCGAGAGAAAGGCGGC 
               
               
                   
                   
                 TTGGAGGGCCTTATTCCCAAGTTCAAGTTGCCTATTCAAAAAGAAACGTGGGAGACGTGGTGGACTGAATAT 
               
               
                   
                   
                 TGGCAGGCGACCTGGATCCCTGAATGGGAGTTCGTGAACACACCCCCACTCGTTAAACTCTGGTATCAGTTG 
               
               
                   
                   
                 GAAAAGGAACCCATCGTGGGCGCCGAGACATTTTACGTCGATGGTGCCGCTAACAGAGAGACCAAGTGGGGG 
               
               
                   
                   
                 TTTACAACGCCTGACAAGAAGCACCAGAAGGAGCCCCCTTTCCTTTGGATGGGATATGAGTTGCACCCCGAC 
               
               
                   
                   
                 AAATGGACCGTGCAACCGATTGTCTTGCCTGAGAAAGACTCTTGGACAGTGAACGATATCCAAAAACTTGTG 
               
               
                   
                   
                 GGAAAATTGAATTGGGCAAGCCAAATCTACCCAGGGATAAAGGTAATCACTAAGATTCAAAACTTCCGAGTA 
               
               
                   
                   
                 TACTACCGAGACAGCAGAGATCCCTTGTGGAAAGGTCCTGCGAAACTGCTCTGGAAAGGCGAGGGAGCTGTG 
               
               
                   
                   
                 GTCATTCAGGACAACTCAGACATCAAAGTAGTCCCACGCCGCAAAGCGAAAATCATACGCGACTATGGCAAA 
               
               
                   
                   
                 CAAATGGCAGGTGATGATTGTGTGGCGAGTCGACAAGATGAGGATGGTACCGTTCTGGTCGGGCCGACACCT 
               
               
                   
                   
                 GTTAATATTATAGGACGCAATTTGTTGACACAAATCGGCTGCACTCTTAACTTCCCGATAAGTCCCATCGAG 
               
               
                   
                   
                 ACAGTGCCAGTTAAATTGAAGCCAGGGATGGACGGTCCTAAGGTTAAGCAGTGGCCCCTCACTGAAGAAAAA 
               
               
                   
                   
                 ATCAAGGCTCTCGTGGAAATTTGCACTGAGATGGAGAAGGAGGGCAAAATCTCCAAGATAGGTCCAGAGAAC 
               
               
                   
                   
                 CCATATAATACGCCGGTATTTGCAATCAAAAAAAAGGACAGCACAAAGTGGCGAAAGCTGGTTGACTTTCGA 
               
               
                   
                   
                 GAGCTGAACAAGCGGACGCAGGACTTTTGGGAAGTCCAATTGGGAATACCGCATCCCGCTGGATTGAAAAAA 
               
               
                   
                   
                 AAAAAGAGCGTAACAGTCCTCGATGTAGGTGATGCATACTTCAGTGTCCCACTCGATAAAGATTTTAGAAAG 
               
               
                   
                   
                 TACACTGCTTTTACGATTCCATCCATTAACAACGAGACTCCCGGTATTCGATATCAATACAATGTACTCCCA 
               
               
                   
                   
                 CAAGGTTGGAAAGGCTCACCTGCGATCTTCCAAAGTAGCATGACT 
               
               
                   
               
               
                 219 
                 M 
                 ATGTTGTCTCCTAGAACTCTGAATGCTTGGGTAAAGGTGATCGAAGAAAAGGCATTCTCACCCGAGGTTATC 
               
               
                   
                 Gag:147-369 
                 CCTATGTTTACTGCGTTGAGCGAAGGCGCAACACCCCATGATCTGAACACAATGCTGAATACAATCGGCGGA 
               
               
                   
                 Pol:747-827 
                 CATCAAGCTGCTATGCAAATGCTTAAGGACACCATCAATGAGGAGGCAGCCGAGTGGGATCGCGTTCATCCA 
               
               
                   
                 Gag:1-53 
                 GTCCACGCTGGGCCCGTTGCGCCTGGTCAGATGAGGGACCCACGAGGATCCGACATCGCAGGGAGCACCAGT 
               
               
                   
                 AA 
                 ACACTCCAAGAGCAGATTGCATGGATGACGAACAATCCACCAATACCTGTCGGTGACATTTACAAAAGGTGG 
               
               
                   
                 Pol:840-920 
                 ATTATTATGGGCTTGAACAAAATTGTACGGATGTATAGCCCGGTGAGCATACTGGACATTAAACAGGGTCCA 
               
               
                   
                 Nef:117-148 
                 AAAGAACCCTTTCGAGATTACGTTGACAGATTTTATAGGACACTGAGGGCGGAACAAGCGTCTCAAGACGTT 
               
               
                   
                 LIK 
                 AAAAACTGGATGACAGAAACGCTGCTTGTACAGAATTCCAACCCAGACTGCAAAACTATACTGAAAGCGCTC 
               
               
                   
                 Pol:683-708 
                 GGTCCCGGTGCGACACTTGAGGAAATGATGAGCGCATGCCAGGGCGTCGGAGGGCCGTCTCACAAGGCCCGC 
               
               
                   
                 RAKR 
                 GTGTTGGCGGAAGCTATGTGCCAGGTGGCTAAGGAGATAGTAGCATGTTGTGATAAATGTCAGCTTAAAGGT 
               
               
                   
                 F2A linker 
                 GAAGCTATACATGGGCAGGTGGATTGTAGCCCGGGTGTATGGCAGCTGGACTGTACTCATCTGGAAGGAAAG 
               
               
                   
                 M 
                 GTAATACTTGTCGCAGTTCATGTCGCGAGCGGATACATTGAAGCTGAAATCATTCCTACGGAGACGGGCCAA 
               
               
                   
                 Pol:56-117 
                 GAGACAGCTTACTTCATACTTAAACTTGCTGGGCGATGGCCGGTGACAACTATGGCGGCGCGCGCTTCAATT 
               
               
                   
                 Pol:367-431 
                 TTGAGTGGTGGAAAGTTGGACAAGTGGGAGAAGATTAGACTCAGACCCGGAGGGAGAAAGAAGTATAAACTG 
               
               
                   
                 AA 
                 AAACATCTGGTTTGGGCTTCACGCGAACTTGAACGGTTTGCTCTCAACCCCGGGCTGCTCGAAACTGCTGCT 
               
               
                   
                 QEE 
                 GCTGTAAAGGCCGCTTGTTGGTGGGCGGGGGTAAAGCAGGAATTCGGAATTCCATATAACACTCAAAGCCAG 
               
               
                   
                 Nef:64-99 
                 GGAGTAGTGGAATCCATGAATAATGAACTTAAGAAGATAATTGGACAGATTCGCGATCAGGCTGAACATCTC 
               
               
                   
                 Pol:932-1003 
                 AAGACGGCCGTACAAATGGCAGTATTGATTCATAACTTTAAACGGAAGGGCGGCATAGGAGAGTATTCTGCG 
               
               
                   
                 Pol:542-606 
                 GGAGAACGCATAATAGATATAATTGCGACTCAGGGGTTCTTTCCGGATTGGCAGAACTATACGCCGGGGCCA 
               
               
                   
                 AA 
                 GGCATTAGGTTCCCCCTCACGTTTGGATGGTGTTTCAAGTTGGTACCGTTGCTCATTAAAAAAGAAAAAATC 
               
               
                   
                 Pol:129-320 
                 TACCTGGCCTGGGTCCCGGCGCACAAGGGTATAGGGGGGAACGAGCAAATTGATAAGCTCGTGTCAAGGGCG 
               
               
                   
                   
                 AAGCGCGCGCCAGTCAAACAGACCTTGAATTTCGACCTCCTTAAGCTCGCTGGAGACGTCGAATCCAACCCT 
               
               
                   
                   
                 GGCCCGATGCTGCCACAAATCACATTGTGGCAACGACCCATTGTAACAATAAAAATCGGGGGCCAGATCAAA 
               
               
                   
                   
                 GAAGCGCTGCTTGACACCGGCGCCGACGATACAGTCCTCGAGGATATGAATTTGCCAGGCAAATGGAAGCCG 
               
               
                   
                   
                 AAGATGATTGGCGGCATTGGCGGCTTTATTAAGGTTAAACAGTATGATCAGTGGGGATTGACCACTCCCGAT 
               
               
                   
                   
                 AAGAAGCATCAGAAAGATCCGCCTTTTCTGTGGATGGGGTACGAACTGCACCCTGATCGATGGACGGTCCAG 
               
               
                   
                   
                 CCGATAGAGCTGCCGGAAAAAGAATCATGGACCGTGAATGATATTCAAAAACTGATCGGAAAACTCAATTGG 
               
               
                   
                   
                 GCGTCCCAGATATATGCTGGCATCAAAGTTGCAGCACAAGAAGAGGAAGAGGTAGGTTTCCCGGTTCGGCCG 
               
               
                   
                   
                 CAAGTTCCCTTGCGACCGATGACATACAAGGGCGCATTGGACCTTTCTCACTTCCTCAAGGAAAAGGGCGGT 
               
               
                   
                   
                 TTGGAGGGCATCACTAAACTTCAGAATTTCAGAGTCTACTATAGAGATAACAGGGACCCATTGTGGAAGGGC 
               
               
                   
                   
                 CCCGCTCGACTTCTCTGGAAAGGGGAGGGAGCGGTTGTAATTCAAGACAACAGTGAAATTAAGGTCGTCCCA 
               
               
                   
                   
                 CGACGGAAGGTTAAAATAATTCGCGACTATGGCAAGCGAATGGCGGGAGACGACTGTGTAGCAGGACGACAA 
               
               
                   
                   
                 GACGAGGACCCAAAGTTTAGATTGCCGATCCAGAAAGAGACATGGGATACGTGGTGGACGGACTATTGGCAG 
               
               
                   
                   
                 GCCACCTGGATACCAGAATGGGAGTTTACAAACACTCCTCCACTCGTGAAATTGTGGTATCAACTTGAGACC 
               
               
                   
                   
                 GAGCCCATAGCTGGTGTAGAGACGTTTTACGTTGACGGTGCTAGCAACAGGGAAACAAAGGCCGCTGGAACC 
               
               
                   
                   
                 GTGCTCATCGGTCCTACTCCTGTGAACATAATTGGACGAAATTTGTTGACCCAGCTGGGATGCACCCTCAAT 
               
               
                   
                   
                 TTCCCCATTAGCCCAATAGATACCGTACCAGTCAAGCTTAAGCCTGGTATGGACGGTCCGCGAGTTAAGCAA 
               
               
                   
                   
                 TGGCCACTTACTGAGGAGAAAATCAAGGCACTCATCGAGATCTGCACCGAAATGGAGAAGGAGGGCAAAATA 
               
               
                   
                   
                 AGCAGGATTGGTCCCGAGAATCCATATAATACGCCGATCTTCGCGATAAAAAAGAAGGACGGCACCAAATGG 
               
               
                   
                   
                 CGAAAACTGGTTGACTTCCGGGAGCTTAACAAAAAAACTCAGGATTTTTGGGAAGTTCAACTCGGGATCCCA 
               
               
                   
                   
                 CACCCGTCTGGTCTTAAAAAAAAAAAAAGCGTAACAGTCCTTGACATCGGCGATGCCTACTTTAGCGTGCCT 
               
               
                   
                   
                 CTCGATAAGGAGTTCAGAAAATACACGGCTTTCACTGTACCAAGCACAAACAATGAGACTCCTGGGGTCAGA 
               
               
                   
                   
                 TACCAGTACAATGTCCTTCCCATGGGGTGGAAAGGAAGCCCCGCAATATTCCAGTGCTCAATGACG 
               
               
                   
               
               
                 226 
                 M 
                 ATGCTTTCACCGAGAACCTTGAACGCGTGGGTTAAAGTAATCGAAGAGAAGGCATTTAGCCCGGAGGTAATC 
               
               
                   
                 Gag:147-369 
                 CCCATGTTTACCGCACTTTCCGAAGGTGCTACACCCCACGACCTGAATACAATGTTGAATACTATTGGCGGC 
               
               
                   
                 Pol:747-827 
                 CACCAAGCTGCCATGCAGATGCTTAAGGACACTATTAACGAGGAAGCCGCCGAATGGGATCGCGTTCACCCT 
               
               
                   
                 Gag:1-53 
                 GTTCACGCGGGTCCAGTCGCACCAGGACAAATGCGAGACCCTCGGGGGTCTGACATCGCAGGATCAACTAGT 
               
               
                   
                 AA 
                 ACATTGCAGGAACAGATTGCTTGGATGACCAATAACCCTCCGATCCCGGTAGGTGACATTTATAAACGGTGG 
               
               
                   
                 Pol:840-920 
                 ATCATCATGGGATTGAACAAAATAGTCCGAATGTACAGTCCAGTGAGTATTCTTGACATTAAACAGGGACCA 
               
               
                   
                 Nef:117-148 
                 AAGGAGCCGTTCCGGGACTACGTTGACCGGTTTTACAGGACCCTGAGAGCCGAACAGGCTTCCCAGGATGTG 
               
               
                   
                 LIK 
                 AAAAACTGGATGACAGAGACCCTGCTTGTTCAGAATTCAAATCCTGACTGTAAAACGATTCTGAAGGCACTC 
               
               
                   
                 Pol:683-708 
                 GGTCCCGGCGCCACGCTGGAGGAAATGATGTCAGCTTGTCAGGGAGTAGGAGGACCTTCTCATAAGGCACGC 
               
               
                   
                 F2A 
                 GTCCTTGCAGAGGCCATGTGCCAAGTCGCGAAAGAGATCGTGGCCTGTTGTGACAAGTGCCAACTTAAGGGA 
               
               
                   
                 M 
                 GAAGCCATCCATGGGCAGGTCGATTGTTCTCCGGGCGTTTGGCAATTGGACTGCACGCACTTGGAGGGTAAG 
               
               
                   
                 Pol:56-117 
                 GTGATTCTTGTTGCCGTTCATGTCGCAAGCGGTTACATTGAAGCGGAGATTATCCCAACTGAGACCGGCCAA 
               
               
                   
                 Pol:367-431 
                 GAGACTGCATATTTCATCCTTAAACTGGCGGGAAGATGGCCGGTCACGACTATGGCTGCACGAGCATCCATA 
               
               
                   
                 AA 
                 CTGTCTGGGGGAAAGCTCGACAAGTGGGAGAAGATTCGACTTAGGCCTGGAGGAAGAAAAAAGTATAAGTTG 
               
               
                   
                 QEE 
                 AAACATCTTGTTTGGGCATCACGAGAACTTGAACGGTTTGCTCTGAATCCGGGATTGCTTGAAACCGCCGCG 
               
               
                   
                 Nef:64-99 
                 GCTGTAAAGGCAGCATGTTGGTGGGCTGGTGTCAAACAAGAGTTCGGTATTCCCTATAACACCCAAAGTCAA 
               
               
                   
                 Pol:932-1003 
                 GGCGTCGTAGAATCCATGAACAATGAACTTAAGAAAATTATCGGACAAATCCGGGACCAAGCGGAACACCTC 
               
               
                   
                 Pol:542-60 
                 AAAACTGCTGTCCAGATGGCAGTTCTGATTCATAACTTTAAAAGAAAGGGGGGGATAGGGGAGTATTCTGCA 
               
               
                   
                 AA 
                 GGTGAACGAATTATAGACATAATTGCCACACAAGGGTTTTTTCCAGATTGGCAAAATTATACACCGGGCCCT 
               
               
                   
                 Pol:129-320 
                 GGGATAAGATTCCCGCTCACCTTCGGCTGGTGCTTCAAACTGGTACCCTTGCTGATCAAGAAAGAGAAGATC 
               
               
                   
                   
                 TATCTTGCTTGGGTGCCAGCCCATAAAGGGATCGGGGGTAACGAACAAATCGATAAGCTGGTGTCTAGAGCT 
               
               
                   
                   
                 AAACGGGCTCCCGTAAAACAGACCTTGAACTTCGATCTGCTTAAATTGGCAGGGGACGTGGAAAGCAACCCC 
               
               
                   
                   
                 GGGCCAATGCTGCCCCAGATAACACTTTGGCAACGCCCCATCGTGACAATCAAGATCGGTGGCCAAATTAAG 
               
               
                   
                   
                 GAAGCACTCTTGGACACGGGAGCAGACGACACTGTGCTGGAGGATATGAACCTGCCGGGCAAGTGGAAACCA 
               
               
                   
                   
                 AAGATGATCGGGGGCATTGGCGGGTTCATAAAGGTTAAACAGTACGACCAATGGGGGTTGACAACGCCTGAT 
               
               
                   
                   
                 AAGAAGCATCAAAAAGATCCCCCATTTTTGTGGATGGGTTATGAACTTCACCCGGACAGGTGGACCGTTCAG 
               
               
                   
                   
                 CCGATAGAGCTCCCAGAAAAGGAGTCTTGGACAGTTAATGACATACAGAAACTTATTGGCAAACTTAACTGG 
               
               
                   
                   
                 GCTTCACAGATTTATGCCGGCATCAAAGTCGCCGCCCAGGAAGAAGAAGAGGTAGGTTTTCCCGTACGACCT 
               
               
                   
                   
                 CAGGTTCCTCTTCGGCCTATGACCTATAAGGGTGCGCTTGATCTTTCTCACTTCCTTAAAGAAAAAGGAGGT 
               
               
                   
                   
                 CTGGAAGGTATCACGAAACTTCAGAATTTTCGGGTGTATTACCGGGACAACAGAGACCCGCTTTGGAAGGGG 
               
               
                   
                   
                 CCGGCTAGGCTTCTGTGGAAAGGCGAGGGAGCGGTAGTTATCCAGGATAACTCTGAGATAAAGGTAGTACCC 
               
               
                   
                   
                 CGACGGAAGGTAAAGATCATCAGAGACTACGGCAAGAGGATGGCTGGAGACGACTGTGTGGCCGGGCGACAG 
               
               
                   
                   
                 GATGAAGATCCTAAATTCAGGCTGCCAATCCAAAAAGAGACGTGGGACACATGGTGGACCGATTATTGGCAG 
               
               
                   
                   
                 GCTACGTGGATCCCCGAATGGGAGTTTACCAATACTCCGCCACTCGTGAAGCTTTGGTACCAATTGGAGACA 
               
               
                   
                   
                 GAGCCTATAGCCGGCGTTGAGACCTTCTACGTGGATGGGGCCAGCAACAGAGAAACCAAAGCGGCCGGAACG 
               
               
                   
                   
                 GTCCTGATCGGTCCCACACCTGTTAACATCATAGGGCGCAATCTGCTTACGCAATTGGGGTGCACATTGAAT 
               
               
                   
                   
                 TTTCCAATATCCCCTATTGATACCGTGCCGGTTAAATTGAAGCCGGGTATGGACGGGCCTCGGGTCAAGCAG 
               
               
                   
                   
                 TGGCCCCTGACCGAAGAAAAGATCAAAGCCCTGATTGAGATCTGCACGGAAATGGAAAAAGAGGGCAAGATT 
               
               
                   
                   
                 AGTCGCATCGGCCCGGAGAACCCATACAATACTCCTATTTTTGCAATTAAAAAAAAGGACGGAACAAAGTGG 
               
               
                   
                   
                 AGGAAACTTGTAGATTTCAGAGAGCTTAATAAGAAAACTCAGGACTTCTGGGAGGTCCAACTCGGTATTCCG 
               
               
                   
                   
                 CATCCCTCCGGACTTAAGAAGAAAAAGTCAGTAACCGTCTTGGATATAGGGGACGCTTATTTTTCAGTGCCC 
               
               
                   
                   
                 CTCGATAAAGAATTTCGCAAATACACGGCGTTTACTGTGCCATCTACTAATAACGAAACGCCAGGCGTGAGA 
               
               
                   
                   
                 TATCAATACAACGTCCTTCCTATGGGCTGGAAGGGTTCACCCGCAATTTTTCAGTGCTCCATGACC 
               
               
                   
               
               
                 225 
                 Gag:147-369 
                 ATTTCTCCTCGGACGCTGAATGCATGGGTGAAGGTAGTGGAGGAAAAGGCATTTTCACCAGAAGTCATTCCG 
               
               
                   
                 Pol:747-827 
                 ATGTTCTCCGCGCTCTCCGAGGGTGCTACGCCACAGGACTTGAATACGATGCTGAATACCGTTGGTGGCCAT 
               
               
                   
                 Gag:1-53 
                 CAGGCGGCGATGCAGATGTTGAAGGAGACAATTAACGAAGAAGCCGCCGAATGGGACAGATTGCACCCGGTG 
               
               
                   
                 AA 
                 CATGCGGGGCCAATAGCTCCTGGCCAGATGCGCGAGCCTAGGGGTTCTGACATTGCTGGTACAACAAGTACC 
               
               
                   
                 Pol:840-920 
                 CTTCAGGAGCAGATTGGTTGGATGACGAATAACCCTCCCATACCTGTTGGCGAGATCTATAAGCGCTGGATT 
               
               
                   
                 Nef:117-148 
                 ATACTTGGGCTGAATAAGATAGTCCGAATGTATTCTCCCACCTCTATTCTGGATATTCGGCAAGGACCTAAG 
               
               
                   
                 LIK 
                 GAGCCGTTTAGAGACTACGTAGACCGGTTTTACAAAACCCTGCGGGCGGAACAAGCTTCTCAGGAAGTCAAA 
               
               
                   
                 Pol:683-708 
                 AATTGGATGACTGAGACCTTGCTCGTCCAGAATGCGAACCCGGACTGTAAAACAATACTCAAAGCGCTGGGC 
               
               
                   
                 F2A 
                 CCCGCTGCAACCCTGGAAGAAATGATGACGGCTTGTCAGGGAGTAGGAGGCCCCGGACATAAGGCACGAGTG 
               
               
                   
                 Pol:56-117 
                 TTGGCAGAAGCCATGAGCCAGCCGCCTGTCGTCGCGAAAGAAATCGTCGCTTCTTGCGACAAATGTCAGCTG 
               
               
                   
                 Pol:367-431 
                 AAGGGGGAGGCGATGCACGGTCAAGTTGATTGCTCTCCCGGTATTTGGCAATTGGACTGTACCCACCTTGAA 
               
               
                   
                 AA 
                 GGCAAAATTATTCTGGTTGCAGTGCACGTAGCATCCGGTTACATCGAAGCTGAAGTGATACCCGCAGAGACA 
               
               
                   
                 QEE 
                 GGCCAGGAGACGGCTTATTTCCTCCTTAAGCTTGCGGGTCGGTGGCCCGTAAAGACCATGGCTGCTCGGGCA 
               
               
                   
                 Nef:64-99 
                 TCTGTCCTCTCCGGTGGTGAACTCGACCGATGGGAAAAGATTCGATTGCGCCCCGGAGGAAAGAAGAAATAT 
               
               
                   
                 Pol:932-1003 
                 AGGCTGAAACATATTGTGTGGGCATCACGGGAACTTGAGCGATTTGCGGTAAACCCAGGCCTTTTGGAAACA 
               
               
                   
                 Pol:542-606 
                 GCTGCAACTGTGAAAGCGGCTTGCTGGTGGGCGGGGATAAAACAGGAGTTTGGTATCCCGTACAATCCCCAA 
               
               
                   
                 AA 
                 TCTCAGGGGGTAGTAGAAAGCATGAACAAAGAATTGAAAAAAATAATTGGCCAGGTTCGCGACCAAGCCGAG 
               
               
                   
                 Pol:129-320 
                 CACCTCAAGACCGCTGTACAGATGGCTGTATTTATTCACAACTTCAAGCGGAAGGGCGGAATAGGAGGATAT 
               
               
                   
                   
                 AGCGCAGGGGAAAGGATTGTTGATATTATTGCAACACAAGGTTACTTTCCTGACTGGCAAAACTACACACCG 
               
               
                   
                   
                 GGCCCTGGCACGCGCTATCCCCTTACGTTCGGTTGGTGCTTCAAGCTGGTGCCGGTAAAAGAAAAAGTTTAT 
               
               
                   
                   
                 TTGGCATGGGTTCCTGCACATAAAGGAATAGGGGGTAACGAACAAGTTGACAAACTCGTCAGCCGCGCTAAA 
               
               
                   
                   
                 AGAGCCCCAGTCAAGCAGACCCTGAATTTTGACCTGCTTAAATTGGCTGGGGACGTCGAGAGTAACCCGGGA 
               
               
                   
                   
                 CCCTTCCCACAAATTACACTCTGGCAGCGACCACTGGTAACAATCAAAATAGGGGGACAATTGAAAGAAGCA 
               
               
                   
                   
                 CTCCTGGATACGGGCGCGGACGATACAGTCCTGGAGGAAATGAATCTCCCCGGCCGCTGGAAACCTAAGATG 
               
               
                   
                   
                 ATAGGGGGGATCGGTGGATTTATTAAAGTGCGGCAGTACGATCAATGGGGTTTTACGACACCTGACAAGAAA 
               
               
                   
                   
                 CATCAAAAGGAGCCGCCATTTCTTTGGATGGGTTATGAGCTTCATCCGGATAAATGGACTGTTCAGCCGATT 
               
               
                   
                   
                 GTCCTCCCCGAGAAGGATAGTTGGACTGTGAACGACATCCAGAAGCTGGTCGGGAAACTTAATTGGGCCAGT 
               
               
                   
                   
                 CAAATATATCCAGGTATTAAAGTTGCCGCACAAGAAGAGGAGGAAGTAGGGTTCCCCGTGAAACCGCAAGTC 
               
               
                   
                   
                 CCTCTCCGGCCCATGACCTTTAAGGGCGCTCTCGACCTGTCCCATTTCCTCCGCGAAAAGGGGGGTTTGGAA 
               
               
                   
                   
                 GGCTTGATCATTACCAAGATTCAAAACTTCAGGGTCTATTATCGAGACAGTCGCGATCCCCTTTGGAAAGGA 
               
               
                   
                   
                 CCTGCGAAACTTCTTTGGAAAGGAGAAGGAGCCGTGGTAATTCAGGATAATTCTGACATAAAGGTCGTCCCA 
               
               
                   
                   
                 CGCCGAAAAGCGAAGATTATAAGAGATTATGGCAAGCAGATGGCCGGGGATGATTGTGTCGCAAGTAGACAG 
               
               
                   
                   
                 GATGAAGACCCTAAATTCAAGCTTCCAATCCAGAAGGAAACGTGGGAGACATGGTGGACCGAGTATTGGCAA 
               
               
                   
                   
                 GCTACTTGGATCCCAGAATGGGAATTTGTGAACACTCCCCCACTCGTAAAGCTGTGGTACCAGCTTGAAAAA 
               
               
                   
                   
                 GAACCTATAGTCGGGGCGGAGACGTTCTATGTAGACGGCGCCGCTAATCGAGAGACAAAAGCAGCAGGCACG 
               
               
                   
                   
                 GTACTGGTAGGCCCGACCCCTGTCAACATCATTGGACGAAATCTGTTGACCCAGATTGGGTGTACCCTTAAC 
               
               
                   
                   
                 TTTCCCATTTCACCAATAGAGACCGTCCCGGTTAAACTGAAACCGGGTATGGATGGTCCCAAAGTAAAACAG 
               
               
                   
                   
                 TGGCCACTTACCGAGGAGAAGATTAAGGCACTCGTTGAAATATGTACAGAAATGGAAAAAGAGGGGAAAATC 
               
               
                   
                   
                 TCTAAAATTGGCCCTGAAAATCCGTACAACACTCCGGTATTCGCCATAAAAAAGAAGGACTCTACCAAGTGG 
               
               
                   
                   
                 CGCAAACTCGTGGACTTTAGAGAACTGAATAAAAGGACCCAGGACTTTTGGGAAGTCCAGCTGGGTATTCCT 
               
               
                   
                   
                 CACCCCGCTGGTCTCAAGAAAAAGAAAAGTGTCACTGTCTTGGATGTTGGAGATGCGTACTTTTCAGTACCT 
               
               
                   
                   
                 CTTGATAAAGATTTTCGAAAGTATACCGCGTTTACCATTCCCTCCATAAATAACGAAACACCGGGGATCAGG 
               
               
                   
                   
                 TATCAATATAACGTGCTTCCACAAGGCTGGAAGGGTTCACCGGCTATTTTCCAATCTTCTATGACG 
               
               
                   
               
            
           
         
       
     
     As appropriate, in certain embodiments, the 3′-end of the polynucleotide encoding the fusion polypeptides or compound fusion polypeptides described herein comprises one or multiple tandem stop codons, e.g., two or more tandem TAG (“amber”), TAA (“ochre”) or TGA (“opal” or “umber”) stop codons. The multiple tandem stop codons can be the same or different. 
     As appropriate, in certain embodiments, the 3′-end of the polynucleotide encoding the fusion polypeptides or compound fusion polypeptides described herein does not comprise a poly A sequence. As appropriate, in certain embodiments, the 3′-end of the polynucleotide encoding the fusion polypeptides or compound fusion polypeptides described herein comprises a poly A sequence. 
     Further provided are expression cassettes, comprising a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, operably linked to one or more regulatory sequences, e.g., a promoter. In some embodiments, the polynucleotide is operably linked to and under the control of a constitutive promoter or an inducible promoter. In some embodiments, the promoter is selected from cytomegalovirus major immediate-early (CMV), the CMV enhancer fused to the chicken beta-actin promoter (CAG), human elongation factor-1α (HEF-1α), mouse cytomegalovirus (mouse CMV), Chinese hamster elongation factor-1α (CHEF-1α), and phosphoglycerate kinase (PGK). In some embodiments, the promoter is a native promoter of the viral expression vector, e.g., an arenavirus vector promoter, an adenovirus vector promoter, etc. 
     Further provided are methods for making a fusion polypeptide or compound fusion polypeptide, pharmaceutical composition, immunogenic composition or vaccine composition comprising same. In some implementations, the methods comprise constructing the fusion polypeptides or compound fusion polypeptides using peptide synthesis. In some implementations, the methods comprise constructing, using synthetic or recombinant DNA technology, polynucleotides encoding each of the polypeptides of the bivalent antigen and expressing the polypeptides from an expression vector. In some implementations, the methods may further comprise inserting the polynucleotides into one or more vectors and expressing the encoded polypeptides in a cell. 
     4. Vectors and Host Cells 
     Further provided are vectors comprising one or more polynucleotides encoding one or more of the fusion polypeptides or compound fusion polypeptides, described herein, or an expression cassette comprising such polynucleotides. A vector can be of any type, for example, a recombinant vector such as an expression vector. Vectors include without limitation, plasmids, cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC) and vectors derived from bacteriophages or plant or animal (including human) viruses. Vectors can comprise an origin of replication recognized by the proposed host cell and in the case of expression vectors, promoter and other regulatory regions recognized by the host cell. In additional embodiments, a vector comprises one or more polynucleotides encoding one or more fusion polypeptides or one or more compound fusion polypeptides, as described herein, operably linked to a promoter and optionally additional regulatory elements. Certain vectors are capable of autonomous replication in a host into which they are introduced (e.g., vectors having a bacterial origin of replication can replicate in bacteria). Other vectors can be integrated into the genome of a host upon introduction into the host, and thereby are replicated along with the host genome. Vectors include without limitation, those suitable for recombinant production of the fusion polypeptides and/or compound fusion polypeptides, disclosed herein. 
     The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Some vectors are suitable for delivering the nucleic acid molecule or polynucleotide of the present application. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as expression vectors. 
     The term “operably linked” refers to two or more nucleic acid sequence elements that are usually physically linked and are in a functional relationship with each other. For instance, a promoter is operably linked to a coding sequence if the promoter is able to initiate or regulate the transcription or expression of a coding sequence, in which case, the coding sequence should be understood as being “under the control of” the promoter. 
     The choice of the vector is dependent on the recombinant procedures followed and the host used. Introduction of vectors into host cells can be effected by inter alia calcium phosphate transfection, DEAE-dextran-mediated transfection, lipofectamine transfection, electroporation, virus infection, or via administration to a subject, as described herein. Vectors may be autonomously replicating or may replicate together with the chromosome into which they have been integrated. In certain embodiments, the vectors contain one or more selection markers. The choice of the markers may depend on the host cells of choice. These include without limitation, kanamycin, neomycin, puromycin, hygromycin, zeocin, thymidine kinase gene from Herpes simplex virus (HSV-TK), and dihydrofolate reductase gene from mouse (dhfr). Vectors comprising one or more nucleic acid molecules encoding the fusion polypeptides or compound fusion polypeptides, described herein, operably linked to one or more nucleic acid molecules encoding proteins or peptides that can be used to isolate the fusion polypeptides or compound fusion polypeptides, are also contemplated. These proteins or peptides include without limitation, glutathione-S-transferase, maltose binding protein, metal-binding polyhistidine, green fluorescent protein, luciferase and beta-galactosidase. 
     In various embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In various embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. 
     In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:82. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 83, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:83. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:85. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 86, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:86. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 87, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:87. In various embodiments, the vector comprising a polynucleotide encoding one or more of the foregoing fusion polypeptides is a Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus. 
     In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:85. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 98, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:98. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 99, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:99. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 100, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 100. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 101, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 101. In various embodiments, the vector comprising a polynucleotide encoding one or more of the foregoing fusion polypeptides is a Lymphocytic choriomeningitis mammarenavirus (LCMV). 
     In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 227. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.       

     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. 
     In various embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 105 or 206, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 107 or 207, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 109, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 111, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 111. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 200, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 201, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 202, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 203, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 204, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 205, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 208, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 209, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 222, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 223, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. 
     In various embodiments, the vector comprises a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 227, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 227. 
     In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. 
     In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 139, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 139. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 142. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 145. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 148. In various embodiments, the vector comprising one or more of the foregoing polynucleotides is a Lymphocytic choriomeningitis mammarenavirus (LCMV). 
     In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 150, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 150. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 152, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 152. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 155, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 155. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 158, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 158. In various embodiments, the vector comprising one or more of the foregoing polynucleotides is a Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus). 
     In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 225, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 225. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a compound fusion polypeptide, as described herein, which has a nucleic acid sequence of SEQ ID NO: 226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence of SEQ ID NO: 226. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide:
         SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;   SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;   SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;   SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;   SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;   SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;   SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;   SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;   SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;   SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;   SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;   SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;   SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;   SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;   SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;   SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;   SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;   SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;   SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;   SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;   SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;   SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;   SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;   SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;   SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;   SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;   SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;   SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;   SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;   SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;   SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;   SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;   SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;   SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;   SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;   SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or   SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.       

     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 130 or SEQ ID NO: 131, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 130 or SEQ ID NO: 131, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 132 or SEQ ID NO: 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 132 or SEQ ID NO: 133, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 139, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 140, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 140, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 146. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 142, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 148. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 143, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 143, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 149. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 150, respectively, and
 
b) a second polynucleotide comprising SEQ ID NO: 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 152.
 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 151, respectively, and
 
b) a second polynucleotide comprising SEQ ID NO: 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 153.
 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 154, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 154, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 157. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 155, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 158. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 156, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 159. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and 
     b) a second polynucleotide comprising SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and 
     b) a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and 
     b) a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and 
     b) a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and 
     b) a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and 
     b) a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and 
     b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In various embodiments, the vector comprises the following first polynucleotide and second polynucleotide: 
     a) a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and 
     b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In various embodiments, the vector comprises a polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225. 
     In various embodiments, the vector comprises a polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In other embodiments, the vector that is used is pcDNA™3.1+ (ThermoFisher, MA). 
     In some embodiments, the vector is viral vector. As appropriate, the viral vector can be a DNA virus or an RNA virus, including a self-replicating RNA virus. Self-replicating RNA viruses include Alphaviruses, and are described, e.g., in Lundstrom,  Molecules . (2018) 23(12). pii: E3310 (PMID: 30551668); and Ljungberg, et al.,  Expert Rev Vaccines . (2015) 14(2):177-94). Additional alphaviruses of use as viral vectors are described, e.g., in WO 2020/097393 and WO 2018/208856. In various embodiments, the viral vector is from a virus selected from adenovirus, adeno-associated virus, arenavirus, alphavirus, self-replicating alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, maraba virus and vaccinia virus. In some embodiments, the viral vector is from a viral family selected from: Adenoviridae (e.g., Adenovirus, adeno-associated virus), Arenaviridae (e.g., lymphocytic choriomeningitis mammarenavirus, Cali mammarenavirus (a.k.a., Pichinde mammarenavirus), Poxviridae (e.g., Vaccinia virus), Herpesviridae (e.g., Cytomegalovirus, Herpesvirus, e.g., HSV-1), Parvoviridae (e.g., Parvovirus H1), Poxviridae (e.g. Vaccinia virus, e.g. modified vaccinia Ankara (MVA)), Flaviviridae (e.g. Yellow fever virus), Reoviridae (e.g., Reovirus), Picornaviridae (e.g., Coxsackievirus, Seneca Valley Virus, Poliovirus), Paramyxoviridae (e.g., Measles virus, Newcastle disease virus (NDV)), Rhabdoviridae (e.g., Vesiculovirus, including Maraba vesiculovirus and Vesicular stomatitis virus (VSV)), Togaviridae (e.g., Alphavirus, e.g., Venezuelan equine encephalitis virus, e.g., self-replicating Alphavirus; Sindbis virus), Enteroviridae (e.g., Echovirus). Illustrative modified vaccinia viral vectors of use for expressing the present fusion polypeptides and/or compound fusion polypeptides are described, e.g., in WO 2019/134049. 
     In some embodiments, the viral expression vector is an arenavirus vector selected from Lymphocytic choriomeningitis mammarenavirus (LCMV)(NCBI:txid11623), Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus) (NCBI:txid2169993), Guanarito virus (GTOV) (NCBI:txid45219), Argentinian mammarenavirus (a.k.a., Junin virus (JUNV))(NCBI:txid2169991), Lassa virus (LASV)(NCBI:txid11620), Lujo virus (LUJV)(NCBI:txid649188), Machupo virus (MACV)(NCBI:txid11628), Brazilian mammarenavirus (a.k.a., Sabia virus (SABV))(NCBI:txid2169992), and Whitewater Arroyo virus (WWAV)(NCBI:txid46919). In some embodiments, the viral expression vector is an arenavirus vector selected from Lymphocytic choriomeningitis mammarenavirus (LCMV) or Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus). Illustrative arenavirus vectors that can be used as delivery and expression vehicles for the herein described fusion polypeptides are described, e.g., in WO 2009/083210; WO 2015/183895; WO 2016/075250; WO 2017/198726; and U.S. Pat. No. 9,943,585. 
     In some embodiments, the viral expression vector is an adenovirus vector, e.g., from a human adenovirus or a simian adenovirus (e.g., a chimpanzee adenovirus, a gorilla adenovirus or a rhesus monkey adenovirus). In various embodiments, the adenovirus vector is selected from adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g. ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (AdC9), ChAd10 (AdC10), ChAd11 (AdC11), ChAd17 (AdC17), ChAd16 (AdC16), ChAd19 (AdC19), ChAd20 (AdC20), ChAd22 (AdC22), ChAd24 (AdC24), ChAdY25, ChAd26 (AdC26), ChAd28 (AdC28), ChAd30 (AdC30), ChAd31 (AdC31), ChAd37 (AdC37), ChAd38 (AdC38), ChAd43 (AdC43), ChAd44 (AdC44), ChAd55 (AdC55), ChAd63 (AdC63), ChAdV63, ChAd68 (AdC68), ChAd73 (AdC73), ChAd82 (AdC82), ChAd83 (AdC83), ChAd143 (AdC143), ChAd144 (AdC144), ChAd145 (AdC145), ChAd147 (AdC147)), gorilla adenovirus (e.g. GC44, GC45, GC46) and rhesus adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66). Illustrative Chimpanzee, Gorilla and Rhesus monkey adenovirus vectors that can be used as delivery and expression vehicles for the herein described fusion polypeptides and/or compound fusion polypeptides are described, e.g., in WO 2019/076880; WO 2019/076877; Andrabi et al., (2019)  Cell Reports  27:2426-2441; Guo, et al.,  Hum Vaccin Immunother . (2018) 14(7):1679-1685; Abbink, et al.,  J Virol . (2015) 89(3):1512-22; Abbink, et al.,  J Virol . (2018) 92(6). pii: e01924-17, and in WO 2020/243719A1 and WO 2018/098362A1. 
     In various embodiments, the viral expression vector is incapable of replication (i.e., replication defective or replication deficient), has reduced or diminished capacity for replication, e.g., in comparison to a wild-type viral vector (i.e., replication attenuated) or is replication competent. 
     Further provided are host cells comprising one or more polynucleotides encoding one or more of the fusion polypeptides or compound fusion polypeptides, or one or more vectors expressing the fusion polypeptides or compound fusion polypeptides, as described herein. Any of a variety of host cells can be used. In one embodiment, a host cell is a prokaryotic cell, for example,  E. coli . In another embodiment, a host cell is a eukaryotic cell, for example, a yeast cell, a plant cell, an insect cell, a mammalian cell, such as a Chinese Hamster Ovary (CHO)-based or CHO-origin cell line (e.g., CHO-S, CHO DG44, ExpiCHO™, CHOZN® ZFN-modified GS−/− CHO cell line, CHO-K1, CHO-K1a), COS cells, BHK cells, NSO cells or Bowes melanoma cells. Examples of human host cells are, inter alia, HeLa, 911, AT1080, A549 and HEK293 (e.g., HEK293E, HEK293F, HEK293H, HEK293T, Expi293™) In addition, the fusion polypeptides and/or compound fusion polypeptides can be expressed in a yeast cell such as  Pichia  (see, e.g., Powers et al.,  J Immunol Methods.  251:123-35 (2001)),  Hanseula , or  Saccharomyces.    
     The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. 
     As appropriate, the host cells can be stably or transiently transfected with one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein. As appropriate, the host cells can be infected with one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. In some embodiments, the host cells are capable of being infected with and propagating one or more replication attenuated or replication competent vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. Illustrative cells useful for infecting with and/or propagating viral vectors include without limitation BHK-21, A549, Vero and HEK293 (e.g., HEK293E, HEK293F, HEK293H, HEK293T, Expi293™) cells. In certain embodiments, the host cells express the Coxsackievirus and adenovirus receptor (CAR), e.g., MDCK, Caco-2 or Calu-3 host cells. In certain embodiments, the polynucleotides integrate into the genome of the host cell. 
     5. Pharmaceutical Compositions/Immunogenic Compositions 
     Provided are pharmaceutical compositions or immunogenic compositions comprising one or more of the fusion polypeptides or compound fusion polypeptides, as described herein, or a polynucleotide encoding one or more of the fusion polypeptides or compound fusion polypeptides, as described herein, or a viral expression vector comprising one or more of such polynucleotides, and a pharmaceutically acceptable diluent, carrier or excipient. Generally, the pharmaceutical compositions described herein are immunogenic. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the one or more fusion polypeptides or compound fusion polypeptides, or one or more polynucleotides encoding one or more of the fusion polypeptides or compound fusion polypeptides, or one or more viral expression vectors containing one or more of the polynucleotides encoding one or more of the fusion polypeptides or compound fusion polypeptides. 
     Various pharmaceutically acceptable diluents, carriers, and excipients, and techniques for the preparation and use of pharmaceutical compositions or immunogenic compositions will be known to those of skill in the art in light of the present disclosure. Illustrative pharmaceutical compositions/immunogenic compositions and pharmaceutically acceptable diluents, carriers, and excipients are also described in, e.g., Loyd V. Allen Jr (Editor), “Remington: The Science and Practice of Pharmacy,” 22 nd  Edition, 2012, Pharmaceutical Press; Brunton, Knollman and Hilal-Dandan, “Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics,” 13th Edition, 2017, McGraw-Hill Education/Medical; McNally and Hastedt (Editors), “Protein Formulation and Delivery, 2nd Edition, 2007, CRC Press; Banga, “Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems,” 3rd Edition, 2015, CRC Press; Lars Hovgaard, Frokjaer and van de Weert (Editors), “Pharmaceutical Formulation Development of Peptides and Proteins,” 2nd Edition, 2012, CRC Press; Carpenter and Manning (Editors), “Rational Design of Stable Protein Formulations: Theory and Practice,” 2002, Springer (Pharmaceutical Biotechnology (Book 13)); Meyer (Editor), “Therapeutic Protein Drug Products: Practical Approaches to Formulation in the Laboratory, Manufacturing, and the Clinic, 2012, Woodhead Publishing. 
     In certain embodiments, the polynucleotides or vectors are formulated into a lipoplex, e.g., a lipid nanoparticle (LNP). As used herein, a “lipoplex” refers to cationic liposomes that are nonviral (synthetic) lipid carriers of one or more polynucleotides, e.g., RNA, DNA. For example, in some embodiments where the fusion polypeptides and/or compound fusion polypeptides are expressed from self-replicating or self-amplifying RNA molecules, the self-replicating or self-amplifying RNA can be formulated into LNPs. As used herein, the term “lipid nanoparticle” refers to one or more spherical nanoparticles with an average diameter of between about 10 to about 1000 nanometers, and which comprise a solid lipid core matrix that can solubilize lipophilic molecules. In certain embodiments, the lipid core is stabilized by surfactants (e.g., emulsifiers), and can comprise one or more of triglycerides (e.g., tristearin), diglycerides (e.g., glycerol bahenate), monoglycerides (e.g., glycerol monostearate), fatty acids (e.g., stearic acid), steroids (e.g., cholesterol), and waxes (e.g., cetyl palmitate), including combinations thereof. Lipid nanoparticles are described, for example, in Petrilli et al., Curr Pharm Biotechnol. 15:847-55, 2014; and U.S. Pat. Nos. 6,217,912; 6,881,421; 7,402,573; 7,404,969; 7,550,441; 7,727,969; 8,003,621; 8,691,750; 8,871,509; 9,017,726; 9,173,853; 9,220,779; 9,227,917; and 9,278,130, each of which is incorporated by reference in its entirety. In one embodiment, a self-replicating or self-amplifying RNA (saRNA) molecule encoding one or more of the fusion polypeptides or compound fusion polypeptides described herein is formulated or condensed into polyethylenimine (PEI)-polyplex delivery vehicles, e.g., as described in Moyo, et al.,  Mol Ther Methods Clin Dev . (2018) 12:32-46; Blakney, et al.,  Gene Therapy  (2019) 26:363-372; Démoulins, et al.,  Nanomedicine . (2016) April; 12(3):711-722 and Démoulins, et al.,  J Control Release . (2017) 266:256-271, which can be nanoparticulate. 
     In embodiments where the fusion polypeptides or compound fusion polypeptides are expressed from a viral expression vector, the viral expression vector can be formulated for the desired route of administration, e.g., as an isotonic pharmaceutically acceptable aqueous solution for intravenous, intramuscular, subcutaneous, intradermal or intranodal administration. In some embodiments, the viral expression vector can be formulated for mucosal, e.g., buccal or intra-rectal delivery. Illustrative formulations for viral expression vectors that can be used in the herein described pharmaceutical compositions/immunogenic compositions and methods are described, e.g., in Manfredsson and Benskey, editors, “Viral Vectors for Gene Therapy: Methods and Protocols (Methods in Molecular Biology),” 2019, Book 1937 in Methods in Molecular Biology Series, Humana Press; WO 2017/013169 (formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration); and Kumru, et al.,  J Pharm Sci . (2018) November; 107(11):2764-3374 (aqueous formulations buffered in Tris and containing proline, lactose, and mannitol as stabilizing additives). Formulation of arenavirus vectors is described, e.g., in WO 2009/083210; WO 2016/075250 and WO 2017/198726. In certain embodiments, the viral expression vectors are delivered via microneedle-mediated delivery, e.g., as described in Zaric, et al.,  Expert Opin Drug Deliv . (2017) October; 14(10):1177-1187. Intranodal delivery of mRNA vaccines are described, e.g., in Jong, et al.,  Vaccines  (Basel). (2019) 7(4):209; Leal, et al.,  AIDS . (2018) 32(17):2533-2545; de Jong, et al.,  Trials . (2019) 20(1):361; and Joe, et al.,  J Transl Med . (2019) 17(1):242. 
     In some embodiments, each carrier, diluent or excipient is “acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical composition/immunogenic composition and not injurious to the subject. Often, the pharmaceutically acceptable carrier is an aqueous pH-buffered solution. Some examples of materials which can serve as pharmaceutically-acceptable carriers, diluents or excipients include: water; buffers, e.g., a buffer having a pKa in the range of about 6.0 to about 8.0, e.g., a physiologically acceptable buffer, e.g., selected from phosphate, carbonate, bicarbonate, citrate, maleate, glycine-glycine, HEPES, HEPPSO, HEPPS, imidazole, BICINE, TRICINE, Tris, and BIS-Tris; sugars, such as lactose, trehalose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Hank&#39;s solution, Ringer&#39;s solution; ethyl alcohol; phosphate buffer solutions; amino acids (e.g., charged amino acids, including without limitation, aspartate, asparagine, glutamate, glutamine, histidine, arginine, lysine); and other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. 
     In one particular formulation, an arenavirus vector (e.g., a LCMV or Pichinde mammarenavirus vector (PICV)) described herein is formulated in an isotonic aqueous solution comprising a biologically compatible buffer having a pKa in the range of about 6.0 to about 8.0 (e.g., HEPES and NaCl), at a neutral or near-neutral pH and a non-ionic surfactant (e.g., PLURONIC® F68 (a.k.a., poloxamer 188)). In one particular formulation, an arenavirus vector (e.g., a LCMV or Pichinde mammarenavirus vector) described herein is formulated in an isotonic aqueous solution comprising HEPES buffer at pH 7.4, NaCl, and PLURONIC® F68 (a.k.a., poloxamer 188). Schleiss, et al. ( Clin Vaccine Immunol.  2017 Jan. 5; 24(1):e00300-16) describes an LCMV formulating LCMV vectors in a diluent of 25 mM HEPES, 150 mM NaCl, 0.01% PLURONIC® F68; pH 7.4), which can be used to formulate the herein described arenavirus vectors. A final concentration of 10% sorbitol was added before freezing below −60° C. 
     The formulation of and delivery methods of pharmaceutical compositions or immunogenic compositions will generally be adapted according to the site and the disease to be treated. Exemplary formulations include without limitation, those suitable for parenteral administration, e.g., intravenous, intra-arterial, intramuscular, subcutaneous or intranodal administration, including formulations encapsulated in micelles, liposomes or drug-release capsules (active agents incorporated within a biocompatible coating designed for slow-release); ingestible formulations; formulations for topical use, such as creams, ointments and gels; and other formulations such as inhalants, aerosols and sprays. In some embodiments, the pharmaceutical compositions or immunogenic compositions are formulated for parenteral, e.g., intravenous, subcutaneous, intranodal or oral administration. In some embodiments, the pharmaceutical compositions or immunogenic compositions are formulated for mucosal, e.g., buccal, intrarectal and/or intravaginal administration. In some embodiments, for intrarectal administration, the pharmaceutical composition or immunogenic composition can be formulated as a suppository or as an enema. In some embodiments, for intravaginal administration, the pharmaceutical composition or immunogenic composition can be formulated as a pessary. 
     In certain embodiments, pharmaceutical compositions/immunogenic compositions are sterile. In certain embodiments, the pharmaceutical composition or immunogenic composition has a pH in the range of 4.5 to 8.5, 4.5 to 6.5, 6.5 to 8.5, or a pH of about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0 or about 8.5. In one embodiment, the pharmaceutical composition/immunogenic composition has an osmolarity in the range of 240-260 or 250-330 mOsmol/L. In certain embodiments, the pharmaceutical composition/immunogenic composition is isotonic or near isotonic. 
     In some embodiments, the pharmaceutical compositions or immunogenic compositions are liquids or solids. In some embodiments, the pharmaceutical composition or immunogenic composition comprises an aqueous solution. In some embodiments, the pharmaceutical composition or immunogenic composition is lyophilized or is a frozen liquid. 
     In some embodiments, the pharmaceutical composition or immunogenic composition further comprises one or more additional therapeutic agents, e.g., a second therapeutic agent, or second and third therapeutic agents, for use in combination therapies, as described herein. 
     In certain embodiments, the pharmaceutical composition or immunogenic composition further comprises an adjuvant. Illustrative adjuvants that can be co-formulated or co-administered with the herein described fusion polypeptides or compound fusion polypeptides, polynucleotides encoding such fusion polypeptides or compound fusion polypeptides, and vectors expressing such fusion polypeptides or compound fusion polypeptides, include without limitation cytokines, chemokines, immune costimulatory molecules, toll-like receptor agonists, second mitochondria-derived activator of caspases (SMAC) mimetics or inhibitors of immune suppressive pathways (e.g., immune checkpoint inhibitors), as described herein, and in Li, et al.,  Curr Issues Mol Biol . (2017) 22:17-40. Other adjuvants that can be co-formulated or co-administered with the herein described fusion polypeptides or compound fusion polypeptides, polynucleotides encoding such fusion polypeptides or compound fusion polypeptides, and vectors expressing such fusion polypeptides or compound fusion polypeptides, include without limitation mineral salts (e.g., aluminum salts (e.g., alum), calcium phosphate, incomplete Freunds&#39;s adjuvant), lipid particles (e.g., MF59, cochleates, virus-like particles), microparticles (e.g., virosomes, polylactic acid (PLA), poly[lactide-coglycolide] (PLG)), immune potentiators (e.g., dsRNA:Poly(I:C), Poly-IC:LC, Monophosphoryl lipid A (MPL), LPS, Flagellin, Imidazoquinolines: imiquimod (R837), resiquimod (848), CpG oligodeoxynucleotides (ODN), Muramyl dipeptide (MDP), Saponins (QS-21)), and mucosal adjuvants (e.g., Cholera toxin (CT), Heat-labile enterotoxin (LTK3 and LTR72), Chitosan). Adjuvants that can be co-formulated or co-administered with the herein described fusion polypeptides, polynucleotides encoding such fusion polypeptides and vectors expressing such fusion polypeptides are summarized in Apostólico, et al.,  J Immunol Res . (2016) 2016:1459394. 
     In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise two or more fusion polypeptides and/or compound fusion polypeptides, two or more polynucleotides encoding such fusion polypeptides and/or compound fusion polypeptides, or two or more vectors expressing such fusion polypeptides and/or compound fusion polypeptides. In various embodiments, the pharmaceutical compositions or immunogenic compositions comprise a first fusion polypeptide and a second fusion polypeptide that are bivalent, or one or more vectors comprising one or more polynucleotides encoding the bivalent first and second fusion polypeptides. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17;   SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11;   SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21;   SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17;   SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11;   SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19;   SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17;   SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11;   SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19;   SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;   SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;   SEQ ID NOs: 6, 20, 4, 24, 32 and 18 and SEQ ID NOs: 8, 12, 30, 26, 14 and 10;   SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;   SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10;   SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19;   SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29;   SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29;   SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29;   SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29;   SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or   SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11.       

     In some embodiments, the pharmaceutical composition or immunogenic composition comprises one or more, e.g., two or more, fusion polypeptides, or one or more, e.g., two or more, vectors comprising one or more polynucleotides encoding one or more, e.g., two or more, fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the pharmaceutical composition or immunogenic composition comprises one or more, e.g., two or more, fusion polypeptides, or one or more, e.g., two or more, vectors comprising one or more polynucleotides encoding one or more, e.g., two or more, fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. 
     In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.       

     In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of SEQ ID NO: 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 227. 
     In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively;   SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively;   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or   SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.       

     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers, SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers, SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) the first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and 
     b) the second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) the first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and 
     b) the second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) the first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and 
     b) the second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) the first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and 
     b) the second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 105 or 206, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 107 or 207, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 109, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 111, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 111. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 200, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 201, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 202, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 203, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 204, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 205, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 208, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 209, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 222, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 223, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 227, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 227. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 200, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 201, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 202, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 204, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 205, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 105, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 107, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 206, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 207, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 208, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 223, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. 
     In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. 
     In some embodiments, the pharmaceutical compositions or immunogenic compositions comprise the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide, the first and second polynucleotides comprising or consisting of, respectively:
         SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;   SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;   SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;   SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;   SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;   SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;   SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;   SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;   SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;   SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;   SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;   SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;   SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;   SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;   SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;   SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;   SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;   SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;   SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;   SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;   SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;   SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;   SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;   SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;   SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;   SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;   SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;   SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;   SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;   SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;   SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;   SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;   SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;   SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;   SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;   SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or   SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.       

     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising first and second polynucleotides of SEQ ID NOs: 131 and 135, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and 
     b) the second viral vector comprising first and second polynucleotides of SEQ ID NOs: 133 and 137, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising first and second polynucleotides of SEQ ID NOs: 139 and 145, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and 
     b) the second viral vector comprising first and second polynucleotides of SEQ ID NOs: 142 and 148, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising first and second polynucleotides of SEQ ID NOs: 140 and 146, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and 
     b) the second viral vector comprising first and second polynucleotides of SEQ ID NOs: 143 and 149, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising first and second polynucleotides of SEQ ID NOs: 150 and 152, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and 
     b) the second viral vector comprising first and second polynucleotides of SEQ ID NOs: 154 and 157, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising first and second polynucleotides of SEQ ID NOs: 150 and 152, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and 
     b) the second viral vector comprising first and second polynucleotides of SEQ ID NOs: 155 and 158, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising first and second polynucleotides of SEQ ID NOs: 151 and 153, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively, and 
     b) the second viral vector comprising first and second polynucleotides of SEQ ID NOs: 156 and 159, or first and second polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167, respectively. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In various embodiments, the immunogenic composition or pharmaceutical composition comprises first and second viral vectors comprising one or more polynucleotides: 
     a) the first viral vector comprising a polynucleotide of SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and 
     b) the second viral vector comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In various embodiments of the pharmaceutical compositions or immunogenic compositions, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In various embodiments of the pharmaceutical compositions or immunogenic compositions, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. 
     6. Methods of Treatment 
     Further provided are methods for treating or preventing an HIV infection or a related disease or disorder in a subject in need thereof (e.g., a human subject), comprising providing to a subject in need thereof an effective amount of one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. As used herein, the term “subject” refers to a mammal. The mammal can be any mammal, for example, a human, a non-human primate, a rodent (e.g., mouse, rat, guinea pig), a dog, a cat, or a domesticated animal such as a cow, a horse, a goat, a camel, a sheep or a pig. The term “patient” refers to a human subject. As used herein, the term “effective amount” in the context of the administration of a therapy to a subject refers to the amount of a therapy that achieves a desired prophylactic or therapeutic effect. The polynucleotide may be present in a vector, e.g., a viral vector, as described herein. In some embodiments, the related disease or disorder is caused by infection with HIV. In other embodiments, it is acquired immune deficiency syndrome (AIDS). In certain embodiments, the subject is a virologically suppressed HIV-infected mammal, while in other embodiments, the subject is a treatment-naïve HIV-infected mammal or a treatment experienced HIV-infected subject that is not virologically suppressed. In certain embodiments, a treatment-naïve subject has a viral load between &lt;50 copies/mL and 10 8  copies/ml. In certain embodiments, a virologically suppressed subject has a viral load &lt;50 copies/ml. In another embodiment, the subject is a mammal, e.g., a human. In certain embodiments, the subject has been diagnosed with an HIV, e.g., HIV-1 or HIV-2, infection or a related disease or disorder, e.g., AIDS, or is considered at risk for developing an HIV, e.g., HIV-1 or HIV-2, infection or a related disease or disorder, e.g., AIDS. Subjects at risk for HIV-related diseases or disorders include patients who have come into contact with an infected person or who have been exposed to HIV in some other way. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of HIV-related disease or disorder, such that a disease or disorder is prevented or, alternatively, delayed in its progression. 
     In some embodiments, the subject is chronically infected with HIV-1. In some embodiments, the subject is acutely infected with HIV-1, e.g., has an HIV-1 infection of Fiebig stage IV or earlier, e.g. Fiebig stage III, Fiebig stage II or Fiebig stage I. In some embodiments, the subject is not receiving antiretroviral therapy (ART) or ART is discontinued prior to administration of the one or more compositions. In some embodiments, ART is discontinued after one or more administrations of the compositions. In some embodiments, ART is administered concurrently with administration of one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. 
     Also provided are methods for preventing or inhibiting an increase in HIV virus titer, virus replication, virus proliferation or an amount of an HIV viral DNA, HIV proviral DNA, or HIV viral protein in a subject (e.g., a human subject). In one embodiment, the method entails providing to the subject in need thereof an amount of an one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, effective to prevent an increase in HIV titer, virus replication, or an amount of an HIV protein of one or more HIV strains or isolates in the subject. In certain embodiments, the method further comprises measuring an amount of HIV viral or proviral DNA or protein at one or more time points, e.g., before and after the subject in provided with one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. Methods and biomarkers for determining an amount of HIV viral or proviral DNA or protein in a subject are known and available in the art, and described for example, in Siliciano, J. D. et al., Curr Opin. HIV AIDS, 5(6):491-7 (2010), and Rouzioux, C. et al., Curr Opin HIV AIDS, 8(3):170-5 (2013). 
     In some embodiments, one or more fusion polypeptides or compound fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, may be used in, for example, methods of inhibiting certain viruses such as HIV isolates described herein, prophylactic inhibiting or preventing infections of certain viruses such as HIV isolates described herein, detection of certain viruses such as HIV isolates described herein in a sample, inhibiting certain viruses such as HIV isolates described herein, or diagnosis of certain viruses such as HIV isolates described herein. 
     For in vivo treatment of mammalian subject, e.g., humans, the subject may be administered or provided a pharmaceutical composition comprising one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. When used for in vivo therapy, the one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, are typically administered or provided to the patient in therapeutically effective amounts (i.e., amounts that eliminate or reduce the patient&#39;s viral burden and/or viral reservoir). The one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, are administered or provided to a mammalian subject, e.g., a human, in accord with known methods, such as, but not limited to, intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intranodal, intraarticular, intrasynovial, intrathecal, oral, topical, or inhalation routes. The one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, may be administered parenterally, when possible, at the target cell site, or intravenously. In one embodiment, administration of the one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, to the subject is via an intravenous route. In another embodiment, administration of the one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein, to the subject is via a subcutaneous route. In additional embodiments, pharmaceutical compositions of the disclosure are administered to a subject systemically, parenterally, or locally (e.g., mucosally, including buccal, intrarectal and/or intravaginal routes). 
     In certain embodiments, the present disclosure provides a method for treating an HIV infection, comprising administering to a human subject in need thereof a therapeutically effective amount of one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. In some embodiments, the present disclosure provides a method for preventing an HIV infection, comprising administering to a human subject in need thereof a therapeutically effective amount of one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides or compound fusion polypeptides, as described herein. 
     In various embodiments, the method entails administering first and second bivalent fusion polypeptides, or first and second polynucleotides (e.g., first and second expression cassettes, first and second open reading frames) encoding the first and second fusion polypeptides, respectively, or a single viral expression vector comprising first and second polynucleotides (e.g., first and second expression cassettes, first and second open reading frames) encoding the first and second fusion polypeptides, respectively, wherein the first and second fusion polypeptides are bivalent fusion polypeptides. In certain embodiments, the single viral expression vector has a bi-segmented genome. In certain embodiments, the single viral expression vector has a tri-segmented genome. In various embodiments, the method entails administering a single compound fusion polypeptide, or a single polynucleotide (e.g., single expression cassette, single open reading frame) encoding the compound fusion polypeptide, or single viral expression vector comprising a polynucleotide encoding the compound fusion polypeptide, wherein the compound fusion polypeptide comprises bivalent fusion polypeptides. 
     In some embodiments, the methods entail administering to the subject: a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17;   SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11;   SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21;   SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17;   SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11;   SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19;   SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17;   SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11;   SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19;   SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;   SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;   SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;   SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10;   SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10;   SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19;   SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29;   SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29;   SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29;   SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29;   SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or   SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11.       

     In some embodiments, the methods entail administering to the subject: one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the methods entail administering to the subject: one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. 
     In some embodiments, the methods entail administering to the subject: the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.       

     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 
     In some embodiments, the methods entail administering to the subject first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively, and (b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. 
     In some embodiments, the methods entail administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 200, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 201, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. 
     In some embodiments, the methods entail administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 202, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 203, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. 
     In some embodiments, the methods entail administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 204, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 205, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. 
     In some embodiments, the methods entail administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 105, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 107, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107. 
     In some embodiments, the methods entail administering first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 207, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207. 
     In some embodiments, the methods entail administering g first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. 
     In some embodiments, the methods entail administering g first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. 
     In some embodiments, the methods entail administering g first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 223, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. 
     In some embodiments, the methods entail administering to the subject a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. 
     In some embodiments, the methods entail administering to the subject a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. 
     In some embodiments, the methods entail administering to the subject: the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively;   SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively;   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or   SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.       

     In some embodiments, the methods entail administering to the subject: a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the methods entail administering to the subject: a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. 
     In some embodiments, the methods entail administering to the subject: the following first polynucleotide and second polynucleotide, or one or more vectors comprising or consisting of the following first polynucleotide and second polynucleotide:
         SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;   SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;   SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;   SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;   SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;   SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;   SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;   SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;   SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;   SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;   SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;   SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;   SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;   SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;   SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;   SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;   SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;   SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;   SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;   SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;   SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;   SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;   SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;   SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;   SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;   SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;   SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;   SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;   SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;   SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;   SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;   SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;   SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;   SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;   SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;   SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or   SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.       

     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 211. 
     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 213. 
     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 215. 
     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 217. 
     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 219. 
     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 226. 
     In some embodiments, the method entails administering: (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 226. 
     In some embodiments, the methods entail administering to the subject: a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the methods entail administering to the subject: a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. 
     In various embodiments of the methods, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In various embodiments of the methods, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. 
     In some embodiments, the methods entail administering one or more viral expression vectors that express one or more of the fusion polypeptides. In various embodiments, the methods entail administering from about 10 3  to about 10 12  viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g. from about 10 4  to about 10 7  viral FFU or PFU or IU or vp, e.g. from about 10 3  to about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 ,  10   10 , 10 11 , 10 12 , 10 13 , 10 14  or 10 15  viral FFU or PFU or IU or vp, per administration. 
     In various embodiments, the methods implement a prime-boost regimen comprising administering a priming composition at a first time point and administering one or more boosting compositions at one or more subsequent time points. Generally, in a prime-boost regimen, the priming composition and the boosting composition are administered sequentially. Illustrative prime-boost regimens include prime-boost-prime-boost and prime-boost-boost-boost. In some embodiments, the administrations of the priming composition and the one or more boosting compositions are spaced at least 1 week, 2 weeks, 3 weeks or 1 month apart, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months apart. In some embodiments, the priming composition and the boosting composition comprise the same immunogenic composition. In some embodiments, the priming composition and the boosting composition comprise different immunogenic compositions. In some embodiments, the priming composition and the boosting composition comprise the same one or more fusion polypeptides and same viral expression vector. In some embodiments, the priming composition and the boosting composition comprise different fusion polypeptides and the same viral expression vectors. In some embodiments, the priming composition and the boosting composition comprise the same fusion polypeptides and different viral expression vectors. In some embodiments, the methods entail priming with a first viral expression vector, and boosting with a second viral expression vector. As appropriate, a prime-boost regimen can be repeated one or more iterations. 
     In various embodiments, the prime-boost regimen comprises:
         Priming with one or more viral expression vectors and boosting with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA or self-replicating RNA;   Priming with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA, self-amplifying or self-replicating RNA, and boosting with one or more viral expression vectors;   Priming with one or more viral expression vectors, and boosting with one or more viral expression vectors, wherein the one or more viral expression vectors in the priming composition and the one or more viral expression vectors in the boosting composition are from identical, related or unrelated taxonomical families;   Priming with one or more replication-deficient viral expression vectors and boosting with one or more replication-deficient viral expression vectors, wherein the one or more replication-deficient viral expression vectors in the priming composition and the one or more replication-deficient viral expression vectors in the boosting composition are from identical, related or unrelated taxonomical families;   Priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-attenuated viral expression vectors, wherein the one or more replication-attenuated viral expression vectors in the priming composition and the one or more replication-attenuated viral expression vectors in the boosting composition are from identical, related or unrelated taxonomical families;   Priming with one or more replication-deficient viral expression vectors and boosting with one or more replication-attenuated viral expression vectors;   Priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-deficient viral expression vectors;   Priming with one or more Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors and boosting with one or more Pichinde mammarenavirus viral expression vectors;   Priming with one or more Pichinde mammarenavirus viral expression vectors and boosting with one or more Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors;   Priming with one or more replication deficient Pichinde mammarenavirus viral expression vectors and boosting with one or more replication deficient Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors;   Priming with one or more replication deficient Lymphocytic choriomeningitis mammarenavirus (LCMV) viral expression vectors and boosting with one or more replication deficient Pichinde mammarenavirus viral expression vectors;   Priming with one or more arenavirus viral expression vectors and boosting with one or more adenovirus viral expression vectors;   Priming with one or more adenovirus viral expression vectors and boosting with boosting composition comprising one or more arenavirus viral expression vectors;   Priming with one or more adenovirus viral expression vectors and boosting with boosting composition comprising one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA);   Priming with one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA) and boosting with boosting composition comprising one or more adenovirus viral expression vectors;   Priming with one or more chimpanzee adenoviral (ChAd) expression vectors and boosting with boosting composition comprising one or more self-amplifying or self-replicating RNA (saRNA or samRNA);   Priming with one or more self-amplifying or self-replicating RNA (saRNA or samRNA) and boosting with boosting composition comprising one or more chimpanzee adenoviral (ChAd) expression vectors;   Priming with one or more poxvirus (e.g., Vaccinia) viral expression vectors and boosting with one or more arenavirus viral expression vectors;   Priming with one or more arenavirus viral expression vectors and boosting with boosting composition comprising one or more poxvirus (e.g., Vaccinia) viral expression vectors;   Priming with one or more poxvirus (e.g., Vaccinia) viral expression vectors and boosting with one or more adenovirus viral expression vectors; or   Priming with one or more adenovirus viral expression vectors and boosting with boosting composition comprising one or more poxvirus (e.g., Vaccinia) viral expression vectors.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; and       

     2) Boosting with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   b) SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   c) SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   d) SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and/or   e) SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; and       

     2) Boosting with an immunogenic composition comprising the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively;   b) SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively;   c) SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or   d) SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.       

     In some embodiments, the prime-boost regimen comprises: 1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In various embodiments of this method, the priming vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus) and the boosting vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs:83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In various embodiments of this method, the priming vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus) and the boosting vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In various embodiments of this method, the priming vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) and the boosting vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In various embodiments of this method, the priming vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) and the boosting vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, or one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; and       

     2) Boosting with an immunogenic composition comprising first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         a) a first viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or   b) a second viral vector comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.       

     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first fusion polypeptide and second fusion polypeptides, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 105, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 109, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 105 or 206, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 107 or 207, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 105, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 107, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107, respectively. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 207, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 208, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 222, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 222, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 223, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. In various embodiments of this method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, e.g., analogous to the prime-boost regimen described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, in WO 2021/203104 for infectious disease vaccines and in WO 2020/243719. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. In various embodiments of this method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, e.g., analogous to the prime-boost regimen described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, in WO 2021/203104 for infectious disease vaccines and in WO 2020/243719. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 223, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223, respectively. In various embodiments of this method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, e.g., analogous to the prime-boost regimen described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, in WO 2021/203104 for infectious disease vaccines and in WO 2020/243719. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 107, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 111, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 111. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 200, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 201, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 202, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 203, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. 
     In some embodiments, the prime-boost regimen comprises: 
     1) Priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 204, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204; and 
     2) Boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a compound fusion polypeptide comprising SEQ ID NO: 205, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 204, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204, respectively; and a second viral vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide, comprising SEQ ID NO: 205, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205, respectively. 
     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; and   
           2) Boosting with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; and   
           2) Boosting with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; and   
           2) Boosting with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In various embodiments of this method, the priming vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus) and the boosting vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively; and   
           2) Boosting with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In various embodiments of this method, the priming vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus) and the boosting vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; and   
           2) Boosting with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; and   
           2) Boosting with an immunogenic composition comprising first and second viral vectors comprising the following polynucleotides:
           a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In various embodiments of this method, the priming vectors are Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus) and the boosting vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV). In various embodiments of this method the priming vectors and boosting vectors are replication attenuated or replication competent.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; and
           2) Boosting with an immunogenic composition comprising a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 162 and 163, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively.   
               

     In some embodiments, the prime-boost regimen comprises:
         1) Priming with an immunogenic composition comprising a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; and   2) Boosting with an immunogenic composition comprising a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 166 and 167, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively.       

     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 211, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 213, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 215, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 217, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 219, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In various embodiments of this method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, e.g., analogous to the prime-boost regimen described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, in WO 2021/203104 for infectious disease vaccines and in WO 2020/243719. 
     In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In various embodiments of this method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, e.g., analogous to the prime-boost regimen described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, in WO 2021/203104 for infectious disease vaccines and in WO 2020/243719. 
     In some embodiments, after one or more administrations of the one or more fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides, as described herein, optionally with one or more additional therapeutic agents, described herein, the subject does not exhibit symptoms of HIV or AIDS in the absence of anti-retroviral treatment (ART) for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or more. In some embodiments, after one or more administrations of the one or more fusion polypeptides, as described herein, or one or more polynucleotides encoding one or more fusion polypeptides, as described herein, or one or more vectors expressing one or more fusion polypeptides, as described herein, optionally with one or more additional therapeutic agents, the subject has a viral load of copies/ml blood of less than 500, e.g., less than 400, less than 300, less than 200, less than 100, less than 50, in the absence of anti-retroviral treatment (ART) for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or more. 
     7. Combination Therapies 
     In certain embodiments, a method for treating or preventing an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents. In one embodiment, a method for treating an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents. 
     In various embodiments, of one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, are administered in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent, or excipient. 
     In certain embodiments, the provided are methods for treating an HIV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents which are suitable for treating an HIV infection. 
     In certain embodiments, one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, is co-formulated with one, two, three, four, or more additional therapeutic agents, and a pharmaceutically acceptable carrier. In certain embodiments, one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. As appropriate, the one, two, three, four, or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents. 
     Administration of HIV Combination Therapy 
     In certain embodiments, a one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, are administered with one or more additional therapeutic agents. Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or concurrent, or sequential, administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of the compound disclosed herein and the one or more additional therapeutic agents are both present in the body of the patient. When administered sequentially, the combination may be administered in two or more administrations. 
     Co-administration includes administration of unit dosages of a unit dose of the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents. For example, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, may be administered within seconds, minutes, or hours of the administration of the one or more additional therapeutic agents. In some embodiments, a unit dose of a one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, within seconds or minutes. In other embodiments, a unit dose of one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In yet other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein. In some embodiments, the one or more additional therapeutic agents are not co-administered, but are separately administered as part of a combination therapy regimen. In such approaches, a unit dose of one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, and the one or more additional therapeutic agents can be administered at longer time intervals, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days or more apart. 
     In certain embodiments, one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, is combined or co-administered with one or more additional therapeutic agents in a unitary dosage form for simultaneous or concurrent administration to a patient, for example as an aqueous formulation for intravenous, intramuscular, intradermal, intranodal or subcutaneous administration. In certain embodiments, one or more fusion polypeptides, or polynucleotides encoding or vectors expressing such fusion polypeptides, as disclosed herein, is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous or concurrent administration to a patient, for example as an intrarectal suppository. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, can be co-formulated or co-administered with one or more other compounds useful for treating HIV. In certain embodiments, the co-formulation or co-administration can comprise another active agent for treating HIV, such as anti-HIV antibodies (e.g., HIV bNAbs), bispecific antibodies, and “antibody-like” therapeutic proteins, toll-like receptor (TLR) agonists (e.g., agonists of TLR7, TLR8, and/or TLR9), an immune checkpoint inhibitor, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, immune-based therapies, PI3K inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, Nef inhibitors, latency reversing agents, HIV vaccines, cytokines, immune checkpoint inhibitors, FLT3 agonists, T cell and NK cell recruiting bispecific antibodies, chimeric T cell receptors targeting HIV antigens, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof. 
     In some embodiments, the additional therapeutic agent or agents are selected from dolutegravir, cabotegravir, islatravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir, and combinations thereof. 
     In certain embodiments, the one or more active agents are suitable for once daily dosing, weekly dosing, monthly dosing, every 3 months dosing, every four months dosing, bi-annual dosing, or annual dosing, as appropriate. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, and the one or more additional therapeutic agents may be an anti-HIV agent. In some instances, the additional therapeutic agent can be HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T-cell receptors, TCR-T, autologous T-cell therapies, engineered B cells, NK cells), latency reversing agents, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, fatty acid synthase inhibitor, HIV vifgene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, interferon (IFN) antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, Cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-Glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, prolylendopeptidase inhibitors, phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, anti-HIV peptides and combinations thereof. 
     In some embodiments, the additional therapeutic agent is selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and “antibody-like” therapeutic proteins, and combinations thereof. 
     Combination Drugs 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV combination drug. Examples of combination drugs that can be employed with an agent of this disclosure include ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); darunavir, tenofovir alafenamide hemifumarate, emtricitabine, and cobicistat; efavirenz, lamivudine, and tenofovir disoproxil fumarate; lamivudine and tenofovir disoproxil fumarate; tenofovir and lamivudine; tenofovir alafenamide and emtricitabine; tenofovir alafenamide hemifumarate and emtricitabine; tenofovir alafenamide hemifumarate, emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate, emtricitabine, cobicistat, and elvitegravir; tenofovir analog; COMBIVIR® (zidovudine and lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine; ABC+3TC); KALETRA® (ALUVIA®; lopinavir and ritonavir); TRIUMEQ® (dolutegravir, abacavir, and lamivudine); BIKTARVY® (bictegravir+emtricitabine+tenofovir alafenamide), DOVATO® (dolutegravir+lamivudine), TRIZIVIR® (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); atazanavir and cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate and ritonavir; darunavir and cobicistat; dolutegravir and rilpivirine; dolutegravir and rilpivirine hydrochloride; dolutegravir, abacavir sulfate, and lamivudine; lamivudine, nevirapine, and zidovudine; raltegravir and lamivudine; doravirine, lamivudine, and tenofovir disoproxil fumarate; doravirine, lamivudine, and tenofovir disoproxil; dolutegravir+lamivudine, lamivudine+abacavir+zidovudine, lamivudine+abacavir, lamivudine+tenofovir disoproxil fumarate, lamivudine+zidovudine+nevirapine, lopinavir+ritonavir, lopinavir+ritonavir+abacavir+lamivudine, lopinavir+ritonavir+zidovudine+lamivudine, tenofovir+lamivudine, and tenofovir disoproxil fumarate+emtricitabine+rilpivirine hydrochloride, lopinavir, ritonavir, zidovudine, lopinavir+ritonavir+abacavir+lamivudine, lamivudine, cabotegravir+rilpivirine, 3-BNC117+albuvirtide, elpida (elsulfavirine, VM-1500), and VM-1500A, lenacapavir+islatravir (oral, injectable), and dual-target HIV-1 reverse transcriptase/nucleocapsid protein 7 inhibitors. 
     Examples of other drugs for treating HIV that can be combined with the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, include without limitation aspernigrin C, acemannan, alisporivir, BanLec, deferiprone, Gamimune, metenkefalin, naltrexone, Prolastin, REP 9, RPI-MN, VSSP, Hlviral, SB-728-T, 1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene therapy, MazF gene therapy, BlockAide, bevirimat derivatives, ABBV-382, ABX-464, AG-1105, APH-0812, APH0202, bryostatin-1, bryostatin analogs, BG-HIV, BIT-225, BRII-732, BRII-778, CYT-107, CS-TATI-1, fluoro-beta-D-arabinose nucleic acid (FANA)-modified antisense oligonucleotides, FX-101, griffithsin, GSK-3739937, GSK-3739937 (long-acting), HGTV-43, HPH-116, HS-10234, hydroxychloroquine, IB-10035, IMO-3100, IND-02, JL-18008, LADAVRU, MK-1376, MK-2048, MK-4250, MK-8507, MK-8558, MK-8591, islatravir, NOV-205, OB-002H, ODE-Bn-TFV, PA-1050040 (PA-040), PC-707, PGN-007, QF-036, S-648414, SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111, TEV-90113, RN-18, DIACC-1010, Fasnall, Immuglo, 2-CLIPS peptide, HRF-4467, thrombospondin analogs, TBL-1004HI, VG-1177, xl-081, AVI-CO-004, rfhSP-D, [18F]-MC-225, URMC-099-C, RES-529, Verdinexor, IMC-Mi 13V, IML-106, antiviral fc conjugate (AVC), WP-1096, WP-1097, Gammora, ISR-CO48, ISR-48, ISR-49, MK-8527, cannabinoids, ENOB-HV-32, HiviCide-I, T-1144, VIR-576, nipamovir, Covimro, and ABBV-1882. 
     HIV Protease Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV protease inhibitor. Examples of HIV protease inhibitors that can be co-administered or combined include amprenavir, atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, ASC-09+ritonavir, AEBL-2, DG-17, GS-1156, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, GRL-02031, and TMC-310911. Additional examples of HIV protease inhibitors are described, e.g., in U.S. Pat. No. 10,294,234 and U.S. Patent Publ. Nos. US2020030327 and US2019210978. 
     HIV Gag Protein Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV Gag protein inhibitor. Examples of HIV Gag protein inhibitors that can be combined or co-administered include, but are not limited to, HRF-10071. 
     HIV Ribonuclease H Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV ribonuclease H inhibitor. Examples of HIV ribonuclease H inhibitors that can be combined or co-administered include, but are not limited to, NSC-727447. 
     HIV Nef Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV Nef inhibitor. Examples of HIV Nef inhibitors that can be combined or co-administered include, but are not limited to, FP-1. 
     HIV Reverse Transcriptase Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a non-nucleoside or non-nucleotide inhibitor. Examples of HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase that can be combined or co-administered include dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, nevirapine, rilpivirine, ACC-007, ACC-008, AIC-292, F-18, KM-023, PC-1005, M1-TFV, M2-TFV, VM-1500A-LAI, PF-3450074, elsulfavirine (sustained release oral, HIV infection), doravirine+islatravir (fixed dose combination/oral tablet formulation, HIV-1 infection), elsulfavirine (long acting injectable nanosuspension, HIV infection), and elsulfavirine (VM-1500). 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV nucleoside or nucleotide inhibitor. Examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase that can be combined or co-administered include adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, VIDEX® and VIDEX EC® (didanosine, ddl), abacavir, abacavir sulfate, alovudine, apricitabine, censavudine, didanosine, elvucitabine, festinavir, fosalvudine tidoxil, CMX-157, dapivirine, doravirine, etravirine, OCR-5753, tenofovir disoproxil orotate, fozivudine tidoxil, lamivudine, phosphazid, stavudine, zalcitabine, zidovudine, rovafovir etalafenamide (GS-9131), GS-9148, MK-8504, MK-8591, MK-858, VM-2500 and KP-1461. 
     HIV Integrase Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV integrase inhibitor. Examples of HIV integrase inhibitors that can be combined or co-administered include without limitation elvitegravir, elvitegravir (extended-release microcapsules), curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, raltegravir, PEGylated raltegravir, dolutegravir, JTK-351, bictegravir, AVX-15567, cabotegravir (long acting injectable), diketo quinolin-4-1 derivatives, integrase-LEDGF inhibitor, ledgins, M-522, M-532, MK-0536, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, stilbenedisulfonic acid, T169, STP-0404, VM-3500, XVIR-110, ACC-017 and cabotegravir. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a HIV non-catalytic site, or allosteric, integrase inhibitor (NCINI). Examples of HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) that can be combined or co-administered include CX-05045, CX-05168, and CX-14442. Additional examples of HIV capsid inhibitors include, without limitation those described in U.S. Patent Publ. Nos. US2014221356 and US2016016973. 
     HIV Viral Infectivity Factor Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a HIV Viral Infectivity Factor Inhibitor. Examples of HIV viral infectivity factor inhibitors include, but are not limited to 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)thio)benzamide derivatives and Irino-L. 
     HIV Entry Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV entry inhibitor. Examples of HIV entry (fusion) inhibitors that can be combined or co-administered include without limitation AAR-501, LBT-5001, cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gp120 inhibitors, gp160 inhibitors, and CXCR4 inhibitors. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a CCR5 inhibitor. Examples of CCR5 inhibitors that can be combined or co-administered include without limitation aplaviroc, vicriviroc, maraviroc, maraviroc (long acting injectable nanoemulsion), cenicriviroc, leronlimab (PRO-140), adaptavir (RAP-101), nifeviroc (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, thioraviroc and vMIP (Haimipu). 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a gp41 inhibitor. Examples of gp41 inhibitors that can be combined or co-administered include without limitation albuvirtide, enfuvirtide, griffithsin (gp41/gp120/gp160 inhibitor), BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, Cl3hmAb, lipuvirtide, PIE-12 trimer and sifuvirtide. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a CD4 attachment inhibitor. Examples of CD4 attachment inhibitors that can be combined or co-administered include ibalizumab and CADA analogs. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a gp120 inhibitor. Examples of gp120 inhibitors that can be combined or co-administered include without limitation anti-HIV microbicide, Radha-108 (receptol) 3B3-PE38, BMS818251, BanLec, bentonite-based nanomedicine, fostemsavir tromethamine, IQP-0831, VVX-004, and BMS-663068. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a gp160 inhibitor. Examples of gp160 inhibitors that can be combined or co-administered include without limitation fangchinoline. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a CXCR4 inhibitor. Examples of CXCR4 inhibitors that can be combined or co-administered include plerixafor, ALT-1188, N15 peptide, and vMIP (Haimipu). 
     Maturation Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a HIV maturation inhibitor. Examples of HIV maturation inhibitors that can be combined or co-administered include BMS-955176, GSK-3640254 and GSK-2838232. 
     Latency Reversing Agents 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a latency reversing agent (LRA). Examples of latency reversing agents that can be combined or co-administered include toll-like receptor (TLR) agonists (including TLR7 agonists, e.g., GS-9620 (vesatolimod), TLR8 agonists, e.g., GS-9688 (Selgantolimod), TLR9 agonists, e.g., lefitolimod (MGN-1703)), histone deacetylase (HDAC) inhibitors, proteasome inhibitors such as velcade, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors (such as ZL-0580, apabetalone), ionomycin, IAP antagonists (inhibitor of apoptosis proteins, such as APG-1387, LBW-242), SMAC mimetics (including TL32711, LCL161, GDC-0917, HGS1029, AT-406, Debio-1143), PMA, SAHA (suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic acid), NIZ-985, IL-15 modulating antibodies (including IL-15, IL-15 fusion proteins, and IL-15 receptor agonists), JQ1, disulfiram, amphotericin B, and ubiquitin inhibitors such as largazole analogs, APH-0812, and GSK-343. Examples of PKC activators include, but are not limited to indolactam, prostratin, ingenol B, and DAG-lactones. Additional examples of TLR7 agonists includes but are not limited to those described in U.S. Patent No. US2010/143301. Additional examples of TLR8 agonists includes but are not limited to those described in U.S. Patent No. US2017/071944. 
     Histone Deacetylase (HDAC) Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an inhibitor of a histone deacetylase 1, histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734). Examples of HDAC inhibitors include without limitation, abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HIBI-8000), CT-101, CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, romidepsin, SHP-141, TMB-ADC, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, and entinostat. 
     Capsid Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a capsid inhibitor. Examples of capsid inhibitors that can be combined or co-administered include without limitation capsid polymerization inhibitors or capsid disrupting compounds, HIV nucleocapsid p7 (NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein inhibitors, lenacapavir (GS-6207), GS-CA1, AVI-621, AVI-101, AVI-201, AVI-301, and AVI-CAN1-15 series, PF-3450074, HIV-1 capsid inhibitors (HIV-1 infection, Shandong University), and compounds described in (WO 2019/087016 (GSK)). Additional examples of capsid inhibitors include without limitation those described in US Patent Publ. Nos. US2018051005, US2016108030. 
     HIV Long-Acting Therapy 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an HIV long-acting therapy. Examples of as long acting regimens that can be combined or co-administered include without limitation cabotegravir, rilpivirine, any integrase LA, VM-1500 LAI, maraviroc (LAI), tenofovir implant, islatravir implant, doravirine, raltegravir, and long acting dolutegravir. 
     Additionally encompassed as HIV long-acting therapies include anti-HIV broadly neutralizing antibodies (bNAbs), described herein, having serum half-life extended amino acid substitutions in the Fc region. Fc region amino acid substitutions that increase the half-life of an antibody have been described. For example, a “YTE mutant” (a methionine to tyrosine substitution at position 252, a serine to threonine substitution at position 254, and a threonine to glutamic acid substitution at position 256 (EU numbering)) exhibits a four-fold increased half-life relative to wild-type versions of the same antibody (Dall&#39;Acqua, et al., J Biol Chem, 281: 23514-24 (2006); Robbie, et al., Antimicrob Agents Chemotherap., 57(12):6147-6153 (2013)). See also, U.S. Pat. No. 7,658,921. In a further example, M428L and N434S (EU numbering; “LS”) substitutions can increase the pharmacokinetic half-life of the bNAb. In other embodiments, the bNAbs described herein comprise T250Q and M428L (EU numbering) mutations. In other embodiments, the bNAbs described herein comprise H433K and N434F (EU numbering) mutations. Illustrative serum half-life extended bNAbs that may be combined or co-administered with the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, include 3BNC117-LS, 10-1074-LS, 10-1074-LS-J, GS-5423 and GS-2872. 
     Cytochrome P450 3 Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a Cytochrome P450 3 inhibitor. Examples of Cytochrome P450 3 inhibitors include without limitation those described in U.S. Pat. No. 7,939,553. 
     RNA Polymerase Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an RNA polymerase modulator. Examples of RNA polymerase modulators include without limitation those described in U.S. Pat. Nos. 10,065,958; and 8,008,264. 
     Immune Checkpoint Modulators 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and/or with one or more stimulators, activators or agonists of one or more stimulatory immune checkpoint proteins or receptors. Blockade or inhibition of inhibitory immune checkpoints can positively regulate T-cell or NK cell activation and prevent immune escape of infected cells. Activation or stimulation of stimulatory immune check points can augment the effect of immune checkpoint inhibitors in infective therapeutics. In various embodiments, the immune checkpoint proteins or receptors regulate T cell responses (e.g., reviewed in Xu, et al., J Exp Clin Cancer Res. (2018) 37:110). In various embodiments, the immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis, et al., Semin Immunol. (2017) 31:64-75 and Chiossone, et al., Nat Rev Immunol. (2018) 18(11):671-688). 
     Examples of immune checkpoint proteins or receptors include without limitation CD27 (NCBI Gene ID: 939), CD70 (NCBI Gene ID: 970), CD40 (NCBI Gene ID: 958), CD40LG (NCBI Gene ID: 959), CD47 (NCBI Gene ID: 961), CD48 (SLAMF2; NCBI Gene ID: 962), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H; NCBI Gene ID: 126259), CD84 (LY9B, SLAMF5; NCBI Gene ID: 8832), CD96 (NCBI Gene ID: 10225), CD160 (NCBI Gene ID: 11126), MS4A1 (CD20; NCBI Gene ID: 931), CD244 (SLAMF4; NCBI Gene ID: 51744); CD276 (B7H3; NCBI Gene ID: 80381); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4; NCBI Gene ID: 79679); V-set immunoregulatory receptor (VSIR, B7H5, VISTA; NCBI Gene ID: 64115); immunoglobulin superfamily member 11 (IGSF11, VSIG3; NCBI Gene ID: 152404); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6; NCBI Gene ID: 374383); HERV-H LTR-associating 2 (HHLA2, B7H7; NCBI Gene ID: 11148); inducible T cell co-stimulator (ICOS, CD278; NCBI Gene ID: 29851); inducible T cell co-stimulator ligand (ICOSLG, B7H2; NCBI Gene ID: 23308); TNF receptor superfamily member 4 (TNFRSF4, OX40; NCBI Gene ID: 7293); TNF superfamily member 4 (TNFSF4, OX40L; NCBI Gene ID: 7292); TNFRSF8 (CD30; NCBI Gene ID: 943), TNFSF8 (CD30L; NCBI Gene ID: 944); TNFRSF10A (CD261, DR4, TRAILR1; NCBI Gene ID: 8797), TNFRSF9 (CD137; NCBI Gene ID: 3604), TNFSF9 (CD137L; NCBI Gene ID: 8744); TNFRSF10B (CD262, DR5, TRAILR2; NCBI Gene ID: 8795), TNFRSF10 (TRAIL; NCBI Gene ID: 8743); TNFRSF14 (HVEM, CD270; NCBI Gene ID: 8764), TNFSF14 (HVEML; NCBI Gene ID: 8740); CD272 (B and T lymphocyte associated (BTLA); NCBI Gene ID: 151888); TNFRSF17 (BCMA, CD269; NCBI Gene ID: 608), TNFSF13B (BAFF; NCBI Gene ID: 10673); TNFRSF18 (GITR; NCBI Gene ID: 8784), TNFSF18 (GITRL; NCBI Gene ID: 8995); MHC class I polypeptide-related sequence A (MICA; NCBI Gene ID: 100507436); MHC class I polypeptide-related sequence B (MICB; NCBI Gene ID: 4277); CD274 (CD274, PDL1, PD-L1; NCBI Gene ID: 29126); programmed cell death 1 (PDCD1, PD1, PD-1; CD279; NCBI Gene ID: 5133); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152; NCBI Gene ID: 1493); CD80 (B7-1; NCBI Gene ID: 941), CD28 (NCBI Gene ID: 940); nectin cell adhesion molecule 2 (NECTIN2, CD112; NCBI Gene ID: 5819); CD226 (DNAM-1; NCBI Gene ID: 10666); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155; NCBI Gene ID: 5817); PVR related immunoglobulin domain containing (PVRIG, CD112R; NCBI Gene ID: 79037); T cell immunoreceptor with Ig and ITIM domains (TIGIT; NCBI Gene ID: 201633); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4; NCBI Gene ID: 91937); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3; NCBI Gene ID: 84868); galectin 9 (LGALS9; NCBI Gene ID: 3965); lymphocyte activating 3 (LAG3, CD223; NCBI Gene ID: 3902); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD150; NCBI Gene ID: 6504); lymphocyte antigen 9 (LY9, CD229, SLAMF3; NCBI Gene ID: 4063); SLAM family member 6 (SLAMF6, CD352; NCBI Gene ID: 114836); SLAM family member 7 (SLAMF7, CD319; NCBI Gene ID: 57823); UL16 binding protein 1 (ULBP1; NCBI Gene ID: 80329); UL16 binding protein 2 (ULBP2; NCBI Gene ID: 80328); UL16 binding protein 3 (ULBP3; NCBI Gene ID: 79465); retinoic acid early transcript 1E (RAETIE; ULBP4; NCBI Gene ID: 135250); retinoic acid early transcript 1G (RAETIG; ULBP5; NCBI Gene ID: 353091); retinoic acid early transcript 1L (RAET1L; ULBP6; NCBI Gene ID: 154064); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A; NCBI Gene ID: 3821); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314; NCBI Gene ID: 22914); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C; NCBI Gene ID: 3822); killer cell lectin like receptor C3 (KLRC3, NKG2E; NCBI Gene ID: 3823); killer cell lectin like receptor C4 (KLRC4, NKG2F; NCBI Gene ID: 8302); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1; NCBI Gene ID: 3802); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2; NCBI Gene ID: 3803); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3; NCBI Gene ID: 3804); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1, KIR, CD158E1; NCBI Gene ID: 3811) (e.g., Lirilumab (IPH2102/BMS-986015), IPH-4102); killer cell lectin like receptor D1 (KLRD1; NCBI Gene ID: 3824) and mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, a.k.a., Hematopoietic Progenitor Kinase 1 (HPK1); NCBI Gene ID: 11184). 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. Illustrative T-cell inhibitory immune checkpoint proteins or receptors include without limitation CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CDI 12R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). Lirilumab is an illustrative antibody that binds to and blocks KIR2DL1/2L3 receptors. In various embodiments, the fusion polypeptides, polynucleotides, vectors, LNPs, immunogenic compositions and/or pharmaceutical compositions, as described herein, are combined with one or more agonist or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. Illustrative T-cell stimulatory immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, e.g., Xu, et al., J Exp Clin Cancer Res. (2018) 37:110. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. Illustrative NK-cell inhibitory immune checkpoint proteins or receptors include without limitation killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A), e.g., monalizumab (IPH2201); and killer cell lectin like receptor D1 (KLRD1, CD94). In various embodiments, the agents as described herein, are combined with one or more agonist or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. Illustrative NK-cell stimulatory immune checkpoint proteins or receptors include without limitation CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis, et al., Semin Immunol. (2017) 31:64-75; Fang, et al., Semin Immunol. (2017) 31:37-54; and Chiossone, et al., Nat Rev Immunol. (2018) 18(11):671-688. 
     In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the one or more immune checkpoint inhibitors comprises a small organic molecule inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. 
     Examples of inhibitors of CTLA4 that can be co-administered include without limitation ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, BPI-002, as well as multi-specific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4), and AK-104 (CTLA4/PD-1). 
     Examples of inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) that can be co-administered include without limitation pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181 (budigalimab), PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS-4224, GS-4416, INCB086550, MAX10181, as well as multi-specific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-013 (PD-1/LAG-3), FS-118 (LAG-3/PD-L1) MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), RO-7121661 (PD-1/TIM-3), XmAb-20717 (PD-1/CTLA4), AK-104 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1), and INBRX-105 (4-1BB/PDL1). 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with anti-TIGIT antibodies, such as etigilimab, BMS-986207, tiragolumab (a.k.a., MTIG-7192A; RG-6058; RO 7092284), vibostolimab (MK-7684), AGEN1307, AGEN1327, AGEN1777, COM-902, IBI-939, AB154, SGN-TGT, MG1131 and EOS884448 (EOS-448). 
     TNF Receptor Superfamily (TNFRSF) Member Agonists or Activators 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with one or more agonists of one or more TNF receptor superfamily (TNFRSF) members, e.g., an agonist of one or more of TNFRSF1A (NCBI Gene ID: 7132), TNFRSF1B (NCBI Gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI Gene ID: 7293), TNFRSF5 (CD40; NCBI Gene ID: 958), TNFRSF6 (FAS, NCBI Gene ID: 355), TNFRSF7 (CD27, NCBI Gene ID: 939), TNFRSF8 (CD30, NCBI Gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI Gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI Gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI Gene ID: 8795), TNFRSF10C (CD263, TRAILR3, NCBI Gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI Gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI Gene ID: 8792), TNFRSF11B (NCBI Gene ID: 4982), TNFRSF12A (CD266, NCBI Gene ID: 51330), TNFRSF13B (CD267, NCBI Gene ID: 23495), TNFRSF13C (CD268, NCBI Gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI Gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI Gene ID: 608), TNFRSF18 (GITR, CD357, NCBI Gene ID: 8784), TNFRSF19 (NCBI Gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI Gene ID: 27242), and TNFRSF25 (DR3, NCBI Gene ID: 8718). 
     Example anti-TNFRSF4 (OX40) antibodies that can be co-administered include without limitation, MEDI6469, MEDI6383, MEDI0562 (tavolixizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628. 
     Example anti-TNFRSF5 (CD40) antibodies that can be co-administered include without limitation RG7876, SEA-CD40, APX-005M and ABBV-428. 
     In some embodiments, the anti-TNFRSF7 (CD27) antibody varlilumab (CDX-1127) is co-administered. 
     Example anti-TNFRSF9 (4-1BB, CD137) antibodies that can be co-administered include without limitation urelumab, utomilumab (PF-05082566), AGEN2373 and ADG-106. 
     Example anti-TNFRSF18 (GITR) antibodies that can be co-administered include without limitation, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, an antibody, or fragment thereof, co-targeting TNFRSF4 (OX40) and TNFRSF18 (GITR) is co-administered. Such antibodies are described, e.g., in WO2017096179 and WO2018089628. 
     Bi- and Tri-Specific Natural Killer (NK)-Cell Engagers 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a bi-specific NK-cell engager (BiKE) or a tri-specific NK-cell engager (TriKE) (e.g., not having an Fc) or bi-specific antibody (e.g., having an Fc) against an NK cell activating receptor, e.g., CD16A, C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptor (NKp65, NKp80), Fc receptor FcγR (which mediates antibody-dependent cell cytotoxicity), SLAM family receptors (e.g., 2B4, SLAM6 and SLAM7), killer cell immunoglobulin-like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD137 (4-1B). As appropriate, the anti-CD16 binding bi-specific molecules may or may not have an Fc. Illustrative bi-specific NK-cell engagers that can be co-administered target CD16 and one or more HIV-associated antigens as described herein. BiKEs and TriKEs are described, e.g., in Felices, et al., Methods Mol Biol. (2016) 1441:333-346; Fang, et al., Semin Immunol. (2017) 31:37-54. Examples of a trispecific NK cell engager (TRiKE) include OXS-3550, HIV-TriKE and CD16-IL-15-B7H3 TriKe. 
     Indoleamine-Pyrrole-2,3-Dioxygenase (IDO1) Inhibitors 
     In various embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI Gene ID: 3620). Examples of IDO1 inhibitors include without limitation, BLV-0801, epacadostat, F-001287, GBV-1012, GBV-1028, GDC-0919, indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, BMS-986205, and shIDO-ST, EOS-200271, KHK-2455, LY-3381916. 
     Toll-Like Receptor (TLR) Agonists 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an agonist of a toll-like receptor (TLR), e.g., an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and/or TLR10 (NCBI Gene ID: 81793). Example TLR7 agonists that can be co-administered include without limitation AL-034, DSP-0509, GS-9620 (vesatolimod), vesatolimod analog, LHC-165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7854, RG-7795, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). An TLR7/TLR8 agonist that can be co-administered is NKTR-262, telratolimod and BDB-001. Example TLR8 agonists that can be co-administered include without limitation E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688 (Selgantolimod), VTX-1463, VTX-763, 3M-051, 3M-052, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). Example TLR9 agonists that can be co-administered include without limitation AST-008 (cavrotolimod), cobitolimod, CMP-001, IMO-2055, IMO-2125, 5-540956, litenimod, MGN-1601, BB-001, BB1-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, lefitolimod (MGN-1703), CYT-003, CYT-003-QbG10, tilsotolimod and PUL-042. Examples of TLR3 agonists include rintatolimod, poly-ICLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND-1.1. Examples of TLR4 agonists include G-100, and GSK-1795091. 
     CDK Inhibitors or Antagonists 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a CDK inhibitor or antagonist. In some embodiments, the agents described herein are combined with an inhibitor or antagonist of CDK. In some embodiments, the CDK inhibitor or antagonist is selected from VS2-370. 
     STING Agonists, RIG-I and NOD2 Modulators 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a stimulator of interferon genes (STING) receptor (a.k.a, stimulator of interferon response cGAMP interactor 1 (STINGI); transmembrane protein 173 (TMEM173); NCBI Gene ID: 340061) agonist. In some embodiments, the STING receptor agonist or activator is selected from ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, STING agonist (latent HIV), 5,6-dimethylxanthenone-4-acetic acid (DMXAA), cyclic-GAMP (cGAMP) and cyclic-di-AMP. In some embodiments, the agents described herein are combined with a RIG-I modulator such as RGT-100, or NOD2 modulator, such as SB-9200, and IR-103. 
     In some embodiments, the additional therapeutic agent is an agonist of DExD/H-box helicase 58 (DDX58; a.k.a., RIG-I, RIG1, RIGI, RLR-1, SGMRT2; NCBI Gene ID: 23586). Illustrative RIG-I agonists include inarigivir soproxil (SB-9200; GS-9992); SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI-9198, ORI-7170, RGT-100 and KIN1148, described by Hemann, et al.,  J Immunol May  1, 2016, 196 (1 Supplement) 76.1. Additional RIG-I agonists are described, e.g., in Elion, et al.,  Cancer Res . (2018) 78(21):6183-6195; and Liu, et al.,  J Virol . (2016) 90(20):9406-19. RIG-I agonists are commercially available, e.g., from Invivogen (invivogen.com). In some embodiments, the agents described herein are combined with a nucleotide binding oligomerization domain containing 2 (NOD2; NCBI Gene ID: 64127) agonist, such as inarigivir soproxil (SB-9200; GS-9992) and IR-103. 
     LAG-3 and TIM-3 Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an anti-TIM-3 antibody, such as TSR-022, LY-3321367, MBG-453, INCAGN-2390. 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with anti-LAG-3 (Lymphocyte-activation) antibody, such as relatlimab (ONO-4482), LAG-525, MK-4280, REGN-3767, INCAGN2385. 
     Interleukin or Cytokine Receptor Agonists 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an interleukin receptor agonist, such as IL-2, IL-7, IL-15, IL-10, IL-12 receptor agonists. Examples of IL-2 receptor agonists that can be co-administered include proleukin (aldesleukin, IL-2); BC-IL (Cel-Sci), pegylated IL-2 (e.g., NKTR-214); modified variants of IL-2 (e.g., THOR-707, Fc-IL-2 fusion protein), bempegaldesleukin, AIC-284, ALKS-4230, CUI-101, Neo-2/15. Examples of IL-15 receptor agonists that can be co-administered include ALT-803, NKTR-255, and hetIL-15, interleukin-15/Fc fusion protein, AM-0015, NIZ-985, SO-C101, IL-15 Synthorin (pegylated Il-15), P-22339, and an IL-15-PD-1 fusion protein N-809. Examples of IL-7 receptor agonist that can be co-administered include CYT-107. 
     Examples of additional immune-based therapies that can be combined or co-administered include interferon alfa; interferon alfa-2b; interferon alfa-n3; pegylated interferon alfa; interferon gamma; fms related tyrosine kinase 3 (FLT3) agonists (e.g., GS-3583, CDX-301); gepon; normferon, peginterferon alfa-2a, peginterferon alfa-2b, RPI-MN. In various embodiments, a fms related tyrosine kinase 3 (FLT3) agonists (e.g., GS-3583, CDX-301) is administered at a first time point and the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are administered at a time point at least 6, 7, 8, 9, 10 days, e.g., 1 week, after the first time point. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an fms related tyrosine kinase 3 (FLT3) agonist (e.g., GS-3583, CDX-301). Illustrative FLT3 agonists that can be co-administered are described, e.g., in WO 2020/263830A1. In various embodiments, the co-administration of a FLT3 agonist increases the vaccine-induced T cell response in comparison to administration of the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides in the absence of a FLT3 agonist. 
     Phosphatidylinositol 3-Kinase (PI3K) Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a PI3K inhibitor. Examples of PI3K inhibitors that can be combined or co-administered include idelalisib, alpelisib, buparlisib, CAI orotate, copanlisib, duvelisib, gedatolisib, neratinib, panulisib, perifosine, pictilisib, pilaralisib, puquitinib mesylate, rigosertib, rigosertib sodium, sonolisib, taselisib, AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457, CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771, INCB-040093, LY-3023414, MLN-1117, PQR-309, RG-7666, RP-6530, RV-1729, SAR-245409, SAR-260301, SF-1126, TGR-1202, UCB-5857, VS-5584, XL-765, and ZSTK-474. 
     Diacylglycerol Kinase Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an inhibitor of a diacylglycerol kinase (DGK), e.g., diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ). Examples of DGK inhibitors that can be combined or co-administered include ritanserin and the DGK inhibitors described in WO2020006016 and WO2020006018. 
     Alpha-4/Beta-7 Antagonists 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an alpha-4/beta-7 antagonist. Examples of Integrin alpha-4/beta-7 antagonists that can be combined or co-administered include PTG-100, TRK-170, abrilumab, etrolizumab, carotegrast methyl, and vedolizumab. 
     HPK1/MAP4K1 Inhibitors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with an inhibitor of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, a.k.a., Hematopoietic Progenitor Kinase 1 (HPK1); NCBI Gene ID: 11184). Examples of HPK1 inhibitors include, but are not limited to, ZYF-0272, and ZYF-0057. 
     HIV-Targeting Antibodies 
     Examples of HIV antibodies, bispecific antibodies, and “antibody-like” therapeutic proteins that can be combined or co-administered include DARTs®, DUOBODIES®, BITES®, XmAbs®, TandAbs®, Fab derivatives, bNAbs (broadly neutralizing HIV-1 antibodies), TMB-360, TMB-370, and those targeting HIV gp120 or gp41, antibody-Recruiting Molecules targeting HIV, anti-CD63 monoclonal antibodies, anti-GB virus C antibodies, anti-GP120/CD4, gp120 bispecific monoclonal antibody, CCR5 bispecific antibodies, anti-Nef single domain antibodies, anti-Rev antibody, camelid derived anti-CD18 antibodies, camelid-derived anti-ICAM-1 antibodies, DCVax-001, gp140 targeted antibodies, gp41-based HIV therapeutic antibodies, human recombinant mAbs, ibalizumab, ibalizumab (second generation), Immuglo, MB-66, clone 3 human monoclonal antibody targeting KLIC (HIV infection). Various bNAbs may be used, as described herein. 
     In certain embodiments, the co-administered antibody or antigen-binding fragment thereof, or an antigen-binding molecule, is or is derived from human neutralizing antibodies (e.g., monoclonal) that target HIV-1. A “neutralizing antibody” is one that can neutralize the ability of HIV to initiate and/or perpetuate an infection in a host and/or in target cells in vitro. The disclosure provides neutralizing monoclonal human antibodies, wherein the antibody recognizes an antigen from HIV, e.g., a gp120 polypeptide. In certain embodiments, a “neutralizing antibody” may inhibit the entry of HIV-1 virus, e.g., SF162 and/or JR-CSF, with a neutralization index &gt;1.5 or &gt;2.0 (Kostrikis L G et al., J. Virol., 70(1): 445-458 (1996)). 
     In some embodiments, the co-administered antibody or antigen-binding fragment thereof, or an antigen-binding molecule, is or is derived from a human broadly neutralizing antibody (e.g., monoclonal) that target HIV-1. By “broadly neutralizing antibodies” are meant antibodies that neutralize more than one HIV-1 virus species (from diverse clades and different strains within a clade) in a neutralization assay. A broad neutralizing antibody may neutralize at least 2, 3, 4, 5, 6, 7, 8, 9 or more different strains of HIV-1, the strains belonging to the same or different clades. Illustrative broadly neutralizing antibodies (bNAbs) which can be co-administered as an additional therapeutic agent in a combination therapy are described, e.g., in U.S. Pat. Nos. 8,673,307; 9,493,549; 9,783,594; and WO 2012/154312; WO2012/158948; WO 2013/086533; WO 2013/142324; WO2014/063059; WO 2014/089152, WO 2015/048462; WO 2015/103549; WO 2015/117008; WO2016/014484; WO 2016/154003; WO 2016/196975; WO 2016/149710; WO2017/096221; WO 2017/133639; WO 2017/133640, which are hereby incorporated herein by reference in their entireties for all purposes. Illustrative bNAbs that can be co-administered include without limitation 12A12, 12A21, NIH45-46, bANC131, 8ANC134, 132530, INC9, 8ANC195, 8ANC196, 10-259, 10-303, 10-410, 10-847, 10-996, 10-1074, 10-1074-LS, 10-1074-LS-J, 10-1121, 10-1130, 10-1146, 10-1341, 10-1369, 10-1074GM, PGT-121, PGT-121.414, GS-9721, GS-9722, GS-2872. Additional examples include those described in Sajadi, et al., Cell. (2018) 173(7):1783-1795; Sajadi, et al., J Infect Dis. (2016) 213(1):156-64; Klein et al., Nature, 492(7427): 118-22 (2012), Horwitz et al., Proc Natl Acad Sci USA, 110(41): 16538-43 (2013), Scheid, et al., Science, 333: 1633-1637 (2011), Scheid, et al., Nature, 458:636-640 (2009), Eroshkin et al, Nucleic Acids Res., 42 (Database issue):Dl 133-9 (2014), Mascola et al., Immunol Rev., 254(1):225-44 (2013), such as 2F5, 4E10, M66.6, CAP206-CH12, 10E81 (all of which bind the MPER of gp41); PG9, PG16, CH01-04 (all of which bind V1V2-glycan), 2G12 (which binds to outer domain glycan); b12, HJ16, CH130-149, VRC01-03, VRC-PG04, 04b, VRC-CH30-34, 3BNC62, 3BNC89, 3BNC91, 3BNC95, 3BNC104, 3BNC117, 3BNC176, 8ANC131, GS-9723, GS-5423 (all of which bind to the CD4 binding site), which are hereby incorporated herein by reference in their entireties for all purposes. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of gp120 selected from: (i) the third variable loop (V3) and/or high mannose patch comprising a N332 oligomannose glycan; (ii) second variable loop (V2) and/or Env trimer apex; (iii) CD4 binding site (CD4bs); (iv) gp120/gp41 interface; or (v) silent face of gp120. The foregoing epitopes or regions of gp120 bound by broadly neutralizing antibodies are described, e.g., in McCoy,  Retrovirology  (2018) 15:70; Sok and Burton,  Nat Immunol.  2018 19(11):1179-1188; Possas, et al.,  Expert Opin Ther Pat.  2018 July; 28(7):551-560; and Stephenson and Barouch,  Curr HIV/AIDS Rep  (2016) 13:31-37, which are hereby incorporated herein by reference in their entirety for all purposes. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp120 in the third variable loop (V3) and/or high mannose patch comprising a N332 oligomannose glycan and competes with or comprises VH and VL regions from an antibody selected from GS-9722, PGT-121.60, PGT-121.66, PGT-121, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. Additional broadly neutralizing antibodies that bind to gp120 in the third variable loop (V3) and/or high mannose patch comprising a N332 oligomannose glycan and which can be used as the second antibody or antigen-binding fragment thereof are described, e.g., in WO 2012/030904; WO 2014/063059; WO 2016/149698; WO 2017/106346; WO 2018/075564, WO 2018/125813 and WO 2018/237148, which are hereby incorporated herein by reference in their entireties for all purposes. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of gp120 in the CD4 binding site (CD4bs) and competes with or comprises CDRs and/or VH and VL regions from an antibody selected from b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01 VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N49-P7, NC-Cowl, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25. Additional broadly neutralizing antibodies that bind to gp120 CD4 binding site (CD4bs) and which can be used as the second antibody or antigen-binding fragment thereof are described, e.g., in WO 2012/154312, WO 2012/158948, WO 2013/090644, WO 2013/192589, WO 2018/125813, which are hereby incorporated herein by reference in their entireties for all purposes. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of gp120 in the second variable loop (V2) and/or Env trimer apex and competes with or comprises VH and VL regions from an antibody selected from PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E and VRC38.01. Additional broadly neutralizing antibodies that bind to gp120 in the second variable loop (V2) and/or Env trimer apex and which can be used as the second antibody or antigen-binding fragment thereof are described, e.g., in WO 2010/107939; WO 2012/030904; WO 2018/075564 and WO 2018/125813, which are hereby incorporated herein by reference in their entireties for all purposes. 
     In some embodiments the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of gp120 in the gp120/gp41 interface and competes with or comprises VH and VL regions from an antibody selected from PGT-151, CAP248-2B, 35022, 8ANC195, ACS202, VRC34 and VRC34.01. Additional broadly neutralizing antibodies that bind to gp120 in the gp120/gp41 interface and which can be used as the second antibody or antigen-binding fragment thereof are described, e.g., in WO 2011/038290; WO 2012/030904 and WO2017/079479, which are hereby incorporated herein by reference in their entireties for all purposes. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of the gp120 silent face and competes with or comprises VH and VL regions from an antibody selected from VRC-PG05 and SF12. See, e.g., Schoofs, et al., “Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope,”  Immunity  (2019) May 14. pii: S1074-7613(19)30194-3 (PMID 31126879). 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of gp41 in the membrane proximal region (MIPER). Additional broadly neutralizing antibodies that bind to gp41 in the MPER and which can be used as the second antibody or antigen-binding fragment thereof are described, e.g., in WO 2011/034582; WO 2011/038290; WO 2011/046623 and WO 2013/070776, which are hereby incorporated herein by reference in their entireties for all purposes. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of gp41 in the membrane proximal region (MPER) and competes with or comprises VH and VL regions from an antibody selected from 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined or co-administered with a broadly neutralizing antibody (bNAb)) that binds to an epitope or region of the gp41 fusion peptide and competes with or comprises VH and VL regions from an antibody selected from VRC34 and ACS202. 
     Examples of additional antibodies that can be co-administered include bavituximab, UB-421, BF520.1, BiIA-SG, CH01, CH59, C2F5, C4E10, C2F5+C2G12+C4E10, CAP256V2LS, 3BNC117, 3BNC117-LS, 3BNC60, DH270.1, DH270.6, D1D2, 10-1074-LS, Cl3hmAb, GS-9722 (elipovimab), PGT-121.414, PGT-121.60, PGT-121.66, PGT122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-151, PGT-130, PGT-133, PGT-134, PGT-135, PGT-128, PGT-136, PGT-137, PGT-138, PGT-139, MDX010 (ipilimumab), DH511, DH511-2, N6, N6LS, N49P6, N49P7, N49P7.1, N49P9, N49P11, N60P1.1, N60P25.1, N60P2.1, N60P31.1, N60P22, NIH 45-46, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGDM1400, PGDM12, PGDM21, PCDN-33A, 2Dm2m, 4Dm2m, 6Dm2m, PGDM1400, MDX010 (ipilimumab), VRC01, VRC-01-LS, A32, 7B2, 10E8, VRC-07-523, VRC07-523LS, VRC24, VRC41.01, 10E8VLS, 3810109, 10E8v4, IMC-HIV, iMabm36, eCD4-Ig, IOMA, CAP256-VRC26.25, DRVIA7, VRC-HIVMAB080-00-AB, VRC-HIVMAB060-00-AB, P2G12, VRC07, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, VRC29.03, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E and VRC38.01, PGT-151, CAP248-2B, 35022, ACS202, VRC34 and VRC34.01, 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. 
     Example of HIV bispecific and trispecific antibodies include MGD014, B12BiTe, BiIA-SG, TMB-bispecific, SAR-441236, VRC-01/PGDM-1400/10E8v4, 10E8.4/iMab, 10E8v4/PGT121-VRC01. 
     In some embodiments, the bNAbs can be expressed in vivo in the patient. Examples of in vivo delivered bNAbs include AAV8-VRC07; mRNA encoding anti-HIV antibody VRC01; and engineered B-cells encoding 3BNC117 (Hartweger et al, J. Exp. Med. 2019, 1301). 
     Pharmacokinetic Enhancers 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a pharmacokinetic enhancer. Examples of pharmacokinetic enhancers that can be combined or co-administered include cobicistat and ritonavir. 
     Additional Therapeutic Agents 
     Examples of additional therapeutic agents that can be combined with the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, include the compounds disclosed in WO 2004/096286 (Gilead Sciences), WO 2006/015261 (Gilead Sciences), WO 2006/110157 (Gilead Sciences), WO 2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences), WO 2012/145728 (Gilead Sciences), WO 2013/006738 (Gilead Sciences), WO 2013/159064 (Gilead Sciences), WO 2014/100323 (Gilead Sciences), US 2013/0165489 (University of Pennsylvania), US 2014/0221378 (Japan Tobacco), US 2014/0221380 (Japan Tobacco), WO 2009/062285 (Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO 2013/006792 (Pharma Resources), US 20140221356 (Gilead Sciences), US 20100143301 (Gilead Sciences) and WO 2013/091096 (Boehringer Ingelheim). 
     HIV Vaccines 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with an HIV vaccine. Examples of HIV vaccines that can be combined or co-administered include peptide vaccines, recombinant subunit protein vaccines, live vector vaccines, DNA vaccines, HIV MAG DNA vaccine, CD4-derived peptide vaccines, vaccine combinations, adenoviral vector vaccines (an adenoviral vector such as Ad5, Ad26 or Ad35), simian adenovirus (chimpanzee, gorilla, rhesus i.e. rhAd), adeno-associated virus vector vaccines, Chimpanzee adenoviral vaccines (e.g., ChAdOXI, ChAd68, ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan5, Pan6, Pan7, Pan9), Coxsackieviruses based vaccines, enteric virus based vaccines, Gorilla adenovirus vaccines, lentiviral vector based vaccine, arenavirus vaccines (such as LCMV, Pichinde), bi-segmented or tri-segmented arenavirus based vaccine, trimer-based HIV-1 vaccine, measles virus based vaccine, flavivirus vector based vaccines, tobacco mosaic virus vector based vaccine, Varicella-zoster virus based vaccine, Human parainfluenza virus 3 (PIV3) based vaccines, poxvirus based vaccine (modified vaccinia virus Ankara (MVA), orthopoxvirus-derived NYVAC, and avipoxvirus-derived ALVAC (canarypox virus) strains); fowlpox virus based vaccine, rhabdovirus-based vaccines, such as VSV and marabavirus; recombinant human CMV (rhCMV) based vaccine, alphavirus-based vaccines, such as semliki forest virus, venezuelan equine encephalitis virus and sindbis virus; (see Lauer, Clinical and Vaccine Immunology, 2017, DOI: 10.1128/CVI.00298-16); LNP formulated mRNA based therapeutic vaccines; LNP-formulated self-replicating RNA/self-amplifying RNA vaccines. 
     Examples of HIV vaccines that can be co-administered include without limitation AAVLP-HIV vaccine, AE-298p, anti-CD40.Env-gp140 vaccine, Ad4-EnvC150, BG505 SOSIP.664 gp140 adjuvanted vaccine, BG505 SOSIP.GT1.1 gp140 adjuvanted vaccine, ChAdOx1.tHIVconsv1 vaccine, CMV-MVA triplex vaccine, ChAdOx1.HTI, Chimigen HIV vaccine, ConM SOSIP.v7 gp140, ALVAC HIV (vCP1521), AIDSVAX B/E (gp120), monomeric gp120 HIV-1 subtype C vaccine, MPER-656 liposome subunit vaccine, Remune, ITV-1, Contre Vir, Ad5-ENVA-48, DCVax-001 (CDX-2401), Vacc-4x, Vacc-C5, VAC-3S, multiclade DNA recombinant adenovirus-5 (rAd5), rAd5 gag-pol env A/B/C vaccine, Pennvax-G, Pennvax-GP, Pennvax-G/MVA-CMDR, HIV-TriMix-mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN, NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines, TatImmune, GTU-multiHIV (FIT-06), ChAdV63.HIVconsv, gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag vaccine, SeV-EnvF, SeV-Gag vaccine, AT-20, DNK-4, ad35-Grin/ENV, TBC-M4, HIVAX, HIVAX-2, N123-VRC-34.01 inducing epitope-based HIV vaccine, NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123, rAAV1-PG9DP, GOVX-B11, GOVX-B21, GOVX-C55, TVI-HIV-1, Ad-4 (Ad4-env Clade C+Ad4-mGag), Paxvax, EN41-UGR7C, EN41-FPA2, ENOB-HV-11, ENOB-HV-12, PreVaxTat, AE-H, MYM-V101, CombiHIVvac, ADVAX, MYM-V201, MVA-CMDR, MagaVax, DNA-Ad5 gag/pol/nef/nev (HVTN505), MVATG-17401, ETV-01, CDX-1401, DNA and Sev vectors vaccine expressing SCaVII, rcAD26.MOS1.HIV-Env, Ad26.Mod.HIV vaccine, Ad26.Mod.HIV+MVA mosaic vaccine+gp140, AGS-004, AVX-101, AVX-201, PEP-6409, SAV-001, ThV-01, TL-01, TUTI-16, VGX-3300, VIR-1111, IHV-001, and virus-like particle vaccines such as pseudovirion vaccine, CombiVICHvac, LFn-p24 B/C fusion vaccine, GTU-based DNA vaccine, HIV gag/pol/nef/env DNA vaccine, anti-TAT HIV vaccine, conjugate polypeptides vaccine, dendritic-cell vaccines (such as DermaVir), gag-based DNA vaccine, GI-2010, gp41 HIV-1 vaccine, HIV vaccine (PIKA adjuvant), i-key/MHC class II epitope hybrid peptide vaccines, ITV-2, ITV-3, ITV-4, LIPO-5, multiclade Env vaccine, MVA vaccine, Pennvax-GP, pp71-deficient HCMV vector HIV gag vaccine, rgp160 HIV vaccine, RNActive HIV vaccine, SCB-703, Tat Oyi vaccine, TBC-M4, UBI HIV gp120, Vacc-4x+romidepsin, variant gp120 polypeptide vaccine, rAd5 gag-pol env A/B/C vaccine, DNA.HTI and MVA.HTI, VRC-HIVDNA016-00-VP+VRC-HIVADV014-00-VP, INO-6145, JNJ-9220, gp145 C.6980; eOD-GT8 60mer based vaccine, PD-201401, env (A, B, C, A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) protein vaccine, PDPHV-201401, Ad4-EnvCN54, EnvSeq-1 Envs HIV-1 vaccine (GLA-SE adjuvanted), HIV p24gag prime-boost plasmid DNA vaccine, HIV-1 iglbl2 neutralizing VRC-01 antibody-stimulating anti-CD4 vaccine, arenavirus vector-based vaccines (VaxWave®, TheraT®), MVA-BN HIV-1 vaccine regimen, UBI HIV gp120, mRNA based prophylactic vaccines, VPI-211, multimeric HIV gp120 vaccine (Fred Hutchinson cancer center), TBL-1203HI, CH505 TF chTrimer, CD40.HIVRI.Env vaccine, Drep-HIV-PT-1, mRNA-1644, and mRNA-1574. 
     Birth Control (Contraceptive) Combination Therapy 
     In certain embodiments, the agents described herein are combined with a birth control or contraceptive regimen. Therapeutic agents used for birth control (contraceptive) that can be combined or co-administered include cyproterone acetate, desogestrel, dienogest, drospirenone, estradiol valerate, ethinyl Estradiol, ethynodiol, etonogestrel, levomefolate, levonorgestrel, lynestrenol, medroxyprogesterone acetate, mestranol, mifepristone, misoprostol, nomegestrol acetate, norelgestromin, norethindrone, noretynodrel, norgestimate, ormeloxifene, segestersone acetate, ulipristal acetate, and any combinations thereof. 
     In one embodiment, an agent disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents selected from ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); BIKTARVY (bictegravir+emtricitabine+tenofovir alafenamide), adefovir; adefovir dipivoxil; cobicistat; emtricitabine; tenofovir; tenofovir alafenamide and elvitegravir; tenofovir alafenamide+elvitegravir (rectal formulation, HIV infection); tenofovir disoproxil; tenofovir disoproxil fumarate; tenofovir alafenamide; tenofovir alafenamide hemifumarate; TRIUMEQ® (dolutegravir, abacavir, and lamivudine); dolutegravir, abacavir sulfate, and lamivudine; raltegravir; PEGylated raltegravir; raltegravir and lamivudine; lamivudine+lopinavir+ritonavir+abacavir; maraviroc; tenofovir+emtricitabine+maraviroc, enfuvirtide; ALUVIA® (KALETRA®; lopinavir and ritonavir); COMBIVIR® (zidovudine and lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine; ABC+3TC); TRIZIVIR® (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride; atazanavir sulfate and cobicistat; atazanavir and cobicistat; darunavir and cobicistat; atazanavir; atazanavir sulfate; dolutegravir; elvitegravir; ritonavir; atazanavir sulfate and ritonavir; darunavir; lamivudine; prolastin; fosamprenavir; fosamprenavir calcium efavirenz; etravirine; nelfinavir; nelfinavir mesylate; interferon; didanosine; stavudine; indinavir; indinavir sulfate; tenofovir and lamivudine; zidovudine; nevirapine; saquinavir; saquinavir mesylate; aldesleukin; zalcitabine; tipranavir; amprenavir; delavirdine; delavirdine mesylate; Radha-108 (receptol); lamivudine and tenofovir disoproxil fumarate; efavirenz, lamivudine, and tenofovir disoproxil fumarate; phosphazid; lamivudine, nevirapine, and zidovudine; abacavir; and abacavir sulfate. 
     In some embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase. In another specific embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In an additional embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer. In certain embodiments, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with at least one HIV nucleoside inhibitor of reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer. In another embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with two HIV nucleoside or nucleotide inhibitors of reverse transcriptase. 
     In a certain embodiment, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate. 
     In another embodiment, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate. 
     In yet another embodiment, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a first additional therapeutic agent selected from abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, and a second additional therapeutic agent selected from emtricitabine and lamivudine. 
     In yet another embodiment, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a first additional therapeutic agent selected from dolutegravir, cabotegravir, islatravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir, and a second additional therapeutic agent selected from emtricitabine and lamivudine. 
     In another embodiment, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a first additional therapeutic agent selected from tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, and a second additional therapeutic agent, wherein the second additional therapeutic agent is emtricitabine. 
     the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a first additional therapeutic agent (a contraceptive) selected from cyproterone acetate, desogestrel, dienogest, drospirenone, estradiol valerate, ethinyl Estradiol, ethynodiol, etonogestrel, levomefolate, levonorgestrel, lynestrenol, medroxyprogesterone acetate, mestranol, mifepristone, misoprostol, nomegestrol acetate, norelgestromin, norethindrone, noretynodrel, norgestimate, ormeloxifene, segestersone acetate, ulipristal acetate, and any combinations thereof. 
     Gene Therapy and Cell Therapy 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a gene or cell therapy regimen. Gene therapy and cell therapy include without limitation the genetic modification to silence a gene; genetic approaches to directly kill the infected cells; the infusion of immune cells designed to replace most of the patient&#39;s own immune system to enhance the immune response to infected cells, or activate the patient&#39;s own immune system to kill infected cells, or find and kill the infected cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against the infection. Examples of cell therapy include without limitation LB-1903, ENOB-HV-01, ENOB-HV-21, ENOB-HV-31, GOVX-B01, HSPCs overexpressing ALDH1 (LV-800, HIV infection), AGT103-T, and SupTI cell-based therapy. Examples of dendritic cell therapy include without limitation AGS-004. CCR5 gene editing agents include without limitation SB-728T, SB-728-HSPC. CCR5 gene inhibitors include without limitation Cal-1, and lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells (HIV infection/HIV-related lymphoma). In some embodiments, C34-CCR5/C34-CXCR4 expressing CD4-positive T-cells are co-administered with one or more fusion polypeptides. In some embodiments, the agents described herein are co-administered with AGT-103-transduced autologous T-cell therapy or AAV-eCD4-Ig gene therapy. 
     Gene Editors 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a gene editor, e.g., an HIV targeted gene editor. In various embodiments, the genome editing system can be selected from: a CRISPR/Cas9 complex, a zinc finger nuclease complex, a TALEN complex, a homing endonucleases complex, and a meganuclease complex. An illustrative HIV targeting CRISPR/Cas9 system includes without limitation EBT-101. 
     CAR-T-Cell Therapy 
     In some embodiments, the agents described herein can be co-administered with a population of immune effector cells engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises an HIV antigen binding domain. The HIV antigen include an HIV envelope protein or a portion thereof, gp120 or a portion thereof, a CD4 binding site on gp120, the CD4-induced binding site on gp120, N-glycan on gp120, the V2 of gp120, the membrane proximal region on gp41. The immune effector cell is a T-cell or an NK cell. In some embodiments, the T-cell is a CD4+ T-cell, a CD8+ T-cell, or a combination thereof. Cells can be autologous or allogeneic. Examples of HIV CAR-T include A-1801, A-1902, convertible CAR-T, VC-CAR-T, CMV-N6-CART, anti-HIV duoCAR-T, anti-CD4 CART-cell therapy, CD4 CAR+C34-CXCR4+CCR5 ZFN T-cells, dual anti-CD4 CART-T cell therapy (CD4 CAR+C34-CXCR4 T-cells), anti-CD4 MicAbody antibody+anti-MicAbody CAR T-cell therapy (iNKG2D CAR, HIV infection), GP-120 CAR-T therapy, autologous hematopoietic stem cells genetically engineered to express a CD4 CAR and the C46 peptide. 
     TCR-T-cell therapy 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a population of TCR-T-cells. TCR-T-cells are engineered to target HIV derived peptides present on the surface of virus-infected cells, for example ImmTAV. 
     B-Cell Therapy 
     In certain embodiments, the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, as disclosed herein, are combined with a population of B cells genetically modified to express broadly neutralizing antibodies, such as 3BNC117 (Hartweger et al, J. Exp. Med. 2019, 1301, Moffett et al., Sci. Immunol. 4, eaax0644 (2019) 17 May 2019). 
     8. Kits 
     Further provided are kits comprising one or more unitary doses of one or more of the fusion polypeptides or compound fusion polypeptides, as described herein, or one or more polynucleotides encoding such fusion polypeptides or compound fusion polypeptides, as described herein, or one or more vectors expressing such fusion polypeptides or compound fusion polypeptides, as described herein. In some embodiments, the kit comprises two or more unitary doses of one or more of the fusion polypeptides or compound fusion polypeptides, as described herein, or two or more polynucleotides encoding such fusion polypeptides or compound fusion polypeptides, as described herein, or two or more vectors expressing such fusion polypeptides or compound fusion polypeptides, as described herein. In some embodiments, the one or more unitary doses are in a single container. In some embodiments, the one or more unitary doses are in two or more separate containers. In certain embodiments, the unitary doses can be the same or different, e.g., can comprise the same or different unitary doses, e.g., can comprise polypeptides, polynucleotides, vectors or combinations thereof. 
     In various embodiments, the kit comprises one or more pharmaceutical packs or one or more containers (e.g., vials, ampules, pre-loaded syringes) containing one or more of the ingredients of the pharmaceutical compositions described herein, such as one or more of the fusion polypeptides, as described herein, or one or more polynucleotides encoding such fusion polypeptides, as described herein, or one or more vectors expressing such fusion polypeptides, as described herein. In various embodiments, the kit comprises one or more containers comprising the one or more of the fusion polypeptides, as described herein, or one or more polynucleotides encoding such fusion polypeptides, as described herein, or one or more vectors expressing such fusion polypeptides, as described herein, in an aqueous solution. In various embodiments, the kit comprises one or more containers comprising the one or more of the fusion polypeptides, as described herein, or one or more polynucleotides encoding such fusion polypeptides, as described herein, or one or more vectors expressing such fusion polypeptides, as described herein, in lyophilized form. 
     In some embodiments, the kit comprises one or more unitary doses of one or more viral vectors capable of expressing the fusion polypeptides. In some embodiments, the unitary doses of the one or more viral vectors are in the range of about 10 3  to about 10 12  viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g. from about 10 4  to about 10 7  viral FFU or PFU or IU or vp, e.g. from about 10 3  to about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14  or 10 15  viral FFU or PFU or IU or vp, per administration. 
     In some embodiments, the kit comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17;   SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11;   SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21;   SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17;   SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11;   SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19;   SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17;   SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11;   SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19;   SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19;   SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;   SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;   SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;   SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10;   SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10;   SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28;   SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19;   SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29;   SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29;   SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29;   SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29;   SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29;   SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or   SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11.       

     In some embodiments, the kit comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the kit comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. 
     In some embodiments, the kit comprises the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.       

     In some embodiments, the kit comprises first, second, third and fourth viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; 
     c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and 
     d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. 
     In some embodiments, the kit comprises first, second, third and fourth viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; 
     c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and 
     d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. 
     In some embodiments, the kit comprises first, second, third and fourth viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; 
     c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and 
     d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. 
     In some embodiments, the kit comprises first, second, third and fourth viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; 
     c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and 
     d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: 
     a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively, and 
     b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising polynucleotides encoding the following first compound fusion polypeptide and second compound fusion polypeptide: 
     a) a first viral vector comprising a polynucleotide encoding a first compound fusion polypeptide comprising SEQ ID NO: 105, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, and 
     b) a second viral vector comprising a polynucleotide encoding a first compound fusion polypeptide comprising SEQ ID NO: 109, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109. 
     In some embodiments, the kit comprises first and second viral vectors comprising polynucleotides encoding the following first compound fusion polypeptide and second compound fusion polypeptide: 
     a) a first viral vector comprising a polynucleotide encoding a first compound fusion polypeptide comprising SEQ ID NO: 107, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107, and 
     b) a second viral vector comprising a polynucleotide encoding a first compound fusion polypeptide comprising SEQ ID NO: 111, or a compound fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 111. 
     In some embodiments, the kit comprises the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers:
         SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively;   SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively;   SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively;   SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively;   SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively;   SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively;   SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;   SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively;   SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively;   SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively;   SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;   SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively;   SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;   SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively;   SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;   SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively;   SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively;   SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively;   SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;   SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively;   SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;   SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively;   SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;   SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively;   SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;   SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively;   SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;   SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively;   SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;   SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively;   SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively;   SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively;   SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively;   SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;   SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively;   SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;   SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;   SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively;   SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively;   SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;   SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively;   SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;   SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively;   SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;   SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively;   SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;   SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively;   SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;   SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively;   SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;   SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;   SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;   SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;   SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively;   SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;   SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively;   SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively;   SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or   SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.       

     In some embodiments, the kit comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the kit comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. 
     In some embodiments, the kit comprises the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide:
         SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;   SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;   SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;   SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;   SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;   SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;   SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;   SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;   SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;   SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;   SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;   SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;   SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;   SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;   SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;   SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;   SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;   SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;   SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;   SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;   SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;   SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;   SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;   SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;   SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;   SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;   SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;   SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;   SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;   SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;   SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;   SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;   SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;   SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;   SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;   SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or   SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.       

     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and 
     b) a second vector comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the first and second viral vectors are adenoviral vectors. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and 
     b) a second vector comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the first and second viral vectors are adenoviral vectors. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and 
     b) a second vector comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and 
     b) a second vector comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. 
     In some embodiments, the kit comprises first, second, third and fourth viral vectors, each vector comprising first and second polynucleotides:
         a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;   c) a third viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and   d) a fourth viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively.       

     In some embodiments, the kit comprises first, second, third and fourth viral vectors, each vector comprising first and second polynucleotides:
         a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;   c) a third viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and   d) a fourth viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some embodiments, one or more of the first, second, third and fourth viral vectors are adenoviral vectors.       

     In some embodiments, the kit comprises first, second, third and fourth viral vectors, each vector comprising first and second polynucleotides:
         a) a first viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;   b) a second viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;   c) a third viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and   d) a fourth viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively.       

     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising first and second polynucleotides comprising SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively, and 
     b) a second vector comprising first and second polynucleotides comprising SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising first and second polynucleotides comprising SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively, and 
     b) a second vector comprising first and second polynucleotides comprising SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In some embodiments, the kit comprises first and second viral vectors comprising the following first polynucleotide and second polynucleotide: 
     a) a first vector comprising a first polynucleotides comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and 
     b) a second vector comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 
     In some embodiments, the kit comprises a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the kit comprises a compound fusion polypeptide or a vector comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. 
     In various embodiments of the kits, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In various embodiments of the kits, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. 
     In some embodiments, the kits further comprise one or more unitary doses of one or more additional therapeutic agents. For example, in some embodiments, the kit comprises one or more agonists or activators of one or more toll-like receptors (TLRs). In some embodiments, the TLR agonist or activator is selected from a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR7 agonist, a TLR8 agonist and a TLR9 agonist. In some embodiments, the TLR7 agonist is selected from GS 9620 (vesatolimod), R848 (Resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from GS-9688 (Selgantolimod), R848 (Resiquimod) and NKTR-262 (dual TLR7/TLR8 agonist). 
     In some embodiments, the kit comprises one or more antagonists or inhibitors of an inhibitory immune checkpoint protein or receptor and/or one or more activators or agonists of a stimulatory immune checkpoint protein or receptor. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associating 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activating 3 (LAG3, CD223); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); retinoic acid early transcript IE (RAETIE; ULBP4); retinoic acid early transcript 1G (RAETIG; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activating 3 (CD223); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin like receptor C3 (KLRC3, NKG2E); killer cell lectin like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T-cell inhibitory immune checkpoint proteins or receptors are selected from CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). Lirilumab is an illustrative antibody that binds to and blocks KIR2DL1/2L3 receptors. In some embodiments, the kit comprises one or more agonists or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the T-cell stimulatory immune checkpoint proteins or receptors are selected from CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK-cell inhibitory immune checkpoint proteins or receptors are selected from killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A), e.g., monalizumab (IPH2201); and killer cell lectin like receptor D1 (KLRD1, CD94). In some embodiments, the kit comprises one or more agonists or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the NK-cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the proteinaceous or antibody inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4) and AK-104 (CTLA4/PD-1). In various embodiments, the co-administration of a proteinaceous or antibody inhibitor of CTLA4 increases the vaccine-induced T cell response in comparison to administration of the one or more fusion polypeptides, or polynucleotides encoding, lipoplexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides in the absence of a proteinaceous or antibody inhibitor of CTLA4. In some embodiments, the proteinaceous inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-013 (PD-1/LAG-3), FS-118 (LAG-3/PD-L1) MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), RO-7121661 (PD-1/Tim-3), XmAb-20717 (PD-1/CTLA4), AK-104 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1), and INBRX-105 (4-1BB/PDL1). In some embodiments, the one or more immune checkpoint inhibitors comprises a small molecule inhibitor of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. 
     In some embodiments, the kit comprises one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, and capsid inhibitors. 
     Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. 
     9. Methods of Designing Fusion Polypeptides Useful to Promote Antiviral Immune Responses 
     Provided are methods for designing a vaccine construct or an immunogen that is capable of eliciting an immune response in a human against one or more viral antigens. The immunogenic fusion polypeptides are designed employing a combination of computational, experiential and manual steps, and can be used to elicit an immune response against a highly variable virus. The design methods can be applied to creating an immunogen capable of inducing an immune response in a human against one or more viral antigens of a desired target virus, including without limitation human immunodeficiency virus (HIV), hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus (HSV), Ebola virus, Zika virus and Chikungunya virus. Generally, the immunogen design methods provide a vaccine construct designed for maximum epitope coverage of a broad-based population, referred to herein as a “population” construct or antigen. Usually, the segments comprising each of the constructs represent one or more MHC class I and/or MHC class II T cell epitopes. The population-based polypeptide segments can be combined and assembled into immunogenic fusion polypeptides. 
     Most of the steps can be performed in silico, but some steps can be performed manually (e.g., inclusion and/or exclusion selections of certain polypeptide sequences; selection of linker or linkers) and may incorporate information based on experimental data (e.g., experimentally determined MHC class II epitopes). The input information is a viral sequence data set (e.g., for HIV, internal and publicly available HIV population data sets). As summarized in the flow chart of  FIG. 1 , the vaccine design methods involve at least 2, e.g., at least 3 of the steps of:
         1. Identify conserved regions. All 9 amino acid segments (9-mers) are considered in naturally occurring viral sequences as potential T-cell epitopes. 9-mer positions having a conservation of at least 80% across interpatient viral populations, are identified as conserved regions and included for further analysis.   2. Build bivalent sequences from conserved regions. This can be done by employing a graph-based algorithm. 9-mers are assembled from conserved regions to include the maximum number of naturally occurring 9-mers.   3. Arrange polypeptide segments to reduce or avoid the creation of human-recognizable neoepitopes and cross-reactivities with human proteins at junctions. This can be done by evaluating 9-mers around junctions for MHC class I binding, cross-recognition with host (e.g., human, dog, cat, horse) proteins, and checking whether there are identical or substantially identical 9-mers between multiple antigen sequences if multiple insert sequences are developed simultaneously. As used herein, “substantially identical” 9-mers have at least 5 of 9 identical amino acid residues, e.g., have at least 55% (5 of 9), e.g., at least 65% (6 of 9), e.g., at least 75% (7 of 9), e.g., at least 85% (8 of 9) identical amino acid residues.       

     In one aspect, these methods comprise screening a set of candidate polypeptide segments of a population/conservation-based construct for MHC peptide binding affinity. MHC binding affinity can be predicted using one or more algorithms. Exemplary predictive algorithms include NetMHC (Vita et al. Nucleic Acids Res 2015 43:D405-D412), NetMHCpan (Andreatta and Nielsen Bioinformatics 2016 32:511-517), and MHCflurry (O&#39;Donnell et al. Cell Syst 2018 7:12-132). Other T-cell epitope prediction tools are publicly available and are described, for example in Sanchez-Trincado et al. J. Immunology Res. 2017 Article ID 2680160. Additional methods for identifying MHC binding peptides include those employing machine learning tools, for example, as described in U.S. Pat. No. 10,055,540, WO 2019/104203 and the “EDGE” tool described in Bulik-Sullivan et al. Nature Biotechnology 2019 37:55. 
     In some implementations, the disclosure provides methods for producing a bivalent population/conservation-based construct designed both to capture the unique diversity of a viral proteome (e.g., HIV proteome) by providing mathematically determined and improved coverage of all potential T cell epitopes and to ensure that the epitopes in each polypeptide of the pair of constructed polypeptides retain the positional information of the original input viral sequences, e.g., by retaining the same order of the polypeptide segments as found in the naturally occurring viral proteome. The epitopes of the resulting pair of polypeptides will therefore more closely resemble those of the naturally occurring viral sequences, increasing the likelihood of their eliciting a relevant T cell response. 
     Generally, the methods described here comprise initially providing a set of mathematically determined and improved potential T cell epitopes (“PTE”) in terms of their coverage of all PTEs in a population of viral proteome sequences, using a graph-based approach. Unlike similar graph-based approaches to vaccine design, the approach described here builds segments of connected PTE&#39;s using only adjacent PTE&#39;s that are also adjacent in the natural sequences. This provides constructs that retain the positional information of the PTE&#39;s within the source set of sequences. Also, unlike other graph-based approaches, the methods described here simultaneously build a bivalent construct to provide maximal coverage of the most highly conserved PTEs in the population. The result is an initial bivalent vaccine construct that advantageously maximizes highly conserved PTEs that are most likely to be highly similar to conserved epitopes in the natural sequences. Further advantageously, the use of only the most highly conserved PTEs reduces the likelihood of escape mutants because the highly conserved sequences are more likely to be essential for viral function. 
     The methods described herein generally begin with the identification of a conserved region bivalent sequences, using a process referred to herein as the “Conservation Analysis” or “Conservation Algorithm”. The methods further generally comprise a step of building a bivalent vaccine construct having maximal epitope coverage while retaining the positional information of the PTE&#39;s from the natural sequences, using a process referred to referred to herein as a “Conserved Walking Algorithm” or “CWA”. Thus, in some implementations, an initial step in the method is identifying a set of all conserved regions in a viral proteome for a selected set of viral genes. In implementations for designing a fusion polypeptide to elicit an immune response against HIV-1, the set of HIV-1 viral genes is selected from two or more of Gag, Pol and Nef. In some implementations, the set of viral genes consists of Gag, Pol and Nef. In some implementations, the set of viral genes consists of Pol and Nef. 
     In accordance with the methods described here, a population of viral proteome sequences is first aligned to a reference sequence, for example, the HIV reference sequence HXB2 identified by GenBank No. Accession K03455. Reference sequences for polypeptides encoded by the Gag, Nef and Pol genes are provided herein as SEQ ID NOs: 1-3, in Table A. The initial input or ‘source’ population of viral proteome sequences consists of sequences obtained from naturally occurring viruses. Such sequences are publicly available, for example, from the HIV Databases maintained by the Los Alamos National Laboratory, the U.S. Dept. of Health and Human Services, and the National Institutes of Health. In some implementations of the methods described herein, the source viral sequences may consist of sequences corresponding to a specific viral group and/or clade. In some implementations, in order to improve the identification of conserved regions and sequences, the input viral sequences may be restricted to a single viral clade and/or group. In some implementations, the input viral sequences are restricted to Group M clade B sequences. 
     The alignment of the source viral sequences to the reference sequence may be accomplished using a multiple alignment algorithm, for example, the fast Fourier transform algorithm, MAFFT. Katoh et al. 2002 Nucleic Acids Res. 30 (14):3059-66. The base MAFFT software is publicly available and distributed, e.g., under the Berkeley Software Distribution (BSD) license. 
     Next, the Conservation Algorithm is applied to the aligned sequences. For each sequence in the alignment, starting from the first amino acid position, the method shifts one amino acid position at a time and creates all possible amino acid segments that are 9 amino acids in length, referred to herein as “9-mers”. The algorithm thus creates, for each sequence in the alignment, a set of 9-amino acid subsequences (“9-mers”) starting with the N-terminal amino acid, each subsequence overlapping the preceding subsequence by eight amino acids such that each sequence of length 1 in the alignment contains (1-8) 9-mers. 
     Next, for each 9-mer position, the method identifies the two most common unique 9-mers and their prevalence in the aligned set of source viral proteome sequences. Stated another way, starting at position i the two most common unique 9-mers at each position are identified based on their frequency, calculated as the number of times the unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment. 
     Computationally, each sequence of length l, contains l-8 9-mers. We define all the 9-mers starting at position i as s ij  and frequency as f ij , j=1, 2, 3, . . . m. In total there are m unique 9-mers at position i. Each two unique 9-mers (s iu , s iv ) can constitute a 9-mer pair and its frequency is f iu +f iv . And each 9-mer itself can constitute a 9-mer pair as (s iu , s iv ) and its frequency is f iu . Thus, in total, there are m+(m−1)+(m−2)+ . . . +2+1=m*(m+1)/2 9-mer pairs at each position. 
     The method then calculates the bivalent conservation for each 9-mer position by summing up the proportions of aligned set of source viral proteome sequences containing either of the two most common 9-mers. To do this, a “bivalent conservation” is calculated for each position by summing the proportion of sequences in the alignment containing either of the two most common unique 9-mers. As used herein, “bivalent conservation” refers to the percentage of sequences containing exactly the same 9 amino acid segments (9-mers) as either of the two most prevalent ones in a 9-mer position. 
     Next, a new alignment of conserved regions is created by extracting the sequences in the alignment having a desired bivalent conservation, for example, a bivalent conservation of greater than 80% or greater than 90%, meaning that the two most common 9-mers at position i account for more than 80% or more than 90% of the 9-mers at that position in the new alignment of conserved regions. Stated another way, the method identifies the conserved regions in the new alignment as those in which the sum of the frequencies of the two most common 9-mers at each position is greater than a certain cutoff, e.g., greater than 80% or greater than 90%. Thus, the method also calculates the frequency of each pair of unique 9-mers at each position in the new alignment of conserved regions. 
     In some implementations, further selection criteria may be applied to the conserved regions, such as restricting to regions having greater than 90% conservation and removing short segments of less than 35 amino acids. 
     Using this modified set of conserved regions, certain implementations of the method apply the CWA to build bivalent sequence constructs. The CWA connects 9-mer pairs in adjacent positions of the alignment of conserved regions that share an overlap of eight amino acids. 
     Computationally, each 9-mer s contains 9 amino acids, we write s[x:y] to represent the amino acid subsequence from position x to y, y−x+1 amino acids in total:
         s iu [2:9]==s i+lp [1:8] and s iv [2:9]==s i+lq [1:8]
           or   
           s iu [2:9]==s i+lp [1:8] and s iv [2:9]==s i+lq [1:8].       

     Next, the algorithm builds a directed acyclic graph in which each 9-mer pair is a node and the edges between adjacent nodes are formed from the connected 9-mer pairs in the adjacent positions with the weight of each edge equal to the frequency of the downstream 9-mer pair. This directed acyclic graph is a positional De Brujin graph. Such graphs have been described in connection with assemblies of next generation sequencing data, for example as described in Ronen et al., Bioinformatics 2012 28:188-196. The method further adds a source node, connecting it with all of the nodes in the first position; and a sink node, connecting it with all of the nodes in the last position. The weights are then negated and the optimal path is found from the source node to the sink node, where the optimal path is defined as the path that has the largest sum of the frequencies of all 9-mer pairs among all the paths from the source node to the sink node. The task of finding the optimal path is performed, for example, using the Bellman-Ford algorithm. Generally, the Bellman-Ford algorithm computes the shortest paths from a single source vertex to all of the other vertices in a weighted directed graph which is made up of a set of vertices connected by edges, where the edges have a direction associated with them. The computational steps can be summarized as follows:
         (4-1) Treat each 9-mer pair as a node, and build edges between adjacent nodes in Step 3;   (4-2) Adding a source node and connect it with all the nodes at the 1st position;   (4-3) Adding a sink node and connect it with all the nodes at the last position;   (4-4) Weight of each edge equals to the frequency of downstream 9-mer pair;   (4-5) Negating all the weights and finding the optimal path using the Bellman-Ford algorithm.       

     A further step of the method is to build bivalent vaccine sequences based on the optimal bivalent 9-mer pair path and connect two 9-mers in adjacent positions within the optimal bivalent 9-mer pair path if they share an overlap of 8 amino acids. A bivalent construct is built by connecting two 9-mers in adjacent positions within the optimal bivalent 9-mer path if they share an overlap of eight amino acids, thereby creating two sequences of connected 9-mers which together form the bivalent construct. The connected adjacent 9-mer pairs all have an 8 amino acid overlap, so they will be assembled into two sequences. For example, one 9-mer pair (AIIIIIIIS (SEQ ID NO: 190),MIIIIIIII (SEQ ID NO: 191))canbe connected with another 9-mer pair (IIIIIIISK (SEQ ID NO: 192), IIIIIIIIR (SEQ ID NO: 184)) and make two sequences (bivalent sequences): AIIIIIIISK (SEQ ID NO: 193) andMIIIIIIIIR (SEQ ID NO: 194). 
     Computationally, the methodology can be described as a positional De Brujin graph based bivalent vaccine sequence design algorithm comprising the following 5 basic steps: 
     Step 1: align all the population sequences 
     Step 2: for each 9-mer position, pull out all the unique 9-mers and their frequencies, and build 9-mer pair sets with frequencies. Each sequence of length l, contains l-8 9-mers. We define all the 9-mers starting at position i as s ij  and frequency as f ij , j=1, 2, 3, . . . m. In total there are m unique 9-mers at position i. Each two unique 9-mers (s iu , s iv ) can constitute a 9-mer pair and its frequency is f iu +f iv . And each 9-mer itself can constitute a 9-mer pair as (s iu , s iv ) and its frequency is f iu . Thus, in total, there are m+(m−1)+(m−2)+ . . . +2+1=m*(m+1)/2 9-mer pairs at each position. 
     Step 3: connect 9-mer pairs in adjacent positions if they do not have any conflicting amino acids. As used herein, “conflicting amino acid residues” refers to different amino acid residues at overlapped positions between two 9-mers. Each 9-mer s contains 9 amino acids, we write s[x:y] to represent the amino acid subsequence from position x to y, y−x+1 amino acids in total:
         s iu [2:9]==s i+lp [1:8] and s iv [2:9]==s i+lq [1:8]
           or   
           s iu [2:9]==s i+lp [1:8] and s iv [2:9]==s i+lq [1:8].       

     Step 4: find the optimal path from the 1st 9-mer position to the last position in terms of the sum of the frequencies of all the 9-mers within the path. The basic idea is to model the maximum coverage bivalent vaccine construction problem as a classic graph theory problem where the solution is finding the minimum path in a directed acyclic graph. 
     Step 5: build bivalent vaccine sequences based on the optimal bivalent 9-mer pair path and connect two 9-mers in adjacent positions within the optimal bivalent 9-mer pair path if they share an overlap of 8 amino acids. Take for example the following cases: 
     Case 1: if s iu [2:9]=s i+lp [1:8] and s iv [2:9]=s i+lq [1:8], connect s iu  with s i+lp  and s iv  with s i+lq ; 
     Case 2: if s iu [2:9]=s i+lq [1:8] and s iv [2:9]=s i+lp [1:8], connect s iv  with s i+lq  and s iv  with s i+lp ; 
     Case 3: if s iu [2:9]=s i+lp [1:8] and s iv [2:9]=s i+lq [1:8] and s iu [2:9]=s i+lq [1:8] and s iv [2:9]=s i+lp [1:8], the selection of connection is based on the prevalence of the two connections in natural sequences: 
     Denote the prevalence of the co-existence of s ix  and s i+ly  in input sequences as C ixy    
     If C iup +C ivq &gt;C iuq +C ivp , connect s iu  with s i+lp  and s iv  with s i+lq ; 
     If C iuq +C ivp &gt;C iup +C ivq , connect s iu  with s i+lq  and s iv  with s i+lp ; 
     If C iup +C ivq =C iuq +C ivp , backtrack and combine the prevalence of the co-existence of 9-mer pairs in positions i−1 and i until the 1 st  position. If there is no difference between two different connections, randomly pick one. 
     In some implementations, the construct is further improved by performing a human proteome cross-recognition analysis, for example by a method comprising searching all of the 9-mers in the construct against a human proteome database such as UniProt to identify any 9-mers having a certain amino acid sequence identity with human peptides, e.g., at least 5 residues, or that share T cell receptor (TCR) facing residues with human proteins. Any such 9-mers may then be excluded from the construct. In some implementations, the polypeptide segments may optionally be rearranged to reduce or avoid deleterious junctional responses, for example by performing an HLA binding analysis, a human proteome cross-recognition analysis, or both, with respect to the junctional segments. Illustrative methods for reducing junction epitope presentation for neoantigens, in the context of designing anticancer vaccines, are described in WO 2019/104203. Alternatively, if multiple antigen sequences are developed, the polypeptide segments can be rearranged to avoid near-identical or identical 9-mers at junction between antigen sequences. 
     In some implementations, the conserved regions are further defined by performing one or more of the following steps in silico: (i) removing short polypeptide segments, e.g., polypeptide segments of 35 or fewer amino acids in length, e.g., 9-35 amino acids in length; (ii) removing segments that are weakly immunogenic or non-immunogenic in humans; (iii) removing segments that are less than 90% conserved, in certain instances, less than 80% conserved, amongst a predetermined population of sequences; (iv) including additional segments from HIV-1 proteins, e.g., Env, Gag, Nef and Pol, that are known to be immunogenic in humans (see, e.g., epitope maps at hiv.lanl.gov/content/immunology/maps/maps.html; Fischer, et al.,  Nat Med . (2007) 13(1):100-6; and Addo, et al.,  J Virol , (2003) 77(3):2081-92). 
     In some implementations, adjacent polypeptide segments may optionally be separated with a linker sequence, as described above. In some implementations, the linker sequence or sequences comprise a cleavable linker, optionally further comprising an additional linker sequence located adjacent to the cleavable linker. The additional linker may be another cleavable linker, a polyalanine linker, a polyglycine linker, a flexible linker, or a rigid linker, as described above and herein. In some embodiments, a furin recognition site precedes or is positioned N-terminal to a 2A cleavable linker. In a specific implementation, where the linker sequence comprises a foot-and-mouth disease virus (FMDV) cleavable peptide, FMDV 2A, or derivative thereof, the additional linker sequence may be a REKR (SEQ ID NO: 61) sequence, or derivative thereof. In some implementations, the linker is selected from a short polyalanine peptide, for example a peptide consisting of from 2 to 4 alanine residues, or having the sequence AAY (SEQ ID NO: 49) or AAX, where X is any amino acid residue (SEQ ID NO: 50). 
     In some implementations, the linker is inserted between each adjacent conserved region of the bivalent polypeptide. In some implementations, e.g., when no deleterious junctional epitope is created, no linker is inserted between adjacent segments of the same protein in the polypeptide. A linker can be inserted between adjacent segments of different proteins. 
     EXAMPLES 
     The following examples are offered to illustrate, but not to limit the claimed invention. 
     Example 1 
     Illustrated Implementation of the Conservation Analysis and Conserved Walking Analysis (CWA) to Generate a Bivalent Vaccine Construct 
     This Example describes the design of population-based bivalent polypeptide constructs by a specific implementation of the Conservation Analysis and CWA to generate a bivalent vaccine construct based on conserved protein regions encoded by the HIV-1 Gag, Nef and/or Pol genes. 
     First, we identified a set of all conserved regions in a viral proteome for a selected set of viral genes. In this example, the set of viral genes consisted of HIV-1 Gag, Pol, and Nef. 
     Computationally, the combination of the Conservation Algorithm and the CWA is a positional De Brujin graph based bivalent vaccine sequence design algorithm comprising the following 5 basic steps, illustrated in  FIG. 3 : 
     Step 1: Align a Set of Source Viral Proteome Sequences to a Reference Sequence. 
     In Step 1, a source population of viral proteome sequences was aligned to a reference sequence. In this example, the reference sequence used was the HIV-1 HXB2, identified by GenBank No. Accession K03455. The amino acid sequences of HXB2 reference polypeptides Gag, Nef and Pol are provided herein as SEQ ID NOs: 1, 2 and 3, respectively, in Table A. The source population of viral proteome sequences consists of sequences obtained from naturally occurring viruses. Such sequences are publicly available, for example, from the HIV Databases maintained by the Los Alamos National Laboratory, the U.S. Dept. of Health and Human Services, and the National Institutes of Health (hiv.lanl.gov), which was the database used for the source population of sequences in this example. For the purposes of illustration, we focused our analysis on a subset of the viral sequences, here, sequences of Group M Clade B. The alignment was performed using a multiple alignment algorithm, specifically a fast Fourier transform algorithm, MAFFT. Katoh, et al. (2002) Nucleic Acids Res. 30 (14):3059-66. The base MAFFT software is publicly available and distributed, e.g., under the Berkeley Software Distribution (BSD) license. 
     Step 2: for each 9-mer position, pull out all the unique 9-mers and their frequencies, and build 9-mer pair sets with frequencies 
     In Step 2, we applied the Conservation Algorithm to the set of aligned sequences. For each sequence in the alignment, starting from the first amino acid of the N-terminus, the algorithm shifts one amino acid position at a time to create a set of all possible amino acid segments that are 9 amino acids in length, referred to as “9-mers.” The algorithm thus created, for each sequence in the alignment, a set of 9-amino acid subsequences (“9-mers”) starting with the N-terminal amino acid, each subsequence overlapping the preceding subsequence by eight amino acids such that each sequence of length l in the alignment contains (1-8) 9-mers. 
     Next, for each 9-mer position, the method identified the two most common unique 9-mers and their prevalence in the aligned set of source viral proteome sequences. Stated another way, starting at position i the two most common unique 9-mers at each position were identified based on their frequency, calculated as the number of times the unique 9-mer occurred at position i in the alignment divided by the total number of sequences in the alignment. 
     Computationally, each sequence of length l, contained 1-8 9-mers. We defined all the 9-mers starting at position i as s; and frequency as f ij , j=1, 2, 3, . . . m. In total there were m unique 9-mers at position i. Each two unique 9-mers (s iu , s iv ) can constitute a 9-mer pair and its frequency is f iu +f iv . And each 9-mer itself can constitute a 9-mer pair as (s iu , s iu ) and its frequency is f iu . Thus, in total, there were m*(m+1)/2 9-mer pairs at each position. 
     The method then calculated the bivalent conservation for each 9-mer position by summing up the proportions of aligned set of source viral proteome sequences containing either of the two most common 9-mers. To do this, a “bivalent conservation” was calculated for each position by summing the proportion of sequences in the alignment containing either of the two most common unique 9-mers. 
     Next, a new alignment of conserved regions was created by extracting the sequences in the alignment having a desired bivalent conservation. In this example, we used a bivalent conservation of greater than 80% or greater than 90%, meaning that the two most common 9-mers at position i accounted for more than 80% or more than 90% of the 9-mers at that position in the new alignment of conserved regions. Stated another way, the method identified the conserved regions in the new alignment as those in which the sum of the frequencies of the two most common 9-mers at each position was greater than a certain cutoff, e.g., greater than 80% or greater than 90%. Thus, the method also calculated the frequency of each pair of unique 9-mers at each position in the new alignment of conserved regions. 
     This is illustrated graphically in  FIG. 4A .  FIG. 4A  shows a hypothetical set of 10 input natural sequences, each having a single amino acid variation within the first 9-mer. Across the set of 10 sequences, the 9-mer having an “L” at the third amino acid position occurs 6 times, the 9-mer having an “I” at that location occurs 3 times, and the 9-mer having an “I” at that location but a different amino acid in the first position occurs once. Thus, the Conservation Algorithm selected the two most prevalent 9-mers which together account for 90% of the possible 9-mers at that position in the population of aligned sequences. 
     Using this analysis, the distribution of highly conserved 9-mers at each position across all of the protein sequences in the population was determined. This is illustrated graphically in  FIG. 4B . The plot shows the conservation distribution for proteins encoded by the Gag gene p24 protein in 9,846 Group M Clade B input sequences obtained from the Los Alamos HIV Sequence database. The y-axis shows bivalent conservation and the x-axis shows the location of the 9-mer relative to the reference sequence, Gag p24 from HXB2. Across the top of the graph the horizontal bars depict conserved regions as those having at least 80% bivalent conservation using the two most prevalent 9-mers at each position. The dark gray line with the squares plots the bivalent conservation at each position using the two most prevalent 9-mers while the light gray line with the diamonds shows conservation using only the most prevalent 9-mer at each position. This analysis demonstrates that the use of the two most prevalent 9-mers improved the identification of structurally conserved sequences with an input population. 
     We next applied further selection criteria to define the conserved regions, including restricting to regions having greater than 90% bivalent conservation and removing short segments of less than 35 amino acids, e.g., segments 9-35 amino acids in length. 
     We also included some additional segments from certain regions having at least 80% bivalent conservation and known to be highly immunogenic, in particular, the region of Nef corresponding to amino acids 64-99 of the reference sequence HXB2_K03455 (see, e.g., epitope maps at hiv.lanl.gov/content/immunology/maps/maps.html; Fischer, et al.,  Nat Med . (2007) 13(1):100-6; and Addo, et al.,  J Virol , (2003) 77(3):2081-92). 
     Step 3: Connect 9-Mer Pairs in Adjacent Positions if they do not have any Conflicting Amino Acids. 
     Using this modified set of conserved regions, we applied the CWA to build bivalent sequence constructs. The CWA connects 9-mer pairs in adjacent positions of the alignment of conserved regions that share an overlap of eight amino acids. 
     Computationally, each 9-mer s contains 9 amino acids, and s[x:y] represented the amino acid subsequence from position x to y, y−x+1 amino acids in total:
         s iu [2:9]==s i+lp [1:8] and s iv [2:9]==s i+lq [1:8]
           or   
           s iu [2:9]==s i+lq [1:8] and s iv [2:9]==s i+lp [1:8].
 
Step 4: Find the Optimal Path from the First 9-Mer Position to the Last Position in Terms of the Sum of the Frequencies of all the 9-Mers within the Path.
       

     In Step 4, the algorithm built a directed acyclic graph in which each 9-mer pair was a node and the edges between adjacent nodes were formed from the connected 9-mer pairs in the adjacent positions with the weight of each edge equal to the frequency of the downstream 9-mer pair. This directed acyclic graph is a positional De Brujin graph. Such graphs have been described in connection with assemblies of next generation sequencing data, for example as described in Ronen et al.,  Bioinformatics  (2012) 28:188-196. 
     In the present example, we added a source node and connected it with all of the nodes in the first position; and we added a sink node and connected it with all of the nodes in the last position. In a directed graph, a source node was a node that only has out flow and a sink node was a node that only has in flow. Here, the source node was a dummy node that connects to all the 9-mer pair nodes in the first position, and the sink node was a dummy node that connects to all the 9-mer pair nodes in the last position. 
     We then negate all of the weights and find the optimal path from the source node to the sink node, where the optimal path is defined in terms of the sum of the frequencies of all 9-mer pairs. The task of finding the optimal path is performed, for example, using the Bellman-Ford algorithm. Generally, the Bellman-Ford algorithm computes the shortest paths from a single source vertex to all of the other vertices in a weighted directed graph. A directed graph is one made up of a set of vertices connected by edges, where the edges have a direction associated with them. 
     Computationally, the basic idea was to model the maximum coverage bivalent vaccine construction problem as a classic graph theory problem where the solution was finding the minimum path in a directed acyclic graph. The computational steps are summarized as follows:
         (4-1) Treat each 9-mer pair as a node, and build edges between adjacent nodes in Step 3;   (4-2) Adding a source node and connect it with all the nodes at the 1st position;   (4-3) Adding a sink node and connect it with all the nodes at the last position;   (4-4) Weight of each edge equals to the frequency of downstream 9-mer pair; and   (4-5) Negating all the weights and finding the optimal path using the Bellman-Ford algorithm.
 
Step 5: Build Bivalent Vaccine Sequences Based on the Optimal Bivalent 9-Mer Pair Path and Connect Two 9-Mers in Adjacent Positions within the Optimal Bivalent 9-Mer Pair Path if they Share an Overlap of 8 Amino Acids.
       

     In Step 5, a bivalent construct was built by connecting two 9-mers in adjacent positions within the optimal bivalent 9-mer path if they shared an overlap of eight amino acids, thereby creating two sequences of connected 9-mers which together form the bivalent construct. The connected adjacent 9-mer pairs all had an 8 amino acid overlap, so they were assembled into two sequences. For example, one 9-mer pair (AIIIIIIIS (SEQ ID NO: 190), MIIIIIIII (SEQ ID NO: 191)) was connected with another 9-mer pair (IIIIIIISK (SEQ ID NO: 192), IIIIIIIIR (SEQ ID NO: 184)) and made two sequences (bivalent sequences):AIIIIIIISK (SEQ ID NO: 193) and MIIIIIIIIR (SEQ ID NO: 194). 
     This method is illustrated graphically in  FIGS. 5A-5C .  FIG. 5A  shows a hypothetical set of 9 source viral sequences having, at the first position, 2 unique 9-mers and at the second adjacent position 3 unique 9-mers. The frequency of each sequence is indicated to the right of the sequence as ‘times’, e.g., “×5” means that sequence occurs 5 times in the source set.  FIG. 5B  depicts the building of the positional De Brujin graph in which each node is one bivalent 9-mer pair. Where two bivalent 9-mer pairs in adjacent positions shared an overlap of eight amino acids they were connected to build an edge. In this manner the directed acyclic graph was created.  FIG. 5C  illustrates the finding of the optimal path. As noted above, the optimal path was defined in terms of the sum of the frequencies of all 9-mer pairs. This was accomplished by finding the connection between adjacent 9-mers that provided the highest conservation with reference to the input sequences. Thus, in  FIG. 5C , connecting the two 9-mer pairs as shown in the top set of four pairs provided the following bivalent sequences, 
     
       
         
           
               
               
            
               
                   
                 GIIIIIIIIK (SEQ ID NO: 195) x0 
               
               
                   
                   
               
               
                   
                 AIIIIIIIIH (SEQ ID NO: 196) x0. 
               
            
           
         
       
     
     Neither of these sequences was present in the source sequences shown in  FIG. 5A . 
     In contrast, connecting the two 9-mer pairs as shown in the bottom set of four pairs in  FIG. 5C  provided the following bivalent sequences, 
                            GIIIIIIIIH (SEQ ID NO: 178) x3                       AIIIIIIIIK (SEQ ID NO: 177) x4.            
Each of these was present, 3 or 4 times, respectively, in the source sequences shown in  FIG. 5A . Accordingly, it is these second pairs of bivalent sequences that were selected by the algorithm because it maximized conservation relative to the source sequences.
 
     Computationally, this can be illustrated by the following exemplary cases: 
     Case 1: if s iu [2:9]=s i+lp [1:8] and s iv [2:9]=s i+lq [1:8], connect s iu  with s i+lp  and s iv  with s i+lq ; 
     Case 2: if s iu [2:9]=s i+lq [1:8] and s iv [2:9]=s i+lp [1:8], connect s iv  with s i+lq  and s iv  with s i+lp ; 
     Case 3: if s iu [2:9]=s i+lp [1:8] and s iv [2:9]=s i+lq [1:8] and s iu [2:9]=s i+lq [1:8] and s iv [2:9]=s i+lp [1:8], the selection of connection is based on the prevalence of the two connections in natural sequences: 
     Denote the prevalence of the co-existence of s ix  and s i+ly  in input sequences as C ixy    
     If C iup +C ivq &gt;C iuq +C ivp , connect s iu  with s i+lp  and s iv  with s i+lq ; 
     If C iuq +C ivp &gt;C iup +C ivq , connect s iu  with s i+lq  and s iv  with s i+lp ; 
     If C iup +C ivq =C iuq +C ivp , backtrack and combine the prevalence of the co-existence of 9-mer pairs in positions i−1 and i until the first position. If there is no difference between two different connections, randomly pick one. 
     This backtrack and co-existence prevalence approach considered prevalence of peptides longer than 9 amino acids and further differentiated the present algorithm from other graph-based methods. 
     Next, constructed sequences from regions not adjacent to one another in the natural sequence, that is, regions which could not be joined according to the CWA as described above due to their lacking an 8 amino acid overlap, were combined using one of three different linker strategies: 1. direct fusion without any linker; 2. insert ‘AAA’ (SEQ ID NO: 48) linker between each two conserved regions; 3. direct fusion without any linker for segments within the same protein and insertion of an F2A linker between segments from different proteins. 
     An overview of the Conserved Walking Analysis (CWA) method is shown in  FIGS. 1 and 2 . 
     Example 2 
     Illustrated Implementation of the Conservation Analysis and Conserved Walking Analysis (CWA) Applied to Proteins Encoded by HIV-1 Genes 
     This example describes a similar implementation based on conserved HIV-1 regions of (1) Gag, Pol and Nef or (2) Pol and Nef. 
     In Example 1 above, the Conservation algorithm was applied to identify a set of all candidate conserved regions in the protein coding regions of the target genes Gag, Nef and Pol. In this example, we utilized the protein coding regions of (1) Gag, Pol and Nef, (2) Pol and Nef to generate different bivalent constructs. As in Steps 1-2 of Example 1 above, we first aligned the source sequences and then applied the Conservation Algorithm to identify a set of all candidate conserved regions in the protein coding regions of the target genes, which were either from (1) Gag and Nef, Pol, or (2) Pol and Nef. As above, we then we applied further selection criteria based on conservation and known immunogenicity (see, e.g., epitope maps at hiv.lanl.gov/content/immunology/maps/maps.html and Fischer, et al.,  Nat Med . (2007) 13(1):100-6). In certain sequences including polypeptide segments encoding by the Pol gene, we excluded sequence segments including one or both of the “YMDD” motif (SEQ ID NO: 197) in reverse transcriptase and the “DTG” motif in protease, because they may affect one or both of the expression and maintenance of enzymatic activity. 
     Using this modified set of conserved regions, we applied the CWA to build bivalent sequence constructs, as in Steps 3-5 in Example 1. 
     Some polypeptide segments were connected by a polyalanine linker (e.g., AA, AAA (SEQ ID NO: 48) or AAY (SEQ ID NO: 49)), chosen for demonstration purposes because it is a small flexible linker that is unlikely to have a significant influence on protein structure. Some polypeptide segments were connected by natural short linkers (e.g., K, I, LI, EE, PPV, LIK, KIL, QEE, or SEG), chosen from the natural HIV protein sequences that flanking the conserved polypeptide segments to be fused. If we determined that it was possible to fuse polypeptide segments without creating a deleterious or undesirable junctional epitope, e.g., such as one that may stimulate T cells that may cross react to self-antigens, a fusion approach was used. If we determined that a deleterious or undesirable junctional epitope may be created, a flexible or natural short linker was inserted between polypeptide segments. 
     For this Example, we applied a further analysis of the junctional regions for possible presentation of deleterious epitopes and arranged the segments to reduce or avoid the creation of such junctional epitopes. 
     Different arrangements of peptide segments generate different junction 9-mers that can induce different junction responses. We developed a polypeptide segment arrangement tool to examine MHC binding affinities and cross-recognition with human peptides for all the junction 9-mers in each arrangement. Our internally developed polypeptide segment arrangement tool searched different arrangements of peptides and determined the best arrangement with minimal junction response based on in silico prediction results of applying the two analyses described below ((1) in-silico HLA binding analysis and (2) human proteome analysis to identify epitopes that may prime T cells that may recognize self-antigens) on the junctions of 9-mers. The junctional response score between each two adjacent segments was determined by the sum of the number of junction 9-mers that were predicted to have high binding affinities to target HLA alleles and the number of human proteins predicted to have peptides or T cell recognition motifs with any junction 9-mers. The score of each segment arrangement was determined by the sum of the junctional response scores for all the junctional regions in each segment arrangement.
         1) When there were less than 15 peptide segments, our internally developed polypeptide segment arrangement tool searched all the possible arrangements and determined the best one with minimal junction response (the lowest segment arrangement score).   2) When there were at least 15 peptide segments, our internally developed polypeptide segment arrangement tool uses a ‘greedy’ strategy. It first created all the junctions and then started from the best junction in terms of predicted junctional response. Next, it searched for the next compatible best junction iteratively and assembled all the peptide segments.       

     In-silico MHC class I (human HLA) binding analysis: Antigen processing, presentation, and T cell receptor recognition are complex processes that remain incompletely understood. Intracellular and extracellular antigens are processed within endosomal compartments, and the cytoplasm by the proteasome and trafficked to endosomal compartments such as the ER where they peptide fragments interact with MHC molecules. Stable peptide-MHC complexes are trafficked to the cell surface where they can be recognized by a T cell expressing a TCR with the appropriate specificity. One of the most selective steps in antigen processing and presentation is HLA binding. HLA binding affinities can be predicted using various tools such as NetNMC or MHCflurry, or large internal datasets derived from immunopeptidome analyses and confirmed by experimental binding data as well as epitopes defined from patient samples. These tools are publicly available and are described, for example, in Lundegarrd et al.,  Nucleic Acids Res.  2008 Jul. 1; 36(Web Server issue):W509-12 and O&#39;Donnell, et al.,  Cell Systems  2018 7:129-132. In this example we used NetNMC, version 4.0. The default settings were used for all the parameters in NetNMC, along with inputting information for peptide sequences and HLA alleles. Predicted binding affinities with an IC50 value less than 1,000 nM were considered as low binding affinities. 
     Human proteome cross-recognition analysis: Epitopes similar to human peptides may induce tolerogenic responses or responses that may cross-react with self-antigens. We searched all the 9-mers in our vaccine against public human protein databases (e.g., Uniprot, NCBI). If an HIV peptide 9-mer has at least a 5-residue amino acid sequence identity with a human peptide 9-mer, and both were predicted to have high binding affinities to the same alleles, they were considered as cross-conserved 9-mers. We downloaded all the human protein sequences from the UniProt database and built a tool to support efficient search of a given 9-mer against all the human protein 9-mers with up to 4 mismatches (at least 5 matches). 
       FIG. 6  illustrates the results of human proteome cross-recognition analysis. In this example, we searched HIV-1 peptide 9-mers over human protein databases and identified all the human protein 9-mers sharing a certain number of amino acids (at least 5 tentatively) and were predicted to have high binding affinities (e.g., IC50 of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments) to the same alleles based on the in silico MHC class I analysis described herein. Such HIV 9-mers having both substantial or high sequence identity (e.g., having at least 55% (5 of 9 amino acid residues), e.g., at least 65% (6 of 9 amino acid residues), e.g., at least 75% (7 of 9 amino acid residues), e.g., at least 85% (8 of 9 amino acid residues)) to a peptide segment of a human protein and high predicted MHC class I binding affinity were excluded because they may induce tolerogenic responses or responses that may cross-react with human self-antigens (defined herein as “deleterious epitopes”). 
       FIG. 7  illustrates how polypeptide segment arrangement analysis can reduce or eliminate possible presentation of deleterious or undesirable epitopes injunction regions. In the illustrated default arrangement, the junction 9-mers between Seg 2 and Seg 3, and between Seg 3 and Seg 4 were predicted to produce junctional sequences that may induce tolerogenic or self-reactive responses in a human (e.g., having either high MHC binding affinity based on in silico HLA binding analysis or cross-recognition with human proteins based on human proteome cross-recognition analysis). We applied an algorithm that searched different arrangements and determined an arrangement that results in reduced or eliminated predicted junctional sequences that may induce tolerogenic or self-reactive responses in a human. Additionally, if multiple antigen sequences were developed, the polypeptide segments were also rearranged to avoid identical or nearly identical 9-mers at junction between antigen sequences. 
     The fusion polypeptides and compound fusion polypeptides described herein are exemplary immunogenic fusion polypeptide sequences designed according to the herein described immunogen design methods. The fusion polypeptides of SEQ ID NOs: 70-101 (provided in Table E), particularly SEQ ID NOs: 94-101 (immunogen version 1), and the compound fusion polypeptides of SEQ ID NOs: 105-112, 200-209, 222-223 and 227 (provided in Table F), which have polypeptide segments encoding by the HIV-1 Gag, Nef and Pol genes, are exemplary immunogenic fusion polypeptide sequences designed according to this method.  FIG. 8  provides a schematic of viral vectors containing the fusion proteins of immunogen version 1. 
     Example 3 
     Immunogen Design Improved with Deep sequencing Analysis and Immunogenicity Data: Immunogen Version 2 
     In Example 1 above, the Conservation algorithm was applied to identify a set of all candidate conserved regions in the protein coding regions of the target genes Gag, Nef and Pol. In Example 2, we utilized the protein coding regions of (1) Gag, Pol and Nef, (2) Pol and Nef to generate different bivalent constructs. In this example, we describe the design of immunogen version 2 by incorporating both deep sequencing data and immunogenicity data to identify which conserved regions from immunogen version 1 to be included in shortened bivalent polypeptide constructs. For the design of this improved immunogen, as in Steps 1-2 of Example 1 above, we first aligned the source sequences and then applied the herein described conserved walking algorithm (CWA) to identify a set of all candidate conserved regions in the protein coding regions of the target genes. The target genes were Gag, Nef and Pol, and we applied the CWA to build bivalent sequences in those regions, as in Steps 3-5 of Example 1. 
     INTRA-patient Conservation Analysis using Deep Sequencing. In addition to the 9-mers derived from downloaded population sequences, we also analyzed viral deep sequencing data from HIV-1 subtype B chronically infected individuals to identify intra-patient diversity within those conserved regions. To identify intra-patient 9-mer variants using deep sequencing data, deep sequencing data of N=238 HIV chronically infected treatment-naïve subjects were analyzed to evaluate intra-patient diversity within conserved regions defined by CWA. To evaluate intra-patient 9-mer variants using deep sequencing data, deep sequencing reads were assembled to create subject-specific consensus sequence. Reads were aligned to subject-specific consensus sequence and then the alignment was mapped to HXB2 position coordinates based on alignment of subject-specific consensus to HXB2 reference sequence. At each 9-mer position, corresponding sequencing reads completely covering the 27 bp of the 9-mer were extracted and converted into 9-mer amino acid sequences. Only 9-mer positions with ≥1000 sequencing read depth were included in the analysis and variants were analyzed with a 1% frequency cutoff. The 9-mer variants were used to evaluate the bivalent vaccine sequences for coverage of quasi-species variants. Here we defined the intra-patient conservation of a 9-mer position as percentage of patients (Total N=238 samples) that were covered by the bivalent vaccine sequences without escape variants. High intra-patient conserved 9-mers are the 9-mers that were covered by bivalent population-based vaccine sequences without any escape variants in &gt;70% patients. The intra-patient conservation was evaluated for the regions of Pol, Gag, and Nef that were selected based on population conservation as described in Example 1. 
       FIG. 10  provides a flow diagram illustrating the basic methodology of the approach for designing immunogen version 2. The fusion polypeptides of SEQ ID NOs: 82-89 are illustrative amino acid sequences designed according to this method. 
     Known epitopes from Los Alamos National Laboratory (LANL) database and Gilead ELISPOT Assay Identified Epitopes. To evaluate immunogenicity of the previously identified conserved regions, described CD8+ T-cell epitopes (e.g., from LANL database) and internally conducted ELISpot assays were analyzed. Any 9-mer positions in conserved regions of Pol, Gag, and Nef with &gt;1 mapped epitope defined by ELISPOT assay or from LANL database were considered as an immunogenic region. Immunogenicity results were not limited to specific HLA alleles. 
       FIGS. 10A-10C  illustrate the regions that were selected for immunogen version 2 by combining deep sequencing data and immunogenicity data. The intra-patient conservation is represented as the black horizontal lines for each 9-mer position in the plot. The number of epitopes overlapped at each 9-mer region is shown as stacked bar in the plot. We selected the amino acid 9-mers that have intra-patient conservation &gt;70% and overlap with epitopes reported by LANL database or defined by ELISpot assay. After identifying the amino acid 9-mers to use for the improved immunogen, those 9-mers that were from the same viral protein and contiguous were connected (e.g., via a linker or directly fused) to form fusion amino acid segments as highlighted in the plot. 
     We utilized the protein coding regions of (1) Gag and Pol, (2) Pol and Nef to generate different bivalent constructs. In a final step, we applied our internally developed polypeptide segment arrangement tool described in Example 2 on the segments to reduce or eliminate possible presentation of deleterious or undesirable epitopes injunction regions. We anchored Nef conserved sequence to the C-terminus of the vaccine sequence during segment rearrangement for immunogen 2, because our previous experiments showed that positioning a Nef segment on the C-terminus of the vaccine sequences was more likely to induce immune responses.  FIG. 11  provides a schematic of viral vectors containing the fusion proteins of immunogen version 2 (e.g., SEQ ID NOs: 82-89). 
     Median response and epitope density of the improved immunogen design. To assess whether the shortened immunogen is enriched with immunogenic regions, we compared the number of internally defined epitopes per sample between the fusion proteins designed according to the methods of Examples 1-2 (e.g., immunogen version 1; SEQ ID NOs: 94-101) and the fusion proteins designed according to the methods of Examples 1-3 (e.g., immunogen version 2; SEQ ID NOs: 82-89).  FIGS. 12A-12B  illustrate the median responses remain stable with size modification. Total of 93 samples were analyzed. We measured the median number of epitopes identified in each sample. The median number of epitopes of immunogen version 2 is 4 while the median number of epitopes of immunogen 1 is 5. Two non-responders were observed using shorter immunogen version 2. Epitope density was examined by assessing epitope rate. The epitope rate was defined as the number of in vitro clinical trial defined epitopes divided by the total potential epitopes in the immunogen. As illustrated in Table 1, the epitope rate analysis results demonstrate that we maximized the epitope density after size reduction of the fusion proteins of immunogen version 1 (516-527 amino acids in length) to the fusion proteins of immunogen version 2 (351-365 amino acids in length). The epitope rate of immunogen version 1 was maintained in immunogen version 2. We define the epitope rate as the percentage of all 9-mers that are recognized as epitopes by ELISpot assay (Total number of epitopes/the number of 9-mer positions). 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Epitope Rate Analysis Between Immunogen Versions 1 and 2 
               
            
           
           
               
               
               
            
               
                   
                 Immunogen version 1 
                 Immunogen version 2 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Number of 
                 Number of 
                   
                 Number of 
                 Number of 
                   
               
               
                   
                 unique 
                 9mer 
                 Epitope 
                 unique 
                 9mer 
                 Epitope 
               
               
                 Gene 
                 epitopes 
                 positions 
                 rate (%) 
                 epitopes 
                 positions 
                 rate (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Gag 
                 64 
                 259 
                 24.71 
                 53 
                 215 
                 24.65 
               
               
                 Nef 
                 13 
                 50 
                 26.00 
                 2 
                 5 
                 40.00 
               
               
                 Pol 
                 107 
                 572 
                 18.71 
                 84 
                 419 
                 20.04 
               
               
                 Total 
                 184 
                 881 
                 20.89 
                 138 
                 639 
                 21.60 
               
               
                   
               
            
           
         
       
     
     Example 4 
     Shortened Construct Suitable for Expression from Single Priming Vector and Single Boosting Vector: Immunogen Version 3 
     In this Example, as in Steps 1-2 of Example 1 above, we first aligned the source sequences and then applied the CWA to identify a set of all candidate conserved regions in the protein coding regions of the target genes. In this example, the target genes were Gag, Nef and Pol. We applied the CWA to build bivalent sequences in those regions, as in Steps 3-5 of Example 1. 
     As Example 3 above, we applied deep sequencing and immunogenicity data to identify a subset of highly conserved and immunogenic regions within immunogen version 1 to retain in a shortened immunogen.  FIG. 13  provides a flow diagram illustrating the basic methodology of the fusion polypeptides of immunogen version 3. SEQ ID NOs: 90-93 are illustrative fusion polypeptides designed according to this method. We utilized the same method described in Example 3 to design the shortened bivalent fusion polypeptides of immunogen version 3 (391-394 amino acids in length) of a length such that four fusion polypeptides could be expressed from two virus vectors (e.g., two arenavirus vectors). Immunogenicity data showed that Gag p24 and Nef segment (64-76) elicited strong immune responses, so Nef 64-76 was retained in Immunogen version 3. For Pol, as above, we identified the continuous regions in Pol that have intra-patient conservation &gt;75% and contain multiple epitopes defined by in vitro assay. The  FIGS. 14A-14D  illustrate the regions selected for immunogen 3. We utilized the protein coding regions of (1) Gag and Pol, (2) Pol and Nef to generate different bivalent constructs. In a final step, we applied our internally developed polypeptide segment arrangement tool described in Example 2 on the segments to reduce or eliminate possible presentation of deleterious or undesirable epitopes injunction regions. A conserved subsequence of Nef was positioned at the C-terminus of the immunogen version 3 fusion polypeptides.  FIG. 15  provides a schematic of viral vectors containing the fusion proteins of immunogen version 3 (e.g., SEQ ID NOs: 90-93). 
     Example 5 
     Viral Expression Vectors Containing Immunogenic Fusion Polypeptides in Immunogen 1 
     In this example, we generated viral expression vectors encoding the computationally defined polypeptide segments containing conserved regions of HIV-1 encoded by Gag, Nef and Pol genes as a transgene and confirmed expression of the transgene in mammalian cells. The polypeptide segments containing conserved regions were concatenated or connected by a variety of approaches including direct fusion, linkage of regions by the addition of a proteolytic cleavage site sequence or the addition of a flexible linker between regions 
     Methods 
     Evaluation of target gene expression in vitro. To improve assembly of viral vectors encoding the vaccine expression cassette, the genes were cloned into vector plasmids (ThermoFisher Scientific) containing restriction sites for cloning target genes and a GFP marker. DNA was transformed into One Shot™ TOP10 competent cells (Invitrogen, Carlsbad, Calif.) following manufacturer&#39;s protocol and plated onto LB agar plate supplemented with 100 pg/ml ampicillin. The plate was incubated overnight at 37° C. A single colony was picked from the plate and inoculated into a 10 ml liquid LB+ampicillin culture and shaken overnight at 37° C. at 250 rpm in an Eppendorf bench top shaker. The bacterial pellet was processed using QIAprep Spin miniprep kit (Qiagen, Germantown, Md.) to obtain the plasmid DNA following manufacturer&#39;s protocol. Nucleic acid concentration was determined by reading absorbance at 280 nm using NanoDrop™2000 (Thermo Scientific). To evaluate in vitro expression, the Adenovirus serotype 5 (Ad5) expression vectors expressing a compound fusion protein of SEQ ID NO: 105, 107, 109 or 111 were used to transduce monocyte derived dendritic cells (moDCs) as outlined in Example 9 below. At day 2 post-transduction, when the viability of cells was still at &gt;80%, they were evaluated for GFP expression by flow cytometry or pelleted. The cell lysates were evaluated for HIV-1 Gag p24 expression by ELISA. 
     Construction of viral expression vector containing transgene encoding fusion polypeptide variants. Ad5 vectors expressing an HIV-1 computationally defined vaccine immunogen with various approaches to linkage of conserved HIV-1 sequences, were generated by in vitro recombination using standard methods (Vector Biolabs). Expression cassettes were generated by PCR using synthetic oligonucleotides codon-biased for improved human expression (IDT), and placed under the control of the CMV promoter using standard gene cloning techniques. The immunogen version 1 compound fusion polypeptide constructs developed for this evaluation are listed in Table F and schematically depicted in  FIG. 19 . 
     Results 
     The data depicted in  FIG. 20  demonstrate that all conserved region fusion polypeptide sequences were efficiently expressed ( FIG. 20A ) and transduced ( FIG. 20B ) as demonstrated by GFP expression and Gag p24 ELISA. 
     Example 6 
     Viral Expression Vectors Containing Immunogenic Fusion Polypeptides in Immunogen 2 
     This example evaluates target gene expression in vitro and construction of Ad5 viral expression vectors. Similar strategy was adopted for evaluating the expression of conserved regions HIV Immunogen 2 (SEQ ID NO: 82-89) as described above in Example 5 for immunogen version 1 fusion polypeptides. The immunogen version 2 fusion polypeptide constructs are listed in Table E and schematically depicted in  FIG. 21 . 
     Results 
     The data depicted in  FIGS. 22A-22B  demonstrate that all conserved region polypeptide sequences resulted in the efficient expression ( FIG. 22A ) and transduction ( FIG. 22B ) of polynucleotides encoding the fusion polypeptides of SEQ ID NOs: 82-89. 
     Example 7 
     Viral Expression Vectors Containing Immunogenic Fusion Polypeptides in Immunogen 3 
     This example evaluates target gene expression in vitro and Construction of Ad5 viral expression vectors. Similar strategy was adopted for evaluating the expression of conserved regions HIV Immunogen 3 (SEQ ID NO: 90-93) as described above in Example 5 for the fusion polypeptides of immunogen version 1. The immunogen version 3 fusion polypeptide constructs are listed in Table E and schematically depicted in  FIG. 23 . 
     Results 
     The data depicted in  FIGS. 24A-24B  demonstrate that all conserved region polypeptide sequences resulted in the efficient expression ( FIG. 24A ) and transduction ( FIG. 24B ) of polynucleotides encoding the fusion polypeptides of SEQ ID NOs: 90-93. 
     We then tested the efficiency of these constructs in various viral vector systems to prime T cell responses in vitro and in vivo. 
     Example 8 
     In Vivo T Cell Activation Assays 
     In this example, we evaluated the efficacy of in vivo T cell priming by vaccine constructs in a mouse model. To do this, we immunized groups of mice with Ad5 vectors expressing computationally defined conserved regions vaccine immunogen sequences. We investigated the magnitude and functional phenotype of those responses to determine the immunogenicity of the vaccine sequences. 
     The vaccines were administered in a homologous (with respect to viral expression vector) prime-boost approach. Each viral Ad5 vector in the prime-boost pair had different rearrangements of the HIV gene segments encoded in the fusion polypeptide construct. This gene rearrangement reduced or eliminated the formation of junctional responses. Vectors may differ in the size of transgene that they can stably express. In the design of the vaccine immunogens two complementary fusion polypeptides of less than 600 amino acids in length each were expressed from a single viral vector. Vectors that can accommodate larger transgenes may combine two segments, e.g., using an F2A linker (described herein as “compound fusion polypeptides;” see Table F). We tested the immunogenicity of each individual fusion polypeptide sequence in a priming sequence, and again in a prime-boost sequence using vectors expressing compound fusion polypeptides with and without the F2A linker. Vectors that contained F2A linker also had an N-terminal tissue plasminogen (t-PA) signal peptide sequence (MDAMKRGLCCVLLLCGAVFVSAR (SEQ ID NO: 121)). The immunogen version 1 fusion polypeptide constructs are listed in Table E and schematically depicted in  FIG. 25 . The immunogen version 1 compound fusion polypeptide constructs are listed in Table F and schematically depicted in  FIG. 19 . 
     Methods 
     In Vivo Evaluation of Immunogenicity 
     Immunizations. Five or six-week-old Balb/c mice were immunized with 1×10 9  PFU of Ad5 vectors expressing HIV immunogens by intramuscular (I.M.) injections in both hind leg muscles. The vaccine vector was administered in 100 μl of phosphate-buffered saline (PBS) injections (50 μl per quadriceps). Mice were anesthetized with isoflurane prior to vaccine immunization. Animals were housed at the animal facility (Bioqual, Maryland) and experiments were performed according to approved IACUC protocol. A schematic of the regimen is provided in  FIG. 26 . 
     Single vector immunogenicity. Mice were randomly assigned into 8 groups and were primed with 1×10 9  PFU of Ad5 vectors expressing HIV immunogens (SEQ ID NOs: 94-101, schematically depicted in  FIG. 25 ) by intramuscular (I.M.) injections in both hind leg muscles and rested for 16 days before splenocytes were harvested. Immunogenicity was evaluated by analyzing splenocytes by IFN-γ ELISpot assay as previously described (Miyahira, et al.,  J Immunol Methods , (1995) 181(1):45-54). 
     ELISpot Assays. Pre-coated strip ELISpot plates (Cellular Technologies Limited) were used for all ELISpot analyses. Briefly, 2×10 5  splenocytes from immunized animals were seeded to each well. Peptide pools having 15-mer peptides overlapping by 11 amino acid residues spanning the HIV Gag, Pol and Nef conserved regions sequences were used in IFN-γ ELISpot assays to evaluate vaccine immunogenicity. 2.5 ng/ml PMA and 250 ng/mL ionomycicn as well as 1 μg/mL ConA were used as positive controls. Plates were incubated at 37° C. in 5% CO 2  overnight and up to 18 hrs. After overnight stimulation, the cells were removed from the plates and the wells were washed two times in PBS prior to two washes with PBS containing 0.05% tween. Biotinylated anti-IFN-γ detection antibody was then added to the plates for 2 hours at room temperature. The plates were then washed three times with PBS containing 0.05% tween prior to the addition of streptavidin-conjugated alkaline phosphatase (AP). Wells were then washed two times with 0.05% tween-PBS and then two times with distilled water prior to the addition of the blue developer solution. The plates were then incubated at room temperature for 15 minutes before the reaction was stopped using tap water. The wells were then dried overnight and spot forming units (SFUs) were counted on an Immunospot ELISpot reader. The settings were identical for all plates and counts were expressed at SFU per 10 6  splenocytes. A schematic of the vector variants is provided in  FIG. 25 , the immunization regimen is provided in  FIG. 26 , and the results are shown in  FIGS. 27-28 . 
     Homologous prime-boost. Mice were randomly allocated into 6 groups. Groups 1 and 2 mice were immunized with 1×10 9  PFU of Ad5 vectors expressing bivalent fusion polypeptides of SEQ ID NO: 105 (Seq 94-F2A-95) and SEQ ID NO: 109 (Seq 98-F2A-99) having N-terminal t-PA leader sequences, respectively, by intramuscular (i.m.) injections in both hind leg muscles and rested for 16 days before splenocytes were harvested. Groups 3 and 4 mice were immunized with 1×10 9  PFU of Ad5 vectors expressing bivalent fusion polypeptides of SEQ ID NO: 107 (Seq 96-F2A-97) and SEQ ID NO: 111 (Seq 100-F2A-101) having N-terminal t-PA leader sequences, respectively, by i.m. injections in both hind leg muscles and rested for 16 days before splenocytes were harvested. 
     Group 5 and 6 mice were immunized with 1×10 9  PFU of Ad5 vectors Seq-94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 96-F2A-97 (tPA-SEQ ID NO: 107) expressing HIV immunogens utilized in Group 1 or 3 respectively, by i.m. injections in both hind leg muscles and rested for 29 days before homologous boost with vectors expressing the same antigens but rearranged to minimize junctional responses (Seq 98-F2A-99 (tPA-SEQ ID NO:109) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) immunogens utilized in Group 2 and 4 respectively). Immunogenicity and cellular phenotype were evaluated by analyzing splenocytes on Day 36 by ELISpot assay as previously described (Miyahira, et al.,  J Immunol Methods , (1995) 181(1):45-54), ICS by flow cytometry was conducted at day 16 after prime and day 36 after prime/boost. A schematic of the vector variants is provided in  FIG. 19 , the immunization regimen provided in  FIG. 29  and results are shown in  FIGS. 30-31 . 
     Flow cytometry. Cell counts for prepared single-cell suspensions were determined using a hemacytometer. 1×10 6  cells/condition were stimulated with relevant HIV peptides in the presence of Golgi plug for a total of 6 hr (no more than 18 hrs). Washed cells were surface stained with live dead Aqua (Thermo fisher L34957) dye first and incubated with a mixture of fluorescence-conjugated anti-mouse antibodies for 20 min at 4° C. CD3 APC-Cy7 clone 17A2, CD4 PE-Cy7 clone GK 1.5, CD8 percp-Cy5.5 clone 53-6.7 were used for surface staining. After surface staining, cells were fixed and permeabilized in preparation for intracellular cytokine staining. Briefly, 1×10 6  cells already stained with surface antibodies were incubated with 200 μl BD cytofix/cytoperm buffer for 25 minutes on ice. Subsequently, cells were washed twice with 200 μl 1XPerm buffer each time and were then incubated with a cocktail of antibodies diluted in 100 μl of Perm buffer per 1×10 6  cells. A cocktail of fluorophore-conjugated anti mouse anti-IFN-γ APC clone XMG1.2, anti-IL-2 PE clone JES6-5H4 and anti-TNF-α FITC clone MP6-XT22 were used for intracellular cytokine staining. Permeabilized cells were then washed with 100 μl Perm buffer twice and immediately analyzed on MACSQUANT 10 Analyzer using MACS Quantify version 2.13 (Miltenyi Biotech) and analyzed using FlowJo software version 10.7 (TreeStar). 
     Results 
     The various viral Ad5 vector constructs expressing immunogen version 1 fusion polypeptides (SEQ ID NOs: 94-101; depicted in  FIG. 25 ) were effective in priming a T cell response. Immunogenicity of these sequences was studied in a Balb/C mouse model by IM immunization as shown in  FIG. 26 . 
     Priming bivalent fusion polypeptides SEQ ID NOs: 94-95 and boosting bivalent fusion polypeptides SEQ ID NOs: 98-99 having HIV-1 Gag, Pol and Nef sequence segments induced robust responses to HIV-1 Gag ( FIG. 27A (i and ii), with weaker but detectable responses to Pol proteins (protease, RT and integrase, ( FIG. 27A (iii to vi). No responses were detected to HIV-Nef ( FIG. 27A (vii and viii) in this model likely due to previously described immunodominance patterns for HIV-1 Gag epitopes in Balb/c mice and reflecting the lack of Nef epitopes that can be presented in Balb/c mice. 
     Priming bivalent fusion polypeptides SEQ ID NOs: 96-97 and boosting bivalent fusion polypeptides SEQ ID NOs: 100-101 having HIV-1 Pol and Nef induced robust responses to HIV-1 Pol, especially protease and RT ( FIG. 28 ( i  and  ii ), with weaker responses to Pol integrase ( FIG. 28 ( iii  and  iv ). Responses to HIV-Nef ( FIG. 28 ( v  and  vi ) were also not seen with this set of sequences corroborating the observations from previous set of sequences ( FIG. 27A (vii and viii)). 
     To test if combining these bivalent construct sequences designed to ensure coverage of &gt;80% of circulating HIV-1 viral sequences into a single construct affects immunogenicity, individual sequences were combined using an F2A linker as shown in  FIG. 19  (SEQ ID NOs: 105, 107, 109 and 111). The compound fusion polypeptides each had an N-terminal tPA leader sequence. Bivalent fusion polypeptide pairs, SEQ ID NOs: 94 and 95 were combined into Seq 94-F2A-95 (tPA-SEQ ID NO: 105), SEQ ID NOs: 96 and 97 were combined into Seq 96-F2A-Seq 97 (tPA-SEQ ID NO: 107), SEQ ID NOs: 98 and 99 were combined into Seq 98-F2A-Seq 99 (tPA-SEQ ID NO: 109) and SEQ ID NOs: 100 and 101 were combined into Seq 100-F2A-Seq 101 (tPA-SEQ ID NO: 111), respectively. 
     To test immunogenicity, these combined sequences were tested by IM immunization in Balb/C mice ( FIG. 29 ), as single vectors in a prime only mode ( FIG. 30A  and in a homologous prime boost combination mode ( FIG. 30B ). Sequences Seq 94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 98-F2A-99 (tPA-SEQ ID NO: 107) were used as bivalent fusion polypeptides having HIV-1 Gag, Pol and Nef sequence segments and were tested as prime and boost sequences in homologous vector prime boost combination mode. Seq 96-F2A-97 (tPA-SEQ ID NO: 109) and Seq 100-F2A-Seq 101 (tPA-SEQ ID NO: 111) were used as bivalent fusion polypeptides having HIV-1 Pol and Nef and were tested as prime and boost sequences in homologous vector prime-boost combination mode. The priming and boosting fusion polypeptides encode similar regions but are rearranged in order to reduce or eliminate creation of de novo epitopes that resemble epitopes from the human proteome and to reduce or eliminate boosting of junctional responses in prime boost sequences. 
     Combined sequences Seq 94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 98-F2A-99 (tPA-SEQ ID NO: 109) when tested for immunogenicity either as single prime or in a prime/boost combination were immunogenic ( FIG. 31A , responses to HIV-Gag(i), Pol (protease and RT(iii), Pol (integrase(v)) and Nef(vii) respectively and  FIG. 27  HIV-1 Gag(i and ii), Pol (protease, RT and integrase(iii to vi) and Nef(vii and viii). Bivalent sequences concatenated with F2A did not inhibit their immunogenicity. Overall, responses to HIV-1 Gag were robust with weaker but detectable responses to Pol proteins (protease, RT and integrase) and minimal responses to HIV-Nef. Responses induced by priming sequence Seq 94-F2A-95 (tPA-SEQ ID NO: 105) were enhanced by boosting sequence Seq 98-F2A-99 (tPA-SEQ ID NO: 109), especially for Pol (integrase) ( FIG. 30B (vi) and Nef ( FIG. 30B (viii). No responses were generated to the F2A and tPA sequences. 
     Combined sequences Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) when tested for immunogenicity either as single prime or in a prime/boost combination were immunogenic, inducing robust responses to HIV-1 Pol, particularly protease and RT, with weaker responses detected toward integrase ( FIG. 31A  (i to iv). Magnitude of IFN-γ ELISpot responses induced by the combination vector Seq 96-F2A-97 (tPA-SEQ ID NO: 107) to Pol (protease and RT,  FIG. 31B (i) were weaker than responses previously observed individual vectors expressing a fusion polypeptide of SEQ ID NO: 96 or 97 ( FIG. 28( i ) . The responses were boosted in sequential dosing with Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) ( FIG. 31B (ii). The responses induced by priming sequence Seq 96-F2A-97 (tPA-SEQ ID NO: 107) were enhanced by boosting sequence Seq 100-F2A-101 (tPA-SEQ ID NO: 111) against both Pol (integrase) ( FIG. 31B (iv) and Nef ( FIG. 31B (vi)). 
     The ability to produce cytokines is a functional measure of effector and memory CD4+ and CD8+ T cells. We evaluated the phenotypic and functional characteristics of CD4+ and CD8+ T cell responses generated following immunization with Ad5 vectors expressing compound fusion proteins of SEQ ID NOs: 105, 107, 109 or 111, using both single vector prime immunization and homologous prime/boost immunization. Responses were measured using ICS and Flow cytometry. 
       FIGS. 32-35  show immunogenicity against HIV-1 Gag, Pol and Nef antigens by intracellular cytokine staining (ICS) following single vector immunization with Seq 94-F2A-95 (tPA-SEQ ID NO: 105), or Seq 98-F2A-99 (tPA-SEQ ID NO: 109), and by homologous vector prime-boost immunization. The Y axis represents proportion of CD8+ (i, ii and iii) or CD4+ (iv, v and vi) T cells exhibiting HIV-1 Gag ( FIG. 32 ), Pol (protease and RT) ( FIG. 33 ), Pol (integrase ( FIG. 34 ) and Nef ( FIG. 35 ) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X axis. Antigen specific values were obtained by subtracting no antigen stimulated control to exclude nonspecific responses. Strong HIV-1 Gag specific CD8+ and CD4+ T cell responses were seen in response to vaccination, with demonstrated polyfunctionality most robust in CD8+ T cells. Homologous prime-boost enhanced polyfunctionality of the CD8+ T cell responses. Even though generated, the Pol (protease, RT and integrase) specific and Nef specific CD8+ and CD4+ T cell responses produced after vaccination were weaker than Gag responses and tend to be monofunctional, with limited boosting. 
       FIGS. 36-38  show immunogenicity against HIV-1 Pol and Nef antigens by intracellular cytokine staining (ICS) following single vector immunization with Seq 96-F2A-97 (tPA-SEQ ID NO: 107), or Seq 100-F2A-101 (tPA-SEQ ID NO: 111), and by homologous vector prime-boost immunization. The Y axis represents proportion of CD8+ (i, ii and iii) or CD4+ (iv, v and vi) T cells exhibiting HIV-1 Pol (protease and RT) ( FIG. 36 ), Pol (integrase ( FIG. 37 ) and Nef ( FIG. 38 ) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α, either as individual cytokines or combination of cytokines, as shown on X axis. Antigen specific values were obtained by subtracting no antigen stimulated control to exclude nonspecific responses. HIV-1 Pol (Protease and RT) specific CD4+ and CD8+ T cell responses were seen in response to vaccination with robust CD8+ T cell responses. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) demonstrated strong immunogenicity with polyfunctionality (≥2 cytokines produced). Low levels of Pol (Integrase) and Nef specific CD4+ and CD8+ T cell responses were generated in response to vaccination and higher responses were seen with CD4+ T cells. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) demonstrated and induced mostly monokine production. Homologous vector prime-boost immunization with the vectors encoding the fusion polypeptides enhanced both CD4+ and CD8+ T cell responses. 
     The data are consistent with the conclusion that the above tested HIV-1 bivalent sequences are immunogenic either as individual priming sequences, or when combined with an F2A linker, except for the Seq 96-F2A-Seq97 (tPA-SEQ ID NO: 107), and also in a homologous prime boost immunization. The magnitude of responses generated were antigen specific, CD4+ and CD8+ and expressed polyfunctionality. 
     Example 9 
     In Vitro Assays Demonstrating Human T Cell Activation Induced by Immunogens 1-3 
     In this example, we established an in vitro method for testing the efficacy of T cell priming in humans by vaccine constructs in expression vectors. The application of this method in vaccinology allows evaluation of antigen processing, presentation and priming of T cells in humans of the transgene cassette, as well as the study of immune parameters including adjuvants and immune modulators that may modify the efficacy of priming. 
     Methods 
     Monocyte purification and maturation of monocyte derived dendritic cells (moDCs). Freshly isolated or cryopreserved PBMCs were used in the moDC-based T cell stimulation assays. CD14+monocytes were purified from PBMCS from individuals with or without HIV, and ART naïve or on ART using the EasySep human anti-CD14 positive selection antibody kit (StemCell Technologies). Flow cytometry was used to confirm the purification of the isolated CD14+monocytes to &gt;90% prior to the establishment of the culture. To generate immature moDCs, 2×10 6  purified CD14+monocytes were cultured in 3 mL of moDC differentiation media (complete RPMI 1640 containing 10% heat inactivated fetal calf serum, 1% penicillin streptomycin/mL, 0.5 mM HEPES, 800U/mL of GM-CSF (Miltenyi Biotec), and 1000U of IL-4 (Miltenyi Biotec)) in 6 well culture plates. The plates were incubated at 37° C. and 5% CO 2  for 6 days and monitored daily to ensure adherence of monocytes. To generate mature moDCs, adherent immature moDC cultures were supplemented with recombinant soluble CD40L (0.5 μg/ml), IFN-γ (1,000U/ml), PGE2 (5 μM), TNF-α (10 ng/ml), IL-6 (100 ng/ml) and IL-1β (10 ng/ml) with an additional 3 ml of moDC differentiation media on day 6 and incubated at 37° C. and 5% CO 2  for an additional 48 hrs. 
     On day 8, adherent mature moDCs were detached using ice-cold PBS and a cell scrapper to manually detach the moDCs. Following this procedure, unattached cells were washed using moDC differentiation media and transferred to a 50 ml centrifuge tube. The resulting cell mixture was centrifuged at 1500 rpm for 5 minutes at room temperature. Next, the supernatant was discarded and the cell pellet was resuspended in 5 ml of moDC differentiation media. A fraction of the mature moDCs were isolated and stained to characterize the differentiation phenotype of the moDCs with antiCD11c+, anti-HLA-DR+, anti-CD14-, anti-CD40+, anti-DCSIGN+, anti-CD83, anti-CD86 and anti-OX40L antibodies. 
     Transduction of moDCs with Adenovirus 5 (Ad5) viral vectors. The purified moDCs were harvested, washed twice in serum-free media, and re-suspended in X-Vivo 15 (BioWhittaker, Walkersville, Md.) at 10 7 /ml. Cells were equilibrated at 37° C. in a water bath for 20-30 min before transduction. Ad5 stocks expressing vaccine immunogen or empty vector controls were thawed on ice and added to the moDC suspension at a multiplicity of infection (MOI) of 500. Cells were gently mixed and placed immediately in the 37° C. incubator. After 2 hours, warm moDC differentiation media containing GM-CSF and IL-4 were added to dilute the moDCs to a final concentration of 10 6 /ml. Transduced moDCs (4×10 6 ) were transferred to T75 cell culture flasks and maintained at 37° C. in 5% CO 2  for an additional 48 h before addition of autologous PBMCs. 
     Co-culture of autologous PBMCs with moDCs. In experiments evaluating the immunogenicity of our conserved regions vaccines, autologous PBMCs were enumerated and 80×10 6  PBMCs were co-cultured with 4×10 6  moDCs that had been transduced with Ad5 vectors expressing vaccine immunogens or Ad5 empty vector controls. The PBMC-moDC co-cultures proceeded for a period of 10 days in the presence of IL-2 (50U/ml), IL-7 (10 ng/ml), Efavirenz (0.1 μM) and Elvitegravir (0.1 μM). Co-cultures of moDC and PBMCs were set up at a moDC:PBMC ratio of 1:20. 
     IFN-γ ELISpot Assays. Pre-coated strip ELISpot plates (Cellular Technologies Limited) were used for all ELISpot analyses. Briefly, 3×10 4  cells from Day 10 moDC-PBMC cultures were seeded to each well. Vaccine-matched peptides consisting of 15-mers overlapping by 11 amino acids spanning the entire HIV conserved regions immunogen were assembled into 384 ELISpot plates with each individual well corresponding to an individual 15-mer peptide and used in IFN-γ ELISpot assays to evaluate vaccine immunogenicity. For positive controls, 50 ng/ml PMA (Sigma) was added. Plates were incubated at 37° C. in 5% CO 2  for 24 h. After 24 h stimulation, the cells were removed from the plates and the wells were washed three times in PBS prior to three washes with PBS containing 0.05% tween. Biotinylated anti-IFN-γ detection antibody was then added to the plates for 2 hours at room temperature. The plates were then washed three times with PBS containing 0.05% tween prior to the addition of streptavidin-conjugated alkaline phosphatase (AP). Wells were then washed two times with 0.05% tween-PBS and then two times with distilled water prior to the addition of the blue developer solution. The plates were then incubated at room temperature for 15 minutes before the reaction was stopped using tap water. The wells were then dried overnight and spot forming units (SFUs) were counted on an Immunospot ELISpot reader. The settings were identical for all plates and counts were expressed at SFU per 3×10 4  PBMCs. The SFU were calculated as number of spots in test wells minus the mean number of spots in medium control wells. Positive responses were defined as &gt;3-fold higher SFUs compared to medium control wells and &gt;5 spots per well (3×10 4  cells). Medium control wells contained media reconstituted with a similar composition of DMSO as peptide stimulated test wells. A schematic summarizing the moDC-PBMC culture and ELISpot assay is depicted in  FIG. 39 . 
     In vitro viral inhibition assay. The capacity of vaccine-induced CD8+ T cells to suppress HIV-1 infection of autologous CD4+ T cells was evaluated to determine cytotoxicity. CD4+ T cells were isolated using negative magnetic bead selection (StemCell Technologies) from cryopreserved PBMCs, rested for 24 h and cultured in RPMI and 10% FBS. After 24 h, cultured CD4+ T cells were washed, counted and added to 50 ml conical tubes for spinoculation with HIV-1BaL at a multiplicity of infection (MOI) of 0.01. Spinoculation was performed by centrifugation at 1200 g for 2 h. After infection, CD4+ T cells were washed twice and cultured in in RPMI and 10% FBS and IL-2 (30U/ml) for 72 h. After 72 h, CD8+ T cells were isolated at the end of the PBMC-moDC co-cultures using negative magnetic bead selection (StemCell Technologies), labeled with CFSE and counted. Meanwhile, cultured CD4+ T cells were washed, counted and plated in U-bottom 96 well plates with vaccine-induced CD8+ T cells at a 1:1 ratio in RPMI and 10% FBS. Three days post co-culture of CD4+ T cells and CD8+ T cells, cells were stained with viability dye and surface markers, followed by intracellular detection of HIV-1 Gag (Beckman Coulter) using the IC Fixation/Permeabilization kit (BD Biosciences) according to the manufacturer&#39;s protocol. Cells were incubated with a mixture of fluorescence-conjugated anti-human antibodies for 30 min at 4° C. Stained cells were washed twice using FACS buffer (PBS, 2% FCS, 0.1% NaN 3 ), acquired with an LSR II flow cytometer using FACSDiva software (BD), and analyzed using FlowJo software version 10.2 (TreeStar). For surface staining, cells were stained with anti-CD4 BV605 clone OKT4, anti-CD8 BV650 clone RPA-T8, anti CD3 AF700 clone SK7, anti-CD20 BV421 clone 2H7, Live-dead Aqua dye (ThermoFischer). For intracellular detection of p24, cells were fixed and permeabilized using Cytofix/cytoperm buffers (BD Biosciences) and stained with anti-HIV Gag p24 PE (KC57). All experiments were performed in duplicate or triplicate, depending on cell availability. Uninfected CD4+ T cells were included as negative controls and infected CD4+ T cells cultured without CD8+ T cells served as 100% infectivity controls. Productive infection was considered only when &gt;0.1% p24 Gag+CD4− cells were detected by flow cytometry for each independent sample. 
     Results 
     In this example, we used the in vitro T cell priming assay described herein to evaluate immunogenicity and decode the CD8+ T cell responses to the vaccine immunogen (schematic provided in  FIG. 39 ). We focused on determining the epitopes within conserved regions vaccine that induce antigen specific T cell responses and evaluated the impact of pre-existing responses on induction of de novo responses. Monocyte derived DCs were transduced with viral vectors containing a vaccine transgene were able to prime autologous vaccine antigen specific T cells in vitro. This assay can facilitate the preclinical evaluation of vaccine constructs and provides a useful tool for the identification of immunogenic regions within the conserved region vaccine across a broad repertoire of participants prior to initiation of large-scale vaccine trials. 
     We completed the evaluation of immunogenicity for immunogen 1 (SEQ ID NOs: 105, 107, 109 and 111) in N=93 HIV-1+participant samples. Patient to patient variability is observed in transduction efficiency of moDCs and may reflect variability in expression of receptors to facilitate uptake of viral vectors as would be expected in a heterogeneous human population ( FIGS. 40-41 ). 
     The heat map depicted in  FIG. 40  summarizes the profile of the breadth of immune responses to each HIV protein in all 93 participants after in vitro priming with SEQ ID NOs: 105, 107, 109 and 111. Our data shows that in vitro vaccination resulted in induction of responses to conserved regions (≥1 epitope) in 80% ( 74/93) of tested samples, suggesting that vaccination re-focuses immune responses to conserved regions. Additionally, while vaccination with conserved regions vaccine boosted 25% of pre-existing detectable responses, 69% of all responses identified post vaccination were de novo T cell responses primarily to conserved Gag and Pol epitopes that were not detected in the pre-vaccine condition (Ad5-empty vector control) ( FIG. 42 ). Vaccination also significantly enhanced the breadth of immune responses to Gag, Pol and Nef antigens (median total breadth of responses=5, median Gag breadth=2, median Pol breadth=2 and median Nef breadth=0;  FIG. 40 ). Detailed analysis further showed that vaccination significantly enhanced the fraction of participants responding to ≥3 epitopes within each of Gag, Pol and Nef ( FIG. 41 ). We chose to evaluate responses that were greater than 3 epitopes given the data from the STEP Trial. See, Janes, et al.,  J Infect Dis  (2013) 208(8):1231-1239; ClinicalTrials.gov identifier: NCT00095576. 
     To determine whether vaccine-induced CD8+ T cells could eliminate HIV-1 infected cells in vitro, we performed HIV-1 viral inhibition assays. CD4+ T cells from participants were infected with HIV-1BaL and co-cultured either alone or in the presence of purified vaccine or empty vector primed CD8+ T cells. Data from 51/68 participants who demonstrated a productive infection rate with HIV-1BaL (≥0.1% p24 Gag+ cells) were used in our analysis ( FIG. 43 ). The data in  FIG. 44B  shows that CD8+ T cells from 69% (N= 35/51) of participants demonstrated increased suppression of HIV-1BaL in vitro in the presence of vaccine (SEQ ID NOs: 105, 107, 109 and 111) primed CD8+ T cells compared to empty vector primed CD8+ T cells. To evaluate whether there was a correlation between breadth of responses and CD8+ T cell mediated suppression of HIV-1BaL, we evaluated breadth and cytotoxicity in each participant that had demonstrated a productive infection rate with HIV-1BaL (≥0.1% p24 Gag+ cells). The data in  FIG. 44B  shows a lack of correlation between % residual Gag+ cells with Gag/Pol breadth which may be indicative that the quality of responses was more important. 
     We also evaluated immunogenicity of immunogen version 2 (SEQ ID NOs: 82-89) and immunogen version 3 (SEQ ID NOs: 90-93), using the moDC-T cell priming assay described above, in N=3 participants. The data, summarized in  FIGS. 45A and 45B , show the breadth and magnitude of total, Gag, Pol and Nef immune responses to each immunogen. For immunogen version 2, in a single donor in vitro priming with the vaccine sequence resulted in expansion of the response from 2 to 14 independent epitopes; for immunogen version 3, the median breadth of the response was 3. 
     Example 10 
     Non-Human Primate (NHP) Arenavirus Vector Data 
     Heterologous prime-boost in non-human primates. Simian immunodeficiency virus infection in NHPs serves as a good model for evaluating HIV vaccine vector immunogenicity. To evaluate the immunogenicity of replication-competent LCMV (TT1) and replication-competent PICV (TT2) vectors in NHPs (e.g., vectors as described in WO2016075250 and WO2017198726), we developed vectors expressing full length SIV proteins Gag, Env or Pol derived from the SIV sme543  strain. The amino acid sequences are provided in Table 2. Indian-origin healthy rhesus macaques were immunized via IM route with the arenavirus vectors. The Gag and Env expressing vectors (replication attenuated Pichinde arenavirus (TT2) and replication attenuated LCMV arenavirus (T T1)) were administered on the left quadricep whereas the Pol expressing vectors (TT2 and TT1) were administered on the right quadricep. The doses administered are as below: 1×10 6  RCV of TT2 Gag, 1×10 6  RCV of TT2 Env, 1×10 6  RCV of TT2 Poll/Pol 2, 4×10 6  RCV of TT1 Gag, 4×10 6  RCV of TT1 Env, and 2×10 6  RCV of TT1 Poll/Pol 2. In the placebo group, NHPs were administered placebo buffer solution composed of 10 mM HEPES, 150 mM NaCl, 20 mM Glycine and 0.1% macaque serum albumin. 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 amino acid sequences of full length SIV proteins Gag, Env or Pol derived 
               
               
                 from the SIVsme543 strain 
               
            
           
           
               
               
               
            
               
                 SEQ 
                   
                   
               
               
                 ID 
                 SIV 
                   
               
               
                 NO: 
                 protein 
                 Amino acid sequence 
               
               
                   
               
               
                 228 
                 SIV GAG 
                 MGARNSVLSGKKADELEKIRLRPNGKKKYMLKHVVWAANELDRFGLAESLLDNKEGCQKILSVLAPLVPTGSENLKSLYNTVCV 
               
               
                   
                   
                 IWCIHAEEKVKHTEEAKQIVQRHLVVETGTADKMPATSRPTAPPSGRGGNYPVQQVGGNYVHLPLSPRTLNAWVKLVEEKKFGA 
               
               
                   
                   
                 EVVPGFQALSEGCTPYDINQMLNCVGEHQAAMQIIREIINEEAADWDLQHPQPGPLPAGQLREPRGSDIAGTTSTVEEQIQWMY 
               
               
                   
                   
                 RQQNPIPVGNIYRRWIQLGLQKCVRMYNPTNILDVKQGPKEPFQSYVDRFYKSLRAEQTDPAVKNWMTQTLLIQNANPDCKLVL 
               
               
                   
                   
                 KGLGMNPTLEEMLTACQGIGGPGQKARLMAEALKEALRPDQLPFAAVQQKGQRRTIKCWNCGKEGHSARQCRAPRRQGCWGCGK 
               
               
                   
                   
                 TGHVMAKCPERQAGFLGFGPWGKKPRNFPMAQMPQGLTPTAPPEDPAVDLLKNYMKMGRKQRENRERPYKEVTEDLLHLNSLFG 
               
               
                   
                   
                 EDQ 
               
               
                   
               
               
                 229 
                 Pol1- 
                 PQFSLWRRPVVTAYIEEQPVEVLLADDSIVIGIELGPNYTPKIVGGIGGFINTKEYKDVKIKVLGKVIKGTIMIGDTPINIFGR 
               
               
                   
                 Protease/ 
                 NLLTAMGMSLNFPIAKVEPIKVTLKPGKEGPKLRQWPLSKEKIIALREICEKMEKDGQLEEAPPINPYNTPTFAIKKKDKNKWR 
               
               
                   
                 RT 
                 MLIDFRELNKVTQDFTEVQLGIPHPAGLAKRRRITVLDVGDAYFSIPLDEEFRQYTAFTLPSVNNAEPGKRYIYKVLPQGWKGS 
               
               
                   
                   
                 PAIFQYTMRNVLEPFRKANPDVTLIQILIASDRIDLEHDRVVLQLKELLNGIGFSTPEEKFQKDPPFQWMGYELWPTKWKLQKI 
               
               
                   
                   
                 ELPQRETWTVNDIQKLVGVLNWAAQIYPGIKTKHLCRLIRGKMTLTEEVQWTEMAEAEYEENKIILSQEQEGCYYQEGKPIEAT 
               
               
                   
                   
                 VIKSQDNQWSYKIHQEDKVLKVGKFAKVKNTHINGVRLLAHVVQKIGKEALVIWGEVPKFHLPVEREIWEQWWTDYWQVTWIPD 
               
               
                   
                   
                 WDFVSTPPLVRLVFNLVKEPIQGAETF 
               
               
                   
               
               
                 230 
                 Pol2- 
                 YVDGSCNRQSREGKAGYVTDRGRDKAKLLEQTTNQQALEAFYLALADSGPKANIIVDSQYVMGIVAGQPTESESRLVNQIIEEM 
               
               
                   
                 RNaseH/ 
                 IKKEAIYVAWVPAHKGIGGNQEVDHLVSQGIRQVLFLEKIEPAQEEHEKYHSNVKELVFKFGIPRLVAKQIVDTCDRCHQKGEA 
               
               
                   
                 Integrase 
                 IHGQVNAELGTWQMCTHLEGKIIIVAVHVASGFIEAEVIPQETGRQTALFLLKLAGRWPITHLHTNGANFTSQEVKMVAWWAGI 
               
               
                   
                   
                 EQTFGVPYNPQSQGVVAMNHHLKTQIDRIREQANSVETIVLMAVHCMNFKRRGGIGDMTPAERLVNMITTEQEIQFQQSKNSKF 
               
               
                   
                   
                 KNFRVYYREGRDQLWRGPGELLWKGEGAVILKVGTEIKVVPRRKAKIIKDYGGGKELDSGSHLEDTGEAREVA 
               
               
                   
               
               
                 231 
                 SIV sm543 
                 MGCLGNQLLIALLLVSVLEICCVQYVIVFYGVPAWKNATIPLFCATRNRDTWGTTQCLPDNDDYSELAVNITEAFDAWNNTVTE 
               
               
                   
                 Env 
                 QAIEDVWNLFETSIKPCVKLTPLCIAMRCNKTETDRWGLTGRAETTTTAKSTTSTTTTTVTPKVINEGDSCIKNNSCAGLEQEP 
               
               
                   
                   
                 MIGCKFNMTGLKRDKKIEYNETWYSRDLICEQPANGSESKCYMQHCNTSVIQESCDKHYWDAIRFRYCAPPGYALLRCNDSNYS 
               
               
                   
                   
                 GFAPKCSKVVVSSCTRMMETQTSTWFGENGTRAENRTYIYWHGNSNRTIISLNKYYNLTMKCRRPGNKTVLPVTIMSGLVFHSQ 
               
               
                   
                   
                 PINERPKQAWCRFGGNWSEAIQEVKETLVKHPRYTGTNDTRKINLTAPAGGDPEVTFMWTNCRGEFLYCKMNWFLNWVEDRDQN 
               
               
                   
                   
                 SNRWKQQKKPEQQKRNYVPCHIRQIINTWHKVGKNVYLPPREGDLTCNSTVTSLIAEIDWINNNETNITMSAEVAELYRLELGD 
               
               
                   
                   
                 YKLVEITPIGLAPTDVRRSLTLSAQSRTLLAGIVQQQQQLLDVVKRQHELLRLTVWGTKNLQTRVTAIEKYLKDQAQLNDSLVP 
               
               
                   
                   
                 NWDNMTWQEWEGKVDFLEANITQLLEEAQIQQEKNMYELQKLNSWDIFGNWFDLTSWIRYIQ 
               
               
                   
               
            
           
         
       
     
     IFN-γ ELISpot Assays. Pre-coated strip ELISpot plates (MabTech) were used for all ELISpot analyses. Briefly, 2×10 5  PBMCs isolated from whole blood at each of the timepoints analyzed was seeded to each well. SIV smE543 peptides consisting of 15-mers overlapping by 11 amino acids spanning the SIV immunogens Gag, Env and Pol at a final concentration of 1 μg/ml were assembled into 96-well ELISpot plates. To determine breadth of responses to Gag, Env and Pol, sub-pools of 12, 16 or 23 peptides respectively were tested individually at a final concentration of 1 ug/ml. Each sub-pool had 10 peptides composed of 15-mers overlapping by 11 amino acids. Each sample was tested in duplicates. For positive controls, 5 μg/ml PHA (Sigma) was added. Medium control wells contained cell culture media reconstituted with a similar composition of DMSO as peptide stimulated test wells. Plates were incubated at 37° C. in 5% CO 2  for 20-24 h. After overnight stimulation, the cells were removed from the plates and the wells were washed three times in PBS prior to three washes with PBS containing 0.05% tween. Biotinylated anti-IFN-γ detection antibody was then added to the plates for 2 hours at room temperature. The plates were then washed three times with PBS containing 0.05% tween prior to the addition of streptavidin-conjugated alkaline phosphatase (AP). Wells were then washed two times with 0.05% tween-PBS and then two times with distilled water prior to the addition of the blue developer solution. The plates were then incubated at room temperature for 15 minutes before the reaction was stopped using tap water. The wells were then dried overnight and spot forming units (SFUs) were counted on an Immunospot ELISpot reader. The settings were identical for all plates and counts were expressed at SFU per 2×10 5  PBMCs. To determine a proper spot count using the CTL Single Color immunospot counting software, multiple parameters were normalized relative to the sample. Signal sensitivity is set to the highest value before non-specific spots begin to appear. Spot size is reduced to the point where all real spots are counted but artifacts are not. Background signal reduction is set to avoid counting artifacts. The SFU were calculated as number of spots in test wells minus the mean number of spots in medium control wells. Positive responses were defined as &gt;3-fold higher SFUs compared to medium control wells and &gt;50 spots per 1×10 6  PBMCs. 
     SIV Challenge and Viral Load. All animals in the study were challenged at 4 weeks post the last vaccine dose (i.e., week 32 of study) with a single intravenous (IV) inoculation of a heterologous SIV virus swarm (SIVmac251, 8.19 TCID 50 ). The viral sequence of the challenge virus differs from that in the vaccine sequence (SIVsme543). The estimated AID50 of the SIVmac251 challenge stock is 0.29 TCID 50  via the IV route. Post challenge, all animals were monitored for clinical and laboratory progression as well as viral load to determine peak viral load (calculated at 2 weeks post challenge) and set point viral load (calculated over weeks 10-40 post challenge). Plasma SIV viral load as copies/ml was quantified by two-step RT-PCR assay performed in duplicates. 
     Results 
       FIG. 47A  shows the magnitude of SIV-specific IFN-γ responses as assessed by IFN-γ ELISpot. Boosting by TT1 results in a robust increase in response at week 14. The peak magnitude of response observed at 2 weeks post each vaccine dose is maintained with each subsequent boost. 
       FIG. 47B  shows the categorization of the animals that received the heterologous TT2/TT1 vaccine as moderate or high responders. This is based on the magnitude of peak response post each vaccine dose being less or more than 1000 SFU/million PBMCs respectively. The majority of the animals (17 of 24) were high responders with all animals showing a positive response to at least one SIV immunogen. 
       FIGS. 48A-D  demonstrate the magnitude of peak SIV-specific IFN-γ responses at 2 weeks post each vaccine dose. Peak Gag- and Pol-specific responses are maintained after doses 2, 3 and 4. Env-specific responses increased with each subsequent dose. After four doses of the heterologous vaccine, a positive response to Gag, Env and Pol is observed in at least 21 of 24 NHPs (response rate=87.5%). 
     With respect to breadth, highest total SIV-specific breadth was observed post-dose 3 compared to post-doses 2 and 4. Similarly, significantly higher Env- and Pol-specific breadth observed post-dose 3 compared to post dose 2 and 4. Gag-specific breadth is significantly high post dose 3 and 4 compared to post dose 2. These results suggest the induction of TT2/TT1 vaccine-induced breadth of responses to Gag, Env and Pol-specific immunogens at 2 weeks post each vaccine boost dose. See,  FIGS. 49A-D . 
     With respect to SIV challenge and viral load, post-challenge, reduced viral load was observed in the TT2/TT1 group compared with the placebo group ( FIG. 50A ). The median peak viral load measured at 2 weeks post challenge with SIVmac251 was 6.54 log 10 SIV copies/ml in the TT2/TT1 group and 7.2 log 10 SIV copies/ml in the placebo group. A significant decrease in peak viral load (** p=0.0046, Mann-Whitney t-test) was observed in the TT2/TT1 vaccinated NHPs compared to the placebo group ( FIG. 50B ). The setpoint viral load was calculated as the average SIV viral load over weeks 10-40 post challenge. The median setpoint VL was 5.5 log 10 SIV copies/ml in the TT2/TT1 group and 6.7 log 10 SIV copies/ml in the placebo group. A significant decrease of 1.2 log 10 SIV copies/ml in setpoint viral load (* p=0.0291, Mann-Whitney t-test) was observed in the TT2/TT1 vaccinated NHPs compared to the placebo group ( FIG. 50C ). These data demonstrate the prophylactic efficacy of heterologous TT2/TT1 prime-boost schemes of PICV/LMCV replication-attenuated arenavirus vectors encoding SIV immunogens in a SIV challenge model in NHPs. 
     Example 11 
     Replication-Attenuated Arenavirus Vectors Containing HIV-1 Immunogen Version 1 Fusion Polypeptide-Encoding Transgenes 
     In this example, we generated replication-attenuated arenavirus-based viral vectors encoding the computationally defined polypeptide antigens containing conserved regions of HIV-1 encoded by Gag, Nef and Pol genes as a transgene. Replication-attenuated arenavirus vectors based on Pichinde Virus (PICV) and Lymphocytic choriomeningitis virus (LCMV) were generated. The polypeptide segments containing conserved regions were concatenated or connected by different approaches including direct fusion, or the addition of various flexible linkers between regions. The transgenes were segregated and encoded on both viral S-Segments (NP-Segment and GP-Segment). In a first replication-attenuated LCMV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 98 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 100. In a second replication-attenuated LCMV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 99 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 101. In a first replication-attenuated PICV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 94 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 96. In a second replication-attenuated PICV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 95 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 97. Schematics of the fusion polypeptides are provided in  FIG. 25 . 
     Methods 
     Construction and generation of replication-attenuated arenavirus vectors containing HIV-1 fusion polypeptide transgene polypeptide variants. Replication-attenuated arena virus vectors expressing HIV-1 computationally defined vaccine immunogens, were generated as described previously (Kallert, et al,  Nat Commun . (2017) 8:15327; see also, WO2016075250 and WO2017198726). Briefly, cDNA sequences were synthesized and subdloned into the respective backbone plasmids. Plasmids for each viral genomic segment and plasmids expressing the viral trans-acting factors NP and L, were transfected into LCMV-GP complementing cells. Cell culture supernatant was harvested and further propagated on HEK293 suspension cells, to generated vector stock material (passage 1 (P1)). The vectors developed for this evaluation are listed in Table 3 and schematically depicted in  FIG. 25 . 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 Arenavirus Vectors Encoding HIV-1 Immunogen 1 Fusion Polypeptides 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 Fusion Polypeptide 
                 Transgene 
               
               
                 Vector Name 
                 Arenavirus 
                 (SEQ ID NOs) 
                 (SEQ ID NOs) 
               
               
                   
               
               
                 TT1-HIV-GNP1/PN1 
                 LCMV 
                 NP - SEQ ID NO: 98 
                 NP - SEQ ID NO: 140 
               
               
                   
                   
                 GP - SEQ ID NO: 100 
                 GP - SEQ ID NO: 146 
               
               
                 TT1-HIV-GNP2/PN2 
                 LCMV 
                 NP - SEQ ID NO: 99 
                 NP - SEQ ID NO: 143 
               
               
                   
                   
                 GP - SEQ ID NO: 101 
                 GP - SEQ ID NO: 149 
               
               
                 TT2-HIV-GNP1/PN1 
                 PICV 
                 NP - SEQ ID NO: 94 
                 NP - SEQ ID NO: 131 
               
               
                   
                   
                 GP - SEQ ID NO: 96 
                 GP - SEQ ID NO: 135 
               
               
                 TT2-HIV-GNP2/PN2 
                 PICV 
                 NP - SEQ ID NO: 95 
                 NP - SEQ ID NO: 133 
               
               
                   
                   
                 GP - SEQ ID NO: 97 
                 GP - SEQ ID NO: 137 
               
               
                   
               
            
           
         
       
     
     Evaluation of target gene expression by detection of the conserved region for Gag (p24). We evaluated transgene expression by detection of the conserved region for Gag (p24) either by Immunoblot or Double-Immuno staining (DI). For immunoblot analysis, infected HEK293 cells were harvested and lysed, before applying whole cell lysates to acrylamide gel electrophoresis. After blotting, membranes were incubated using either a mouse mAb [39/5.4A] to detect HIV1 p24 (Abcam (ab9071)), a rabbit pAb ERK-2 (sc-154; Santa Cruz) or antibodies for detection of successful infection (rabbit pAb anti LCMV-NP (University of Genf, Prof. Doron Merkler); mouse mAb anti PICV-NP (University of Basel; Prof. Daniel Pinschewer). 
     Evaluation of stable transgene integration by serial passaging of viral vectors. We evaluated transgene stability of replication-attenuated arenavirus vectors, by serial passaging of vectors stock material in HEK293 suspension cells. To this end, P1 stock material infectious titer was determined by Focus Forming Assay, and HEK293 cells were infected using a multiplicity of infection (MOI) of 0.001. Progeny virus was harvested 72 hours post infection and again titrated. Further passages were infected applying the same principle. After a maximum eight passages, virus containing supernatant samples were analyzed by transgene PCR and/or DI staining. For transgene PCR analysis, RNA from virus containing supernatant was extracted and subsequently reverse transcribed and amplified by PCR using specific HIV-transgene flanking primers. PCR products were applied to gel electrophoresis analysis to evaluate transgene PCR fragment length as an indicator of transgene stability. 
     Results 
     Evaluation of HIV-I fusion polypeptide transgene expression by immunoblot analysis. We could verify expression of Gag/Nef/Pol antigen by immunoblot analysis of cell lysates of three replicates per vector. The results are shown in  FIG. 52 . 
     Evaluation of stable integration of HIV-1 fusion polypeptide transgene by serial passaging. To evaluate, whether HIV-1 Immunogen 1 transgenes are stably encoded in replication attenuated arenaviral vectors over several passages, we analyzed cell culture supernatant and performed transgene PCR analysis. The passage level at which the majority (≥50%) of the transgene specific band still shows the expected full-length size, was considered the last passage level with stable transgene insertion. Results are shown in Table 4 and  FIGS. 53-56 . Further, where applicable, supernatant samples harvested from each passaging step were applied to double-immuno staining (DI staining), to determine the ratio of HIV-1 Gag and arenavirus-NP expression. A combination of both results allowed for a more accurate assessment of transgene stability of HIV-1 Immunogen 1 transgenes. 
     We found that replication attenuated-LCMV HIV antigen encoding vectors to stably encoded the transgenes up to passage level 7, while replication attenuated-PICV HIV antigen encoding vectors stably encoded the transgenes to passage levels 4 and 6. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Overview Table for Assessment of Transgene Genetic Stability 
               
            
           
           
               
               
               
               
            
               
                   
                   
                   
                 Transgene Stability 
               
               
                   
                 Vector Name 
                 Arenavirus 
                 Through Passage (P) 
               
               
                   
                   
               
               
                   
                 TT1-HIV-GNP1/PN1 
                 LCMV 
                 P7 
               
               
                   
                 TT1-HIV-GNP2/PN2 
                 LCMV 
                 P7 
               
               
                   
                 TT2-HIV-GNP1/PN1 
                 PICV 
                 P6 
               
               
                   
                 TT2-HIV-GNP2/PN2 
                 PICV 
                 P4 
               
               
                   
                   
               
               
                   
                 P# indicates number of passages 
               
            
           
         
       
     
     Replication-attenuated-LCMV HIV antigen encoding vectors stably retained the transgenes encoding the fusion polypeptides SEQ ID NOs 98 and 100 (TT1-HIV-GNP1/PN1) and SEQ ID NOs: 99 and 101 (TT1-HIV-GNP2/PN2) up to passage level 7. Replication-attenuated-PICV vector TT2-HIV-GNP1/PN1 stably retained transgenes encoding fusion polypeptides SEQ ID NOs: 94 and 96 up to passage level 6 and replication attenuated-PICV vector TT2-HIV-GNP2/PN2 stably retained transgenes encoding fusion polypeptides SEQ ID NOs: 95 and 97 up to passage level 4, however. 
     Example 12 
     Replication-Attenuated Arenavirus Vectors Containing HIV-1 Immunogen Version 2 Fusion Polypeptide-Encoding Transgenes 
     In this example, we generated replication attenuated arenavirus based viral vectors encoding shorter computationally defined polypeptide antigen HIV-1 Immunogen 2, containing conserved regions of HIV-1 including Gag, Nef and Pol genes as a transgene. Replication-attenuated arenavirus vectors based on Pichinde Virus (PICV) and Lymphocytic choriomeningitis virus (LCMV) were generated. The polypeptide segments containing conserved regions were concatenated or connected by different approaches including direct fusion, or the addition of various flexible linkers between regions. The transgenes were segregated and encoded on both viral S-Segments (NP-Segment and GP-Segment). In a first replication-attenuated LCMV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 84 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 88. In a second replication-attenuated LCMV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 85 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 89. In a first replication-attenuated PICV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 82 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 86. In a second replication-attenuated PICV vector, the NP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 83 and the GP-Segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 87. Schematics of the fusion polypeptides are provided in  FIG. 21 . 
     Methods 
     Construction and generation of replication attenuated arenavirus vectors containing HIV-1 Immunogen 2 transgene polypeptide variants. Replication-attenuated PICV and replication-attenuated LCMV viral vectors expressing HIV-1 computationally defined vaccine immunogens, were generated as described previously (Kallert, et al, (2017)  Nat. Comm ., supra). Briefly, cDNA sequences were synthesized and subcloned into the respective backbone plasmids. Plasmids for each viral genomic segment and plasmids expressing the viral trans-acting factors NP and L, were transfected into LCMV-GP complementing cells. Cell culture supernatant was harvested and further propagated on HEK293 suspension cells, to generate vector stock material (passage 1). The vectors developed for this evaluation are listed in Table 5 and schematically depicted in  FIG. 21 . 
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 Arenavirus Vectors Encoding HIV-1 Immunogen 2 Fusion Polypeptides 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 Fusion Polypeptide 
                 Transgene 
               
               
                 Vector Name 
                 Arenavirus 
                 (SEQ ID NOs) 
                 (SEQ ID NOs) 
               
               
                   
               
               
                 TT1-HIV(C2)-GP1/PN1 
                 LCMV 
                 NP - SEQ ID NO: 84 
                 NP - SEQ ID NO: 151 
               
               
                   
                   
                 GP - SEQ ID NO: 88 
                 GP - SEQ ID NO: 153 
               
               
                 TT1-HIV(C2)-GP2/PN2 
                 LCMV 
                 NP - SEQ ID NO: 85 
                 NP - SEQ ID NO: 156 
               
               
                   
                   
                 GP - SEQ ID NO: 89 
                 GP - SEQ ID NO: 159 
               
               
                 TT2-HIV(C2)-GP1/PN1 
                 PICV 
                 NP - SEQ ID NO: 82 
                 NP - SEQ ID NO: 150 
               
               
                   
                   
                 GP - SEQ ID NO: 86 
                 GP - SEQ ID NO: 152 
               
               
                 TT2-HIV(C2)-GP2/PN2 
                 PICV 
                 NP - SEQ ID NO: 83 
                 NP - SEQ ID NO: 154 
               
               
                   
                   
                 GP - SEQ ID NO: 87 
                 GP - SEQ ID NO: 157 
               
               
                   
               
            
           
         
       
     
     Evaluation of target gene expression by detection of the conserved region for Gag (p24). We evaluated transgene expression by detection of the conserved region for Gag (p24) either by Immunoblot or Double-Immunostaining (DI). For immunoblot analysis, infected HEK293 cells were harvested and lysed, before applying whole cell lysates to acrylamide gel electrophoresis. After blotting, membranes were incubated using either a mouse mAb [39/5.4A] to detect HIV1 p24 (Abcam (ab9071)), a rabbit pAb ERK-2 (sc-154; Santa Cruz) or antibodies for detection of successful infection (rabbit pAb anti LCMV-NP (University of Genf; Prof. Doron Merkler); mouse mAb anti PICV-NP (University of Basel; Prof. Daniel Pinschewer). 
     Evaluation of stable transgene integration by serial passaging of viral vectors. We evaluated transgene stability of replication attenuated arenavirus vectors, by serial passaging of vector stock material in HEK293 suspension cells. To this end, P1 stock material infectious titer was determined by Focus Forming Assay, and HEK293 cells were infected using a MOI 0.001. Progeny virus was harvested 72 hours post infection and again titrated. Further passages were infected applying the same principle. After a maximum of eight passages, virus containing supernatant samples were analyzed by transgene PCR and/or DI staining. For transgene PCR analysis, RNA from virus containing supernatant was extracted and subsequently reverse transcribed and amplified by PCR using specific HIV-transgene flanking primers. PCR products were applied to Gel electrophoresis analysis to evaluate transgene PCR fragment length as an indicator of transgene stability. 
     Results 
     Evaluation of HIV Immunogen 2 transgene expression by immunoblot analysis. We verified expression of Gag/Nef/Pol antigen by immunoblot analysis of cell lysates of four (TT1-HIV(C2)-GP1/PN1) or two (TT1-HIV(C2)-GP2/PN2) replicates per replication-attenuated-LCMV vector (left panel) and one representative vector stock per replication-attenuated-PICV vector (right panel). We determined antigen expression by staining of HIV-1 Gag-Pol in passage level 1 (P1) and 4 (P4). Cells infected with TT2-HIV(C2)-GP2/PN2 showed an additional band around 30 kDa size, when stained by Gag antibody. Results are shown in  FIG. 57 . 
     Evaluation of stable integration of HIV-1 Immunogen 2 transgene by serial passaging. To evaluate whether HIV-1 Immunogen 2 transgenes are stably encoded in replication attenuated arenavirus vectors over several passages, we analyzed cell culture supernatant and performed transgene PCR analysis. The passage level at which the majority (≥50%) of the transgene specific band still shows the expected full-length size, was considered the last passage level with stable transgene insertion. Results are shown in Table 6 and  FIGS. 58-61 . Further, where applicable, supernatant samples harvested from each passaging step were applied to double-immunostaining (DI staining), to determine the ratio of HIV-1 Gag and replication attenuated arenavirus-NP expression. A combination of both results allowed for a more accurate assessment of transgene stability of HIV-1 Immunogen 2 transgenes. 
     We found that replication attenuated-LCMV HIV antigen encoding vectors to stably encoded the transgenes greater than passage level 8, while replication attenuated-PICV HIV antigen encoding vectors stably encoded the transgenes to passage levels 6 and 8. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Overview Table for Assessment of Transgene Genetic Stability 
               
            
           
           
               
               
               
               
            
               
                   
                 SEQ ID 
                   
                 Transgene Stability 
               
               
                 Vector Name 
                 NOs: 
                 Arenavirus 
                 Through Passage (P) 
               
               
                   
               
               
                 TT1-HIV(C2)-GP1/PN1 
                 84 and 88 
                 LCMV 
                 &gt;P8 
               
               
                 TT1-HIV(C2)-GP2/PN2 
                 85 and 89 
                 LCMV 
                 &gt;P8 
               
               
                 TT2-HIV(C2)-GP1/PN1 
                 82 and 86 
                 PICV 
                  P8 
               
               
                 TT2-HIV(C2)-GP2/PN2 
                 83 and 87 
                 PICV 
                 &gt;P6 
               
               
                   
               
               
                 P# indicates number of passages 
               
            
           
         
       
     
     Replication-attenuated-LCMV HIV antigen encoding vectors stably retained the transgenes encoding the fusion polypeptides SEQ ID NOs 84 and 88 (TT1-HIV(C2)-GP1/PN1) and SEQ ID NOs: 85 and 89 (TT1-HIV(C2)-GP2/PN2) greater than passage level 8. Replication-attenuated-PICV vector TT2-HIV(C2)-GP1/PN1 stably retained transgenes encoding fusion polypeptides SEQ ID NOs: 82 and 86 up to passage level 8 and replication attenuated-PICV vector TT2-HIV(C2)-GP2/PN2 stably retained transgenes encoding fusion polypeptides SEQ ID NOs: 83 and 87 greater than passage level 6, however. 
     Example 13 
     Vaccine and Immune Modulator Combinations 
     In non-human primates, administration of an adenoviral vector based vaccine encoding SIV immunogens in combination with checkpoint inhibitors such as αPD1 antibody has shown an increase in durability of vaccine induced T cell responses whereas combination with αCTLA4 antibody has demonstrated an increase in magnitude of T cell responses. See, Pan, et al.,  Front Immunol . (2018) 9:2415; and Loffredo, et al., Poster P55, Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting and Pre-Conference Programs; 2017, 8-12 Nov.; National Harbor, Md.). FLT3L-FLT3 interaction leads to expansion and maturation of dendritic cells. Arenavirus based vectors show dendritic cell tropism (Flatz, et al.,  Nat Med  (2010) 16(3):339-45). Therefore, we postulated that combining DC expansion with arenavirus vectors would enhance immunogenicity observed with the TT2/TT1 replication-attenuated PICV/LCMV arenavirus vector prime-boost scheme. 
     Methods 
       FIG. 62  provides a schematic of immunization schedule prime-boost with arenavirus vectors (TT2/TT1) in non-human primates (NHPs) in combination with immune modulators. Indian-origin healthy rhesus macaques were immunized via intramuscular (I.M.) route with the arenavirus vectors and via intravenous (I.V.) route with immune modulators with thirteen (13) NHPs in each group. The Gag and Env expressing vectors TT2 (replication-attenuated Pichinde (PICV)) and TT1 (replication-attenuated LCMV)) were administered in the left quadricep whereas the Pol expressing vectors (TT2 and TT1) were administered in the right quadricep. The doses administered are as below: 1×10 6  replication competent virus particles (RCV) of TT2 Gag, Env and Poll/Pol 2 vectors, 4×10 6  RCV of TT1 Gag, Env, and 2×10 6  RCV of TT1 Poll/Pol 2. 
     The heterologous TT2/TT1 vaccine was administered every 4 weeks for a total of 4 doses either alone (Group 1, Vaccine) or in combination with checkpoint inhibitors (0PD1 antibody in group 2, or αCTLA4 antibody in group 3, 10 mg/kg each) administered immediately after the vaccine. The FLT3L-Fc FLT3 agonist was administered 1 week before the vaccine dose (Group 4, 0.3 mg/kg). 
     IFN-γ ELISpot assays were performed as described in Example 10. 
     Results 
       FIG. 63  shows the magnitude of SIV-specific IFN-γ responses as assessed by IFN-γ ELISpot in peripheral blood. Addition of αCTLA4 antibody with TT2/TT1 vaccine led to a robust and sustained increase in magnitude of SIV-specific responses compared to TT2/TT1 vaccine alone (p&lt;0.05 at week 4, 6, 8, 10, 12, 14 and 16; Two-way ANOVA with Dunnett&#39;s multiple comparison test). Combination with the FLT3L-Fc FLT3 agonist also led to a significant increase in magnitude of SIV-specific response post boost (p&lt;0.05 at weeks 8, 10 and 14; Two-way ANOVA with Dunnett&#39;s multiple comparison test). Administration of αPD1 antibody did not have any effect on the magnitude of vaccine-induced T cell response. Both checkpoint inhibitor αCTLA4 antibody and DC agonist FLT3L-Fc induced a significant increase in peak magnitude of T cell response consistent with the conclusion that vaccine-induced responses were augmented by these immune modulators. 
     With respect to breadth,  FIG. 64  shows that the highest total SIV-specific breadth at 2 weeks post last vaccine dose is observed in groups that received vaccine in combination with αCTLA4 antibody or FLT3L-Fc FLT3 agonist. Administration of TT2/TT1 vaccine in combination with FLT3L-Fc FLT3 agonist resulted in a significant increase in Gag, Env and Pol-specific breadth of responses. Administration of TT2/TT1 vaccine in combination with αCTLA4 antibody resulted in a significant increase in Env and Pol-specific breadth of responses. Taken together, these results are consistent with the conclusion that combination of heterologous TT2/TT1 vaccine with αCTLA4 antibody or FLT3L-Fc FLT3 agonist leads to a significant increase in breadth of SIV-specific T cell responses. 
     It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.